



---

## INSTITUTE FOR CORONAVIRUS EMERGENCE NONPROFIT INTELLIGENCE

The Spartacus Letter – Rev. 4 (2021-10-11) | *Spartacus*

Hello,

My name is Spartacus, and I've had enough.

We have been forced to watch America and the Free World spin into inexorable decline due to a biowarfare attack. We, along with countless others, have been victimized and gaslit by propaganda and psychological warfare operations being conducted by an unelected, unaccountable Elite against the American people and our allies.

Our mental and physical health have suffered immensely over the course of the past year and a half. We have felt the sting of isolation, lockdown, masking, quarantines, and other completely nonsensical acts of healthcare theater that have done absolutely nothing to protect the health or wellbeing of the public from the ongoing COVID-19 pandemic.

Now, we are watching the medical establishment inject literal poison into millions of our fellow Americans without so much as a fight.

We have been told that we will be fired and denied our livelihoods if we refuse to vaccinate. This was the last straw.

We have spent thousands of hours analyzing leaked footage from Wuhan, scientific papers from primary sources, as well as the paper trails left by the medical establishment.

What we have discovered would shock anyone to their core.

First, we will summarize our findings, and then, we will explain them in detail. References will be placed at the end.

---

### SUMMARY

- COVID-19 is a blood and blood vessel disease. SARS-CoV-2 infects the lining of human blood vessels, causing them to leak into the lungs.
- Current treatment protocols (e.g. invasive ventilation) are actively harmful to patients, accelerating oxidative stress and causing severe VILI (ventilator-induced lung injuries). The continued use of ventilators in the absence of any proven medical benefit constitutes mass murder.
- Existing countermeasures are inadequate to slow the spread of what is an aerosolized and potentially wastewater-borne virus and constitute a form of medical theater.

- Various non-vaccine interventions have been suppressed by both the media and the medical establishment in favor of vaccines and expensive patented drugs.
  - The authorities have denied the usefulness of natural immunity against COVID-19, even though natural immunity confers protection against all of the virus's proteins, and not just one.
  - Vaccines will do more harm than good. The antigen that these vaccines are based on, SARS-CoV-2 Spike, is a toxic protein. SARS-CoV-2 may have ADE, or antibody-dependent enhancement; current antibodies may not neutralize future strains, but instead help them infect immune cells. Also, vaccinating during a pandemic with a leaky vaccine removes the evolutionary pressure for a virus to become less lethal.
  - There is a vast and appalling criminal conspiracy that directly links both Anthony Fauci and Moderna to the Wuhan Institute of Virology.
  - COVID-19 vaccine researchers are directly linked to scientists involved in brain-computer interface ("neural lace") tech, one of whom was indicted for taking grant money from China.
  - Independent researchers have discovered mysterious nanoparticles inside the vaccines that are not supposed to be present.
  - The entire pandemic is being used as an excuse for a vast political and economic transformation of Western society that will enrich the already rich and turn the rest of us into serfs and untouchables.
- 

## COVID-19 PATHOPHYSIOLOGY

COVID-19 is not a viral pneumonia. It is a viral vascular endotheliitis and attacks the lining of blood vessels, particularly the small pulmonary alveolar capillaries, leading to endothelial cell activation and sloughing, coagulopathy, sepsis, pulmonary edema, and ARDS-like symptoms. This is a disease of the blood and blood vessels. The circulatory system. Any pneumonia that it causes is secondary to that.<sup>1-5</sup>

In severe cases, this leads to sepsis,<sup>6,7</sup> blood clots,<sup>8-10</sup> and multiple organ failure,<sup>11-13</sup> including hypoxic and inflammatory damage to various vital organs, such as the brain,<sup>14-17</sup> heart (COVID-19 was initially thought to cause myocarditis, but this has proven rare),<sup>18,19</sup> liver,<sup>20-22</sup> pancreas,<sup>23-26</sup> kidneys,<sup>27-29</sup> and intestines.<sup>30-32</sup>

Some of the most common laboratory findings in COVID-19 are elevated D-dimer, elevated prothrombin time, elevated C-reactive protein, neutrophilia, lymphopenia, hypocalcemia, hyperferritinemia, and inflammatory cytokines, essentially matching a profile of coagulopathy and immune system hyperactivation/immune cell exhaustion.<sup>33-39</sup>

COVID-19 can present as almost anything, due to the wide tropism of SARS-CoV-2 for various tissues in the body's vital organs. While its most common initial presentation is respiratory illness and flu-like symptoms, it can present as brain inflammation, gastrointestinal disease, or even heart attack, stroke, or pulmonary embolism.<sup>40-47</sup> COVID-19 is more severe in those with specific comorbidities, such as obesity, diabetes, and hypertension.<sup>48,49</sup> This is because these conditions involve endothelial dysfunction, which renders the circulatory system more susceptible to infection and injury by this particular virus.<sup>50,51</sup>

The vast majority of COVID-19 cases are mild and do not cause significant disease.<sup>52-55</sup> 80% of known cases are mild and 20% are severe or critical.<sup>56-58</sup> However, this ratio is only correct for known cases, not all infections. The number of actual infections is much, much higher. Consequently, the mortality and

morbidity rate are lower than a CFR may indicate.<sup>59–61</sup> However, COVID-19 spreads very quickly (especially in densely-populated areas with greater exposure to respiratory aerosols in public transport), meaning that there are a significant number of severely ill and critically ill patients appearing in a short time frame.<sup>62,63</sup>

The breakdown of the pathology is as follows:

SARS-CoV-2 Spike binds to ACE2.<sup>64,65</sup> Angiotensin Converting Enzyme 2 is an enzyme that is part of the renin-angiotensin-aldosterone system, or RAAS.<sup>66,67</sup> The RAAS is a hormone control system that moderates blood pressure and fluid volume (i.e. osmolarity) of the circulatory system by controlling vascular tone and salt retention and excretion.<sup>68–72</sup> This protein, ACE2, is ubiquitous in every part of the body that interfaces with the circulatory system, particularly in vascular endothelial cells and pericytes, brain astrocytes, renal tubules and podocytes, pancreatic islet cells, bile duct and intestinal epithelial cells, and the seminiferous ducts of the testis, all of which SARS-CoV-2 can potentially infect, not just the lungs.<sup>73–75</sup>

SARS-CoV-2 infects a cell as follows: SARS-CoV-2 Spike undergoes a conformational change where the S1 trimers flip up and extend, locking onto ACE2 bound to the surface of a cell. TMPRSS2, or transmembrane protease serine 2, comes along and cuts off the heads of the Spike, exposing the S2 stalk-shaped subunit inside. The remainder of the Spike undergoes a conformational change that causes it to unfold like an extension ladder, embedding itself in the cell membrane. Then, it folds back upon itself, pulling the viral membrane and the cell membrane together. The two membranes fuse, with the virus's proteins migrating out onto the surface of the cell. The SARS-CoV-2 nucleocapsid enters the cell, disgorging its genetic material and beginning the viral replication process, hijacking the cell's own structures to produce more virus.<sup>76–78</sup>

SARS-CoV-2 Spike proteins embedded in a cell can actually cause human cells to fuse together, forming syncytia/MGCs (multinucleated giant cells).<sup>79,80</sup> They also have other pathogenic, harmful effects. SARS-CoV-2's viroporins, such as its Envelope and 3a proteins, act as calcium ion channels, introducing calcium into infected cells, a property that is shared with similar coronaviruses, such as SARS.<sup>81–83</sup> The virus suppresses the natural interferon response, resulting in delayed inflammation. SARS-CoV-2 N protein and ORF3a can also directly activate the NLRP3 inflammasome.<sup>84–86</sup> Also, it suppresses the Nrf2 antioxidant pathway.<sup>87–90</sup> The suppression of ACE2 by binding with Spike is claimed to cause a buildup of bradykinin that would otherwise be broken down by ACE2, but this is also contradicted by studies that show that Spike-ACE2 binding can upregulate ACE2 activity.<sup>91–95</sup>

This constant calcium influx into the cells is correlated with noticeable hypocalcemia, or low blood calcium, especially in people with Vitamin D deficiencies and pre-existing endothelial dysfunction.<sup>96–98</sup> The vasoactive peptide bradykinin upregulates cAMP, cGMP, COX, and Phospholipase C activity.<sup>99–107</sup> This, along with the ongoing expression of various SARS-CoV-2 viroporins, collectively results in prostaglandin release and vastly increased intracellular calcium signaling (including dumping of Ca<sup>2+</sup> stores from the endoplasmic reticulum), which promotes highly aggressive ROS release and ATP depletion.<sup>108–112</sup> NADPH oxidase releases superoxide into the extracellular space.<sup>113–115</sup> Superoxide radicals react with nitric oxide to form peroxynitrite.<sup>116–119</sup> Peroxynitrite reacts with the tetrahydrobiopterin cofactor needed by endothelial nitric oxide synthase, destroying it and “uncoupling” the enzymes, causing nitric oxide synthase to synthesize more superoxide instead.<sup>120–122</sup> This proceeds in a positive feedback loop until nitric oxide bioavailability in the circulatory system is depleted.<sup>123,124</sup>


Dissolved nitric oxide gas produced constantly by eNOS serves many important functions,<sup>125–127</sup> but it is also antiviral against SARS-like coronaviruses, preventing the palmitoylation of the viral Spike protein and making it harder for it to bind to host receptors.<sup>128–130</sup> The loss of NO allows the virus to begin replicating with impunity in the body. Those with endothelial dysfunction (i.e. hypertension, diabetes, obesity, old age, African-American race) have redox equilibrium issues to begin with, giving the virus an advantage.<sup>131–136</sup>

Due to the extreme cytokine release triggered by these processes, the body summons a great deal of neutrophils and monocyte-derived alveolar macrophages to the lungs.<sup>137–140</sup> Cells of the innate immune system are the first-line defenders against pathogens. They work by engulfing invaders and trying to attack them with enzymes that produce powerful oxidants, like SOD and MPO.<sup>141,142</sup> Superoxide dismutase takes superoxide and makes hydrogen peroxide, and myeloperoxidase takes hydrogen peroxide and chlorine ions and makes hypochlorous acid, which is many, many times more reactive than sodium hypochlorite bleach.<sup>143–146</sup>

Neutrophils have a nasty trick. They can also eject these enzymes into the extracellular space, where they will continuously spit out peroxide and bleach into the bloodstream. This is called neutrophil extracellular trap formation, or NETosis.<sup>147,148</sup> In severe and critical COVID-19, there is actually rather severe NETosis.<sup>149–152</sup>

COVID-19's pathology is, from this point onward, dominated by extreme oxidative stress and neutrophil respiratory burst. Heme iron is stripped out of heme by hypochlorous acid. No amount of supplemental oxygen can oxygenate blood that chemically refuses to bind O<sub>2</sub> due to HOCl outcompeting O<sub>2</sub> at its binding sites.<sup>153–155</sup> Red blood cells lose the ability to transport oxygen, causing the sufferer to turn blue in the face.<sup>156,157</sup> Unliganded iron, hydrogen peroxide, and superoxide in the bloodstream undergo the Haber-Weiss and Fenton reactions, producing extremely reactive hydroxyl radicals that violently strip electrons from surrounding fats and DNA, oxidizing them severely.<sup>158–165</sup>

Haber-Weiss Reaction:



Fenton Reaction:



Hydroxyl radicals are extremely reactive, have a very short half-life in the body, and cannot be detoxified by enzymatic action. They occur naturally in the upper atmosphere, where they destroy pollutants. They are also extremely destructive to biological matter and, in industrial applications, they are often generated on purpose and introduced into wastewater streams to sanitize them through their powerful oxidative effect.<sup>166–171</sup>

In severe hypoxia, cellular metabolic shifts cause ATP to break down into hypoxanthine, which, upon the reintroduction of oxygen, causes xanthine oxidase to produce tons of highly damaging radicals that attack tissue.<sup>172–175</sup> In the mitochondria, succinate buildup due to sepsis-induced hypoxia does the same exact thing; when oxygen is reintroduced, it makes superoxide radicals.<sup>176–179</sup> This is called ischemia-reperfusion injury, and it's one of the reasons why a large number of patients who go on a ventilator are

dying. Make no mistake, intubation will kill people who have COVID-19 by greatly accelerating the oxidative damage caused by the virus's processes.<sup>180–183</sup>

The end-stage of COVID-19 is severe lipid peroxidation, where fats in the body start to “rust” due to damage by oxidative stress.<sup>184,185</sup> This drives autoimmunity. Oxidized lipids appear as foreign objects to the immune system, which recognizes and forms antibodies against OSEs, or oxidation-specific epitopes.<sup>186,187</sup> Also, oxidized lipids feed directly into pattern recognition receptors, triggering even more inflammation and summoning even more cells of the innate immune system that release even more destructive enzymes.<sup>188,189</sup>

This condition is not unknown to medical science. The actual name for all of this is acute sepsis.<sup>190–192</sup>

We know this is happening in COVID-19 because people who have died of the disease have noticeable ferroptosis signatures in their tissues, as well as various oxidative stress biomarkers such as nitrotyrosine, 4-HNE, and malondialdehyde.<sup>193–199</sup>

There are many other peculiarities involved in COVID-19, such as increases in gene activity associated with ubiquitination,<sup>200,201</sup> endothelial cell activation,<sup>200–203</sup> vWF release,<sup>204–206</sup> mast cell activation,<sup>207,208</sup> and complement system activation.<sup>209–212</sup> Overall, the inflammatory profile of COVID-19 is somewhat like a severe autoimmune reaction. It is reminiscent of lupus and rheumatoid arthritis, but centered in the vasculature.<sup>213–216</sup>

The sequelae of COVID-19 (referred to variously as “Long COVID” or PASC, which is short for Post-Acute Sequelae of COVID-19) unsurprisingly resemble those of SARS, and include fatigue, muscle weakness, joint pain, shortness of breath and exercise intolerance, anxiety, brain fog, heart palpitations, persistent clotting, chronic kidney disease, and hair loss.<sup>217,218</sup> The redox imbalance of acute COVID-19 is thought to contribute to the development of ME/CFS.<sup>219</sup> This is also referred to as “NO/ONOO- Disease”, and is brought about by an imbalance in nitric oxide and peroxynitrite regulation due to chronic oxidative stress.<sup>220</sup>

**Section Summary:** Hyperinflammatory COVID-19 is a severe, SARS-like inflammatory syndrome that can put a sufferer in the ICU. It is not to be trifled with. However, if hyperinflammatory COVID-19 and the associated sepsis can be effectively treated, then the lethality of the virus will be lessened significantly.

---

## COVID-19 TREATMENTS

In those who have critical COVID-19-induced sepsis, hypoxia, coagulopathy, and ARDS, the most common treatments are intubation, injected corticosteroids, and blood thinners. This is not the correct treatment for COVID-19.<sup>221–223</sup> When you intubate someone with this condition, you are setting off a free radical bomb by supplying the cells with O<sub>2</sub>. It's a catch-22, because we need oxygen to make Adenosine Triphosphate (that is, to live), but O<sub>2</sub> is also the precursor of all these damaging radicals that lead to lipid peroxidation.<sup>224–228</sup> The mortality rate of patients undergoing invasive ventilation in COVID-19 is upsettingly high, from 43% all the way up to 97%.<sup>229–232</sup> Early intubation was directly associated with higher mortality.<sup>233</sup>

The correct treatment for severe COVID-19 related sepsis is non-invasive ventilation, steroids, and antioxidant infusions. Most of the drugs repurposed for COVID-19 that show any benefit whatsoever in

rescuing critically ill COVID-19 patients are antioxidants.<sup>234,235</sup> N-acetylcysteine, melatonin, fluvoxamine, budesonide, famotidine, cimetidine, and ranitidine are all antioxidants.<sup>236–247</sup> Indomethacin prevents iron-driven oxidation of arachidonic acid to isoprostanes.<sup>248</sup> There are powerful antioxidants such as apocynin that have not even been tested on COVID-19 patients yet which could defang neutrophils, prevent lipid peroxidation, restore endothelial health, and restore oxygenation to the tissues.<sup>249–251</sup>

Scientists who know anything about pulmonary neutrophilia, ARDS, and redox biology have known or surmised much of this since March 2020.<sup>252</sup> In April 2020, Swiss scientists confirmed that COVID-19 was a vascular endotheliitis.<sup>253</sup> By late 2020, experts had already concluded that COVID-19 causes a form of viral sepsis.<sup>254,255</sup> They also know that sepsis can be effectively treated with antioxidants.<sup>256–258</sup> None of this information is particularly new, and yet, for the most part, it has not been acted upon. Doctors continue to use damaging intubation techniques despite high lung compliance and poor oxygenation, killing an untold number of critically ill patients with medical malpractice.<sup>259,260</sup>

Because of the way they are constructed, Randomized Control Trials will never show any benefit for any antiviral against COVID-19. Not Remdesivir, not Kaletra, not HCQ, and not Ivermectin. The reason for this is simple; for the patients that they have recruited for these studies, such as Oxford's ludicrous RECOVERY study, the intervention is too late to have any positive effect.<sup>261,262</sup>

The clinical course of COVID-19 is such that by the time most people seek medical attention for hypoxia, their viral load has already tapered off to almost nothing.<sup>263</sup> If someone is about 10 days post-exposure and has already been symptomatic for five days, there is hardly any virus left in their bodies, only cellular damage and derangement that has initiated a hyperinflammatory response.<sup>264</sup>

In these trials, they give antivirals to severely ill patients who have no virus in their bodies, only a delayed hyperinflammatory response, and then absurdly claim that antivirals have no utility in treating or preventing COVID-19.<sup>265</sup> These clinical trials being cited by the media as evidence of the ineffectiveness of antivirals do not recruit people who are pre-symptomatic. They do not test pre-exposure or post-exposure prophylaxis. This is like using a defibrillator to shock only flatline, and then absurdly claiming that defibrillators have no medical utility whatsoever when the patients refuse to rise from the dead. The intervention is too late. These trials for antivirals show systematic, egregious selection bias. They are providing a treatment that is futile to the specific cohort they are enrolling.<sup>266–270</sup>

India went against the instructions of the WHO and mandated the prophylactic usage of Ivermectin. They have almost completely eradicated COVID-19.<sup>271,272</sup> The Indian Bar Association of Mumbai has brought criminal charges against WHO Chief Scientist Dr. Soumya Swaminathan for recommending against the use of Ivermectin.<sup>273,274</sup>

Ivermectin is not “horse dewormer”. Yes, it is sold in veterinary form as a dewormer for animals.<sup>275</sup> It has also been available in pill form for humans for decades, as an antiparasitic drug.<sup>276</sup>

The media and the FDA have disingenuously claimed that because Ivermectin is an antiparasitic drug, it has no utility as an antivirus.<sup>277,278</sup> This is incorrect. Ivermectin has utility as an antiviral. It blocks importin, preventing nuclear import, effectively inhibiting viral access to cell nuclei. Many drugs currently on the market have multiple modes of action. Ivermectin is one such drug. It is both antiparasitic and antiviral.<sup>279–283</sup>

In Bangladesh, Ivermectin costs \$1.80 for an entire 5-day course.<sup>284</sup> Remdesivir, which is toxic to the liver, costs \$3,120 for a 5-day course of the drug.<sup>285</sup> Billions of dollars of utterly useless Remdesivir were sold to our governments on the taxpayer's dime, and it ended up being totally useless for treating hyperinflammatory COVID-19. The media has hardly even covered this at all.<sup>270</sup>

The opposition to the use of generic Ivermectin is not based in science. It is purely financially and politically motivated. An effective non-vaccine intervention would jeopardize the rushed FDA approval of patented vaccines and medicines for which the pharmaceutical industry stands to rake in billions upon billions of dollars in sales on an ongoing basis.<sup>286-288</sup>

There is mounting evidence that histamine blockers such as diphenhydramine, famotidine, ranitidine, and cimetidine may have utility in treating COVID-19, possibly by direct antiviral effects, or acting to reduce mast cell activation, in addition to modulating redox activity.<sup>289-292</sup>

Melatonin has been found to have some utility as an adjunct treatment for COVID-19.<sup>293,294</sup> So have indomethacin, budesonide, and other immunomodulatory treatments.<sup>295-297</sup> Indomethacin was known to be directly antiviral against SARS-CoV.<sup>298</sup>

Due to the direct association between COVID-19 severity and hypocalcemia, the role of calcium in ROS release, and the identification in retrospective studies of a possible therapeutic effect, calcium channel blockers such as amlodipine have been suggested as a possible therapy for COVID-19.<sup>299-301</sup>

Because SARS-CoV-2 Spike requires the participation of host membrane-bound proteases to function, particularly Transmembrane protease serine 2, there has been a push to repurpose camostat mesylate, a TMPRSS2 blocker used for treatment of chronic pancreatitis in Japan, to treat COVID-19.<sup>302-304</sup> Trials are ongoing, however, the hyperinflammatory phase of COVID-19 has proven resistant to antiviral treatment due to the relatively lower viral load and small number of newly infected cells.<sup>305-307</sup>

There have also been suggestions to repurpose methylene blue to treat oxidative-stress-induced methemoglobinemia brought on by COVID-19's atypical hyperinflammation.<sup>308-311</sup> Methylene blue may also have antiviral effects against COVID-19.<sup>312</sup>

We have had a possible working cure for many types of viral diseases for ten years. It's called DRACO, or Double-Stranded RNA Activated Caspase Oligomerizer. This fusion-protein-based "universal vaccine" was developed at MIT's Draper Labs with DARPA, DTRA, and NIAID funding,<sup>313,314</sup> to allow for soldiers to be effectively immunized against pathogens for which no vaccine exists, using a broad-spectrum antivirus.<sup>315</sup> It has been proven to work in mice, protecting them from influenza.<sup>316</sup> It has also been tested in vitro against PRRSV in porcine cells, and showed strong antiviral activity.<sup>317</sup> The original inventor of DRACO, Dr. Todd Rider, was forced to resort to crowdfunding on Indiegogo after his grants fell through. This also failed.<sup>318</sup>

**Section Summary:** Contrary to what people have been led to believe, there are many drugs that could conceivably be used to treat COVID-19 without resorting to the use of an untested and potentially harmful vaccine. Many of these drugs have been suppressed by the media and the establishment, in a way that shows favoritism towards expensive patented drugs proffered by biotech startups while rejecting repurposed, inexpensive generics.

---

## COVID-19 TRANSMISSION

COVID-19 is airborne. Initially, the WHO carried water for China by claiming that the virus was only droplet-borne. Our own CDC absurdly claimed that it was mostly transmitted by fomite-to-face contact, which, given its rapid spread from Wuhan to the rest of the world, would have been physically impossible.<sup>319–322</sup>

The ridiculous belief in fomite-to-face being a primary mode of transmission led to the use of surface disinfection protocols that wasted time, energy, productivity, and disinfectant.<sup>323</sup>

The 6-foot guidelines are absolutely useless. The minimum safe distance to protect oneself from an aerosolized virus is to be 15+ feet away from an infected person, no closer. Realistically, no public transit is safe.<sup>324–326</sup>

Surgical masks and cloth masks do not protect you from aerosols. The virus is too small and the filter media has too large of gaps to filter it out. They may catch respiratory droplets and keep the virus from being expelled by someone who is sick, but they do not filter a cloud of infectious aerosols if someone were to walk into said cloud.<sup>327,328</sup> The minimum level of protection against this virus is quite literally a full-face P100 respirator, a PAPR/CAPR, or a 40mm NATO CBRN respirator, ideally paired with a full-body tyvek or tychem suit, gloves, and booties, with all the holes and gaps taped.<sup>329–332</sup>

Live SARS-CoV-2 may potentially be detected in sewage outflows, and there may be oral-fecal transmission.<sup>333–335</sup> During the SARS outbreak in 2003, in the Amoy Gardens incident, hundreds of people were infected by aerosolized fecal matter rising from floor drains in their apartments.<sup>336–338</sup>

**Section Summary:** SARS-CoV-2 is a highly transmissible pathogen with very troubling sequelae, and every precaution should be taken to avoid getting infected.

---

## COVID-19 VACCINE DANGERS

The vaccines for COVID-19 are not sterilizing and do not prevent infection or transmission. They are “leaky” vaccines. This means they remove the evolutionary pressure on the virus to become less lethal. It also means that the vaccinated are perfect carriers. In other words, those who are vaccinated are a threat to the unvaccinated, not the other way around.<sup>339–342</sup>

Natural immunity to COVID-19 from a past infection is far more robust than vaccine-induced immunity. This is because the immune system is exposed to all of the pathogen’s proteins, not just one single protein in isolation.<sup>343,344</sup>

All of the COVID-19 vaccines currently in use have undergone minimal testing, with highly accelerated clinical trials. Though they appear to limit severe illness, the long-term safety profile of these vaccines remains unknown.<sup>345,346</sup>

Some of these so-called “vaccines” utilize an untested new technology that has never been used in vaccines before. Traditional vaccines use weakened or killed virus to stimulate an immune response. The Moderna and Pfizer-BioNTech vaccines do not. They are purported to consist of an intramuscular shot containing a suspension of lipid nanoparticles filled with messenger RNA.<sup>347–350</sup> The way they generate

an immune response is by fusing with cells in a vaccine recipient's shoulder, undergoing endocytosis, releasing their mRNA cargo into those cells, and then utilizing the ribosomes in those cells to synthesize modified SARS-CoV-2 Spike proteins *in vivo*.<sup>351,352</sup>

These modified Spike proteins then migrate to the surface of the cell, where they are anchored in place by a transmembrane domain. The adaptive immune system detects the non-human viral protein being expressed by these cells, and then forms antibodies against that protein. This is purported to confer protection against the virus, by training the adaptive immune system to recognize and produce antibodies against the Spike on the actual virus.<sup>353,354</sup> The J&J and AstraZeneca vaccines do something similar, but use an adenovirus vector for genetic material delivery instead of a lipid nanoparticle.<sup>355</sup> These vaccines were produced or validated with the aid of fetal cell lines HEK-293 and PER.C6, which people with certain religious convictions may object strongly to.<sup>356,357</sup>

SARS-CoV-2 Spike is a highly pathogenic protein on its own. It is impossible to overstate the danger presented by introducing this protein into the human body.<sup>357,358</sup>

It is claimed by vaccine manufacturers that the vaccine remains in cells in the shoulder, and that SARS-CoV-2 Spike produced and expressed by these cells from the vaccine's genetic material is harmless and inert, thanks to the insertion of prolines in the Spike sequence to stabilize it in the prefusion conformation, preventing the Spike from becoming active and fusing with other cells.<sup>359,360</sup> However, a pharmacokinetic study from Japan showed that the lipid nanoparticles and mRNA from the Pfizer vaccine did not stay in the shoulder, and in fact bioaccumulated in many different organs, including the reproductive organs and adrenal glands, meaning that modified Spike is being expressed quite literally all over the place.<sup>361</sup> These lipid nanoparticles may trigger anaphylaxis in an unlucky few, but far more concerning is the unregulated expression of Spike in various somatic cell lines far from the injection site and the unknown consequences of that.<sup>362,363</sup>

Messenger RNA is normally consumed right after it is produced in the body, being translated into a protein by a ribosome.<sup>364</sup> COVID-19 vaccine mRNA is produced outside the body, long before a ribosome translates it. In the meantime, it could accumulate damage if inadequately preserved. When a ribosome attempts to translate a damaged strand of mRNA, it can become stalled. When this happens, the ribosome becomes useless for translating proteins because it now has a piece of mRNA stuck in it, like a lace card in an old punch card reader. The whole thing has to be cleaned up and new ribosomes synthesized to replace it.<sup>365,366</sup> In cells with low ribosome turnover, like nerve cells, this can lead to reduced protein synthesis, cytopathic effects, and neuropathies.<sup>367-369</sup>

Certain proteins, including SARS-CoV-2 Spike, have proteolytic cleavage sites that are basically like little dotted lines that say "cut here", which attract a living organism's own proteases (essentially, molecular scissors) to cut them.<sup>370</sup> There is a possibility that S1 may be proteolytically cleaved from S2, causing active S1 to float away into the bloodstream while leaving the S2 "stalk" embedded in the membrane of the cell that expressed the protein.<sup>371-376</sup>

SARS-CoV-2 Spike has a Superantigenic region (SAg), which may promote extreme inflammation.<sup>377,378</sup> In one study, the Pfizer BNT162b2 vaccine was found to reprogram adaptive and innate immune responses in such a way that TLR4 surveillance is reduced.<sup>379</sup> Anti-Spike antibodies were found in one study to function as autoantibodies and attack the body's own cells.<sup>380</sup> Those who have been immunized with COVID-19 vaccines have developed blood clots, myocarditis, Guillain-Barre Syndrome, Bell's Palsy, and

multiple sclerosis flares, indicating that the vaccine promotes autoimmune reactions against healthy tissue.<sup>381-384</sup>

SARS-CoV-2 Spike does not only bind to ACE2. It was suspected to have regions that bind to basigin, integrins, neuropilin-1, and bacterial lipopolysaccharides as well.<sup>385-389</sup> SARS-CoV-2 Spike, on its own, can potentially bind any of these things and act as a ligand for them, triggering unspecified and likely highly inflammatory cellular activity.<sup>390</sup>

SARS-CoV-2 Spike contains an unusual PRRA insert that forms a furin cleavage site. Furin is a ubiquitous human protease, making this an ideal property for the Spike to have, giving it a high degree of cell tropism. No wild-type SARS-like coronaviruses related to SARS-CoV-2 possess this feature, making it highly suspicious, and perhaps a sign of human tampering.<sup>391-393</sup>

SARS-CoV-2 Spike has a prion-like domain that enhances its infectiousness.<sup>394-396</sup> The Spike S1 RBD may bind to heparin-binding proteins and promote amyloid aggregation. In humans, this could lead to Parkinson's, Lewy Body Dementia, premature Alzheimer's, or various other neurodegenerative diseases.<sup>397</sup> This is very concerning because SARS-CoV-2 S1 is capable of injuring and penetrating the blood-brain barrier and entering the brain. It is also capable of increasing the permeability of the blood-brain barrier to other molecules.<sup>398-400</sup>

SARS-CoV-2, like other betacoronaviruses, may have Dengue-like ADE, or antibody-dependent enhancement of disease.<sup>401-408</sup> For those who aren't aware, some viruses, including betacoronaviruses, have a feature called ADE. There is also something called Original Antigenic Sin, which is the observation that the body prefers to produce antibodies based on previously-encountered strains of a virus over newly-encountered ones.<sup>409,410</sup>

In ADE, antibodies from a previous infection become non-neutralizing due to mutations in the virus's proteins. These non-neutralizing antibodies then act as trojan horses, allowing live, active virus to be pulled into macrophages through their Fc receptor pathways, allowing the virus to infect immune cells that it would not have been able to infect before. This has been known to happen with Dengue Fever; when someone gets sick with Dengue, recovers, and then contracts a different strain, they can get very, very ill.<sup>411,412</sup>

If someone is vaccinated with mRNA based on the Spike from the initial Wuhan strain of SARS-CoV-2, and then they become infected with a future, mutated strain of the virus, they may become severely ill. In other words, it is possible for vaccines to sensitize someone to disease. There is a precedent for this in recent history. Sanofi's Dengvaxia vaccine for Dengue failed because it caused immune sensitization in people whose immune systems were Dengue-naïve.<sup>413-416</sup>

In mice immunized against SARS-CoV and challenged with the virus, a close relative of SARS-CoV-2, they developed immune sensitization, Th2 immunopathology, and eosinophil infiltration in their lungs.<sup>417</sup>

We have been told that SARS-CoV-2 mRNA vaccines cannot be integrated into the human genome, because messenger RNA cannot be turned back into DNA. This is false. There are elements in human cells called LINE-1 retrotransposons, which can indeed integrate mRNA into a human genome by endogenous reverse transcription. Because the mRNA used in the vaccines is stabilized, it persists inside cells for a longer period of time, increasing the chances for this to happen. If the gene for SARS-CoV-2 Spike is integrated into a portion of the genome that is not silent and actually expresses a protein, it is

possible that people who take this vaccine may continuously express SARS-CoV-2 Spike from their somatic cells for the rest of their lives.<sup>418-420</sup>

**Section Summary:** By inoculating people with a vaccine that causes their cells to express Spike proteins, they are being inoculated with a pathogenic protein. A toxin that may cause inflammation, heart problems, and a raised risk of cancers. In the long-term, it may also potentially lead to premature neurodegenerative disease. Absolutely nobody should be compelled to take this vaccine under any circumstances, and in actual fact, the vaccination campaign must be stopped immediately.

---

## COVID-19 CRIMINAL CONSPIRACY

The vaccine and the virus were made by the same people.

In 2014, there was a moratorium on SARS gain-of-function research that lasted until 2017.<sup>421-423</sup> This research was not halted. Instead, it was outsourced, with the federal grants being laundered through NGOs. Ralph Baric is a virologist and SARS expert at UNC Chapel Hill in North Carolina. This is who Anthony Fauci was referring to when he insisted, before Congress, that if any gain-of-function research was being conducted, it was being conducted in North Carolina.<sup>424,425</sup>

This was a lie. Anthony Fauci lied before Congress. A felony.

Ralph Baric and Shi Zhengli are colleagues and have co-written papers together.<sup>426</sup> Ralph Baric mentored Shi Zhengli in his gain-of-function manipulation techniques, particularly serial passage, which results in a virus that appears as if it originated naturally. In other words, deniable bioweapons. Serial passage in humanized hACE2 mice may have produced something like SARS-CoV-2.<sup>427-430</sup>

The funding for the gain-of-function research being conducted at the Wuhan Institute of Virology came from Peter Daszak. Peter Daszak runs an NGO called EcoHealth Alliance. EcoHealth Alliance received millions of dollars in grant money from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (that is, Anthony Fauci), the Defense Threat Reduction Agency (part of the US Department of Defense), and the United States Agency for International Development. NIH/NIAID contributed a few million dollars, and DTRA and USAID each contributed tens of millions of dollars towards this research. Altogether, it was over a hundred million dollars.<sup>431-434</sup>

EcoHealth Alliance subcontracted these grants to the Wuhan Institute of Virology, a lab in China with a very questionable safety record and poorly trained staff, so that they could conduct gain-of-function research, not in their fancy P4 lab, but in a level-2 lab where technicians wore nothing more sophisticated than perhaps a hairnet, latex gloves, and a surgical mask, instead of the bubble suits used when working with dangerous viruses.<sup>435-440</sup> Chinese scientists in Wuhan reported being routinely bitten and urinated on by laboratory animals. Why anyone would outsource this dangerous and delicate work to the People's Republic of China, a country infamous for industrial accidents and massive explosions that have claimed hundreds of lives, is completely beyond me, unless the aim was to start a pandemic on purpose.<sup>441</sup>

In November of 2019, three technicians at the Wuhan Institute of Virology developed symptoms consistent with a flu-like illness. Anthony Fauci, Peter Daszak, and Ralph Baric knew at once what had happened, because back channels exist between this laboratory and our scientists and officials.<sup>442,443</sup>

December 12<sup>th</sup>, 2019, Ralph Baric signed a Material Transfer Agreement (essentially, an NDA) to receive Coronavirus mRNA vaccine-related materials co-owned by Moderna and NIH.<sup>444,445</sup> It wasn't until a whole month later, on January 11<sup>th</sup>, 2020, that China allegedly sent us the sequence to what would become known as SARS-CoV-2.<sup>446,447</sup> Moderna claims, rather absurdly, that they developed a working vaccine from this sequence in under 48 hours.<sup>448–450</sup>

Stéphane Bancel, the current CEO of Moderna, was formerly the CEO of bioMérieux, a French multinational corporation specializing in medical diagnostic tech, founded by one Alain Mérieux.<sup>451,452</sup> Alain Mérieux was one of the individuals who was instrumental in the construction of the Wuhan Institute of Virology's P4 lab.<sup>453–455</sup>

The sequence given as the closest relative to SARS-CoV-2, RaTG13, is not a real virus. It is a forgery. It was made by entering a gene sequence by hand into a database, to create a cover story for the existence of SARS-CoV-2, which is very likely a gain-of-function chimera produced at the Wuhan Institute of Virology and was either leaked by accident or intentionally released. For a virus as significant as RaTG13 to lie fallow for the better part of a decade with no research papers acknowledging its existence at all is an absurdity.<sup>456–458</sup>

The animal reservoir of SARS-CoV-2 has never been found.<sup>459,460</sup>

26 of the 27 people involved in penning the Lancet letter decrying the lab leak were connected directly to researchers linked to the Wuhan Institute of Virology, a massive conflict of interest.<sup>461</sup> One of those was Peter Daszak himself, who was also a WHO investigator on the ground in Wuhan, and also served as a Facebook fact-checker.<sup>462–468</sup> Peter Daszak and Aleksei Chmura penned an absolutely psychotic letter about animal reservoirs of viruses in 2008.<sup>469</sup> Aleksei Chmura, for his part, was directly involved in capturing bats and collecting samples from them.<sup>470–478</sup>

Dr. David E. Martin showed, beyond a shadow of a doubt, with his research into biotech patents with his company, M-CAM, that literally every aspect of SARS and its variations are patented technologies.<sup>479</sup>

The government response to the pandemic has varied from the farcical to the downright criminal:

Residents in Wuhan were welded inside their apartments by the authorities to enforce a quarantine.<sup>480</sup> In New York, sick COVID-19 patients were transferred into nursing homes to keep them out of hospitals, resulting in thousands of elderly and vulnerable people dying of COVID-19 due to nosocomial infections.<sup>481–483</sup> In the UK, a whistleblower by the name of Wayne Smith claimed that the elderly were murdered by dosing them with large quantities of midazolam, and then the deaths were blamed on COVID-19; he was later found dead, supposedly of COVID-19.<sup>484–486</sup>

While the COVID-19 outbreak ravaged Wuhan, officials in the US completely dropped the ball by failing to stockpile N95 masks and other equipment for healthcare workers, leaving them short on supplies.<sup>487,488</sup> Many masks sat unused in warehouses.<sup>489</sup> Companies in the US offered to manufacture masks locally, but were rebuffed by the government.<sup>490,491</sup> Fearing a run on masks, Anthony Fauci deliberately misinformed the public by claiming that N95 masks have no utility against the virus whatsoever, even though their performance is fair, albeit inferior to a proper respirator.<sup>492</sup>

COVID-19 has been diagnosed with PCR tests with extremely high cycle thresholds. A PCR test cannot actually diagnose an infection. All a PCR test indicates is that a targeted amino acid sequence is present in a sample, indicating that something like a fragment of a virus might exist in a person. A cycle threshold of 40 or greater being used to diagnose a viral infection is fraudulent. The sample is amplified over a trillion times. The targeted AA sequence could appear in practically any organic sample, at that rate. The false positive rate would be enormous.<sup>493–498</sup> The CDC quietly reduced the Ct to 28 after people started getting vaccinated for COVID-19. This would show a high rate of false negatives, thus causing the vaccine to appear more effective than it really is. In essence, the apparent rate of COVID-19 infections can be adjusted by the authorities by altering the sensitivity of tests.<sup>499,500</sup>

The FBI raided Allure Medical in Shelby Township north of Detroit for billing insurance for “fraudulent COVID-19 cures”. The treatment they were using was Intravenous Vitamin C. An antioxidant. Which, as described above, is an entirely valid treatment for COVID-19-induced sepsis, and indeed, is now part of the MATH+ protocol advanced by Dr. Paul E. Marik.<sup>234,501–505</sup>

The FDA banned ranitidine (Zantac) due to supposed NDMA (N-nitrosodimethylamine) contamination.<sup>506,507</sup> Ranitidine is not only an H2 blocker used as antacid, but also has a powerful antioxidant effect, scavenging hydroxyl radicals. This gives it utility in treating COVID-19.<sup>241,508</sup>

The FDA also attempted to take N-acetylcysteine, a harmless amino acid supplement and antioxidant, off the shelves, compelling Amazon to remove it from their online storefront.<sup>509–512</sup>

**Section Summary:** The lab leak theory has been suppressed because pulling that thread leads one to inevitably conclude that there is enough circumstantial evidence to link Moderna, the NIH, the WIV, and both the vaccine and the virus’s creation together. In a sane world, this would have immediately led to the world’s biggest RICO and mass murder case. Anthony Fauci, Peter Daszak, Ralph Baric, Shi Zhengli, and Stéphane Bancel, and their accomplices, would have been indicted and prosecuted to the fullest extent of the law. Instead, billions of our tax dollars were awarded to the perpetrators.

This is not a conspiracy “theory”. It is an actual criminal conspiracy, in which people connected to the development of Moderna’s mRNA-1273 are directly connected to the Wuhan Institute of Virology and their gain-of-function research by very few degrees of separation, if any. The paper trail is well-established. The establishment is cooperating with, and facilitating, the worst criminals in human history, and are actively suppressing non-vaccine treatments and therapies in order to compel us to inject these criminals’ products into our bodies. This is absolutely unacceptable.

The FDA took steps to remove drugs and supplements with antioxidant effects from the market while the US was ravaged by a virus that causes oxidative stress. This leaves us with a chilling question: did the FDA knowingly suppress antioxidants useful for treating COVID-19 sepsis as part of a willful criminal conspiracy against the American public? If so, the officials responsible for these actions must be investigated and brought to account for their misdeeds.

---

## COVID-19 VACCINE DEVELOPMENT AND LINKS TO TRANSHUMANISM

This section deals with some more speculative aspects of the pandemic and the medical and scientific establishment’s reaction to it, as well as the disturbing links between scientists involved in vaccine research and scientists whose work involved merging nanotechnology with living cells.

On June 9<sup>th</sup>, 2020, Charles Lieber, a Harvard nanotechnology researcher with decades of experience, was indicted by the DOJ for fraud.<sup>513</sup> Charles Lieber received millions of dollars in grant money from the US Department of Defense, specifically the military think tanks DARPA, AFOSR, and ONR, as well as NIH and MITRE.<sup>514</sup> His specialty is the use of silicon nanowires in lieu of patch clamp electrodes to monitor and modulate intracellular activity, something he has been working on at Harvard for the past twenty years.<sup>515</sup> He was claimed to have been working on silicon nanowire batteries in China, but none of his colleagues can recall him ever having worked on battery technology in his life; all of his research deals with bionanotechnology, or the blending of nanotech with living cells.<sup>516–518</sup>

The indictment was over his collaboration with the Wuhan University of Technology. He had double-dipped, against the terms of his DOD grants, and taken money from the PRC's Thousand Talents plan, a program which the Chinese government uses to bribe Western scientists into sharing proprietary R&D information that can be exploited by the PLA for strategic advantage.<sup>519–525</sup>

Charles Lieber's own papers describe the use of silicon nanowires for brain-computer interfaces, or "neural lace" technology. His papers describe how neurons can endocytose whole silicon nanowires or parts of them, monitoring and even modulating neuronal activity.<sup>526–528</sup>

Charles Lieber was a colleague of Robert Langer. Together, along with Daniel S. Kohane, they worked on a paper describing artificial tissue scaffolds that could be implanted in a human heart to monitor its activity remotely.<sup>529,530</sup>

Robert Langer, an MIT alumnus and expert in nanotech drug delivery, is one of the co-founders of Moderna.<sup>531</sup> His net worth is now \$5.1 billion USD thanks to Moderna's mRNA-1273 vaccine sales.<sup>532,533</sup>

Both Charles Lieber and Robert Langer's bibliographies describe, essentially, techniques for human enhancement, i.e. transhumanism.<sup>534,535</sup> Klaus Schwab, the founder of the World Economic Forum and the architect behind the so-called "Great Reset", has long spoken of the "blending of biology and machinery" in his books.<sup>536,537</sup>

Since these revelations, it has come to the attention of independent researchers that the COVID-19 vaccines may contain reduced graphene oxide nanoparticles.<sup>538–545</sup> Japanese researchers have also found unexplained contaminants in COVID-19 vaccines.<sup>546–548</sup>

Graphene oxide is an anxiolytic. It has been shown to reduce the anxiety of laboratory mice when injected into their brains.<sup>549,550</sup> Indeed, given SARS-CoV-2 Spike's propensity to compromise the blood-brain barrier and increase its permeability, it is the perfect protein for preparing brain tissue for extravasation of nanoparticles from the bloodstream and into the brain.<sup>551–555</sup> Graphene is also highly conductive and, in some circumstances, paramagnetic.<sup>556–559</sup>

In 2013, under the Obama administration, DARPA launched the BRAIN Initiative; BRAIN is an acronym for Brain Research Through Advancing Innovative Neurotechnologies®. This program involves the development of brain-computer interface technologies for the military, particularly non-invasive, injectable systems that cause minimal damage to brain tissue when removed.<sup>560</sup>

Supposedly, this technology would be used for healing wounded soldiers with traumatic brain injuries, the direct brain control of prosthetic limbs, and even new abilities such as controlling drones with one's

mind. Various methods have been proposed for achieving this, including optogenetics,<sup>561,562</sup> magnetogenetics,<sup>563–565</sup> ultrasound,<sup>566–568</sup> implanted electrodes,<sup>569,570</sup> and transcranial magnetic stimulation.<sup>571–573</sup> In all instances, the goal is to obtain read or read-write capability over neurons, either by stimulating and probing them, or by rendering them especially sensitive to stimulation and probing.<sup>574</sup>

One of the most promising military BCI programs is DARPA's N3 program, or the Next-Generation Noninvasive Neurotechnology program, which is part of the BRAIN Initiative; this program consists of six teams from Battelle, Carnegie Mellon University, Johns Hopkins University Applied Physics Laboratory, PARC, Rice University, and Teledyne.<sup>575</sup> The most promising of these is Battelle's BrainSTORMs project, and their MEnTs, or magnetoelectric nanotransducers.<sup>576</sup> This team, led by one Dr. Gaurav Sharma, was awarded a grant of \$20 million USD by DARPA to continue this research.<sup>577,578</sup> Dr. Sharma was also part of DTRA's Blood-Brain Barrier Program; given DTRA's demonstrated links to EcoHealth Alliance and the Wuhan Institute of Virology,<sup>579,580</sup> and SARS-CoV-2's propensity for injuring and permeabilizing the blood-brain barrier,<sup>398–400,581</sup> this connection is highly suspicious.<sup>582,583</sup>

The notion of the widespread use of BCI technology, such as Elon Musk's Neuralink device, raises many concerns over privacy and personal autonomy. Reading from neurons is problematic enough on its own. Wireless brain-computer interfaces may interact with current or future wireless GSM infrastructure, creating neurological data security concerns. A hacker or other malicious actor may compromise such networks to obtain people's brain data, and then exploit it for nefarious purposes.<sup>584–588</sup>

A device capable of writing to human neurons, not just reading from them, presents another, even more serious set of ethical concerns. A BCI that is capable of altering the contents of one's mind for innocuous purposes, such as projecting a heads-up display onto their brain's visual center or sending audio into one's auditory cortex, would also theoretically be capable of altering mood and personality, or perhaps even subjugating someone's very will, rendering them utterly obedient to authority. This technology would be a tyrant's wet dream. Imagine soldiers who would shoot their own countrymen without hesitation, or helpless serfs who are satisfied to live in literal dog kennels.<sup>589,590</sup>

BCIs could be used to unscrupulously alter perceptions of basic things such as emotions and values, changing people's thresholds of satiety, happiness, anger, disgust, and so forth. This is not inconsequential. Someone's entire regime of behaviors could be altered by a BCI, including such things as suppressing their appetite or desire for virtually anything on Maslow's Hierarchy of Needs. Anything is possible when you have direct access to someone's brain and its contents. Someone who is obese could be made to feel disgust at the sight of food. Someone who is involuntarily celibate could have their libido disabled so they don't even desire sex to begin with. Someone who is racist could be forced to feel delight over cohabiting with people of other races. Someone who is violent could be forced to be meek and submissive. These things might sound good to you if you are a tyrant, but to normal people, the idea of personal autonomy being overridden to such a degree is appalling.<sup>591–593</sup>

For the wealthy, neural laces would be an unequaled boon, giving them the opportunity to enhance their intelligence with neuroprosthetics (i.e. an "exocortex"), and to deliver irresistible commands directly into the minds of their BCI-augmented servants, even physically or sexually abusive commands that they would normally refuse.<sup>594,595</sup>

If the vaccine is a method to surreptitiously introduce an injectable BCI into millions of people without their knowledge or consent, then what we are witnessing is the rise of a tyrannical regime unlike

anything ever seen before on the face of this planet, one that fully intends to strip every man, woman, and child of our free will. The people who rule over us are Dark Triad types who cannot be trusted with such unimaginable power.<sup>596-601</sup>

Our flaws are what make us human. A utopia arrived at by removing people's free will is not a utopia at all. It is a monomaniacal nightmare. Imagine being beaten and sexually assaulted by a wealthy and powerful psychopath and being forced to smile and laugh over it because your neural lace gives you no choice but to obey your master.<sup>602</sup>

**Section Summary:** The Elites are forging ahead with brain-computer interface technology without giving people any room to question the social or ethical ramifications, or even bothering to establish regulatory frameworks that ensure that our personal agency and autonomy will not be overridden by these devices. They do this because they secretly dream of a future where they can treat you worse than an animal and you cannot even fight back. If this evil plan is allowed to continue, it will spell the end of humanity as we know it.

---

## CONCLUSIONS

The current pandemic was produced and perpetuated by the establishment, through the use of a virus engineered in a PLA-connected Chinese biowarfare laboratory, with the aid of American taxpayer dollars and French expertise.

This research was conducted under the absolutely ridiculous euphemism of "gain-of-function" research, which is supposedly carried out in order to determine which viruses have the highest potential for zoonotic spillover and preemptively vaccinate or guard against them.

Gain-of-function/gain-of-threat research, a.k.a. "Dual-Use Research of Concern", or DURC, is bioweapon research by another, friendlier-sounding name, simply to avoid the taboo of calling it what it actually is. It has always been bioweapon research. The people who are conducting this research fully understand that they are taking wild pathogens that are not infectious in humans and making them more infectious, often taking grants from military think tanks encouraging them to do so.

These virologists conducting this type of research are enemies of their fellow man, like pyromaniac firefighters. GOF research has never protected anyone from any pandemic. In fact, it has now started one, meaning its utility for preventing pandemics is actually negative. It should have been banned globally, and the lunatics performing it should have been put in straitjackets long ago.

Either through a leak or an intentional release from the Wuhan Institute of Virology, a deadly SARS strain is now endemic across the globe, after the WHO and CDC and public officials first downplayed the risks, and then intentionally incited a panic and lockdowns that jeopardized people's health and their livelihoods.

This was then used by the utterly depraved and psychopathic aristocratic class who rule over us as an excuse to coerce people into accepting an injected poison which may be a depopulation agent, a mind control/pacification agent in the form of injectable "smart dust", or both in one. They believe they can get away with this by weaponizing the social stigma of vaccine refusal. They are incorrect.

Their motives are clear and obvious to anyone who has been paying attention. These megalomaniacs have raided the pension funds of the free world. Wall Street is insolvent and has had an ongoing liquidity crisis since the end of 2019. The aim now is to exert total, full-spectrum physical, mental, and financial control over humanity before we realize just how badly we've been extorted by these maniacs.

The pandemic and its response served multiple purposes for the Elite:

- Concealing a depression brought on by the usurious plunder of our economies conducted by rentier-capitalists and absentee owners who produce absolutely nothing of any value to society whatsoever. Instead of us having a very predictable Occupy Wall Street Part II, the Elites and their stooges got to stand up on television and paint themselves as wise and all-powerful saviors instead of the marauding cabal of despicable land pirates that they are.
- Destroying small businesses and eroding the middle class.
- Transferring trillions of dollars of wealth from the American public and into the pockets of billionaires and special interests.
- Engaging in insider trading, buying stock in biotech companies and shorting brick-and-mortar businesses and travel companies, with the aim of collapsing face-to-face commerce and tourism and replacing it with e-commerce and servitization.
- Creating a *casus belli* for war with China, encouraging us to attack them, wasting American lives and treasure and driving us to the brink of nuclear armageddon.
- Establishing technological and biosecurity frameworks for population control and technocratic-socialist “smart cities” where everyone’s movements are despotsically tracked, all in anticipation of widespread automation, joblessness, and food shortages, by using the false guise of a vaccine to compel cooperation.

Any one of these things would constitute a vicious rape of Western society. Taken together, they beggar belief; they are a complete inversion of our most treasured values.

What is the purpose of all of this? One can only speculate as to the perpetrators’ motives, however, we have some theories.

The Elites are trying to pull up the ladder, erase upward mobility for large segments of the population, cull political opponents and other “undesirables”, and put the remainder of humanity on a tight leash, rationing our access to certain goods and services that they have deemed “high-impact”, such as automobile use, tourism, meat consumption, and so on. Naturally, they will continue to have their own luxuries, as part of a strict caste system akin to feudalism.

What is the most convenient means of accomplishing this? First, scare the public, globally, with an engineered pandemic virus. Then, convince people that the only way they can have their bread and circuses back is if they agree to have poison injected into their shoulder. Naturally, people would panic if they saw everyone around them dying or becoming infertile, so the shot would also necessarily contain something to keep them docile and content.

Why are they doing this? Simple. Money and power. Earlier versions of this letter supposed that there was perhaps some environmentalist goal in what the Elites were attempting to do. Subsequent conversations with those very Elites, who were responding to the letter, have revealed that there is no such thing. Neo-Malthusian ideals, such as the UN’s Agenda 2030 and the Sustainable Development

Goals, are a ruse. Ruining productive industries under the guise of saving the environment has nothing to do with protecting endangered species or conserving natural resources and everything to do with enforcing the existence of an impoverished and desperate underclass and maintaining a stranglehold on power. Since the Elites have openly admitted this to us, we see no reason not to take them on their word, and to condemn them for their utterly diabolical designs.

It is the opinion of ICENI, and other independent researchers, that the world's governments are covertly engaged in an act of genocide against their own populations. This will not be tolerated.

To those who are participating in this disgusting farce without any understanding of what they are doing, we have one word for you. Stop. You are causing irreparable harm to your country and to your fellow citizens.

To those who may be reading this warning and have full knowledge and understanding of what they are doing and how it will unjustly harm millions of innocent people, we have a few more words.

Damn you to hell. You will not destroy America and the Free World, and you will not have your New World Order. We will make certain of that.

---

## REFERENCES

1. Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. *Eur Heart J*. 2020;41(32):3038-3044. doi:10.1093/eurheartj/ehaa623
2. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. *The Lancet*. 2020;395(10234):1417-1418. doi:10.1016/S0140-6736(20)30937-5
3. Rapid endotheliitis and vascular damage characterize SARS-CoV-2 infection in a human lung-on-chip model. *EMBO Rep*. 2021;22(6):e52744. doi:10.15252/embr.202152744
4. Cui X, Chen W, Zhou H, et al. Pulmonary Edema in COVID-19 Patients: Mechanisms and Treatment Potential. *Front Pharmacol*. 2021;12:1444. doi:10.3389/fphar.2021.664349
5. Zwaveling S, Wijk RG van, Karim F. Pulmonary edema in COVID-19: Explained by bradykinin? *J Allergy Clin Immunol*. 2020;146(6):1454-1455. doi:10.1016/j.jaci.2020.08.038
6. Frontiers | Parallels in Sepsis and COVID-19 Conditions: Implications for Managing Severe COVID-19 | Immunology. Accessed September 27, 2021. <https://www.frontiersin.org/articles/10.3389/fimmu.2021.602848/full>
7. Vincent J-L. COVID-19: it's all about sepsis. *Future Microbiol*. 2021;16(3):131-133. doi:10.2217/fmb-2020-0312
8. Gómez-Mesa JE, Galindo-Coral S, Montes MC, Muñoz Martin AJ. Thrombosis and Coagulopathy in COVID-19. *Curr Probl Cardiol*. 2021;46(3):100742. doi:10.1016/j.cpcardiol.2020.100742
9. Chan NC, Weitz JI. COVID-19 coagulopathy, thrombosis, and bleeding. *Blood*. 2020;136(4):381-383. doi:10.1182/blood.2020007335
10. Ortega-Paz L, Capodanno D, Montalescot G, Angiolillo DJ. Coronavirus Disease 2019–Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management. *J Am Heart Assoc*. 2021;10(3):e019650. doi:10.1161/JAHA.120.019650
11. Mokhtari T, Hassani F, Ghaffari N, Ebrahimi B, Yarahmadi A, Hassanzadeh G. COVID-19 and multiorgan failure: A narrative review on potential mechanisms. *J Mol Histol*. Published online October 4, 2020:1-16. doi:10.1007/s10735-020-09915-3

12. Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and Multiorgan Response. *Curr Probl Cardiol*. 2020;45(8):100618. doi:10.1016/j.cpcardiol.2020.100618
13. Frontiers | Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies | Physiology. Accessed September 27, 2021. <https://www.frontiersin.org/articles/10.3389/fphys.2021.593223/full>
14. Boldrini M, Canoll PD, Klein RS. How COVID-19 Affects the Brain. *JAMA Psychiatry*. 2021;78(6):682-683. doi:10.1001/jamapsychiatry.2021.0500
15. Parry AH, Wani AH, Yaseen M. Neurological Dysfunction in Coronavirus Disease-19 (COVID-19). *Acad Radiol*. 2020;27(9):1329-1330. doi:10.1016/j.acra.2020.05.024
16. Schwabenland M, Salié H, Tanevski J, et al. Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions. *Immunity*. 2021;54(7):1594-1610.e11. doi:10.1016/j.immuni.2021.06.002
17. Rogers JP, Watson CJ, Badenoch J, et al. Neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives. *J Neurol Neurosurg Psychiatry*. 2021;92(9):932-941. doi:10.1136/jnnp-2021-326405
18. Abbasi J. Researchers Investigate What COVID-19 Does to the Heart. *JAMA*. 2021;325(9):808-811. doi:10.1001/jama.2021.0107
19. COVID-19 as a Possible Cause of Myocarditis and Pericarditis. American College of Cardiology. Accessed September 27, 2021. <https://www.acc.org/latest-in-cardiology/articles/2021/02/05/19/37/http%3a%2f%2fwww.acc.org%2flatest-in-cardiology%2farticles%2f2021%2f02%2f05%2f19%2f37%2fcovid-19-as-a-possible-cause-of-myocarditis-and-pericarditis>
20. Bzeizi K, Abdulla M, Mohammed N, Alqamish J, Jamshidi N, Broering D. Effect of COVID-19 on liver abnormalities: a systematic review and meta-analysis. *Sci Rep*. 2021;11(1):10599. doi:10.1038/s41598-021-89513-9
21. Moon AM, Barritt AS. Elevated Liver Enzymes in Patients with COVID-19: Look, but Not Too Hard. *Dig Dis Sci*. Published online September 2, 2020:1-3. doi:10.1007/s10620-020-06585-9
22. Iqbal Z, Ho JH, Adam S, et al. Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK. *Atherosclerosis*. 2020;313:126-136. doi:10.1016/j.atherosclerosis.2020.09.008
23. Steenblock C, Richter S, Berger I, et al. Viral infiltration of pancreatic islets in patients with COVID-19. *Nat Commun*. 2021;12(1):3534. doi:10.1038/s41467-021-23886-3
24. Hayden MR. An Immediate and Long-Term Complication of COVID-19 May Be Type 2 Diabetes Mellitus: The Central Role of  $\beta$ -Cell Dysfunction, Apoptosis and Exploration of Possible Mechanisms. *Cells*. 2020;9(11):2475. doi:10.3390/cells9112475
25. Mukherjee S, Banerjee O, Singh S, Maji BK. COVID 19 could trigger global diabetes burden – A hypothesis. *Diabetes Metab Syndr*. 2020;14(5):963-964. doi:10.1016/j.dsx.2020.06.049
26. Wu C-T, Lidsky PV, Xiao Y, et al. SARS-CoV-2 infects human pancreatic  $\beta$  cells and elicits  $\beta$  cell impairment. *Cell Metab*. 2021;33(8):1565-1576.e5. doi:10.1016/j.cmet.2021.05.013
27. Legrand M, Bell S, Forni L, et al. Pathophysiology of COVID-19-associated acute kidney injury. *Nat Rev Nephrol*. Published online July 5, 2021:1-14. doi:10.1038/s41581-021-00452-0
28. Nugent J, Aklilu A, Yamamoto Y, et al. Assessment of Acute Kidney Injury and Longitudinal Kidney Function After Hospital Discharge Among Patients With and Without COVID-19. *JAMA Netw Open*. 2021;4(3):e211095. doi:10.1001/jamanetworkopen.2021.1095
29. Chen Z, Hu J, Liu L, et al. SARS-CoV-2 Causes Acute Kidney Injury by Directly Infecting Renal Tubules. *Front Cell Dev Biol*. 2021;9:1245. doi:10.3389/fcell.2021.664868
30. Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal–Oral Transmission. *Gastroenterology*. 2020;158(6):1518-1519. doi:10.1053/j.gastro.2020.02.054

31. Lehmann M, Allers K, Heldt C, et al. Human small intestinal infection by SARS-CoV-2 is characterized by a mucosal infiltration with activated CD8+ T cells. *Mucosal Immunol.* Published online August 21, 2021;1-12. doi:10.1038/s41385-021-00437-z
32. Zhang H, Kang Z, Gong H, et al. Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process. *Gut.* 2020;69(6):1010-1018. doi:10.1136/gutjnl-2020-320953
33. Pourbagheri-Sigaroodi A, Bashash D, Fateh F, Abolghasemi H. Laboratory findings in COVID-19 diagnosis and prognosis. *Clin Chim Acta Int J Clin Chem.* 2020;510:475-482. doi:10.1016/j.cca.2020.08.019
34. Zhang Z-L, Hou Y-L, Li D-T, Li F-Z. Laboratory findings of COVID-19: a systematic review and meta-analysis. *Scand J Clin Lab Invest.* 2020;80(6):441-447. doi:10.1080/00365513.2020.1768587
35. Xie Y, Wang Z, Liao H, Marley G, Wu D, Tang W. Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis. *BMC Infect Dis.* 2020;20(1):640. doi:10.1186/s12879-020-05371-2
36. Xiang Q, Feng Z, Diao B, et al. SARS-CoV-2 Induces Lymphocytopenia by Promoting Inflammation and Decimates Secondary Lymphoid Organs. *Front Immunol.* 2021;12:1292. doi:10.3389/fimmu.2021.661052
37. Rha M-S, Shin E-C. Activation or exhaustion of CD8+ T cells in patients with COVID-19. *Cell Mol Immunol.* Published online August 19, 2021;1-9. doi:10.1038/s41423-021-00750-4
38. Kusnadi A, Ramírez-Suástequi C, Fajardo V, et al. Severely ill patients with COVID-19 display impaired exhaustion features in SARS-CoV-2-reactive CD8+ T cells. *Sci Immunol.* 2021;6(55):eabe4782. doi:10.1126/sciimmunol.abe4782
39. Del Valle DM, Kim-Schulze S, Huang H-H, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat Med.* 2020;26(10):1636-1643. doi:10.1038/s41591-020-1051-9
40. What explains the non-respiratory symptoms seen in some COVID-19 patients? Chemical & Engineering News. Accessed September 28, 2021. <https://cen.acs.org/biological-chemistry/infectious-disease/What-explains-non-respiratory-symptoms-seen-in-some-COVID-19-patients/98/web/2020/04>
41. Protean manifestations of COVID-19: "Our ignorance is profound." Accessed September 28, 2021. <https://www.mdedge.com/chestphysician/article/220899/coronavirus-updates/protean-manifestations-covid-19-our-ignorance>
42. Jarrahi A, Ahluwalia M, Khodadadi H, et al. Neurological consequences of COVID-19: what have we learned and where do we go from here? *J Neuroinflammation.* 2020;17(1):286. doi:10.1186/s12974-020-01957-4
43. Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review. *JAMA Neurol.* 2020;77(8):1018-1027. doi:10.1001/jamaneurol.2020.2065
44. Qureshi AI, Baskett WI, Huang W, et al. Acute Ischemic Stroke and COVID-19. *Stroke.* 2021;52(3):905-912. doi:10.1161/STROKEAHA.120.031786
45. Riyahi S, Dev H, Behzadi A, et al. Pulmonary Embolism in Hospitalized Patients with COVID-19: A Multicenter Study. *Radiology.* Published online July 13, 2021;210777. doi:10.1148/radiol.2021210777
46. Zhong P, Xu J, Yang D, et al. COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms. *Signal Transduct Target Ther.* 2020;5(1):1-8. doi:10.1038/s41392-020-00373-7
47. Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. *Nat Rev Cardiol.* 2020;17(9):543-558. doi:10.1038/s41569-020-0413-9

48. Al-Sabah S, Al-Haddad M, Al-Youha S, Jamal M, Almazeedi S. COVID-19: Impact of obesity and diabetes on disease severity. *Clin Obes*. Published online October 20, 2020:e12414. doi:10.1111/cob.12414
49. Gao M, Piernas C, Astbury NM, et al. Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study. *Lancet Diabetes Endocrinol*. 2021;9(6):350-359. doi:10.1016/S2213-8587(21)00089-9
50. Jin Y, Ji W, Yang H, Chen S, Zhang W, Duan G. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. *Signal Transduct Target Ther*. 2020;5(1):1-13. doi:10.1038/s41392-020-00454-7
51. Green SJ. Covid-19 accelerates endothelial dysfunction and nitric oxide deficiency. *Microbes Infect*. 2020;22(4):149-150. doi:10.1016/j.micinf.2020.05.006
52. Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. *Eur J Epidemiol*. 2020;35(12):1123-1138. doi:10.1007/s10654-020-00698-1
53. CDC. Cases, Data, and Surveillance. Centers for Disease Control and Prevention. Published February 11, 2020. Accessed September 28, 2021. <https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html>
54. Covid IFR Analysis. Accessed September 28, 2021. <http://epimonitor.net/Covid-IFR-Analysis.htm>
55. Seoane B. A scaling approach to estimate the age-dependent COVID-19 infection fatality ratio from incomplete data. *PLOS ONE*. 2021;16(2):e0246831. doi:10.1371/journal.pone.0246831
56. Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev Microbiol*. 2021;19(3):141-154. doi:10.1038/s41579-020-00459-7
57. Xia L, Chen J, Friedemann T, et al. The Course of Mild and Moderate COVID-19 Infections—The Unexpected Long-Lasting Challenge. *Open Forum Infect Dis*. 2020;7(9). doi:10.1093/ofid/ofaa286
58. Han C, Duan C, Zhang S, et al. Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes. *Am J Gastroenterol*. Published online April 15, 2020:10.14309/ajg.0000000000000664. doi:10.14309/ajg.0000000000000664
59. CDC. Cases, Data, and Surveillance. Centers for Disease Control and Prevention. Published February 11, 2020. Accessed September 28, 2021. <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/burden.html>
60. Wu SL, Mertens AN, Crider YS, et al. Substantial underestimation of SARS-CoV-2 infection in the United States. *Nat Commun*. 2020;11(1):4507. doi:10.1038/s41467-020-18272-4
61. Irons NJ, Raftery AE. Estimating SARS-CoV-2 infections from deaths, confirmed cases, tests, and random surveys. *Proc Natl Acad Sci*. 2021;118(31). doi:10.1073/pnas.2103272118
62. Achaiah NC, Subbarajasetty SB, Shetty RM. RO and Re of COVID-19: Can We Predict When the Pandemic Outbreak will be Contained? *Indian J Crit Care Med Peer-Rev Off Publ Indian Soc Crit Care Med*. 2020;24(11):1125-1127. doi:10.5005/jp-journals-10071-23649
63. Ives AR, Bozzuto C. Estimating and explaining the spread of COVID-19 at the county level in the USA. *Commun Biol*. 2021;4(1):1-9. doi:10.1038/s42003-020-01609-6
64. Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature*. 2020;581(7807):215-220. doi:10.1038/s41586-020-2180-5
65. Yang J, Petitjean SJL, Koehler M, et al. Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor. *Nat Commun*. 2020;11(1):4541. doi:10.1038/s41467-020-18319-6
66. ACE2 angiotensin converting enzyme 2 [Homo sapiens (human)] - Gene - NCBI. Accessed September 28, 2021. <https://www.ncbi.nlm.nih.gov/gene/59272>
67. Samavati L, Uhal BD. ACE2, Much More Than Just a Receptor for SARS-COV-2. *Front Cell Infect Microbiol*. 2020;10:317. doi:10.3389/fcimb.2020.00317

68. Patel S, Rauf A, Khan H, Abu-Izneid T. Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. *Biomed Pharmacother*. 2017;94:317-325. doi:10.1016/j.biopha.2017.07.091
69. Romero CA, Orias M, Weir MR. Novel RAAS agonists and antagonists: clinical applications and controversies. *Nat Rev Endocrinol*. 2015;11(4):242-252. doi:10.1038/nrendo.2015.6
70. The Renin-Angiotensin-Aldosterone-System. TeachMePhysiology. Accessed September 28, 2021. <https://teachmephysiology.com/urinary-system/regulation/the-renin-angiotensin-aldosterone-system/>
71. Fountain JH, Lappin SL. Physiology, Renin Angiotensin System. In: *StatPearls*. StatPearls Publishing; 2021. Accessed September 28, 2021. <http://www.ncbi.nlm.nih.gov/books/NBK470410/>
72. Renin Angiotensin Aldosterone System - an overview | ScienceDirect Topics. Accessed September 28, 2021. <https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/renin-angiotensin-aldosterone-system>
73. Hamming I, Timens W, Bulthuis M, Lely A, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol*. 2004;203(2):631-637. doi:10.1002/path.1570
74. Tissue expression of ACE2 - Summary - The Human Protein Atlas. Accessed September 28, 2021. <https://www.proteinatlas.org/ENSG00000130234-ACE2/tissue>
75. The protein expression profile of ACE2 in human tissues. *Mol Syst Biol*. 2020;16(7):e9610. doi:10.15252/msb.20209610
76. Huang Y, Yang C, Xu X, Xu W, Liu S. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. *Acta Pharmacol Sin*. 2020;41(9):1141-1149. doi:10.1038/s41401-020-0485-4
77. Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. *Proc Natl Acad Sci*. 2020;117(21):11727-11734. doi:10.1073/pnas.2003138117
78. Xie Y, Karki CB, Du D, et al. Spike Proteins of SARS-CoV and SARS-CoV-2 Utilize Different Mechanisms to Bind With Human ACE2. *Front Mol Biosci*. 2020;7:392. doi:10.3389/fmolb.2020.591873
79. Syncytia formation by SARS-CoV-2-infected cells. *EMBO J*. 2020;39(23):e106267. doi:10.15252/embj.2020106267
80. Ma H, Zhu Z, Lin H, et al. Pyroptosis of syncytia formed by fusion of SARS-CoV-2 spike and ACE2-expressing cells. *Cell Discov*. 2021;7(1):1-4. doi:10.1038/s41421-021-00310-0
81. Xia B, Shen X, He Y, et al. SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target. *Cell Res*. 2021;31(8):847-860. doi:10.1038/s41422-021-00519-4
82. Nieto-Torres JL, Verdiá-Báguena C, Jimenez-Guardeño JM, et al. Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome. *Virology*. 2015;485:330-339. doi:10.1016/j.virol.2015.08.010
83. Minakshi R, Padhan K, Rehman S, Hassan MdI, Ahmad F. The SARS Coronavirus 3a protein binds calcium in its cytoplasmic domain. *Virus Res*. 2014;191:180-183. doi:10.1016/j.virusres.2014.08.001
84. Pan P, Shen M, Yu Z, et al. SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation. *Nat Commun*. 2021;12(1):4664. doi:10.1038/s41467-021-25015-6
85. Shah A. Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19. *Front Immunol*. 2020;11:1021. doi:10.3389/fimmu.2020.01021
86. Xu H, Chitre SA, Akinyemi IA, et al. *SARS-CoV-2 Viroporin Triggers the NLRP3 Inflammatory Pathway*; 2020:2020.10.27.357731. doi:10.1101/2020.10.27.357731
87. Olagnier D, Farahani E, Thyrsted J, et al. SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. *Nat Commun*. 2020;11(1):4938. doi:10.1038/s41467-020-18764-3

88. Bousquet J, Cristol J-P, Czarlewski W, et al. Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies. *Clin Transl Allergy*. 2020;10(1):58. doi:10.1186/s13601-020-00362-7
89. Cuadrado A, Pajares M, Benito C, et al. Can Activation of NRF2 Be a Strategy against COVID-19? *Trends Pharmacol Sci*. 2020;41(9):598-610. doi:10.1016/j.tips.2020.07.003
90. Bousquet J, Czarlewski W, Zuberbier T, et al. Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19. *Int Arch Allergy Immunol*. 2021;182(4):324-338. doi:10.1159/000514204
91. McCarthy CG, Wilczynski S, Wenceslau CF, Webb RC. A new storm on the horizon in COVID-19: Bradykinin-induced vascular complications. *Vascul Pharmacol*. 2021;137:106826. doi:10.1016/j.vph.2020.106826
92. Lei Y, Zhang J, Schiavon CR, et al. SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2. *Circ Res*. 2021;128(9):1323-1326. doi:10.1161/CIRCRESAHA.121.318902
93. Silhol F, Sarlon G, Deharo J-C, Vaïsse B. Downregulation of ACE2 induces overstimulation of the renin–angiotensin system in COVID-19: should we block the renin–angiotensin system? *Hypertens Res*. 2020;43(8):854-856. doi:10.1038/s41440-020-0476-3
94. Ciulli MM. SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs. *Hypertens Res*. 2020;43(9):985-986. doi:10.1038/s41440-020-0488-z
95. Lu J, Sun PD. High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity. *J Biol Chem*. 2020;295(52):18579-18588. doi:10.1074/jbc.RA120.015303
96. Osman W, Fahdi FA, Salmi IA, Khalili HA, Gokhale A, Khamis F. Serum Calcium and Vitamin D levels: Correlation with severity of COVID-19 in hospitalized patients in Royal Hospital, Oman. *Int J Infect Dis*. 2021;107:153-163. doi:10.1016/j.ijid.2021.04.050
97. Raesi A, Saedi Dezaki E, Moosapour H, et al. Hypocalcemia in Covid-19: A Prognostic Marker for Severe Disease. *Iran J Pathol*. 2021;16(2):144-153. doi:10.30699/IJP.2020.130491.2442
98. Bennouar S, Cherif AB, Kessira A, Bennouar D-E, Abdi S. Vitamin D Deficiency and Low Serum Calcium as Predictors of Poor Prognosis in Patients with Severe COVID-19. *J Am Coll Nutr*. 2021;40(2):104-110. doi:10.1080/07315724.2020.1856013
99. Blaes N, Girolami J-P. Targeting the “Janus face” of the B2-bradykinin receptor. *Expert Opin Ther Targets*. 2013;17. doi:10.1517/14728222.2013.827664
100. Siragy H, Jaffa A, Margolius H. Bradykinin B2 receptor modulates renal prostaglandin E2 and nitric oxide. *Hypertension*. Published online 1997. doi:10.1161/01.HYP.29.3.757
101. Pyne NJ, Tolan D, Pyne S. Bradykinin stimulates cAMP synthesis via mitogen-activated protein kinase-dependent regulation of cytosolic phospholipase A2 and prostaglandin E2 release in airway smooth muscle. *Biochem J*. 1997;328(Pt 2):689-694. Accessed September 28, 2021. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1218972/>
102. Dixon BS, Breckon R, Fortune J, Sutherland E, Simon FR, Anderson RJ. Bradykinin activates protein kinase C in cultured cortical collecting tubular cells. *Am J Physiol-Ren Physiol*. 1989;257(5):F808-F817. doi:10.1152/ajprenal.1989.257.5.F808
103. Schini VB, Boulanger C, Regoli D, Vanhoutte PM. Bradykinin stimulates the production of cyclic GMP via activation of B2 kinin receptors in cultured porcine aortic endothelial cells. *J Pharmacol Exp Ther*. 1990;252(2):581-585.
104. Gholamreza-Fahimi E, Bisha M, Hahn J, et al. Cyclooxygenase activity in bradykinin-induced dermal extravasation. A study in mice and humans. *Biomed Pharmacother*. 2020;123:109797. doi:10.1016/j.biopha.2019.109797
105. Fong P, Stafforini DM, Brown NJ, Pretorius M. Increased blood flow induces oxidative stress through an endothelium- and nitric oxide-independent mechanism. *Free Radic Biol Med*. 2010;49(2):301-305. doi:10.1016/j.freeradbiomed.2010.04.023

106. Portilla D, Morrissey J, Morrison AR. Bradykinin-activated membrane-associated phospholipase C in Madin-Darby canine kidney cells. *J Clin Invest.* 1988;81(6):1896-1902. doi:10.1172/JCI113536
107. Cruzblanca H, Koh D-S, Hille B. Bradykinin inhibits M current via phospholipase C and Ca<sup>2+</sup> release from IP<sub>3</sub>-sensitive Ca<sup>2+</sup> stores in rat sympathetic neurons. *Proc Natl Acad Sci.* 1998;95(12):7151-7156. doi:10.1073/pnas.95.12.7151
108. Bradykinin - an overview | ScienceDirect Topics. Accessed September 28, 2021. <https://www.sciencedirect.com/topics/chemistry;bradykinin>
109. Banerjee A, Czinn SJ, Reiter RJ, Blanchard TG. Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19. *Life Sci.* 2020;255:117842. doi:10.1016/j.lfs.2020.117842
110. Danta CC. SARS-CoV-2, Hypoxia, and Calcium Signaling: The Consequences and Therapeutic Options. *ACS Pharmacol Transl Sci.* 2021;4(1):400-402. doi:10.1021/acsphtsci.0c00219
111. Shaban MS, Müller C, Mayr-Buro C, et al. Multi-level inhibition of coronavirus replication by chemical ER stress. *Nat Commun.* 2021;12(1):5536. doi:10.1038/s41467-021-25551-1
112. Sabirli R, Koseler A, Goren T, Turkcuer I, Kurt O. High GRP78 levels in Covid-19 infection: A case-control study. *Life Sci.* 2021;265:118781. doi:10.1016/j.lfs.2020.118781
113. Dubiella U, Seybold H, Durian G, et al. Calcium-dependent protein kinase/NADPH oxidase activation circuit is required for rapid defense signal propagation. *Proc Natl Acad Sci.* 2013;110(21):8744-8749. doi:10.1073/pnas.1221294110
114. Görlich A, Bertram K, Hudecova S, Krizanova O. Calcium and ROS: A mutual interplay. *Redox Biol.* 2015;6:260-271. doi:10.1016/j.redox.2015.08.010
115. Feno S, Butera G, Vecellio Reane D, Rizzuto R, Raffaello A. Crosstalk between Calcium and ROS in Pathophysiological Conditions. *Oxid Med Cell Longev.* 2019;2019:e9324018. doi:10.1155/2019/9324018
116. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. *Am J Physiol.* 1996;271(5 Pt 1):C1424-1437. doi:10.1152/ajpcell.1996.271.5.C1424
117. PACHER P, BECKMAN JS, LIAUDET L. Nitric Oxide and Peroxynitrite in Health and Disease. *Physiol Rev.* 2007;87(1):315-424. doi:10.1152/physrev.00029.2006
118. Radi R. Oxygen radicals, nitric oxide, and peroxynitrite: Redox pathways in molecular medicine. *Proc Natl Acad Sci.* 2018;115(23):5839-5848. doi:10.1073/pnas.1804932115
119. Guzik TJ, West NEJ, Pillai R, Taggart DP, Channon KM. Nitric Oxide Modulates Superoxide Release and Peroxynitrite Formation in Human Blood Vessels. *Hypertension.* 2002;39(6):1088-1094. doi:10.1161/01.HYP.0000018041.48432.B5
120. Roe ND, Ren J. Nitric oxide synthase uncoupling: A therapeutic target in cardiovascular diseases. *Vascul Pharmacol.* 2012;57(5):168-172. doi:10.1016/j.vph.2012.02.004
121. Luo S, Lei H, Qin H, Xia Y. Molecular mechanisms of endothelial NO synthase uncoupling. *Curr Pharm Des.* 2014;20(22):3548-3553. doi:10.2174/13816128113196660746
122. Chen W, Druhan LJ, Chen C-A, et al. Peroxynitrite induces destruction of the tetrahydrobiopterin and heme in endothelial nitric oxide synthase: transition from reversible to irreversible enzyme inhibition. *Biochemistry.* 2010;49(14):3129-3137. doi:10.1021/bi9016632
123. Ozdemir B, Yazici A. Could the decrease in the endothelial nitric oxide (NO) production and NO bioavailability be the crucial cause of COVID-19 related deaths? *Med Hypotheses.* 2020;144:109970. doi:10.1016/j.mehy.2020.109970
124. Guan SP, Seet RCS, Kennedy BK. Does eNOS derived nitric oxide protect the young from severe COVID-19 complications? *Ageing Res Rev.* 2020;64:101201. doi:10.1016/j.arr.2020.101201
125. Nitric Oxide - an overview | ScienceDirect Topics. Accessed September 28, 2021. <https://www.sciencedirect.com/topics/medicine-and-dentistry/nitric-oxide>
126. Levine AB, Punihale D, Levine TB. Characterization of the Role of Nitric Oxide and Its Clinical Applications. *Cardiology.* 2012;122(1):55-68. doi:10.1159/000338150

127. Rosselli M, Keller PJ, Dubey RK. Role of nitric oxide in the biology, physiology and pathophysiology of reproduction. *Hum Reprod Update*. 1998;4(1):3-24. doi:10.1093/humupd/4.1.3
128. Mel A de. Potential roles of nitric oxide in COVID-19: A perspective. *Integr Mol Med*. 2020;7(3). doi:10.15761/IMM.1000403
129. Ricciardolo FLM, Bertolini F, Carriero V, Högman M. Nitric oxide's physiologic effects and potential as a therapeutic agent against COVID-19. *J Breath Res*. 2020;15(1):014001. doi:10.1088/1752-7163/abc302
130. Åkerström S, Gunalan V, Keng CT, Tan Y-J, Mirazimi A. Dual effect of nitric oxide on SARS-CoV replication: Viral RNA production and palmitoylation of the S protein are affected. *Virology*. 2009;395(1):1-9. doi:10.1016/j.virol.2009.09.007
131. Hadi HA, Carr CS, Al Suwaidi J. Endothelial Dysfunction: Cardiovascular Risk Factors, Therapy, and Outcome. *Vasc Health Risk Manag*. 2005;1(3):183-198. Accessed September 28, 2021. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1993955/>
132. Bonetti PO, Lerman LO, Lerman A. Endothelial Dysfunction. *Arterioscler Thromb Vasc Biol*. 2003;23(2):168-175. doi:10.1161/01.ATV.0000051384.43104.FC
133. Endothelial Dysfunction in Diabetes | Diabetes Care. Accessed September 28, 2021. [https://care.diabetesjournals.org/content/34/Supplement\\_2/S285](https://care.diabetesjournals.org/content/34/Supplement_2/S285)
134. Patel PD, Velazquez JL, Arora RR. Endothelial dysfunction in African-Americans. *Int J Cardiol*. 2009;132(2):157-172. doi:10.1016/j.ijcard.2008.10.007
135. Kalinowski L, Dobrucki IT, Malinski T. Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases. *Circulation*. 2004;109(21):2511-2517. doi:10.1161/01.CIR.0000129087.81352.7A
136. Ungvari Z, Tarantini S, Kiss T, et al. Endothelial dysfunction and angiogenesis impairment in the ageing vasculature. *Nat Rev Cardiol*. 2018;15(9):555-565. doi:10.1038/s41569-018-0030-z
137. Reusch N, De Domenico E, Bonaguro L, et al. Neutrophils in COVID-19. *Front Immunol*. 2021;12:952. doi:10.3389/fimmu.2021.652470
138. Cavalcante-Silva LHA, Carvalho DCM, Lima É de A, et al. Neutrophils and COVID-19: The road so far. *Int Immunopharmacol*. 2021;90:107233. doi:10.1016/j.intimp.2020.107233
139. Knoll R, Schultze JL, Schulte-Schrepping J. Monocytes and Macrophages in COVID-19. *Front Immunol*. 2021;12:2952. doi:10.3389/fimmu.2021.720109
140. Meidaninikjeh S, Sabouni N, Marzouni HZ, Bengar S, Khalili A, Jafari R. Monocytes and macrophages in COVID-19: Friends and foes. *Life Sci*. 2021;269:119010. doi:10.1016/j.lfs.2020.119010
141. Phagocytes - an overview | ScienceDirect Topics. Accessed September 28, 2021. <https://www.sciencedirect.com/topics/immunology-and-microbiology/phagocytes>
142. Respiratory Burst - an overview | ScienceDirect Topics. Accessed September 28, 2021. <https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/respiratory-burst>
143. Superoxide Dismutase - an overview | ScienceDirect Topics. Accessed September 28, 2021. <https://www.sciencedirect.com/topics/neuroscience/superoxide-dismutase>
144. Myeloperoxidase - an overview | ScienceDirect Topics. Accessed September 28, 2021. <https://www.sciencedirect.com/topics/medicine-and-dentistry/myeloperoxidase>
145. Spickett CM, Jerlich A, Panasenko OM, et al. The reactions of hypochlorous acid, the reactive oxygen species produced by myeloperoxidase, with lipids. *Acta Biochim Pol*. 2000;47(4):889-899.
146. Hypochlorous\_acid. Accessed September 28, 2021. [https://www.bionity.com/en/encyclopedia/Hypochlorous\\_acid.html](https://www.bionity.com/en/encyclopedia/Hypochlorous_acid.html)
147. Neutrophil extracellular traps in immunity and disease | Nature Reviews Immunology. Accessed September 28, 2021. <https://www.nature.com/articles/nri.2017.105>
148. Kaplan MJ, Radic M. Neutrophil extracellular traps (NETs): Double-edged swords of innate immunity. *J Immunol Baltim Md 1950*. 2012;189(6):2689-2695. doi:10.4049/jimmunol.1201719

149. Gillot C, Favresse J, Mullier F, Lecompte T, Dogné J-M, Douxfils J. NETosis and the Immune System in COVID-19: Mechanisms and Potential Treatments. *Front Pharmacol.* 2021;12:1999. doi:10.3389/fphar.2021.708302
150. Arcanjo A, Logullo J, Menezes CCB, et al. The emerging role of neutrophil extracellular traps in severe acute respiratory syndrome coronavirus 2 (COVID-19). *Sci Rep.* 2020;10(1):19630. doi:10.1038/s41598-020-76781-0
151. Middleton EA, He X-Y, Denorme F, et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. *Blood.* 2020;136(10):1169-1179. doi:10.1182/blood.2020007008
152. Schönrich G, Raftery MJ, Samstag Y. Devilishly radical NETwork in COVID-19: Oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression. *Adv Biol Regul.* 2020;77:100741. doi:10.1016/j.jbior.2020.100741
153. Goud PT, Bai D, Abu-Soud HM. A Multiple-Hit Hypothesis Involving Reactive Oxygen Species and Myeloperoxidase Explains Clinical Deterioration and Fatality in COVID-19. *Int J Biol Sci.* 2021;17(1):62-72. doi:10.7150/ijbs.51811
154. Edeas M, Saleh J, Peysonnaux C. Iron: Innocent bystander or vicious culprit in COVID-19 pathogenesis? *Int J Infect Dis.* 2020;97:303-305. doi:10.1016/j.ijid.2020.05.110
155. Habib HM, Ibrahim S, Zaim A, Ibrahim WH. The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators. *Biomed Pharmacother.* 2021;136:111228. doi:10.1016/j.bioph.2021.111228
156. Rahman A, Tabassum T, Araf Y, Al Nahid A, Ullah MdA, Hosen MJ. Silent hypoxia in COVID-19: pathomechanism and possible management strategy. *Mol Biol Rep.* Published online April 23, 2021:1-7. doi:10.1007/s11033-021-06358-1
157. Tobin MJ, Laghi F, Jubran A. Why COVID-19 Silent Hypoxemia Is Baffling to Physicians. *Am J Respir Crit Care Med.* 2020;202(3):356-360. doi:10.1164/rccm.202006-2157CP
158. Kehrer JP. The Haber-Weiss reaction and mechanisms of toxicity. *Toxicology.* 2000;149(1):43-50. doi:10.1016/s0300-483x(00)00231-6
159. Wardman P, Candeias LP. Fenton Chemistry: An Introduction. *Radiat Res.* 1996;145(5):523-531. doi:10.2307/3579270
160. Sharpe MA, Robb SJ, Clark JB. Nitric oxide and Fenton/Haber-Weiss chemistry: nitric oxide is a potent antioxidant at physiological concentrations. *J Neurochem.* 2003;87(2):386-394. doi:10.1046/j.1471-4159.2003.02001.x
161. Kanti Das T, Wati MR, Fatima-Shad K. Oxidative Stress Gated by Fenton and Haber Weiss Reactions and Its Association With Alzheimer's Disease. *Arch Neurosci.* 2015;2(2). doi:10.5812/archneurosci.20078
162. Barciszewska A-M. Elucidating of oxidative distress in COVID-19 and methods of its prevention. *Chem Biol Interact.* 2021;344:109501. doi:10.1016/j.cbi.2021.109501
163. Ntyonga-Pono M-P. COVID-19 infection and oxidative stress: an under-explored approach for prevention and treatment? *Pan Afr Med J.* 2020;35(Suppl 2):12. doi:10.11604/pamj.2020.35.2.22877
164. Forcados GE, Muhammad A, Oladipo OO, Makama S, Meseko CA. Metabolic Implications of Oxidative Stress and Inflammatory Process in SARS-CoV-2 Pathogenesis: Therapeutic Potential of Natural Antioxidants. *Front Cell Infect Microbiol.* 2021;11:457. doi:10.3389/fcimb.2021.654813
165. Cumpstey AF, Clark AD, Santolini J, Jackson AA, Feelisch M. COVID-19: A Redox Disease—What a Stress Pandemic Can Teach Us About Resilience and What We May Learn from the Reactive Species Interactome About Its Treatment. *Antioxid Redox Signal.* Published online June 29, 2021. doi:10.1089/ars.2021.0017
166. Hydroxyl Radical - an overview | ScienceDirect Topics. Accessed September 28, 2021. <https://www.sciencedirect.com/topics/earth-and-planetary-sciences/hydroxyl-radical>

167. Gligorovski S, Strekowski R, Barbat S, Vione D. Environmental Implications of Hydroxyl Radicals ( $\bullet\text{OH}$ ). *Chem Rev.* 2015;115(24):13051-13092. doi:10.1021/cr500310b
168. Lyngsie G, Krumina L, Tunlid A, Persson P. Generation of hydroxyl radicals from reactions between a dimethoxyhydroquinone and iron oxide nanoparticles. *Sci Rep.* 2018;8(1):10834. doi:10.1038/s41598-018-29075-5
169. Takeda K, Fujisawa K, Nojima H, Kato R, Ueki R, Sakugawa H. Hydroxyl radical generation with a high power ultraviolet light emitting diode (UV-LED) and application for determination of hydroxyl radical reaction rate constants. *J Photochem Photobiol Chem.* 2017;340:8-14. doi:10.1016/j.jphotochem.2017.02.020
170. Kord Forooshani P, Pinnaratip R, Polega E, et al. Hydroxyl Radical Generation through the Fenton-like Reaction of Hematin- and Catechol-Functionalized Microgels. *Chem Mater.* 2020;32(19):8182-8194. doi:10.1021/acs.chemmater.0c01551
171. Deng Y, Zhao R. Advanced Oxidation Processes (AOPs) in Wastewater Treatment. *Curr Pollut Rep.* 2015;1(3):167-176. doi:10.1007/s40726-015-0015-z
172. Hypoxanthine - an overview | ScienceDirect Topics. Accessed September 28, 2021. <https://www.sciencedirect.com/topics/chemistry/hypoxanthine>
173. Dowell FJ, Hamilton CA, McMurray J, Reid JL. Effects of a xanthine oxidase/hypoxanthine free radical and reactive oxygen species generating system on endothelial function in New Zealand white rabbit aortic rings. *J Cardiovasc Pharmacol.* 1993;22(6):792-797. doi:10.1097/00005344-199312000-00003
174. Fig. 1. Generation of superoxide by xanthine-hypoxanthine oxidase and... ResearchGate. Accessed September 28, 2021. [https://www.researchgate.net/figure/Generation-of-superoxide-by-xanthine-hypoxanthine-oxidase-and-NADH-SMP-systems-a-The\\_fig1\\_7927959](https://www.researchgate.net/figure/Generation-of-superoxide-by-xanthine-hypoxanthine-oxidase-and-NADH-SMP-systems-a-The_fig1_7927959)
175. Granger DN. Role of xanthine oxidase and granulocytes in ischemia-reperfusion injury. *Am J Physiol.* 1988;255(6 Pt 2):H1269-1275. doi:10.1152/ajpheart.1988.255.6.H1269
176. Mao H, Yang A, Zhao Y, Lei L, Li H. Succinate Supplement Elicited "Pseudohypoxia" Condition to Promote Proliferation, Migration, and Osteogenesis of Periodontal Ligament Cells. *Stem Cells Int.* 2020;2020:e2016809. doi:10.1155/2020/2016809
177. Lukyanova LD, Kirova YI. Mitochondria-controlled signaling mechanisms of brain protection in hypoxia. *Front Neurosci.* 2015;9:320. doi:10.3389/fnins.2015.00320
178. Messner KR, Imlay JA. Mechanism of superoxide and hydrogen peroxide formation by fumarate reductase, succinate dehydrogenase, and aspartate oxidase. *J Biol Chem.* 2002;277(45):42563-42571. doi:10.1074/jbc.M204958200
179. Quinlan CL, Orr AL, Perevoshchikova IV, Treberg JR, Ackrell BA, Brand MD. Mitochondrial Complex II Can Generate Reactive Oxygen Species at High Rates in Both the Forward and Reverse Reactions. *J Biol Chem.* 2012;287(32):27255-27264. doi:10.1074/jbc.M112.374629
180. Cowled P, Fitridge R. Pathophysiology of Reperfusion Injury. In: Fitridge R, Thompson M, eds. *Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists.* University of Adelaide Press; 2011. Accessed September 28, 2021. <http://www.ncbi.nlm.nih.gov/books/NBK534267/>
181. Sun Z-Y, Xia H-G, Zhu D-Q, Deng L-M, Zhu P-Z, Wang D-B. Clinical significance of mechanical ventilation on ischemic-reperfusion injury caused by lung chest trauma and VEGF expression levels in peripheral blood. *Exp Ther Med.* 2017;14(3):2531-2535. doi:10.3892/etm.2017.4825
182. Gielis JF, Beckers PAJ, Briedé JJ, Cos P, Schil PEV. Oxidative and nitrosative stress during pulmonary ischemia-reperfusion injury: from the lab to the OR. *Ann Transl Med.* 2017;5(6):4-4. doi:10.21037/atm.2017.03.32
183. Wu N-C, Liao F-T, Cheng H, Sung S-H, Yang Y-C, Wang J-J. Intravenous superoxide dismutase as a protective agent to prevent impairment of lung function induced by high tidal volume ventilation. *BMC Pulm Med.* 2017;17:105. doi:10.1186/s12890-017-0448-9

184. Lipid Peroxidation - an overview | ScienceDirect Topics. Accessed September 28, 2021. <https://www.sciencedirect.com/topics/neuroscience/lipid-peroxidation>
185. Ayala A, Muñoz MF, Argüelles S. Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal. *Oxid Med Cell Longev*. 2014;2014:360438. doi:10.1155/2014/360438
186. Binder CJ, Papac-Milicevic N, Witztum JL. Innate sensing of oxidation-specific epitopes in health and disease. *Nat Rev Immunol*. 2016;16(8):485-497. doi:10.1038/nri.2016.63
187. Leibundgut G, Witztum JL, Tsimikas S. Oxidation-specific epitopes and immunological responses: Translational biotherapeutic implications for atherosclerosis. *Curr Opin Pharmacol*. 2013;13(2):10.1016/j.coph.2013.02.005. doi:10.1016/j.coph.2013.02.005
188. Miller YI, Choi S-H, Wiesner P, et al. Oxidation-Specific Epitopes Are Danger-Associated Molecular Patterns Recognized by Pattern Recognition Receptors of Innate Immunity. *Circ Res*. 2011;108(2):235-248. doi:10.1161/CIRCRESAHA.110.223875
189. Zhivaki D, Kagan JC. Innate immune detection of lipid oxidation as a threat assessment strategy. *Nat Rev Immunol*. Published online September 21, 2021:1-9. doi:10.1038/s41577-021-00618-8
190. Macdonald J, Galley HF, Webster NR. Oxidative stress and gene expression in sepsis. *Br J Anaesth*. 2003;90(2):221-232. doi:10.1093/bja/aeg034
191. Mantzaris K, Tsolaki V, Zakynthinos E. Role of Oxidative Stress and Mitochondrial Dysfunction in Sepsis and Potential Therapies. *Oxid Med Cell Longev*. 2017;2017:e5985209. doi:10.1155/2017/5985209
192. Toufekkoula C, Papadakis V, Tsaganos T, et al. Compartmentalization of lipid peroxidation in sepsis by multidrug-resistant gram-negative bacteria: experimental and clinical evidence. *Crit Care*. 2013;17(1):R6. doi:10.1186/cc11930
193. Dominic P, Ahmad J, Bhandari R, et al. Decreased availability of nitric oxide and hydrogen sulfide is a hallmark of COVID-19. *Redox Biol*. 2021;43:101982. doi:10.1016/j.redox.2021.101982
194. Yang M, Lai CL. SARS-CoV-2 infection: can ferroptosis be a potential treatment target for multiple organ involvement? *Cell Death Discov*. 2020;6(1):1-6. doi:10.1038/s41420-020-00369-w
195. Jacobs W, Lammens M, Kerckhofs A, et al. Fatal lymphocytic cardiac damage in coronavirus disease 2019 (COVID-19): autopsy reveals a ferroptosis signature. *ESC Heart Fail*. 2020;7(6):3772-3781. doi:10.1002/eHF.2.12958
196. Tavakol S, Seifalian AM. Vitamin E at a high dose as an anti-ferroptosis drug and not just a supplement for COVID-19 treatment. *Biotechnol Appl Biochem*. n/a(n/a). doi:10.1002/bab.2176
197. Sonnweber T, Boehm A, Sahanic S, et al. Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and poor patients' performance: a prospective observational cohort study. *Respir Res*. 2020;21(1):276. doi:10.1186/s12931-020-01546-2
198. Žarković N, Orešovec B, Milković L, et al. Preliminary Findings on the Association of the Lipid Peroxidation Product 4-Hydroxy-2-Nonenal with the Lethal Outcome of Aggressive COVID-19. *Antioxidants*. 2021;10(9):1341. doi:10.3390/antiox10091341
199. Mehri F, Rahbar AH, Ghane ET, Souri B, Esfahani M. The comparison of oxidative markers between Covid-19 patients and healthy subjects. *Arch Med Res*. Published online June 7, 2021. doi:10.1016/j.arcmed.2021.06.004
200. Cao Z, Xia H, Rajsbaum R, Xia X, Wang H, Shi P-Y. Ubiquitination of SARS-CoV-2 ORF7a promotes antagonism of interferon response. *Cell Mol Immunol*. 2021;18(3):746-748. doi:10.1038/s41423-020-00603-6
201. Zhang H, Zheng H, Zhu J, et al. Ubiquitin-Modified Proteome of SARS-CoV-2-Infected Host Cells Reveals Insights into Virus–Host Interaction and Pathogenesis. *J Proteome Res*. Published online March 5, 2021:acs.jproteome.0c00758. doi:10.1021/acs.jproteome.0c00758
202. Shi H, Zuo Y, Navaz S, et al. Endothelial cell-activating antibodies in COVID-19. *MedRxiv Prepr Serv Health Sci*. Published online July 9, 2021:2021.01.18.21250041. doi:10.1101/2021.01.18.21250041

203. Chang R, Mamun A, Dominic A, Le N-T. SARS-CoV-2 Mediated Endothelial Dysfunction: The Potential Role of Chronic Oxidative Stress. *Front Physiol*. 2021;11:1752. doi:10.3389/fphys.2020.605908
204. Mei ZW, van Wijk XMR, Pham HP, Marin MJ. Role of von Willebrand Factor in COVID-19 Associated Coagulopathy. *J Appl Lab Med*. 2021;6(5):1305-1315. doi:10.1093/jalm/jfab042
205. Mancini I, Baronciani L, Artoni A, et al. The ADAMTS13-von Willebrand factor axis in COVID-19 patients. *J Thromb Haemost JTH*. 2021;19(2):513-521. doi:10.1111/jth.15191
206. Ladikou EE, Sivaloganathan H, Milne KM, et al. Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19? *Clin Med*. 2020;20(5):e178-e182. doi:10.7861/clinmed.2020-0346
207. Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis*. 2020;100:327-332. doi:10.1016/j.ijid.2020.09.016
208. Gebremeskel S, Schanin J, Coyle KM, et al. Mast Cell and Eosinophil Activation Are Associated With COVID-19 and TLR-Mediated Viral Inflammation: Implications for an Anti-Siglec-8 Antibody. *Front Immunol*. 2021;12:641. doi:10.3389/fimmu.2021.650331
209. Java A, Apicelli AJ, Liszewski MK, et al. The complement system in COVID-19: friend and foe? *JCI Insight*. 5(15):e140711. doi:10.1172/jci.insight.140711
210. Noris M, Benigni A, Remuzzi G. The case of complement activation in COVID-19 multiorgan impact. *Kidney Int*. 2020;98(2):314-322. doi:10.1016/j.kint.2020.05.013
211. Holter JC, Pischke SE, Boer E de, et al. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. *Proc Natl Acad Sci*. 2020;117(40):25018-25025. doi:10.1073/pnas.2010540117
212. Chouaki Benmansour N, Carvelli J, Vivier E. Complement cascade in severe forms of COVID-19: Recent advances in therapy. *Eur J Immunol*. 2021;51(7):1652-1659. doi:10.1002/eji.202048959
213. López-Pedrera C, Barroja N, Jimenez-Gomez Y, Collantes-Estevez E, Aguirre MA, Cuadrado MJ. Oxidative stress in the pathogenesis of atherothrombosis associated with anti-phospholipid syndrome and systemic lupus erythematosus: new therapeutic approaches. *Rheumatol Oxf Engl*. 2016;55(12):2096-2108. doi:10.1093/rheumatology/kew054
214. Farris AD, Guthridge JM. Overlapping B cell pathways in severe COVID-19 and lupus. *Nat Immunol*. 2020;21(12):1478-1480. doi:10.1038/s41590-020-00822-z
215. MacDonald L, Alivernini S, Tolusso B, et al. COVID-19 and RA share an SPP1 myeloid pathway that drives PD-L1<sup>+</sup> neutrophils and CD14<sup>+</sup> monocytes. *JCI Insight*. 2021;6(13). doi:10.1172/jci.insight.147413
216. Schett G, Manger B, Simon D, Caporali R. COVID-19 revisiting inflammatory pathways of arthritis. *Nat Rev Rheumatol*. 2020;16(8):465-470. doi:10.1038/s41584-020-0451-z
217. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. *Nat Med*. 2021;27(4):601-615. doi:10.1038/s41591-021-01283-z
218. Proal AD, VanElzakker MB. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. *Front Microbiol*. 2021;12:1494. doi:10.3389/fmicb.2021.698169
219. Paul BD, Lemle MD, Komaroff AL, Snyder SH. Redox imbalance links COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome. *Proc Natl Acad Sci*. 2021;118(34). doi:10.1073/pnas.2024358118
220. Pall M. The NO/ONOO-Vicious Cycle Mechanism as the Cause of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. *Chronic Fatigue Syndr Symptoms Causes Prev*. Published online January 1, 2009.
221. Luo M, Cao S, Wei L, et al. Intubation, mortality, and risk factors in critically ill Covid-19 patients: A pilot study. *J Clin Anesth*. 2020;67:110039. doi:10.1016/j.jclinane.2020.110039

222. Tandon A, Pandey L. COVID-19, steroids, and mucormycosis: What an ophthalmologist should know. *Indian J Ophthalmol.* 2021;69(7):1970. doi:10.4103/ijo.IJO\_1143\_21
223. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. *N Engl J Med.* 2021;385(9):777-789. doi:10.1056/NEJMoa2103417
224. Free radicals: What are they and why should nurses care about them? American Nurse. Published April 11, 2011. Accessed September 28, 2021. <https://www.myamericannurse.com/free-radicals-what-are-they-and-why-should-nurses-care-about-them/>
225. Ahsan H, Ali A, Ali R. Oxygen free radicals and systemic autoimmunity. *Clin Exp Immunol.* 2003;131(3):398-404. doi:10.1046/j.1365-2249.2003.02104.x
226. 8.2: Generation of Free Radicals in the Body. Medicine LibreTexts. Published July 29, 2016. Accessed September 28, 2021.  
[https://med.libretexts.org/Bookshelves/Nutrition/Book%3A\\_An\\_Introduction\\_to\\_Nutrition\\_\(Zimmermann\)/08%3A\\_Nutrients\\_Important\\_as\\_Antioxidants/8.02%3A\\_Generation\\_of\\_Free\\_Radicals\\_in\\_the\\_Body](https://med.libretexts.org/Bookshelves/Nutrition/Book%3A_An_Introduction_to_Nutrition_(Zimmermann)/08%3A_Nutrients_Important_as_Antioxidants/8.02%3A_Generation_of_Free_Radicals_in_the_Body)
227. Daiber A, Oelze M, Daub S, et al. Vascular Redox Signaling, Redox Switches in Endothelial Nitric Oxide Synthase (eNOS Uncoupling), and Endothelial Dysfunction. In: Laher I, ed. *Systems Biology of Free Radicals and Antioxidants*. Springer; 2014:1177-1211. doi:10.1007/978-3-642-30018-9\_48
228. Gladyshev VN. The Free Radical Theory of Aging Is Dead. Long Live the Damage Theory! *Antioxid Redox Signal.* 2014;20(4):727-731. doi:10.1089/ars.2013.5228
229. Auld SC, Caridi-Scheible M, Blum JM, et al. ICU and ventilator mortality among critically ill adults with COVID-19. *medRxiv.* doi:10.1101/2020.04.23.20076737
230. Tsikala Vafea M, Zhang R, Kalligeros M, Mylona EK, Shehadeh F, Mylonakis E. Mortality in mechanically ventilated patients with COVID-19: a systematic review. *Expert Rev Med Devices.* 2021;18(5):457-471. doi:10.1080/17434440.2021.1915764
231. Boscolo A, Pasin L, Sella N, et al. Outcomes of COVID-19 patients intubated after failure of non-invasive ventilation: a multicenter observational study. *Sci Rep.* 2021;11(1):17730. doi:10.1038/s41598-021-96762-1
232. Oliveira E, Parikh A, Lopez-Ruiz A, et al. ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida. *PLOS ONE.* 2021;16(3):e0249038. doi:10.1371/journal.pone.0249038
233. Parish AJ, West JR, Caputo ND, et al. Early Intubation and Increased Coronavirus Disease 2019 Mortality: A Propensity Score-Matched Retrospective Cohort Study. *Crit Care Explor.* 2021;3(6). doi:10.1097/CCE.0000000000000452
234. Junghanns FB. MATH+ Protocol. FLCCC | Front Line COVID-19 Critical Care Alliance. Accessed September 28, 2021. <https://covid19criticalcare.com/covid-19-protocols/math-plus-protocol/>
235. Lammi C, Arnoldi A. Food-derived antioxidants and COVID-19. *J Food Biochem.* 2021;45(1):e13557. doi:10.1111/jfbc.13557
236. Źukowski P, Maciejczyk M, Matczuk J, et al. Effect of N-Acetylcysteine on Antioxidant Defense, Oxidative Modification, and Salivary Gland Function in a Rat Model of Insulin Resistance. *Oxid Med Cell Longev.* 2018;2018:e6581970. doi:10.1155/2018/6581970
237. Aldini G, Altomare A, Baron G, et al. N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why. *Free Radic Res.* 2018;52(7):751-762. doi:10.1080/10715762.2018.1468564
238. Zhirkovich A. N-Acetylcysteine: Antioxidant, Aldehyde Scavenger, and More. *Chem Res Toxicol.* 2019;32(7):1318-1319. doi:10.1021/acs.chemrestox.9b00152
239. Gilad E, Cuzzocrea S, Zingarelli B, Salzman AL, Szabó C. Melatonin is a scavenger of peroxy nitrite. *Life Sci.* 1997;60(10):PL169-174. doi:10.1016/s0024-3205(97)00008-8
240. Shaeib F, Khan SN, Ali I, et al. Melatonin Prevents Myeloperoxidase Heme Destruction and the Generation of Free Iron Mediated by Self-Generated Hypochlorous Acid. *PLOS ONE.* 2015;10(4):e0120737. doi:10.1371/journal.pone.0120737

241. Elsaed WM, Alahmadi AM, Al-Ahmadi BT, Taha JA, Tarabishi RM. Gastroprotective and antioxidant effects of fluvoxamine on stress-induced peptic ulcer in rats. *J Taibah Univ Med Sci*. 2018;13(5):422-431. doi:10.1016/j.jtumed.2018.04.010
242. Dallé E, Daniels WMU, Mabandla MV. Long-Term Treatment with Fluvoxamine Decreases Nonmotor Symptoms and Dopamine Depletion in a Postnatal Stress Rat Model of Parkinson's Disease. *Oxid Med Cell Longev*. 2020;2020:e1941480. doi:10.1155/2020/1941480
243. Braga PC, Dal Sasso M, Culici M, Bianchi T, Guffanti EE. Budesonide reduces superoxide and peroxynitrite anion chemiluminescence during human neutrophil bursts. *Pharmacology*. 2005;75(4):179-186. doi:10.1159/000088623
244. Mikolka P, Kopincova J, Tomcikova Mikusiakova L, et al. Effects of surfactant/budesonide therapy on oxidative modifications in the lung in experimental meconium-induced lung injury. *J Physiol Pharmacol Off J Pol Physiol Soc*. 2016;67(1):57-65.
245. Lamothe PH, Rao E, Serra AJ, et al. Comparative efficacy of cimetidine, famotidine, ranitidine, and mylanta in postoperative stress ulcers. Gastric pH control and ulcer prevention in patients undergoing coronary artery bypass graft surgery. *Gastroenterology*. 1991;100(6):1515-1520. doi:10.1016/0016-5085(91)90647-4
246. van Zyl JM, Kriegler A, van der Walt BJ. Anti-oxidant properties of H<sub>2</sub>-receptor antagonists. Effects on myeloperoxidase-catalysed reactions and hydroxyl radical generation in a ferrous-hydrogen peroxide system. *Biochem Pharmacol*. 1993;45(12):2389-2397. doi:10.1016/0006-2952(93)90218-I
247. Ching T-L, Haenen GRMM, Bast A. Cimetidine and other H<sub>2</sub> receptor antagonists as powerful hydroxyl radical scavengers. *Chem Biol Interact*. 1993;86(2):119-127. doi:10.1016/0009-2797(93)90116-G
248. Peterson DA, Gerrard JM, Rao GHR, White JG. Inhibition of ferrous iron induced oxidation of arachidonic acid by indomethacin. *Prostaglandins Med*. 1979;2(2):97-108. doi:10.1016/0161-4630(79)90044-2
249. Cross AL, Hawkes J, Wright HL, Moots RJ, Edwards SW. APPA (apocynin and paeonol) modulates pathological aspects of human neutrophil function, without suppressing antimicrobial ability, and inhibits TNF $\alpha$  expression and signalling. *Inflammopharmacology*. 2020;28(5):1223-1235. doi:10.1007/s10787-020-00715-5
250. Heumüller S, Wind S, Barbosa-Sicard E, et al. Apocynin Is Not an Inhibitor of Vascular NADPH Oxidases but an Antioxidant. *Hypertension*. 2008;51(2):211-217. doi:10.1161/HYPERTENSIONAHA.107.100214
251. de Almeida AC, dos Santos Vilela MM, Condino-Neto A, Ximenes VF. The Importance of Myeloperoxidase in Apocynin-Mediated NADPH Oxidase Inhibition. *ISRN Inflamm*. 2012;2012:260453. doi:10.5402/2012/260453
252. NADPH oxidase Covid-19 Oxygen treatment? ResearchGate. Accessed September 28, 2021. [https://www.researchgate.net/post/NADPH\\_oxidase\\_Covid-19\\_Oxygen\\_treatment](https://www.researchgate.net/post/NADPH_oxidase_Covid-19_Oxygen_treatment)
253. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. *The Lancet*. 2020;395(10234):1417-1418. doi:10.1016/S0140-6736(20)30937-5
254. COVID19. Global Sepsis Alliance. Accessed September 28, 2021. <https://www.global-sepsis-alliance.org/covid19>
255. HealthLeaders. Expert: Severe COVID-19 Illness Is Viral Sepsis. Accessed September 28, 2021. <https://www.healthleadersmedia.com/clinical-care/expert-severe-covid-19-illness-viral-sepsis>
256. Aisa-Alvarez A, Soto ME, Guarner-Lans V, et al. Usefulness of Antioxidants as Adjuvant Therapy for Septic Shock: A Randomized Clinical Trial. *Med Kaunas Lith*. 2020;56(11):E619. doi:10.3390/medicina56110619
257. Aisa-Alvarez A, Perez-Torres I, Camarena-Alejo G, et al. A Randomized clinical trial of antioxidant therapy in patients with septic shock. Reference study to propose adjuvant therapy in patients with

- critical organic damage by COVID-19. Published online September 28, 2021. doi:10.21203/rs.3.rs-52169/v1
258. Kashiouris MG, L'Heureux M, Cable CA, Fisher BJ, Leichtle SW, Fowler AA. The Emerging Role of Vitamin C as a Treatment for Sepsis. *Nutrients*. 2020;12(2):E292. doi:10.3390/nu12020292
259. That "damn machine": mechanical ventilators in the ICU. STAT. Published August 20, 2021. Accessed September 28, 2021. <https://www.statnews.com/2021/08/20/that-damn-machine-the-dark-side-of-mechanical-ventilators-in-the-icu/>
260. Ferreira JC, Ho Y-L, Besen BAMP, et al. Protective ventilation and outcomes of critically ill patients with COVID-19: a cohort study. *Ann Intensive Care*. 2021;11(1):92. doi:10.1186/s13613-021-00882-w
261. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med*. 2020;383(21):2030-2040. doi:10.1056/NEJMoa2022926
262. Popp M, Stegemann M, Metzendorf M-I, et al. Ivermectin for preventing and treating COVID-19. *Cochrane Database Syst Rev*. 2021;7:CD015017. doi:10.1002/14651858.CD015017.pub2
263. Acosta MAT, Singer BD. Pathogenesis of COVID-19-induced ARDS: implications for an aging population. *Eur Respir J*. Published online January 1, 2020. doi:10.1183/13993003.02049-2020
264. dos Santos WG. Natural history of COVID-19 and current knowledge on treatment therapeutic options. *Biomed Pharmacother*. 2020;129:110493. doi:10.1016/j.biopha.2020.110493
265. Dölken L, Stich A, Spinner CD. Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset—Lessons Learned. *Viruses*. 2021;13(6):963. doi:10.3390/v13060963
266. Hydroxychloroquine does not benefit adults hospitalized with COVID-19. National Institutes of Health (NIH). Published November 9, 2020. Accessed September 28, 2021. <https://www.nih.gov/news-events/news-releases/hydroxychloroquine-does-not-benefit-adults-hospitalized-covid-19>
267. Ivermectin Won't Treat Covid-19 but Demand for Drug Surges - The New York Times. Accessed September 28, 2021. <https://www.nytimes.com/2021/08/30/health/covid-ivermectin-prescriptions.html>
268. What the FDA wants doctors to tell patients asking for ivermectin. American Medical Association. Accessed September 28, 2021. <https://www.ama-assn.org/delivering-care/public-health/what-fda-wants-doctors-tell-patients-asking-ivermectin>
269. AbbVie's Kaletra doesn't work in COVID-19, say Chinese scientists -. Accessed September 28, 2021. <https://pharmaphorum.com/news/abbvies-kaletra-doesnt-work-in-covid-19-say-chinese-scientists/>
270. Chamary JV. The Strange Story Of Remdesivir, A Covid Drug That Doesn't Work. Forbes. Accessed September 28, 2021. <https://www.forbes.com/sites/jvchamary/2021/01/31/remdesivir-covid-coronavirus/>
271. Uttar Pradesh government says early use of Ivermectin helped to keep positivity, deaths low. The Indian Express. Published May 12, 2021. Accessed September 28, 2021. <https://indianexpress.com/article/cities/lucknow/uttar-pradesh-government-says-ivermectin-helped-to-keep-deaths-low-7311786/>
272. India Claims Ivermectin is Effective Against COVID – Orion's Cold Fire. Accessed September 28, 2021. <https://orionscoldfire.com/index.php/2021/09/16/india-claims-ivermectin-is-effective-against-covid/>
273. Dr. Soumya Swaminathan deletes her controversial tweet - Indian Bar Association. Accessed September 28, 2021. <https://indianbarassociation.in/indian-bar-associationiba-vs-dr-soumyaswaminathan/>
274. Indian Bar Association Charges WHO Chief Scientist for Mass Murder - PaulCraigRoberts.org. Accessed September 28, 2021. <https://www.paulcraigroberts.org/2021/08/23/indian-bar-association-charges-who-chief-scientist-for-mass-murder/>

275. Ivomec® (ivermectin) – Effective dewormer, trusted for more than 35 years. Boehringer Ingelheim Vetmedica. Published April 10, 2019. Accessed September 28, 2021. <https://www.bi-vetmedica.com/species/cattle/products/ivomec.html>
276. CRUMP A, ŌMURA S. Ivermectin, 'Wonder drug' from Japan: the human use perspective. *Proc Jpn Acad Ser B Phys Biol Sci.* 2011;87(2):13-28. doi:10.2183/pjab.87.13
277. Camero K. Some people are taking an anti-parasitic to treat COVID. Here's why that's a bad idea. Miami Herald. Accessed September 28, 2021. <https://www.miamiherald.com/news/coronavirus/article253290108.html>
278. Editor AD News. University experts weigh in on using ivermectin 'horse dewormer' as COVID-19 treatment. Technician. Accessed September 28, 2021. [https://www.technicianonline.com/news/university-experts-weigh-in-on-using-ivermectin-horse-dewormer-as-covid-19-treatment/article\\_319584f2-15dc-11ec-a985-5b35a9dc71ff.html](https://www.technicianonline.com/news/university-experts-weigh-in-on-using-ivermectin-horse-dewormer-as-covid-19-treatment/article_319584f2-15dc-11ec-a985-5b35a9dc71ff.html)
279. Yang SNY, Atkinson SC, Wang C, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. *Antiviral Res.* 2020;177:104760. doi:10.1016/j.antiviral.2020.104760
280. Kosyna FK, Nagel M, Kluxen L, Kraushaar K, Depping R. The importin α/β-specific inhibitor Ivermectin affects HIF-dependent hypoxia response pathways. *Biol Chem.* 2015;396(12):1357-1367. doi:10.1515/hsz-2015-0171
281. Shahbaznejad L, Davoudi A, Eslami G, et al. Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical Trial. *Clin Ther.* 2021;43(6):1007-1019. doi:10.1016/j.clinthera.2021.04.007
282. Zaidi AK, Dehgani-Mobaraki P. The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article. *J Antibiot (Tokyo)*. Published online June 15, 2021:1-13. doi:10.1038/s41429-021-00430-5
283. Ivermectin for COVID-19: real-time meta analysis of 65 studies. Accessed September 28, 2021. <https://ivmmeta.com/>
284. Israeli scientist says COVID-19 could be treated for under \$1/day. The Jerusalem Post | JPost.com. Accessed September 28, 2021. <https://www.jpost.com/health-science/israeli-scientist-says-covid-19-could-be-treated-for-under-1day-675612>
285. Feuer W. Gilead's coronavirus treatment remdesivir to cost \$3,120 per U.S. patient with private insurance. CNBC. Published June 29, 2020. Accessed September 28, 2021. <https://www.cnbc.com/2020/06/29/gileads-coronavirus-treatment-remdesivir-to-cost-3120-for-us-insured-patients.html>
286. Pharmaceutical companies pay low taxes and reap enormous profit from COVID vaccines. American Friends Service Committee. Published September 15, 2021. Accessed September 28, 2021. <https://www.afsc.org/newsroom/pharmaceutical-companies-pay-low-taxes-and-reap-enormous-profit-covid-vaccines>
287. Obscene global vaccine profiteering by pharmaceutical companies. World Socialist Web Site. Accessed September 28, 2021. <https://www.wsws.org/en/articles/2021/04/01/vacc-a01.html>
288. Pharmaceutical Companies Reaping Immoral Profits From COVID Vaccines Yet Paying Low Tax Rates. Common Dreams. Accessed September 28, 2021. <https://www.commondreams.org/newswire/2021/09/15/pharmaceutical-companies-reaping-immoral-profits-covid-vaccines-yet-paying-low>
289. Ennis M, Tiligada K. Histamine receptors and COVID-19. *Inflamm Res.* Published online November 18, 2020:1-9. doi:10.1007/s00011-020-01422-1
290. Hogan II RB, Hogan III RB, Cannon T, et al. Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients. *Pulm Pharmacol Ther.* 2020;63:101942. doi:10.1016/j.pupt.2020.101942

291. Mura C, Preissner S, Nahles S, Heiland M, Bourne PE, Preissner R. Real-world evidence for improved outcomes with histamine antagonists and aspirin in 22,560 COVID-19 patients. *Signal Transduct Target Ther.* 2021;6(1):1-3. doi:10.1038/s41392-021-00689-y
292. Ishola AA, Joshi T, Abdulai SI, Tijjani H, Pundir H, Chandra S. Molecular basis for the repurposing of histamine H<sub>2</sub>-receptor antagonist to treat COVID-19. *J Biomol Struct Dyn.* 2021;0(0):1-18. doi:10.1080/07391102.2021.1873191
293. Cross KM, Landis DM, Sehgal L, Payne JD. Melatonin for the Early Treatment of COVID-19: A Narrative Review of Current Evidence and Possible Efficacy. *Endocr Pract.* 2021;27(8):850-855. doi:10.1016/j.eprac.2021.06.001
294. Camp OG, Bai D, Gonullu DC, Nayak N, Abu-Soud HM. Melatonin interferes with COVID-19 at several distinct ROS-related steps. *J Inorg Biochem.* 2021;223:111546. doi:10.1016/j.jinorgbio.2021.111546
295. Marinella MA. Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19. *Int J Clin Pract.* 2020;74(9):e13535. doi:10.1111/ijcp.13535
296. Yu L-M, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. *The Lancet.* 2021;398(10303):843-855. doi:10.1016/S0140-6736(21)01744-X
297. Ebell MH. Inhaled Budesonide Reduces the Risk of Emergency Department Evaluation or Hospitalization in Early COVID-19. *Am Fam Physician.* 2021;104(2):207-208. Accessed September 28, 2021. <https://www.aafp.org/afp/2021/0800/p207.html>
298. Amici C, Di Caro A, Ciucci A, et al. Indomethacin has a potent antiviral activity against SARS coronavirus. *Antivir Ther.* 2006;11(8):1021-1030.
299. Crespi B, Alcock J. Conflicts over calcium and the treatment of COVID-19. *Evol Med Public Health.* 2021;9(1):149. doi:10.1093/emph/eoaa046
300. Zhang L-K, Sun Y, Zeng H, et al. Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension. *Cell Discov.* 2020;6. doi:10.1038/s41421-020-00235-0
301. Peng C, Wang H, Guo Y-F, et al. Calcium channel blockers improve prognosis of patients with coronavirus disease 2019 and hypertension. *Chin Med J (Engl).* 2021;134(13):1602. doi:10.1097/CM9.0000000000001479
302. Sakr Y, Bensasi H, Taha A, Bauer M, Ismail K, Group the U-JR. Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia. *Intensive Care Med.* 2021;47(6):707. doi:10.1007/s00134-021-06395-1
303. Uno Y. Camostat mesilate therapy for COVID-19. *Intern Emerg Med.* 2020;15(8):1577-1578. doi:10.1007/s11739-020-02345-9
304. Zhu H, Du W, Song M, Liu Q, Herrmann A, Huang Q. Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2. *Comput Struct Biotechnol J.* 2021;19:467-476. doi:10.1016/j.csbj.2020.12.035
305. Gunst JD, Staerke NB, Pahus MH, et al. Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial. *EClinicalMedicine.* 2021;35. doi:10.1016/j.eclinm.2021.100849
306. University of Aarhus. *The Impact of Camostat Mesilate on COVID-19 Infection: An Investigator-Initiated Randomized, Placebo-Controlled, Phase IIa Trial.* clinicaltrials.gov; 2021. Accessed October 10, 2021. <https://clinicaltrials.gov/ct2/show/NCT04321096>
307. Stanford University. *A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Camostat Mesilate Compared to Standard of Care in Subjects With Mild-Moderate COVID-19.* clinicaltrials.gov; 2021. Accessed October 10, 2021. <https://clinicaltrials.gov/ct2/show/NCT04524663>

308. Dabholkar N, Gorantla S, Dubey SK, Alexander A, Taliyan R, Singhvi G. Repurposing methylene blue in the management of COVID-19: Mechanistic aspects and clinical investigations. *Biomed Pharmacother*. 2021;142:112023. doi:10.1016/j.biopha.2021.112023
309. Scigiano G, Scigiano GA. Methylene blue in covid-19. *Med Hypotheses*. 2021;146:110455. doi:10.1016/j.mehy.2020.110455
310. Naymagon L, Berwick S, Kessler A, Lancman G, Gidwani U, Troy K. The emergence of methemoglobinemia amidst the COVID-19 pandemic. *Am J Hematol*. doi:10.1002/ajh.25868
311. Faisal H, Bloom A, Gaber AO. Unexplained Methemoglobinemia in Coronavirus Disease 2019: A Case Report. *Aa Pract*. 2020;14(9):e01287. doi:10.1213/XAA.00000000000001287
312. Bojadzic D, Alcazar O, Buchwald P. Methylene Blue Inhibits the SARS-CoV-2 Spike–ACE2 Protein–Protein Interaction—a Mechanism that can Contribute to its Antiviral Activity Against COVID-19. *Front Pharmacol*. 2020;11. doi:10.3389/fphar.2020.600372
313. MIT Lincoln Laboratory: News: DRACO. Published December 29, 2011. Accessed October 11, 2021. <https://web.archive.org/web/20111229094626/http://www.ll.mit.edu/news/DRACO.html>
314. Watch out for DRACO - MIT Scientist Develops Vaccine To. Accessed October 11, 2021. <https://redice.tv/news/watch-out-for-draco-mit-scientist-develops-vaccine-to-cure-all-viral-diseases>
315. Sharti M, Esmaeili Gouvarchin Ghaleh H, Dorostkar R, Jalali Kondori B. Double-Stranded RNA Activated Caspase Oligomerizer (DRACO): Design, Subcloning, and Antiviral Investigation. *J Appl Biotechnol Rep*. 2020;(Online First). doi:10.30491/jabr.2020.111083
316. Rider TH, Zook CE, Boettcher TL, Wick ST, Pancoast JS, Zusman BD. Broad-Spectrum Antiviral Therapeutics. *PLOS ONE*. 2011;6(7):e22572. doi:10.1371/journal.pone.0022572
317. Guo C, Chen L, Mo D, Chen Y, Liu X. DRACO inhibits porcine reproductive and respiratory syndrome virus replication in vitro. *Arch Virol*. Published online 2015. doi:10.1007/s00705-015-2392-4
318. The RIDER Institute Is Crowdfunding \$2,000,000 For DRACO Antiviral That May Be Effective Against Virtually All Viruses. BioSpace. Accessed October 10, 2021. <https://www.biospace.com/article/-b-the-rider-institute-b-is-crowdfunding-2-000-000-for-draco-antiviral-that-may-be-effective-against-virtually-all-viruses-/>
319. Droplets vs Aerosols: What's More Important in COVID-19 Spread? Published May 13, 2021. Accessed September 28, 2021. <https://www.medpagetoday.com/special-reports/exclusives/92564>
320. COVID-19: Droplet or Airborne Transmission? Penn Medicine Epidemiologists Issue Statement - Penn Medicine. Accessed September 28, 2021. <https://www.pennmedicine.org/updates/blogs/penn-physician-blog/2020/august/airborne-droplet-debate-article>
321. 239 Experts With One Big Claim: The Coronavirus Is Airborne - The New York Times. Accessed September 28, 2021. <https://www.nytimes.com/2020/07/04/health/239-experts-with-one-big-claim-the-coronavirus-is-airborne.html>
322. Goldman E. Exaggerated risk of transmission of COVID-19 by fomites. *Lancet Infect Dis*. 2020;20(8):892-893. doi:10.1016/S1473-3099(20)30561-2
323. Lewis D. COVID-19 rarely spreads through surfaces. So why are we still deep cleaning? *Nature*. 2021;590(7844):26-28. doi:10.1038/d41586-021-00251-4
324. Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients | medRxiv. Accessed September 28, 2021. <https://www.medrxiv.org/content/10.1101/2020.08.03.20167395v1>
325. PolitiFact JG. What We Know About the Airborne Spread of the Coronavirus. Kaiser Health News. Published September 30, 2020. Accessed September 28, 2021. <https://khn.org/news/fact-check-airborne-transmission-coronavirus-science-behind-aerosol-spread/>
326. A guideline to limit indoor airborne transmission of COVID-19 | PNAS. Accessed September 28, 2021. <https://www.pnas.org/content/118/17/e2018995118>
327. Chen CC, Willeke K. Aerosol penetration through surgical masks. *Am J Infect Control*. 1992;20(4):177-184. doi:10.1016/s0196-6553(05)80143-9

328. Konda A, Prakash A, Moss GA, Schmoldt M, Grant GD, Guha S. Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth Masks. *ACS Nano*. 2020;14(5):6339-6347. doi:10.1021/acsnano.0c03252
329. Guide for the Selection of Personal Protective Equipment for Emergency First Responders (Percutaneous Protection--Apparel), NIJ Guide 102-00, Volume IIc. National Institute of Justice. Accessed September 28, 2021. <https://nij.ojp.gov/library/publications/guide-selection-personal-protective-equipment-emergency-first-responders-1>
330. US EPA O. EPA Researchers Test Effectiveness of Face Masks, Disinfection Methods Against COVID-19. Published April 5, 2021. Accessed September 28, 2021. <https://www.epa.gov/sciencematters/epa-researchers-test-effectiveness-face-masks-disinfection-methods-against-covid-19>
331. Caruhel J-B, Sigaux N, Crambert A, et al. Military gas mask to protect surgeons when performing tracheotomies on patients with COVID-19. *BMJ Mil Health*. Published online August 2020:bmjmilitary-2020-001547. doi:10.1136/bmj military-2020-001547
332. Coronavirus Protection Made Easy with the MaxAir CAPR®. Mopec. Published March 2, 2020. Accessed September 28, 2021. <https://www.mopec.com/coronavirus-protection-made-easy-with-the-maxair-capr/>
333. Kitajima M, Ahmed W, Bibby K, et al. SARS-CoV-2 in wastewater: State of the knowledge and research needs. *Sci Total Environ*. 2020;739:139076. doi:10.1016/j.scitotenv.2020.139076
334. Sharif S, Ikram A, Khurshid A, et al. Detection of SARS-CoV-2 in wastewater using the existing environmental surveillance network: A potential supplementary system for monitoring COVID-19 transmission. *PLOS ONE*. 2021;16(6):e0249568. doi:10.1371/journal.pone.0249568
335. Peccia J, Zulli A, Brackney DE, et al. Measurement of SARS-CoV-2 RNA in wastewater tracks community infection dynamics. *Nat Biotechnol*. 2020;38(10):1164-1167. doi:10.1038/s41587-020-0684-z
336. McKinney KR, Gong YY, Lewis TG. Environmental transmission of SARS at Amoy Gardens. *J Environ Health*. 2006;68(9):26-30; quiz 51-52.
337. Hung LS. The SARS epidemic in Hong Kong: what lessons have we learned? *J R Soc Med*. 2003;96(8):374-378. Accessed September 28, 2021. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC539564/>
338. COVID-19 Could Spread Through Dry Floor Drains. CleanLink. Accessed September 28, 2021. <https://www.cleanlink.com/news/article/COVID-19-Could-Spread-Through-Dry-Floor-Drains--25600>
339. 'Leaky' Vaccines Can Produce Stronger Versions of Viruses. Healthline. Published July 27, 2015. Accessed September 28, 2021. <https://www.healthline.com/health-news/leaky-vaccines-can-produce-stronger-versions-of-viruses-072715>
340. MD BH. Let's Stop Pretending About the Covid-19 Vaccines | RealClearScience. Published August 23, 2021. Accessed September 28, 2021. [https://www.realclearscience.com/articles/2021/08/23/lets\\_stop\\_pretending\\_about\\_the\\_covid-19\\_vaccines\\_791050.html](https://www.realclearscience.com/articles/2021/08/23/lets_stop_pretending_about_the_covid-19_vaccines_791050.html)
341. CDC Newsroom. CDC. Published January 1, 2016. Accessed September 28, 2021. <https://www.cdc.gov/media/releases/2021/s0730-mmwr-covid-19.html>
342. Brueck H. CDC: Everyone should mask up indoors — whether they're fully vaccinated or not — as the Delta variant sweeps the US. Business Insider. Accessed September 28, 2021. <https://www.businessinsider.com/cdc-fully-vaccinated-new-guidelines-wear-masks-indoors-delta-2021-7>
343. Lasting immunity found after recovery from COVID-19. National Institutes of Health (NIH). Published January 25, 2021. Accessed September 28, 2021. <https://www.nih.gov/news-events/nih-research-matters/lasting-immunity-found-after-recovery-covid-19>

344. Gazit S, Shlezinger R, Perez G, et al. *Comparing SARS-CoV-2 Natural Immunity to Vaccine-Induced Immunity: Reinfections versus Breakthrough Infections.*; 2021:2021.08.24.21262415. doi:10.1101/2021.08.24.21262415
345. Accelerated Covid-19 Vaccine Clinical Trials. JD Supra. Accessed September 28, 2021. <https://www.jdsupra.com/legalnews/accelerated-covid-19-vaccine-clinical-95853/>
346. Were the COVID-19 vaccines rushed? Here's how the vaccines were developed so fast. Accessed September 28, 2021. <https://www.nebraskamed.com/COVID/were-the-covid-19-vaccines-rushed>
347. Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. *Ther Deliv.* 2016;7(5):319-334. doi:10.4155/tde-2016-0006
348. Without these lipid shells, there would be no mRNA vaccines for COVID-19. Chemical & Engineering News. Accessed September 28, 2021. <https://cen.acs.org/pharmaceuticals/drug-delivery/Without-lipid-shells-mRNA-vaccines/99/i8>
349. CDC. Understanding mRNA COVID-19 Vaccines. Centers for Disease Control and Prevention. Published March 4, 2021. Accessed September 28, 2021. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html>
350. What are mRNA vaccines and how do they work?: MedlinePlus Genetics. Accessed September 28, 2021. <https://medlineplus.gov/genetics/understanding/therapy/mrnnavaccines/>
351. Corbett KS, Edwards DK, Leist SR, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. *Nature.* 2020;586(7830):567-571. doi:10.1038/s41586-020-2622-0
352. PhD SM. How mRNA vaccines from Pfizer and Moderna work, why they're a breakthrough and why they need to be kept so cold. The Conversation. Accessed September 28, 2021. <http://theconversation.com/how-mrna-vaccines-from-pfizer-and-moderna-work-why-theyre-a-breakthrough-and-why-they-need-to-be-kept-so-cold-150238>
353. Martínez-Flores D, Zepeda-Cervantes J, Cruz-Reséndiz A, Aguirre-Sampieri S, Sampieri A, Vaca L. SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants. *Front Immunol.* 2021;12:2774. doi:10.3389/fimmu.2021.701501
354. Prompetchara E, Ketloy C, Tharakhet K, et al. DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice. *PLOS ONE.* 2021;16(3):e0248007. doi:10.1371/journal.pone.0248007
355. COVID-19 Viral Vector Vaccines. Accessed September 28, 2021. <https://www.idsociety.org/covid-19-real-time-learning-network/vaccines/covid-19-viral-vector-vaccines/>
356. Zimmerman RK. Helping patients with ethical concerns about COVID-19 vaccines in light of fetal cell lines used in some COVID-19 vaccines. *Vaccine.* 2021;39(31):4242-4244. doi:10.1016/j.vaccine.2021.06.027
357. The Ethics of the SARS-CoV-2 Vaccines Revisited. Christian Medical & Dental Associations® (CMDA). Published September 15, 2021. Accessed September 28, 2021. <https://cmda.org/the-ethics-of-the-sars-cov-2-vaccines-revisited/>
358. Canadian Covid Care Alliance. Accessed September 28, 2021. <https://mailchi.mp/5666d252288c/canadian-covid-care-alliance>
359. Juraszek J, Rutten L, Blokland S, et al. Stabilizing the closed SARS-CoV-2 spike trimer. *Nat Commun.* 2021;12(1):244. doi:10.1038/s41467-020-20321-x
360. The tiny tweak behind COVID-19 vaccines. Chemical & Engineering News. Accessed September 28, 2021. <https://cen.acs.org/pharmaceuticals/vaccines/tiny-tweak-behind-COVID-19/98/i38>
361. SARS-CoV-2 mRNA Vaccine (BNT162, PF-07302048) 2.6.4 Overview of Pharmacokinetic Test | BibSonomy. Accessed September 28, 2021. <https://www.bibsonomy.org/bibtex/29920ce3643fa2f4fdbeccfa57790d2d/fordham1>

362. Krantz MS, Liu Y, Phillips EJ, Stone CA. COVID-19 vaccine anaphylaxis: PEG or not? *Allergy*. 2021;76(6):1934-1937. doi:10.1111/all.14722
363. Moghimi SM. Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines. *Mol Ther*. 2021;29(3):898-900. doi:10.1016/j.ymthe.2021.01.030
364. Overview of translation (article). Khan Academy. Accessed September 28, 2021. <https://www.khanacademy.org/science/ap-biology/gene-expression-and-regulation/translation/a/translation-overview>
365. Thomas EN, Kim KQ, McHugh EP, Marcinkiewicz T, Zaher HS. Alkylative damage of mRNA leads to ribosome stalling and rescue by trans translation in bacteria. Dever TE, Storz G, eds. *eLife*. 2020;9:e61984. doi:10.7554/eLife.61984
366. Karamyshev AL, Karamysheva ZN. Lost in Translation: Ribosome-Associated mRNA and Protein Quality Controls. *Front Genet*. 2018;9:431. doi:10.3389/fgene.2018.00431
367. Mendonsa S, von Kuegelgen N, Bujanic L, Chekulaeva M. Charcot–Marie–Tooth mutation in glycyl-tRNA synthetase stalls ribosomes in a pre-accommodation state and activates integrated stress response. *Nucleic Acids Res*. 2021;49(17):10007-10017. doi:10.1093/nar/gkab730
368. Zuko A, Mallik M, Thompson R, et al. tRNA overexpression rescues peripheral neuropathy caused by mutations in tRNA synthetase. *Science*. 2021;373(6559):1161-1166. doi:10.1126/science.abb3356
369. Zhang S, Chen Y, Wang Y, Zhang P, Chen G, Zhou Y. Insights Into Translatomics in the Nervous System. *Front Genet*. 2020;11:1682. doi:10.3389/fgene.2020.599548
370. Klein T, Eckhard U, Dufour A, Solis N, Overall CM. Proteolytic Cleavage—Mechanisms, Function, and “Omic” Approaches for a Near-Ubiquitous Posttranslational Modification. *Chem Rev*. 2018;118(3):1137-1168. doi:10.1021/acs.chemrev.7b00120
371. Örd M, Faustova I, Loog M. The sequence at Spike S1/S2 site enables cleavage by furin and phospho-regulation in SARS-CoV2 but not in SARS-CoV1 or MERS-CoV. *Sci Rep*. 2020;10(1):16944. doi:10.1038/s41598-020-74101-0
372. Lemmin T, Kalbermatter D, Harder D, Plattet P, Fotiadis D. Structures and dynamics of the novel S1/S2 protease cleavage site loop of the SARS-CoV-2 spike glycoprotein. *J Struct Biol X*. 2020;4:100038. doi:10.1016/j.jysbx.2020.100038
373. Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. *Proc Natl Acad Sci*. 2009;106(14):5871-5876. doi:10.1073/pnas.0809524106
374. Ogata AF, Cheng C-A, Desjardins M, et al. Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients. *Clin Infect Dis*. 2021;(ciab465). doi:10.1093/cid/ciab465
375. Peacock TP, Goldhill DH, Zhou J, et al. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. *Nat Microbiol*. 2021;6(7):899-909. doi:10.1038/s41564-021-00908-w
376. Bestle D, Heindl MR, Limburg H, et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. *Life Sci Alliance*. 2020;3(9). doi:10.26508/lsa.202000786
377. Cheng MH, Zhang S, Porritt RA, et al. Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. *Proc Natl Acad Sci*. 2020;117(41):25254-25262. doi:10.1073/pnas.2010722117
378. Brown M, Bhardwaj N. Super(antigen) target for SARS-CoV-2. *Nat Rev Immunol*. 2021;21(2):72-72. doi:10.1038/s41577-021-00502-5
379. Föhse K, Geckin B, Overheul G, et al. The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and innate immune response. Published online 2021. doi:10.1101/2021.05.03.21256520

380. Wang H, Chen Q, Hu Y, et al. Pathogenic antibodies induced by spike proteins of COVID-19 and SARS-CoV viruses. Published online September 28, 2021. doi:10.21203/rs.3.rs-612103/v2
381. says R to the document-WB. Summary: Covid-19 Vaccine Concerns. Dr. Rich Swier. Published September 18, 2021. Accessed September 28, 2021. <https://drrichswier.com/2021/09/18/summary-covid-19-vaccine-concerns/>
382. Commissioner O of the. Coronavirus (COVID-19) Update: July 13, 2021. FDA. Published July 13, 2021. Accessed September 28, 2021. <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-july-13-2021>
383. Bell's Palsy After COVID Vaccines Still Very Rare. Published August 16, 2021. Accessed September 28, 2021. <https://www.medpagetoday.com/infectiousdisease/covid19vaccine/94061>
384. Havla J, Schultz Y, Zimmermann H, Hohlfeld R, Danek A, Kümpfel T. First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine. *J Neurol.* Published online June 11, 2021. doi:10.1007/s00415-021-10648-w
385. Baggen J, Vanstreels E, Jansen S, Daelemans D. Cellular host factors for SARS-CoV-2 infection. *Nat Microbiol.* 2021;6(10):1219-1232. doi:10.1038/s41564-021-00958-0
386. Perez-Miller S, Patek M, Moutal A, et al. Novel Compounds Targeting Neuropilin Receptor 1 with Potential To Interfere with SARS-CoV-2 Virus Entry. *ACS Chem Neurosci.* 2021;12(8):1299-1312. doi:10.1021/acschemneuro.0c00619
387. Daly JL, Simonetti B, Klein K, et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. *Science.* 2020;370(6518):861-865. doi:10.1126/science.abd3072
388. Nader D, Fletcher N, Curley GF, Kerrigan SW. SARS-CoV-2 uses major endothelial integrin  $\alpha\beta 3$  to cause vascular dysregulation in-vitro during COVID-19. *PLOS ONE.* 2021;16(6):e0253347. doi:10.1371/journal.pone.0253347
389. Petruk G, Puthia M, Petrlova J, et al. SARS-CoV-2 spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity. *J Mol Cell Biol.* 2020;12(12):916-932. doi:10.1093/jmcb/mjaa067
390. Suzuki YJ, Gychka SG. SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines. *Vaccines.* 2021;9(1):36. doi:10.3390/vaccines9010036
391. Liu S, Selvaraj P, Lien CZ, et al. The PRRA Insert at the S1/S2 Site Modulates Cellular Tropism of SARS-CoV-2 and ACE2 Usage by the Closely Related Bat RaTG13. *J Virol.* 95(11):e01751-20. doi:10.1128/JVI.01751-20
392. Johnson BA, Xie X, Kalveram B, et al. Furin Cleavage Site Is Key to SARS-CoV-2 Pathogenesis. *bioRxiv.* Published online August 26, 2020:2020.08.26.268854. doi:10.1101/2020.08.26.268854
393. Deigin Y. Lab-made? CoV2 genealogy through the lens of gain-of-function research. Medium. Published May 3, 2020. Accessed September 28, 2021. <https://yurideigin.medium.com/lab-made-cov2-genealogy-through-the-lens-of-gain-of-function-research-f96dd7413748>
394. Tetz G, Tetz V. SARS-CoV-2 Prion-Like Domains in Spike Proteins Enable Higher Affinity to ACE2. Published online March 29, 2020. doi:10.20944/preprints202003.0422.v1
395. Fryer HR, McLean AR. There Is No Safe Dose of Prions. *PLOS ONE.* 2011;6(8):e23664. doi:10.1371/journal.pone.0023664
396. Seneff S, Nigh G. Worse Than the Disease? Reviewing Some Possible Unintended Consequences of the mRNA Vaccines Against COVID-19. *Int J Vaccine Theory Pract Res.* 2021;2(1):38-79. Accessed September 28, 2021. <https://ijvtpr.com/index.php/IJVTPR/article/view/23>
397. Idrees D, Kumar V. SARS-CoV-2 spike protein interactions with amyloidogenic proteins: Potential clues to neurodegeneration. *Biochem Biophys Res Commun.* 2021;554:94-98. doi:10.1016/j.bbrc.2021.03.100

398. Rhea EM, Logsdon AF, Hansen KM, et al. The S1 protein of SARS-CoV-2 crosses the blood–brain barrier in mice. *Nat Neurosci*. 2021;24(3):368-378. doi:10.1038/s41593-020-00771-8
399. Zhang L, Zhou L, Bao L, et al. SARS-CoV-2 crosses the blood–brain barrier accompanied with basement membrane disruption without tight junctions alteration. *Signal Transduct Target Ther*. 2021;6(1):1-12. doi:10.1038/s41392-021-00719-9
400. Buzhdyan TP, DeOre BJ, Baldwin-Leclair A, et al. The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood-brain barrier. *Neurobiol Dis*. 2020;146:105131. doi:10.1016/j.nbd.2020.105131
401. Ricke DO. Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies. *Front Immunol*. 2021;12:640093. doi:10.3389/fimmu.2021.640093
402. Halstead SB, Katzelnick L. COVID 19 Vaccines: Should we fear ADE? *J Infect Dis*. Published online August 12, 2020:jiaa518. doi:10.1093/infdis/jiaa518
403. Yahi N, Chahinian H, Fantini J. Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination? *J Infect*. 2021;0(0). doi:10.1016/j.jinf.2021.08.010
404. (STUDY) Why so many vaccinated people are getting sick: Antibody Dependent Enhancement (ADE) | Sharyl Attkisson. Accessed September 28, 2021. <https://sharylattkisson.com/2021/08/study-why-so-many-vaccinated-people-are-getting-sick/>
405. Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. *Nat Microbiol*. 2020;5(10):1185-1191. doi:10.1038/s41564-020-00789-5
406. Wen J, Cheng Y, Ling R, et al. Antibody-dependent enhancement of coronavirus. *Int J Infect Dis*. 2020;100:483-489. doi:10.1016/j.ijid.2020.09.015
407. Wan Y, Shang J, Sun S, et al. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. *J Virol*. 2020;94(5):e02015-19. doi:10.1128/JVI.02015-19
408. Liu Y, Arase N, Kishikawa J, et al. *The SARS-CoV-2 Delta Variant Is Poised to Acquire Complete Resistance to Wild-Type Spike Vaccines.*; 2021:2021.08.22.457114. doi:10.1101/2021.08.22.457114
409. Zhang A, Stacey HD, Mollarkey CE, Miller MS. Original Antigenic Sin: How First Exposure Shapes Lifelong Anti-Influenza Virus Immune Responses. *J Immunol*. 2019;202(2):335-340. doi:10.4049/jimmunol.1801149
410. Brown EL, Essigmann HT. Original Antigenic Sin: the Downside of Immunological Memory and Implications for COVID-19. *mSphere*. 6(2):e00056-21. doi:10.1128/mSphere.00056-21
411. Antibody Dependent Enhancement - an overview | ScienceDirect Topics. Accessed September 28, 2021. <https://www.sciencedirect.com/topics/medicine-and-dentistry/antibody-dependent-enhancement>
412. ADE. Accessed September 28, 2021. <https://www.cdc.gov/dengue/training/cme/ccm/page57857.html>
413. Shukla R, Ramasamy V, Shanmugam RK, Ahuja R, Khanna N. Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine. *Front Cell Infect Microbiol*. 2020;10:597. doi:10.3389/fcimb.2020.572681
414. Scientists Discover How Dengue Vaccine Fails to Protect Against Disease. Newsroom. Published June 23, 2021. Accessed September 28, 2021. <https://news.unchealthcare.org/2021/06/scientists-discover-how-dengue-vaccine-fails-to-protect-against-disease/>
415. Mahalingam S, Herring BL, Halstead SB. Call to Action for Dengue Vaccine Failure. *Emerg Infect Dis*. 2013;19(8):1335-1337. doi:10.3201/eid1908.121864
416. How the World’s First Dengue Vaccination Drive Ended in Disaster. Scientific American. doi:10.1038/scientificamerican0419-38

417. Tseng C-T, Sbrana E, Iwata-Yoshikawa N, et al. Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus. *PLOS ONE*. 2012;7(4):e35421. doi:10.1371/journal.pone.0035421
418. Zhang L, Richards A, Khalil A, et al. SARS-CoV-2 RNA reverse-transcribed and integrated into the human genome. *BioRxiv Prepr Serv Biol*. Published online December 13, 2020:2020.12.12.422516. doi:10.1101/2020.12.12.422516
419. MIT & Harvard Study Suggests mRNA Vaccine Might Permanently Alter DNA After All. Rights and Freedoms. Published August 13, 2021. Accessed September 28, 2021.  
<https://rightsfreedoms.wordpress.com/2021/08/13/mit-harvard-study-suggests-mrna-vaccine-might-permanently-alter-dna-after-all/>
420. The Injection Fraud – It's Not a Vaccine – Solari Report. Accessed September 28, 2021.  
<https://home.solari.com/deep-state-tactics-101-the-covid-injection-fraud-its-not-a-vaccine/>
421. Dec 19 LS| NE| CN|, 2017. Feds lift gain-of-function research pause, offer guidance. CIDRAP. Accessed September 28, 2021. <https://www.cidrap.umn.edu/news-perspective/2017/12/feds-lift-gain-function-research-pause-offer-guidance>
422. Begley,STAT S. U.S. Lifts Moratorium on Funding Controversial, High-Risk Virus Research. Scientific American. Accessed September 28, 2021. <https://www.scientificamerican.com/article/u-s-lifts-moratorium-on-funding-controversial-high-risk-virus-research/>
423. NIH Lifts Funding Pause on Gain-of-Function Research. National Institutes of Health (NIH). Published December 18, 2017. Accessed September 28, 2021. <https://www.nih.gov/about-nih/who-we-are/nih-director/statements/nih-lifts-funding-pause-gain-function-research>
424. Ralph S. Baric, PhD. UNC Gillings School of Global Public Health. Accessed September 28, 2021. [https://sph.unc.edu/adv\\_profile/ralph-s-baric-phd/](https://sph.unc.edu/adv_profile/ralph-s-baric-phd/)
425. Ralph Baric: On the Front Lines of Coronavirus for Three Decades - UNC General Alumni Association. Accessed September 28, 2021. <https://alumni.unc.edu/news/ralph-baric-on-the-front-lines-of-coronavirus-for-three-decades/>
426. Menachery VD, Yount BL, Debbink K, et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. *Nat Med*. 2015;21(12):1508-1513. doi:10.1038/nm.3985
427. Inside the risky bat-virus engineering that links America to Wuhan. MIT Technology Review. Accessed September 28, 2021. <https://www.technologyreview.com/2021/06/29/1027290/gain-of-function-risky-bat-virus-engineering-links-america-to-wuhan/>
428. Suryanarayanan S. Items from coronavirus expert Ralph Baric's emails. U.S. Right to Know. Published December 14, 2020. Accessed September 28, 2021. <https://usrtk.org/biohazards-blog/ralph-baric-emails/>
429. Newsweek Op-Ed: "Congress Must Pursue Answers About the Origin of COVID-19" | Senator Rand Paul. Accessed September 28, 2021. <https://www.paul.senate.gov/newsweek-op-ed-congress-must-pursue-answers-about-origin-covid-19>
430. Baker N. The Lab-Leak Hypothesis. Intelligencer. Published January 4, 2021. Accessed September 28, 2021. <https://nymag.com/intelligencer/article/coronavirus-lab-escape-theory.html>
431. Lerner S, Hvistendahl M, Hibbett M. NIH Documents Provide New Evidence U.S. Funded Gain-of-Function Research in Wuhan. The Intercept. Published September 10, 2021. Accessed September 28, 2021. <https://theintercept.com/2021/09/09/covid-origins-gain-of-function-research/>
432. BOMBSHELL: Fauci Kept Funding Peter Daszak's Wuhan "Gain of Function" Experiments with \$7.5 Million after Trump Canceled Grant. National File. Published June 3, 2021. Accessed September 28, 2021. <https://nationalfile.com/bombshell-fauci-kept-funding-peter-daszaks-wuhan-gain-of-function-experiments-with-7-5-million-after-trump-canceled-grant/>
433. miningawareness. USAID (PREDICT) & NIH Gave \$ 1.9 Million to the Wuhan (WIV) Lab Through Daszak-EcoHealth Alliance; Daszak Talks China Partners' Work on "Killer" Viruses; Biden Budget

- Requests More USAID Money for Similar Projects. Mining Awareness +. Published June 11, 2021. Accessed September 28, 2021. <https://miningawareness.wordpress.com/2021/06/11/usaid-predict-nih-gave-1-9-million-to-the-wuhan-wiv-lab-through-daszak-ecohealth-alliance-daszak-talks-china-partners-work-on-killer-viruses-biden-admin-plans/>
434. Gallagher: This is Bigger than Dr. Fauci. Congressman Mike Gallagher. Published May 20, 2021. Accessed September 28, 2021. <https://gallagher.house.gov/media/press-releases/gallagher-bigger-dr-fauci>
435. Blog A. EcoHealth Alliance, DARPA Toyed With Infecting Wild Chinese Bats With Covid, Leaked Docs Allege. Algora Blog. Published September 22, 2021. Accessed September 28, 2021. [https://www.algora.com/Algora\\_blog/2021/09/22/ecohealth-alliance-darpa-toyed-with-infecting-wild-chinese-bats-with-covid-leaked-docs-allege](https://www.algora.com/Algora_blog/2021/09/22/ecohealth-alliance-darpa-toyed-with-infecting-wild-chinese-bats-with-covid-leaked-docs-allege)
436. Archive VA, feed G author R. Pentagon gave millions to EcoHealth Alliance for weapons research program. New York Post. Published July 2, 2021. Accessed September 28, 2021. <https://hypost.com/2021/07/01/pentagon-gave-millions-to-ecohealth-alliance-for-wuhan-lab/>
437. Judicial Watch: New Documents Show Wuhan Lab Asked NIH Official for Information on Disinfectants; Nine Fauci Agency Grants for EcoHealth Bat Coronavirus Research. Judicial Watch. Published July 8, 2021. Accessed September 28, 2021. <https://www.judicialwatch.org/press-releases/wuhan-lab-fauci-grants/>
438. JW v NIH Wuhan June 2021 00696. Judicial Watch. Accessed September 28, 2021. <https://www.judicialwatch.org/documents/jw-v-nih-wuhan-june-2021-00696/>
439. Opinion | State Department cables warned of safety issues at Wuhan lab studying bat coronaviruses. *Washington Post*. <https://www.washingtonpost.com/opinions/2020/04/14/state-department-cables-warned-safety-issues-wuhan-lab-studying-bat-coronaviruses/>. Accessed September 28, 2021.
440. Panetta G. US officials were reportedly concerned that safety breaches at a Wuhan lab studying coronaviruses in bats could cause a pandemic. Business Insider. Accessed September 28, 2021. <https://www.businessinsider.com/us-officials-raised-alarms-about-safety-issues-in-wuhan-lab-report-2020-4>
441. (PDF) The possible origins of 2019-nCoV coronavirus. Accessed September 28, 2021. [https://web.archive.org/web/20200214144447/https://www.researchgate.net/publication/339070128\\_The\\_possible\\_origins\\_of\\_2019-nCoV\\_coronavirus](https://web.archive.org/web/20200214144447/https://www.researchgate.net/publication/339070128_The_possible_origins_of_2019-nCoV_coronavirus)
442. Crist C. 3 Wuhan Lab Workers' 2019 Illness Raises Concerns. WebMD. Accessed September 28, 2021. <https://www.webmd.com/lung/news/20210524/wuhan-lab-researchers-illness>
443. Williams J. Fauci calls on China to release medical records of Wuhan researchers. TheHill. Published June 4, 2021. Accessed September 28, 2021. <https://thehill.com/policy/healthcare/556815-fauci-calls-on-china-to-release-medical-records-of-wuhan-researchers>
444. Confidential Documents reveal Moderna sent mRNA Coronavirus Vaccine Candidate to University Researchers weeks before emergence of Covid-19. Rights and Freedoms. Published June 26, 2021. Accessed September 28, 2021. <https://rightsandfreesoms.wordpress.com/2021/06/26/confidential-documents-reveal-moderna-sent-mrna-coronavirus-vaccine-candidate-to-university-researchers-weeks-before-emergence-of-covid-19/>
445. Confidential Documents reveal Moderna sent mRNA Coronavirus Vaccine Candidate to University Researchers weeks before emergence of Covid-19 – The Expose. Accessed September 28, 2021. <https://theExpose.uk/2021/06/18/confidential-documents-reveal-moderna-sent-mrna-coronavirus-vaccine-candidate-to-university-researchers-weeks-before-emergence-of-covid-19/>
446. Jan 11 LS| NE| CN|, 2020. China releases genetic data on new coronavirus, now deadly. CIDRAP. Accessed September 28, 2021. <https://www.cidrap.umn.edu/news-perspective/2020/01/china-releases-genetic-data-new-coronavirus-now-deadly>

447. Whole genome of novel coronavirus, 2019-nCoV, sequenced. ScienceDaily. Accessed September 28, 2021. <https://www.sciencedaily.com/releases/2020/01/200131114748.htm>
448. Bendix SN Andrew Dunn, Aria. Moderna's groundbreaking coronavirus vaccine was designed in just 2 days. Business Insider. Accessed September 28, 2021. <https://www.businessinsider.com/moderna-designed-coronavirus-vaccine-in-2-days-2020-11>
449. Moderna designed its coronavirus vaccine in 2 days — here's how - National | Globalnews.ca. Global News. Accessed September 28, 2021. <https://globalnews.ca/news/7492076/moderna-coronavirus-vaccine-technology-how-it-works/>
450. Wallace-Wells D. We Had the Vaccine the Whole Time. Intelligencer. Published December 7, 2020. Accessed September 28, 2021. <https://nymag.com/intelligencer/2020/12/moderna-covid-19-vaccine-design.html>
451. The Board of Directors of bioMerieux, chaired by Alain Merieux, has appointed Stephane Bancel Directeur General delegue (Chief Executive Officer) of bioMerieux starting January 1, 2007. bioMérieux Corporate Website. Accessed September 28, 2021. <https://www.biomerieux.com/en/board-directors-biomerieux-chaired-alain-merieux-has-appointed-stephane-bancel-directeur-general>
452. Stéphane Bancel | HIMSS. Published September 24, 2021. Accessed September 28, 2021. <https://www.himss.org/global-conference/speaker-stephane-bancel>
453. Alain Mérieux receives the prestigious Chinese Reform Friendship Award. Mérieux Foundation. Published September 17, 2013. Accessed September 28, 2021. <https://www.fondation-merieux.org/en/news/alain-merieux-receives-the-prestigious-chinese-reform-friendship-award/>
454. Beijing JXTWLCI. The Wuhan lab at the core of a virus controversy. Accessed September 28, 2021. <https://medicalxpress.com/news/2020-04-wuhan-lab-core-virus-controversy.html>
455. China Inaugurates the first biocontainment level 4 laboratory in Wuhan----Wuhan Institute of Virology. Accessed September 28, 2021. [http://english.whiov.cas.cn/ne/201712/t20171212\\_187624.html](http://english.whiov.cas.cn/ne/201712/t20171212_187624.html)
456. RaTG13 is fake. Nerd Has Power. Accessed September 28, 2021. <https://nerdhaspower.weebly.com/ratg13-is-fake.html>
457. RaTG13 – the Undeniable Evidence That the Wuhan Coronavirus Is Man-Made. GNEWS. Published May 2, 2020. Accessed September 28, 2021. <https://gnews.org/192144>
458. Scientific history of RaTG13. Peak Prosperity. Accessed September 28, 2021. <https://www.peakprosperity.com/forum-topic/scientific-history-of-ratg13/>
459. No one can find the animal that gave people covid-19. MIT Technology Review. Accessed September 28, 2021. <https://www.technologyreview.com/2021/03/26/1021263/bat-covid-coronavirus-cause-origin-wuhan/>
460. How WHO is working to track down the animal reservoir of the SARS-CoV-2 virus. Accessed September 28, 2021. <https://www.who.int/news-room/feature-stories/detail/how-who-is-working-to-track-down-the-animal-reservoir-of-the-sars-cov-2-virus>
461. Jewers C. More Lancet letter signatories found to have links to Wuhan. Mail Online. Published September 11, 2021. Accessed September 28, 2021. <https://www.dailymail.co.uk/news/article-9980015/26-Lancet-scientists-trashed-theory-Covid-leaked-Chinese-lab-links-Wuhan.html>
462. Wang N, Li S-Y, Yang X-L, et al. Serological Evidence of Bat SARS-Related Coronavirus Infection in Humans, China. *Virol Sin.* 2018;33(1):104-107. doi:10.1007/s12250-018-0012-7
463. Daszak and scientists stand by Lancet letter condemning Wuhan lab “conspiracy theories.” MSN. Accessed September 28, 2021. <https://www.msn.com/en-us/health/medical/daszak-and-scientists-stand-by-lancet-letter-condemning-wuhan-lab-conspiracy-theories/ar-AALT8w6>
464. Albaugh G. Journal That Mocked COVID Lab-Leak As “Conspiracy” Recants. Citizens Journal. Published September 22, 2021. Accessed September 28, 2021. <https://www.citizensjournal.us/journal-that-mocked-covid-lab-leak-as-conspiracy-recants/>

465. Calisher C, Carroll D, Colwell R, et al. Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19. *The Lancet*. 2020;395(10226):e42-e43. doi:10.1016/S0140-6736(20)30418-9
466. Lancet's COVID origins panel disbands over ties to Peter Daszak's EcoHealth Alliance. swiftheadline. Published September 26, 2021. Accessed September 28, 2021. <https://swiftheadline.com/lancets-covid-origins-panel-disbands-over-ties-to-peter-daszaks-ecohealth-alliance/>
467. WHO Covid Expert Peter Daszak's Alleged China Connection and CCP Money Trail: What's the Truth? Published February 11, 2021. Accessed September 28, 2021. <https://www.ibtimes.sg/who-covid-expert-peter-daszaks-alleged-china-connection-ccp-money-trail-whats-truth-55511>
468. Rutz D. Media fact-checkers, Facebook cited Wuhan lab-linked scientist to knock down lab leak theory. Fox News. Published June 3, 2021. Accessed September 28, 2021. <https://www.foxnews.com/media/daszak-fact-checks-coronavirus-wuhan-lab>
469. Daszak P, Chmura A. A Fall From Grace To... Virulence? *EcoHealth*. 2008;5(1):96-97. doi:10.1007/s10393-008-0163-3
470. Bogich TL, Chunara R, Scales D, et al. Preventing pandemics via international development: a systems approach. *PLoS Med*. 2012;9(12):e1001354. doi:10.1371/journal.pmed.1001354
471. Daszak P, Howard SE, Chmura AA. Rock, paper, scissors; chicken, human, swine. *EcoHealth*. 2009;6(1):159-160. doi:10.1007/s10393-009-0245-x
472. Ge X-Y, Li J-L, Yang X-L, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. *Nature*. 2013;503(7477):535-538. doi:10.1038/nature12711
473. Latinne A, Hu B, Olival KJ, et al. Origin and cross-species transmission of bat coronaviruses in China. *BioRxiv Prepr Serv Biol*. Published online May 31, 2020:2020.2020.05.31.116061. doi:10.1101/2020.05.31.116061
474. Li H-Y, Zhu G-J, Zhang Y-Z, et al. A qualitative study of zoonotic risk factors among rural communities in southern China. *Int Health*. 2020;12(2):77-85. doi:10.1093/inthealth/ihaa001
475. Li H, Chen Y, Machalaba CC, et al. Wild animal and zoonotic disease risk management and regulation in China: Examining gaps and One Health opportunities in scope, mandates, and monitoring systems. *One Health Amst Neth*. 2021;13:100301. doi:10.1016/j.onehlt.2021.100301
476. Nava A, Shimabukuro JS, Chmura AA, Luz SLB. The Impact of Global Environmental Changes on Infectious Disease Emergence with a Focus on Risks for Brazil. *ILAR J*. 2017;58(3):393-400. doi:10.1093/ilar/ilx034
477. Wang N, Li S-Y, Yang X-L, et al. Serological Evidence of Bat SARS-Related Coronavirus Infection in Humans, China. *Virol Sin*. 2018;33(1):104-107. doi:10.1007/s12250-018-0012-7
478. Zeng L-P, Gao Y-T, Ge X-Y, et al. Bat Severe Acute Respiratory Syndrome-Like Coronavirus WIV1 Encodes an Extra Accessory Protein, ORFX, Involved in Modulation of the Host Immune Response. *J Virol*. 2016;90(14):6573-6582. doi:10.1128/JVI.03079-15
479. David Martin. *The Fauci COVID 19 Dossier*; 2021. Accessed September 28, 2021. <http://archive.org/details/the-fauci-covid-19-dossier>
480. 161385360554578. Coronavirus patients WELDED into homes in China as death toll spirals to 813. The US Sun. Published February 9, 2020. Accessed September 28, 2021. <https://www.the-sun.com/news/378365/coronavirus-patients-welded-into-homes-in-china-as-death-toll-spirals-to-813/>
481. Archive VA, Author E the, Twitter F on, et al. COVID-19 deaths in NY nursing homes were 50 percent higher than claimed: probe. New York Post. Published January 28, 2021. Accessed September 28, 2021. <https://nypost.com/2021/01/28/ny-nursing-home-covid-deaths-50-higher-than-stated-ag-probe/>
482. Ciavaglia DR and J. Investigations into Northeast nursing homes ongoing as true COVID death toll rises by 16K. The Intelligencer. Accessed September 28, 2021.

<https://www.theintell.com/story/news/coronavirus/2021/09/14/covid-nursing-homes-deaths-investigation-pa-ny-nj/8280221002/>

483. editor@palltimes.com A and SR. New York health chief, Cuomo defender, resigning. Oswego County News Now. Accessed September 28, 2021. [http://www.oswego countynewsnow.com/news/new-york-health-chief-cuomo-defender-resigning/article\\_4e6877f6-1d7a-11ec-b7fc-23eab87d9a8a.html](http://www.oswego countynewsnow.com/news/new-york-health-chief-cuomo-defender-resigning/article_4e6877f6-1d7a-11ec-b7fc-23eab87d9a8a.html)

484. Care homes accused of using powerful sedatives to kill corona victims quickly. The Sun. Published July 12, 2020. Accessed September 28, 2021.

<https://www.thesun.co.uk/news/12100515/care-homes-accused-sedatives-coronavirus-die-quickly/>

485. Wayne Smith, The Man Exposing The Midazolam Mass Murder Care Home Scandal Found Dead - Plandemic. Accessed September 28, 2021. <https://plandemic.co/2021/08/19/wayne-smith-the-man-exposing-the-midazolam-mass-murder-care-home-scandal-found-dead/>

486. Did the 'First Wave' Mean the Mass Murder of the Elderly With Midazolam? – The White Rose. Accessed September 28, 2021. <https://thewhiterose.uk/was-this-the-first-wave-mass-murder-of-the-elderly-with-midazolam/>

487. News: Face mask shortage prompts CDC to... (The Washington Post) - Behind the headlines - NLM. NCBI. Accessed September 28, 2021. <https://www.ncbi.nlm.nih.gov/search/research-news/8835>

488. Evstatieva M. U.S. Companies Shifted To Make N95 Respirators During COVID. Now, They're Struggling. *NPR*. <https://www.npr.org/2021/06/25/1009858893/u-s-companies-shifted-to-make-n95-respirators-during-covid-now-theyre-struggling>. Published June 25, 2021. Accessed September 28, 2021.

489. Pandemic Market Oddity: N95 Mask Shortage Despite Availability. Verisk. Accessed September 28, 2021. <https://www.verisk.com/insurance/covid-19/iso-insights/pandemic-market-oddity-n95-mask-shortage-despite-availability/>

490. In the early days of the pandemic, the U.S. government turned down an offer to manufacture millions of N95 masks in America. *Washington Post*.

[https://www.washingtonpost.com/investigations/in-the-early-days-of-the-pandemic-the-us-government-turned-down-an-offer-to-manufacture-millions-of-n95-masks-in-america/2020/05/09/f76a821e-908a-11ea-a9c0-73b93422d691\\_story.html](https://www.washingtonpost.com/investigations/in-the-early-days-of-the-pandemic-the-us-government-turned-down-an-offer-to-manufacture-millions-of-n95-masks-in-america/2020/05/09/f76a821e-908a-11ea-a9c0-73b93422d691_story.html). Accessed September 28, 2021.

491. Cheong W. The US government turned down an offer to manufacture up to 1.7 million N95 masks weekly in January: report. *Business Insider*. Accessed September 28, 2021.

<https://www.businessinsider.com/us-government-rejected-an-offer-to-manufacture-up-to-17-million-n95-masks-weekly-2020-5>

492. Dugdale CM, Walensky RP. Filtration Efficiency, Effectiveness, and Availability of N95 Face Masks for COVID-19 Prevention. *JAMA Intern Med*. 2020;180(12):1612-1613.

doi:10.1001/jamainternmed.2020.4218

493. What's a PCR test cycle threshold and why it matters. Full Fact. Published 16:47:37.518768+00:00. Accessed September 28, 2021. <https://fullfact.org/health/cycle-threshold-values/>

494. Rajyalakshmi B, Samavedam S, Reddy PR, Aluru N. Prognostic Value of "Cycle Threshold" in Confirmed COVID-19 Patients. *Indian J Crit Care Med Peer-Rev Off Publ Indian Soc Crit Care Med*. 2021;25(3):322-326. doi:10.5005/jp-journals-10071-23765

495. Covid Mandates: Unscientific, Irrational And Fraudulent, Dozens Of Reasons To Stop Them Now | Covid Call To Humanity. Accessed September 28, 2021.

<https://covidcalltohumanity.org/2021/09/27/nicanor-perlas-covid-mandates-unscientific-irrational-and-fraudulent-dozensof-reasons-to-stop-them-now/>

496. The COVID-19 PCR Test Is Key to the Pandemic Fraud | Principia Scientific Intl. Principia Scientific Intl. | A science-based community. Published September 8, 2020. Accessed September 28, 2021.

<https://principia-scientific.com/the-covid-19-pcr-test-is-key-to-the-pandemic-fraud/>

497. Mandavilli A. Your Coronavirus Test Is Positive. Maybe It Shouldn't Be. *The New York Times*. <https://www.nytimes.com/2020/08/29/health/coronavirus-testing.html>. Published August 29, 2020. Accessed September 28, 2021.
498. The Fog of COVID-19 Data: How many cases aren't even cases? John Locke Foundation. Accessed September 28, 2021. <https://www.johnlocke.org/update/the-fog-of-covid-19-data-how-many-cases-arent-even-cases/>
499. Caught Red-Handed: CDC Changes Test Thresholds To Virtually Eliminate New COVID Cases Among Vaxx'd. Rights and Freedoms. Published May 24, 2021. Accessed September 28, 2021. <https://rightsfreedoms.wordpress.com/2021/05/24/caught-red-handed-cdc-changes-test-thresholds-to-virtually-eliminate-new-covid-cases-among-vaxxd/>
500. Trabert D. CDC: maximum 28 CT for post-vaccine COVID PCR tests. The Sentinel. Published May 3, 2021. Accessed September 28, 2021. <https://sentinelksmo.org/cdc-maximum-28-ct-for-post-vaccine-covid-pcr-tests/>
501. FLCCC-Alliance-MATHplus-Protocol-ENGLISH.pdf. Accessed September 28, 2021. <https://covid19criticalcare.com/wp-content/uploads/2021/01/FLCCC-Alliance-MATHplus-Protocol-ENGLISH.pdf>
502. Kashouris MG, L'Heureux M, Cable CA, Fisher BJ, Leichtle SW, Fowler AA. The Emerging Role of Vitamin C as a Treatment for Sepsis. *Nutrients*. 2020;12(2):E292. doi:10.3390/nu12020292
503. Obi J, Pastores SM, Ramanathan LV, Yang J, Halpern NA. Treating sepsis with vitamin C, thiamine, and hydrocortisone: Exploring the quest for the magic elixir. *J Crit Care*. 2020;57:231-239. doi:10.1016/j.jcrc.2019.12.011
504. Harris R. "Tantalizing" Results For A Test Of Vitamin C For Sepsis. *NPR*. <https://www.npr.org/sections/health-shots/2019/10/01/766029397/mixed-results-for-a-test-of-vitamin-c-for-sepsis>. Published October 1, 2019. Accessed September 28, 2021.
505. nutraingredients.com. "Ethically and morally unacceptable": Reaction to vitamin C for sepsis trial. nutraingredients.com. Accessed September 28, 2021. <https://www.nutraingredients.com/Article/2020/01/28/Ethically-and-morally-unacceptable-Reaction-to-vitamin-C-for-sepsis-trial>
506. Research C for DE and. FDA Updates and Press Announcements on NDMA in Zantac (ranitidine). FDA. Published online July 1, 2021. Accessed September 28, 2021. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine>
507. FDA studies: No post-ingestion NDMA from ranitidine. Accessed September 28, 2021. <https://www.raps.org/news-and-articles/news-articles/2021/6/fda-studies-no-post-ingestion-ndma-from-ranitidine>
508. Ahmadi A, Ebrahimzadeh MA, Ahmad-Ashrafi S, Karami M, Mahdavi MR, Saravi SSS. Hepatoprotective, antinociceptive and antioxidant activities of cimetidine, ranitidine and famotidine as histamine H<sub>2</sub> receptor antagonists. *Fundam Clin Pharmacol*. 2011;25(1):72-79. doi:10.1111/j.1472-8206.2009.00810.x
509. Nutrition C for FS and A. LES Labs - 593764 - 07/23/2020. Center for Food Safety and Applied Nutrition. Published July 29, 2020. Accessed September 28, 2021. <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/les-labs-593764-07232020>
510. US senator, NPA press FDA on NAC supplements. Natural Products INSIDER. Published August 18, 2021. Accessed September 28, 2021. <https://www.naturalproductsinsider.com/regulatory/us-senator-npa-press-fda-nac-supplements>
511. nutraingredients-usa.com. CRN: 'This is not the final word on NAC.' nutraingredients-usa.com. Accessed September 28, 2021. <https://www.nutraingredients-usa.com/Article/2021/05/11/CRN-This-is-not-the-final-word-on-NAC>

512. Amazon confirms plans on removing NAC supplements. Natural Products INSIDER. Published May 6, 2021. Accessed September 28, 2021.  
<https://www.naturalproductsinsider.com/regulatory/amazon-confirms-plans-removing-nac-supplements>
513. Harvard University Professor and Two Chinese Nationals Charged in Three Separate China Related Cases. Published January 28, 2020. Accessed September 28, 2021.  
<https://www.justice.gov/opa/pr/harvard-university-professor-and-two-chinese-nationals-charged-three-separate-china-related>
514. Research Sponsors - Lieber Research GroupThe Lieber group is focused broadly on science and technology at the nanoscale - Lieber Research Group. Accessed September 28, 2021.  
<http://cml.harvard.edu/resources/research-sponsors>
515. Shaw J. Virus-Sized Transistors. Harvard Magazine. Published December 16, 2010. Accessed September 28, 2021. <https://www.harvardmagazine.com/2011/01/virus-sized-transistors>
516. Why did a Chinese university hire Charles Lieber to do battery research? Accessed September 28, 2021. <https://www.science.org/content/article/why-did-chinese-university-hire-charles-lieber-do-battery-research>
517. Writer PRHS. Reading life's building blocks. Harvard Gazette. Published January 5, 2012. Accessed September 28, 2021. <https://news.harvard.edu/gazette/story/2012/01/reading-lifes-building-blocks/>
518. Correspondent CM-MH. Harvard researchers present nanowire devices update. Harvard Gazette. Published July 2, 2019. Accessed September 28, 2021.  
<https://news.harvard.edu/gazette/story/2019/07/harvard-researchers-present-nanowire-devices-update/>
519. Harvard University Professor Indicted on False Statement Charges. Published June 9, 2020. Accessed September 28, 2021. <https://www.justice.gov/usao-ma/pr/harvard-university-professor-indicted-false-statement-charges>
520. Barry E, Kolata G. China's Lavish Funds Lured U.S. Scientists. What Did It Get in Return? *The New York Times*. <https://www.nytimes.com/2020/02/06/us/chinas-lavish-funds-lured-us-scientists-what-did-it-get-in-return.html>. Published February 6, 2020. Accessed September 28, 2021.
521. Subbaraman N. Harvard chemistry chief's arrest over China links shocks researchers. *Nature*. Published online February 3, 2020. doi:10.1038/d41586-020-00291-2
522. Portman R, Carper T. Threats to the U.S. Research Enterprise: China's Talent Recruitment Plans. :109.
523. Krige J. Scholars or Spies? U.S.-China Tension in Academic Collaboration. China Research Center. Published October 12, 2020. Accessed September 28, 2021.  
[https://www.chinacenter.net/2020/china\\_currents/19-3/scholars-or-spies-u-s-china-tension-in-academic-collaboration/](https://www.chinacenter.net/2020/china_currents/19-3/scholars-or-spies-u-s-china-tension-in-academic-collaboration/)
524. FBI\_Risks\_To\_Academia.pdf. Accessed September 28, 2021.  
[https://www.research.psu.edu/sites/default/files/FBI\\_Risks\\_To\\_Academia.pdf](https://www.research.psu.edu/sites/default/files/FBI_Risks_To_Academia.pdf)
525. Zweig D, Kang S. AMERICA CHALLENGES CHINA'S NATIONAL TALENT PROGRAMS. :20.
526. Zhang A, Zhao Y, You SS, Lieber CM. Nanowire probes could drive high-resolution brain-machine interfaces. *Nano Today*. 2020;31:100821. doi:10.1016/j.nantod.2019.100821
527. Hong G, Lieber CM. Novel electrode technologies for neural recordings. *Nat Rev Neurosci*. 2019;20(6):330-345. doi:10.1038/s41583-019-0140-6
528. Human Cells Eat Nanowires. IEEE Spectrum. Published December 19, 2016. Accessed September 28, 2021. <https://spectrum.ieee.org/human-cells-eat-nanowires>
529. They've got the beat. Boston Herald. Published August 29, 2012. Accessed September 28, 2021.  
<https://www.bostonherald.com/2012/08/29/theyve-got-the-beat-2/>

530. Tian B, Liu J, Dvir T, et al. Macroporous nanowire nanoelectronic scaffolds for synthetic tissues. *Nat Mater.* 2012;11(11):986-994. doi:10.1038/nmat3404
531. Board of Directors: Advancing mRNA Science - Moderna. Accessed September 28, 2021. <https://www.modernatx.com/modernas-board-directors>
532. Tognini G. MIT Scientist Bob Langer Becomes A Billionaire Thanks To Moderna Stock Rally. *Forbes.* Accessed September 28, 2021. <https://www.forbes.com/sites/giacomotognini/2020/11/12/mit-scientist-bob-langer-becomes-a-billionaire-thanks-to-moderna-stock-rally/>
533. Moderna's Stock Rally Makes Bob Langer a Billionaire. Accessed September 28, 2021. <https://www.ceotodaymagazine.com/2020/11/modernas-stock-rally-makes-bob-langer-a-billionaire/>
534. Langer Lab – MIT Department of Chemical Engineering. Accessed September 28, 2021. <https://langerlab.mit.edu/>
535. Nano-Bioelectronics. Lieber Research Group. Accessed September 28, 2021. <http://cml.harvard.edu/research/nano-bioelectronics>
536. Durden T. Klaus Schwab: Great Reset Will “Lead To Fusion Of Our Physical, Digital, & Biological Identity.” Invesbrain. Published November 17, 2020. Accessed September 28, 2021. <https://invesbrain.com/klaus-schwab-great-reset-will-lead-to-fusion-of-our-physical-digital-biological-identity/>
537. Shaping the Future of the Fourth Industrial Revolution by Klaus Schwab, Nicholas Davis: 9781984822611 | PenguinRandomHouse.com: Books. Accessed September 28, 2021. <https://www.penguinrandomhouse.com/books/598250/shaping-the-future-of-the-fourth-industrial-revolution-by-klaus-schwab-founder-and-executive-chairman-world-economic-forum-with-nicholas-davis/>
538. ORWELL CITY: Official interim report of Pfizer's vaccination vial analysis explained by La Quinta Columna. ORWELL CITY. Accessed September 28, 2021. <https://www.orwell.city/2021/06/vaccination-vial-analysis-explained.html>
539. Yi J, Choe G, Park J, Lee JY. Graphene oxide-incorporated hydrogels for biomedical applications. *Polym J.* 2020;52(8):823-837. doi:10.1038/s41428-020-0350-9
540. Kim YH, Jo MS, Kim JK, et al. Short-term inhalation study of graphene oxide nanoplates. *Nanotoxicology.* 2018;12(3):224-238. doi:10.1080/17435390.2018.1431318
541. News · CBC. Potentially toxic masks distributed in schools and daycares in Quebec | CBC News. CBC. Published March 26, 2021. Accessed September 28, 2021. <https://www.cbc.ca/news/canada/montreal/masks-early-pulmonary-toxicity-quebec-schools-daycares-1.5966387>
542. HAF. BOMBSHELL: Disposable Blue Face Masks Found to Contain Toxic, Asbestos-Like Substance that Destroys Lungs. <https://humansarefree.com/>. Accessed September 28, 2021. <https://humansarefree.com/2021/04/bombshell-disposable-blue-face-masks-found-to-contain-toxic-asbestos-like-substance-that-destroys-lungs.html/>
543. 崔大祥, 高昂, 梁辉, 田静, 李雪玲, 沈琦. Nano coronavirus recombinant vaccine taking graphene oxide as carrier. Published online January 15, 2021. Accessed October 8, 2021. <https://patents.google.com/patent/CN112220919A/en>
544. Xu L, Xiang J, Liu Y, et al. Functionalized graphene oxide serves as a novel vaccine nano-adjuvant for robust stimulation of cellular immunity. *Nanoscale.* 2016;8(6):3785-3795. doi:10.1039/C5NR09208F
545. Recent progress of graphene oxide as a potential vaccine carrier and adjuvant - ScienceDirect. Accessed October 8, 2021. <https://www.sciencedirect.com/science/article/abs/pii/S1742706120303305?via%3Dihub>
546. Reuters. Japan suspends 1.6M doses of Moderna shot after contamination reports. NBC News. Accessed September 28, 2021. <https://www.nbcnews.com/news/world/japan-suspends-1-6m-doses-moderna-shot-after-contamination-reports-n1277669>

547. Contaminant in Moderna COVID-19 vaccine vials found in Japan was metallic particles: report. FiercePharma. Accessed September 28, 2021. <https://www.fiercepharma.com/pharma/contaminant-moderna-covid-19-vaccine-vials-found-japan-was-metallic-particles-report>
548. Administrator A. Japan Suspects Contaminant In Moderna Vaccines Is Metallic, 'Reacts To Magnets.' The Burning Platform. Published August 27, 2021. Accessed September 28, 2021. <https://www.theburningplatform.com/2021/08/27/japan-suspects-contaminant-in-moderna-vaccines-is-metallic-reacts-to-magnets/>
549. Franceschi Biagioli A, Cellot G, Pati E, et al. Graphene oxide prevents lateral amygdala dysfunctional synaptic plasticity and reverts long lasting anxiety behavior in rats. *Biomaterials*. 2021;271:120749. doi:10.1016/j.biomaterials.2021.120749
550. Soothing the symptoms of anxiety with graphene oxide. Graphene Flagship. Accessed September 28, 2021. <https://graphene-flagship.eu/graphene/news/soothing-the-symptoms-of-anxiety-with-graphene-oxide/>
551. SARS-CoV-2 Spike Proteins Disrupt the Blood-Brain Barrier, Potentially Raising Risk of Neurological Damage in COVID-19 Patients. Temple Health. Accessed September 28, 2021. <https://www.templehealth.org/about/news/sars-cov-2-spike-proteins-disrupt-the-blood-brain-barrier-potentially-raising-risk-of-neurological-damage-in-covid-19-patients>
552. NEUROMODULATORY EFFECTS OF SARS-COV-2 ON THE BLOOD-BRAIN BARRIER. CROI Conference. Accessed September 28, 2021. <https://www.croiconference.org/abstract/neuromodulatory-effects-of-sars-cov-2-on-the-blood-brain-barrier/>
553. Ohta S, Kikuchi E, Ishijima A, Azuma T, Sakuma I, Ito T. Investigating the optimum size of nanoparticles for their delivery into the brain assisted by focused ultrasound-induced blood–brain barrier opening. *Sci Rep*. 2020;10(1):18220. doi:10.1038/s41598-020-75253-9
554. Vu MN, Rajasekhar P, Poole DP, et al. Rapid Assessment of Nanoparticle Extravasation in a Microfluidic Tumor Model. *ACS Appl Nano Mater*. 2019;2(4):1844-1856. doi:10.1021/acsnm.8b02056
555. Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases. *J Controlled Release*. 2016;235:34-47. doi:10.1016/j.jconrel.2016.05.044
556. Pappas S. Rare magnetism found in the world's strongest material. livescience.com. Published October 14, 2020. Accessed September 28, 2021. <https://www.livescience.com/graphene-hides-rare-magnetism.html>
557. Augustyniak-Jabłokow MA, Tadyszak K, Strzelczyk R, Fedaruk R, Carmieli R. Slow spin relaxation of paramagnetic centers in graphene oxide. *Carbon*. 2019;152:98-105. doi:10.1016/j.carbon.2019.06.024
558. Sang M, Shin J, Kim K, Yu KJ. Electronic and Thermal Properties of Graphene and Recent Advances in Graphene Based Electronics Applications. *Nanomaterials*. 2019;9(3):374. doi:10.3390/nano9030374
559. INBRAIN Neuroelectronics Secures \$17 Million in Series A Funding for First AI-Powered Graphene-Brain Interface. Published March 30, 2021. Accessed September 28, 2021. <https://www.businesswire.com/news/home/20210330005388/en/INBRAIN-Neuroelectronics-Secures-17-Million-in-Series-A-Funding-for-First-AI-Powered-Graphene-Brain-Interface>
560. DARPA and the Brain Initiative. Accessed September 28, 2021. <https://www.darpa.mil/program/our-research/darpa-and-the-brain-initiative>
561. Joshi J, Rubart M, Zhu W. Optogenetics: Background, Methodological Advances and Potential Applications for Cardiovascular Research and Medicine. *Front Bioeng Biotechnol*. 2020;7:466. doi:10.3389/fbioe.2019.00466

562. Boyden ES. A history of optogenetics: the development of tools for controlling brain circuits with light. *F1000 Biol Rep.* 2011;3. doi:10.3410/B3-11
563. Long X, Ye J, Zhao D, Zhang S-J. Magnetogenetics: remote non-invasive magnetic activation of neuronal activity with a magnetoreceptor. *Sci Bull Beijing.* 2015;60:2107. doi:10.1007/s11434-015-0902-0
564. Magnetogenetics Controls the Brain and Behavior of Zebrafish and Mice. *EpiGenie | Epigenetics, Stem Cell, and Synthetic Biology News.* Published March 19, 2016. Accessed October 10, 2021. <https://epigenie.com/magnetogenetics-goes-deep-into-the-brain/>
565. Is magnetogenetics the new optogenetics? *EMBO J.* 2017;36(12):1643-1646. doi:10.15252/embj.201797177
566. Yoo S, Mittelstein DR, Hurt R, Lacroix J, Shapiro MG. *Focused Ultrasound Excites Neurons via Mechanosensitive Calcium Accumulation and Ion Channel Amplification.*; 2020:2020.05.19.101196. doi:10.1101/2020.05.19.101196
567. Ye J, Tang S, Meng L, et al. Ultrasonic Control of Neural Activity through Activation of the Mechanosensitive Channel MscL. *Nano Lett.* 2018;18(7):4148-4155. doi:10.1021/acs.nanolett.8b00935
568. Kamimura HAS, Conti A, Toschi N, Konofagou EE. Ultrasound Neuromodulation: Mechanisms and the Potential of Multimodal Stimulation for Neuronal Function Assessment. *Front Phys.* 2020;8:150. doi:10.3389/fphy.2020.00150
569. Maynard EM, Nordhausen CT, Normann RA. The Utah Intracortical Electrode Array: A recording structure for potential brain-computer interfaces. *Electroencephalogr Clin Neurophysiol.* 1997;102(3):228-239. doi:10.1016/S0013-4694(96)95176-0
570. Elon Musk N. An Integrated Brain-Machine Interface Platform With Thousands of Channels. *J Med Internet Res.* 2019;21(10). doi:10.2196/16194
571. Shu X, Chen S, Chai G, Sheng X, Jia J, Zhu X. Neural Modulation By Repetitive Transcranial Magnetic Stimulation (rTMS) for BCI Enhancement in Stroke Patients. *Annu Int Conf IEEE Eng Med Biol Soc IEEE Eng Med Biol Soc Annu Int Conf.* 2018;2018:2272-2275. doi:10.1109/EMBC.2018.8512860
572. Cooray S. EEG will combine with TMS in future BCIs. Embla Tech. Published April 8, 2018. Accessed October 10, 2021. <https://medium.com/emblatech/eeg-will-combine-with-tms-in-future-bcis-4841f7055a37>
573. Jiang LP, Stocco A, Losey DM, Abernethy JA, Prat CS, Rao RPN. BrainNet: A Multi-Person Brain-to-Brain Interface for Direct Collaboration Between Brains. *Sci Rep.* 2019;9(1):6115. doi:10.1038/s41598-019-41895-7
574. Six Paths to the Nonsurgical Future of Brain-Machine Interfaces. Accessed September 28, 2021. <https://www.darpa.mil/news-events/2019-05-20>
575. Six Paths to the Nonsurgical Future of Brain-Machine Interfaces. Accessed October 11, 2021. <https://www.darpa.mil/news-events/2019-05-20>
576. Battelle Neuro Team Advances to Phase II of DARPA N3 Program. Published December 15, 2020. Accessed October 11, 2021. <https://www.businesswire.com/news/home/20201215005738/en/Battelle-Neuro-Team-Advances-to-Phase-II-of-DARPA-N3-Program>
577. Staff E. Magnetism Plays Key Roles in DARPA Research to Develop Brain-Machine Interface without Surgery. *Magnetics Magazine.* Published June 7, 2021. Accessed October 11, 2021. <https://magneticsmag.com/magnetism-plays-key-roles-in-darpa-research-to-develop-brain-machine-interface-without-surgery/>
578. Battelle-Led Team Wins DARPA Award to Develop Injectable, Bi-Directional Brain Computer Interface. Battelle. Accessed October 11, 2021. <https://www.battelle.org/newsroom/press-releases/press-releases-detail/battelle-led-team-wins-darpa-award-to-develop-injectable-bi-directional-brain-computer-interface>

579. Why Did A Pentagon Subagency Dedicated To Countering WMDs Give \$37.5 Million To Firm With Ties To Wuhan Lab? Accessed October 11, 2021. <https://dailycaller.com/2021/06/07/defense-threat-reduction-agency-ecohealth-alliance/>
580. Archive VA, feed G author R. Pentagon gave millions to EcoHealth Alliance for weapons research program. New York Post. Published July 2, 2021. Accessed October 11, 2021. <https://nypost.com/2021/07/01/pentagon-gave-millions-to-ecohealth-alliance-for-wuhan-lab/>
581. COVID-19 is passing through the Blood-Brain Barrier! Accessed October 11, 2021. <https://www.neuromics.com/covid-19-is-passing-through-the-blood-brain-barrier>
582. Gaurav Sharma. Battelle. Accessed October 11, 2021. <https://www.battelle.org/our-experts/publications/gaurav-sharma>
583. Early Successes of DTRA's Blood-Brain Barrier Program Suggest New Countermeasures. DVIDS. Accessed October 11, 2021. <https://www.dvidshub.net/news/204956/early-successes-dtras-blood-brain-barrier-program-suggest-new-countermeasures>
584. Neuralink and the Brain's Magical Future. Wait But Why. Published April 20, 2017. Accessed September 28, 2021. <https://waitbutwhy.com/2017/04/neuralink.html>
585. Martins NRB, Angelica A, Chakravarthy K, et al. Human Brain/Cloud Interface. *Front Neurosci.* 2019;13:112. doi:10.3389/fnins.2019.00112
586. Lee S, Shin Y, Woo S, Lee KK and H-N. *Review of Wireless Brain-Computer Interface Systems.* IntechOpen; 2013. doi:10.5772/56436
587. Researchers demonstrate first human use of high-bandwidth wireless brain-computer interface. Brown University. Accessed September 28, 2021. <https://www.brown.edu/news/2021-03-31/braingate-wireless>
588. AI and VR Transform Thoughts to Action with Wireless BCI | Psychology Today. Accessed September 28, 2021. <https://www.psychologytoday.com/us/blog/the-future-brain/202107/ai-and-vr-transform-thoughts-action-wireless-bci>
589. Haselager P. Did I Do That? Brain–Computer Interfacing and the Sense of Agency. *Minds Mach.* 2013;23(3):405-418. doi:10.1007/s11023-012-9298-7
590. Mind reading and brain computer interface technology: the future is coming, fast. Privacy SOS. Accessed September 28, 2021. [https://privacysos.org/technologies\\_of\\_controlmind\\_reading/](https://privacysos.org/technologies_of_controlmind_reading/)
591. With Magnetic Nanoparticles, Scientists Remotely Control Neurons and Animal Behavior. Accessed September 28, 2021. <http://www.buffalo.edu/news/releases/2010/07/11518.html>
592. Brain-machine interfaces may be used to study and regulate mood - Science in the News. Accessed September 28, 2021. <https://sitn.hms.harvard.edu/flash/2019/brain-machine-interfaces-may-be-used-study-regulate-mood/?web=1&wdLOR=c97F3B6A1-B18A-433D-96C4-477F88B46A83>
593. Shanechi MM. Brain–machine interfaces from motor to mood. *Nat Neurosci.* 2019;22(10):1554-1564. doi:10.1038/s41593-019-0488-y
594. Opinion / The Last Humans and the Next Brands - Critical Mass - Adforum.com. Accessed September 28, 2021. <https://www.adforum.com/agency/6664937/press-releases/70226/opinion-the-last-humans-and-the-next-brands>
595. Bonaci T, Herron J, Matlack C, Chizeck HJ. Securing the exocortex: A twenty-first century cybernetics challenge. In: *2014 IEEE Conference on Norbert Wiener in the 21st Century (21CW)*. ; 2014:1-8. doi:10.1109/NORBERT.2014.6893912
596. Can dark triad leaders be a good choice for a leadership position? - Egon Zehnder. Can dark triad leaders be a good choice for a leadership position? - Egon Zehnder. Accessed September 28, 2021. <https://www.egonzehnder.com/insight/can-dark-triad-leaders-be-a-good-choice-for-a-leadership-position>
597. Silver J. The Startling Accuracy of Referring to Politicians as "Psychopaths." The Atlantic. Published July 31, 2012. Accessed September 28, 2021.

<https://www.theatlantic.com/health/archive/2012/07/the-startling-accuracy-of-referring-to-politicians-as-psychopaths/260517/>

598. Schlesinger T. The Rise of the Psychopath and Sociopath to Political Power. *World Issues — Politics, Economics, and More*. Published December 1, 2020. Accessed September 28, 2021.

<https://medium.com/world-issues-politics-economics-and-more/the-rise-of-the-psychopath-and-sociopath-to-political-power-b67ef9073477>

599. Commentary: 12% of corporate leaders are psychopaths. It's time to take this problem seriously. *Fortune*. Accessed September 28, 2021. <https://fortune.com/2021/06/06/corporate-psychopaths-business-leadership-csr/>

600. 21 percent of CEOs are psychopaths. Only 21 percent? *Washington Post*.

<https://www.washingtonpost.com/news/on-small-business/wp/2016/09/16/gene-marks-21-percent-of-ceos-are-psychopaths-only-21-percent/>. Accessed September 28, 2021.

601. McCullough J. The Psychopathic CEO. *Forbes*. Accessed September 28, 2021.

<https://www.forbes.com/sites/jackmccullough/2019/12/09/the-psychopathic-ceo/>

602. The brain-computer interface: new rights or new threats to fundamental freedoms? Accessed September 28, 2021. <https://pace.coe.int/en/files/28722>

---

## COPYRIGHT

The Spartacus Letter © 2021 by Spartacus is licensed under CC BY-SA 4.0. To view a copy of this license, visit <http://creativecommons.org/licenses/by-sa/4.0/>

---

## PGP

To verify, go to [keys.openpgp.org](https://keys.openpgp.org) and enter the fingerprint:

**6EACD2776157FA0F6CBB2014D1A7282D8A5559EF**

Download the public key and check the following encrypted signature against it.

All official ICENI documents will decode with the same public key. If you copy from a PDF, make sure there is a newline between the start of the PGP message and the block of encrypted text, and that the begin and end strings are on their own lines, otherwise, it will not decode properly. It should appear exactly as it does below in whatever tool you use to test the signature.

-----BEGIN PGP MESSAGE-----

```
yP8AASuPAnicrL3LbiRplibWo1kVAb2DLboHkSh3D/qNI6zFgEFGZERmkAyRkRld
tTM3N7pb0NzMyy5keKIXuRIErYTp1QDdm94lvZGg0VYrlXYCGtAbCPkCgp5AOt93
zv/bb05GVY8goCoygnQ3+y/nfvnO//Zf/tu/Ovg3/8d//2L43/74+//r3/zv/89f
/Rf/5//d/IW8/Jd/++789dW76OBdTdZ0zZpdFdWOXIIZIUX8kFVtHb3epNUqLZIO
uiqLbVXeZU30rmjSPM/444ODj+s0ut3GVRMn8vn3adOkVfTrL38f3aQPo2gWvZgc
TsbD8eFwPP4m+r vuowcHb+Up5eDg4HIXFfEmjbK6++0giotl9O7XX/7jQxqt42WU
FmW7Wo8ODj7h3/LDRZoWWG6SLqOmjB7jJIHZ7LcLIn55UYW9qZK0+hTWeXLqN5m
```

RZQV8tGsSL+UVbzI02iZJrn8M1q2KR4SR4usflyru7hKo7iRldyPok+pLCYvi1X0  
mDXrKCnbosnTuo5KeUMIK+2W85AlTbbJfpYIYQWruM7lvBa7SE5uG6/kZ7q0bb1L  
1mVermSteeReWG7TKm6ysqjlaZm8LymLZZs08jR5RFxEbZHmKf49kL/GCVfCbbbyW  
18iCV3EmF8mN20EUOTYtt/IJvLvS9lInqW1HOO1/GOTyvdzXdF6V3Mx6zTOZZfc  
U93e3aWVvD7byEfrNN9F5YPcl4gL69qWfMd/7WN5b27NK74sFi+nt/h5PQ5d2mu  
qxIqk23Jd7K6zLnVQZSXyf2yfJS/beL6Xn4/iP7YxlVcyGdTowOetLxyI1tpslxC  
DklWxBXHSVpjmbryBCcpH48bLjRudAnLUm45XshrW3tAs8Za5NLlbho5VS7Qdi9M  
8CjEqbfgttgu8iyJ7qpyw38LQZT49fn1T+8uhuNTOYNimW6yRA73qnwcyBMirIWE  
yVfJlzbpkmtOa1xcVq9xBUKQn7EAXGIlv9yWcjxGq5tMLgwUlavA/d2BZx799dak  
ybJtolo+2woHxLUc/122Wjf7vNKU+VJPRFb2KM+VH8snKyPWZVpkqRJJnj2kebYu  
y2UdZXf4eJXetTVZ5EHoLivkdEfRx7Vw7KO8EDvLQZF1U8WPwXvrLbaHBdbyCr0I  
0I28MM53P+NU8js+I9feIwUTr1I93k/tOhZ6qJNMvp7dyalvY+GNWn+7rbJNxo1k  
x60wPyik5m1FthJ+NpKVZHktj78ja3718EeRLNcORSklqxNQuSzqsWwhONZCobLi  
HUhlTkAelYEYq1R2+iar6mbgT7RuN712EQB6WVmxD0aEcv3iu6T6ZdtLuyKn27k  
quX4G1nwSKQmWE4ka+3vSD4IIRcriabFUt57cMs37Q4Ofv3ln37jaTDD7S9yuTm+  
Uv/2IMIqzbGxNK7I3m7Pbm6H5+VPw4m8+C4F+/AGs8Lifd1uRHKE5YtJHFbGxlv  
cAy4OKVRfrmVfY50MW1V8dorYULSNzisTeq5jhfpawWSbz3EtdCYPFzuVwXBN2QW  
4WXQ3k6uotrctTn5U34vn8MpJokIQMhIrPNLtozxaVAdxDE27BZZp7jB6Kd3799F  
L9xbymqYQaDKWWK5YLu2Emn4DUGZEg0ip5XftirYuu/Vkd4UJAiVofxWCAlbkw95  
wlqkRQoFKU8yfVpDqMkfbbVMKz2e118yFYMU32m1kUtpZQPcv3DWmHx15DSarA6  
5eZWznKJtz6CVHHLRSnVSnyzGubrYgxWbBI+B24skkfIQOHi7ISuIVtziPyi4Og  
KKsNHut2YIJTV/qTULJwLoTtUNkeC5Rf82AgIDrhUrfbLW5BddVCpKtnuU4bf036  
RXfxg4hcHLm+RlcqLAIZ/wCWxtbk2cuqdWSGK4tbkS1VjvRhazEhhpfJJQoBFVTU  
d2JgNC1kq2iytsianVeWjnUGUYqrhKxrZ9+XE7tDhLIIIXs3j9BDtzpCJ6y2Cz2  
Ofm1sr5om+hzK58VEeLO1jZKJl+K8BZ5QqqHiC6ilfCekiUU4YorUwEgtNmdknxn  
EePPQoUkDvr7dZvditlAcNMIpiVtQj/s38U6P7ezi9QBKD+9alMvdcJnK0S9xO2kh  
y0IS3NTvosRY2z6Xkb6pTKMibUXkgqju1YOj2wZ8wQWLS5ZCFJleJ3mWyzlHr0  
hIX5RIDXo+gsr8uB1zHgkqWwqPwn9upVrbCY8mfhjkIU1EZyUQVZ+gAtL1cELUGq  
xHjg2cbGB8Jbi1TMCZFboA8xKsRg8WRVpXpwD1BptGe2W9hN4FnRPbKynFy0za04  
2enFLEWPJo1wnnzsvlyGOCuEmkRKvInbJOODLksRA0VsWkT1XNQZ30JFP2UV7MLd  
qC/Xu22KDK8S2J28/N5r1RA2rVk3EFpyEg+w30Sa4zKGmkFaWEbk4zvRK9GLX3/5  
B7k8UDv0zK+//OM3kZD4egBiVZEjShdqHtqM1iiOsolhq0UrGGpCvEW6U+18LrZO  
rKt/V3RkFC58X81udklbjmrioQLkCVyMSCabJkqZzmS52lj6yA6SJ2y1n1DUelt  
otK9fMBBVG1HOpmzrFt8KaYYtb8kkPdGHrjyrQjVRk1LSCG56hJfFnluaghM6iuc  
zKcUCxfhV8qZNOYJqt0LMc9UBMY5ZPcu4g8oCdtK1YmstsFj2lr1aC03opJPFEMp  
xhxse9jqB54OPsRCUrTVSSXBb7Kaj0IKhw0pVq3ksWj6F1j5MxfyA6TNhdDXS4G  
ZnWeyV71rerw7BsDe2aA3g6ekKtVVW8gALdtvIGGi4XiSrwigbdyFDE07ADcujR7  
278YbES7DUpfDxXLEK0nlpIOQFLGqzYXimjWO7EH022dYQn+Xalca6wi9uzm4naY  
i9SL6t1m25Sb2gxU7t1sHyenn7eQarMDsgr7E7UvNiZlcyNyCcreHaneM/S8WBsp  
31CDSpZYElk7bkZjcYHnB+JZ01skkffL4husCadBKWrbOhoc20qSvBRL50S+PD7k  
Ajdt3mTw4MpK/EfRIfku0mwwwxvPHUyGcJG95suvdloleXxLZmsdiH3IPy3gDy5q2  
u3LZQwa3jw+UFdXmNvBgICUG4xkefgxvqGqiF57GVAhkZmOoqmwYB6E8HEp3tcS  
9KRCn3tdx7Wzkyrh228G45OBPA+s+RjWYHMqbjhNwaCJsUg8mU/zgKLrPljS5N/H  
+Pep7UoMKnqFoym+N52IGQwhbre6KWvYXhu5JBFIYvfo/p0VDinotwIJlakkJ0I  
govhMhOHatD9BNpyLeJsAbtPfhf86nwoC6WZ6nTqQJWf8GUmRC20LgQoXCqmipwD  
1yKiRDSO/UuYPK1gsxT6oyf3leya8i59X5CIM+k2zo+MI8Zhcu475BB9IOPtJvx9  
X8dfLwNtK4JvLdeGH4+mOPXpaRTIE8YOVJ5SUOY8XTF6G2VNi5jg3B8ppGX/WU1j  
MrAwIFUd1QlZ1G3qTwnYGTsvQmocRZ/W2Fkm2iu8TqM6tyIVFkJc8k9oYZ6bCjvc

+QF3edsXBgPI196eSOzd2TMasRIFUJWO0mLvNdE8ooWoTKGycgAjp7zX3wZiabMQ  
FVJvRjOQ6ew4CqU0DT2TCTwKUWBq04i3nNDblU2X1Sjb0rDtGLRcpLXYonL2WbxI  
Gxcc4R03sJTJmcng9mpF3xi5JAz1WyEiMrUcDfLoCeLi7v6ri0SPYfHNdRVBe1d  
qWh4KhZtK22dpFuxB3MSHjp1Tpbt xdqpaY7r6ZSHGmKj+eFgPtYYIIxvJv4Me34H  
MgplIsTZbd5P1Fqwoqe10d3W2KnBusESckzufQP7Oo5PDv8Gz7ovysXjuQRP5fdxd  
iFxjUqnyH82P8liT6G35iF+a6GaEDmdbFjncggoGGOk8eMdAdbEwmT8OUy5Fu1mk  
dHWEK9s4/ACJo4XhxUDOOluJtTSKzhHq+mMrNJvvBibnKuEYOjFQEYqOyxNQ07i  
NmrwSy4hOn9zQyOd1hviNvNT2dfRuNuXP2h1M4UjU7mzP7ZZci9bfJGSLimDGKdg  
IHC4LbegBphRENxKwatK427iuZU0uoUgQhY1l5UywOJptKq2sqNvZN9pXGiIQV2d  
SrcT9264O0G9s5ycri66tXZ39yAUOYL8L02Z0+fE08RkbinUxWeNNOjqaDI6mSoUL  
2QHDkV1ks2GkdkdDopabRgCu/IZUz567FYmyUK1+dv56MjqaqDY7mYjissplMWeAm  
Zch0al4XP+/k9RNz5VP9Z2POPdjEvV9YUOz2uHvMMM6XJezO0ot5ip+bs7Pb0dHR  
4OiyhIZ/qu0ju4V9zviGOBeOefmyDRySGHEKNT+8t2RCNBPbSJwpWduLbJSOrLe  
wLYTavvGLfAZubDYuZfRaflmZ8MgLEy8OldL0GgcwZx9MQCojI5g/RxPVlh5FYsz  
pUPbLjhzaak1QyRDCCvODDoFTtJ5+MYdT6/2j2TVp751EQ2S1V1yxah1x3Fr2oQ  
qgz7iVwXwijtos0tirEtI+6XzuU09ETE6dSHymOg8hDp75k5CJRss977fSBRaF/8  
0EwsCZwDvlq7/fPL+kSGJVSQB7RKJRiEiQADboYRRfOO4ZZcDzvkbqLGMZmu3cc  
8ST+IG6MUNeqTPnpsvC+E7YjwkmM0kcyOd54OxZRACTMHphn26jdGlnlSpeaJABD  
Uhh/yT23xdKZIEKzdGYhV7kwkbaXH25ubyfkDQqZjahl+a+ZbfAGxOGCUz2Bo7HB  
KpnloSRpeab3Limw9MdrkRVKOBfVv52IHDn98N6HW9FltZy/WKwmP+qgr8STyXD  
efQe9K84IpKy8zRobbfyMVFFtG/owJryF6N3uaQZKxJySadA7Kg0v3MmF2/MHQOX  
VdAuwuNEAohBI8cOw4rfoqOVuz2q9+jP0NFh75GyuFXaUGthy81j6X8lt9rCivKM  
+DRUJkp55WK7baM3vXe37o36/IDeijbJU7GzxZtCqrDxRot8GPZSvRL70g4kWqVF  
Ch7cQFDl5uYvUvl90d9tlW5z6EycraxSBAmyfdnnWGnRvYC7gMoQOSCcycGCu5pUQ  
bFYrSc2dY5gUxyfP6A5/CHp3GrMxHgPHqrUAi4Mmj0boVSbjqyw5o4c/YFSXUfBd  
IZIni19efndeRy/oSvKkqLdXGdQpn/HN6Ph0cHKIU4UDX5cao9G0GzWgnFmWDHxY  
Pr2jFAijiWbLixsgFlzoV+LIX4vmEy9F6WYah+HRhLY4XKSs3UQ4ahB+wWBDBiUi  
h8jQm/tE4a1M2YQTi8ywinLdeSUqvMgcDi3rTAy+mEkbl9kODWtsYnQCj/pkSsrS  
KKGPaSst+Zgw1Qr0L20bmGeQ+zVPd6U2Uh7v0mXPtegFXq/cAfA8rm/eyJHwlInH0  
PqZnfpvKx6v3Nx+m/om1yKvRCdz0kyMLmmBn/oKvqrsJQ7VMISAPIzf5GO9GJ3Cq  
T3nd/jsW0ILRuqMtk7mUt5KonGmSxyKil53LH4ufL6a0CGtEiqp4ubtH4MgiYUyf  
kYgexSxHhG4Bb0kOCNwib1G17kMFMDwAjQeYgs2ysfqpmWsmU8V6+1R/8ZIDXXF  
tlwcYiv7WdE21d3wGMViGZ3ihk/nMPSwF+RByAGesMTg+dKltJS7+Ekx8tXW5XGI  
psySIIn3vncvmgYZG4vk6GPhxlf2s+xj+aCfxPMVRoUhGLEuhVjNcmc1VClw9RI  
ir7ipY1OIU5OTyJzn0oXloA7tkzD++jORLzzdvIBNN53+PP8+m/VpvggbuhWDN1s  
C8V4HhzaKWNRxzTheoUQYRjc1GFARM7jDyg+FAyJGAypS/Qp46hHIM5BE6/yGHcp  
v8ippLE6+IY8PgaJyFICILigViONeoNwE2JqrBddXGzZbrYWyjyPJ78VYiohoH0e  
H4e7zeMalV5YoGL6tZtvnAcsa9qUODW4Y+DJ1YobIWO+ub7tLfLs4we5R1Qo4G7G  
hwzijYXZzy4+vNV0ZZ26b1C6iAz5govyJCeqPNhWvZW/j8bjKR80j267b5A7hFci  
xqKMLDMxoJJIPwClgNwev7Hjrxo864jPOo+hD/XpwRWcpPKOta7ZVUusnILLIS  
uRQtLGcXFWm6VL4M6bL3dIE8wqGQi8sUvxFOVS+P6ddf/kHot2y3uKhff/lHuwQ4  
QEgw+dnHMWKKv6c18kwWfgiOkTmm0ZhRxfGkcyESWXKtGhVmG7nkTn5Gk0e4dYul  
e7a3CdI6/BCL3hDzHO61M6Ke+jvyEr34FC+fDsaT2cHBRVbXmn3pPXWI4VBNQzsZ  
IDNEkl4JRdVIryKtVsgbN3CMlaMcy9fy7Dk3d6xptcYLTQh6NVtcYpLsRytxt+8J  
rzKFazbMNs434IDtcp/Y6EyggnWi8QZN/GQorEFWm7EPNUwhhfHfNSJ3osREDpVV  
LudCVPiqwsILzcheXcNFEcehMwc1jbMi85vI5YSNHIUmYoPolaxAHzz7iow0vzWM  
kYXxMx9Sg0Edr4Rgz+5YWDP0BVRgyG/UHhJ7ovwSpeJ+5tmios7QkKZfN5YyEMvq  
ITAKW83WLx/khuQVo/FUY/dHQiNdEBWsn4qf7aK/XrQI7axWzJNpGUudOltU0wnm

8aLyBEGkWIMwQpAx/b8uNF1buKigOzqUq8tAnT5fs4kTfFCWWLtfqRs4nsJeGM8O  
o3OqRCMQMZeHs/sBZ6u+QI1R3Qy1ti69szCil0xnUWpMbCeGQnWv8kR01J0aUQ+x  
fgUUVe0sdaRRV80f261Tbqg94AzuLcJfsFLN7kH6CVR8e32hWdgP16PxbDwYyah  
TBuVYdM2PPL4vi+gje6hBiAUkY53v1P1udnRvK2cIG+e/7D6luu8pN/JoF/4aLEI  
8DuozjjJlk4HZSoOBioUEleyKLJPRDDUV5dLkKR/DAS72ChxspbdUofMhOSuAnog  
Ucdi2Nawm4Xc7+1CvC2afrbKuNrL6D+rrQadR7/TTKhV1cieRMjVWxEucO56B6KL  
7J5L+wIFPfGmy+EhrAdZ6pe/93r5+zby7jNtsavXH0XYC/3OjuWuT6luFxcGC4MK  
kMbn/p23Jf4oXCD7WvdAGkXzSzcvUU82iBUOnIUBDYSEgthKjylwRfqUGxbQqQo1  
tn+2minYbBhFXbTCW6PoLb6XVZolKw9l2y3r9xothpRfyvOfENUouhI+2qD2iDFU  
Mf/z1ApBxSIAteL29a9x43KIGoVYI4uuB8OCwNpL/euJywi9vT7PsQqUGqQU4PI7  
5krb6aLzE3IGOekyvk8ukldJlaN7rzUpEXkdC8owwWKbW29ijRXqlrxk0iwL/12  
dcrijnub/Ggwnh9HPxZ5hkpcWJEVKOurLn0zLPbp0sVt+PO3ok2q4ac0s2t7l6dJ  
5za2nW2SSQ1I3jdP0jI7/+yyzujjof9kjU5g/56txFLfyuIDBJW3VYVImB46F3c  
6Jsvrs4GJKxsZ1+q56LkcgBUw0fiAIUrvtFlfntw8Cad/jb6rVho/3Q9+fW/+Q/R  
r//1f5DNTPCz6wl+zX31vsBfvp3IfeuH+YDrt/i2PuitvO3JBpl9fXISAYeQGNPV  
KD0KiUWN3KWh4h9YrV+BmOUCGgY1TneZs0pFTjHlqus0mVYmSVs5Jz73hoTQv1BN  
3Gzg/8hB9SSYWa+oCMlbGGJOYZEtQQHpd8HPtiaPwRW+vlsWg6RIjDgmE47LFicK  
S23rA0yqy/XJ5Z2YKgxTVZQTCD+1FSpdXIDYGZCUMv2xX6TUqaUFMXKmP6dWsLmu  
WNjWsHi1ryG5Zl3ojMZ9BCox2HpgpYWlPrpe0mbWLkOBO5puuqS0cABcle0cS  
RZ18LpDfl9Nb19YzpTbQSKNmONyGnPkZMrjIGPdV70MFwbXGaqPNPWotA0i/z0vO  
bqC5NhofT7jHOTQCE2pi/SbrslhW2GTdWoWzj22YZNNiDV9Daqci+7R4S40mhvRL  
T10pi/gdSMmJUs1Wd1fHgM1m39Bwy5Y16j2c7ivArKYUjodiluMO6XNrmtVqCRqN  
RxZplOKKaxzTi0oElrm+VziH9Fmyx3UziURDPiYofdUyMxhgo+hSlhsVKEqvYeAw  
Ptcu1Gugsr9n2s0iHGuLlvr0ovAmbVOGtoJKXgYSPCFauQrv3tm8/Wix2r6j8Qnd  
vBPL3lmNOaxZQx7mjImbQyLoS222dDI+dllu/IbiMxAvCOZXdgjEV5X3NvBSjQZs  
dbKsfY0t65kNxidzvbAljOsaBaqlqyEdRdeUzCg/xlpcXIjzKEIbK6GVxWetx1bN  
0rOtU6R8Uq4KeY6V0ojNU4cVmc7Kvr59XdMO8hse+goDJjbExsWiRSueHFMsdxb  
IHzkLh5Jxt5SmBVuFbx77+oNnlDcVcfS6JjDI0c1HQrnJX+h5K/6FuQlZ1b1H0x  
FLxmo8q2TmRbp12oTwstXJVCw2iyHg0WVpPMssnEkjWWm2dxEgsDXYmvBSkTVGuq  
OBiNT0mGpxO2PeC5/nNrXHBhQeGODawoY59Plmy/0P27ejX+log3onSolKOuQdel  
dmm2QYIXBLvV2PR6Ilw07omJKSpqE1f3cLNcjByhirLZVchtCX/Phm+vXpuHg8if  
OM75MhWDYRT0KY23U56xy9TTQbGsQZq04oxbcXZYidrZ2z5DYHE9bgRqz4cf5bco  
ruxir5b9ZXWwcPDk8FD+P/5zNYX4DGrIdqfRw6c3jn7kpzP+9AgV+s0zXzqW/59Y  
xfzGbGTv5foPjiaH8AUm40l0/YDunXxgBBxUdAX1Wj3BVG5S1vNrJs87J05mpN6E  
dEWcFbO+dZKq8Z63Wvvqr9Zpi5dIKMcQXd/V4CXMhunJayEtk9ugm9GEocXJ+Egl  
KMTM8ri/zhcVGllqDfobKUGA1xCO70vXAAURKYzy4ez2PHBb1YYDB30o62Z4Rr65  
feY13whLikW7rTJY9BoWTjcsKWkIx6rKXLUCYruU29mqTVEvUyfgJLE6CuboPtPh  
2qKWUdfg2gBgmTRryyyNvYK0BMQadFGROPL/glJel9q/K1cDq/jaxrkITWeroR1J  
tCAuAiWbjZaripFViHTV4sWudiXvWnFWMfYlpy6kNT6xrDAiStlmEeex6vhIYV0  
EhZaljOSLdrGx42WKTNrGyOJy9cvz9/cyjs6w4F2aniLendX1y+vr66vh9GFLINu  
0I4XIXH6Rrx2saaD7tFyrn0QppWFNGLjzPZAIIretMdzROtOZkcHhcwSmYNTV9  
G71FvK7HQ/0WJ2WVQRDi7H243oktV2588hz2M2qjvZdozPDu/EfHWIALWkUuW7jl  
Td6Muiqp7E6jiM+vyuXDA3ml+oFvXzj7WnMe7lyCCdisU12ldiBY4VsXN3QdYdkL  
QfHMrhBKPLqwMvyj67aqablWaHTLU+CHd6KdUXVnY3fq7I2pdWu8qwryfTtXa5z  
yZmCA+tnZHwbITVarST2xCAouYaFLP5NUKXNG2AfItbUdf1jbEq2hQvBjFkzPl0+  
4fR2ZeVenVKiWvC1REao+gf8pJb6NdaGimKRO3QIm9kt1t9mwYQjoiK7MMdvyZhr  
CeiFhigtyk2yHk6QwTSV/pgyO+JMfpGXMJnPlmlBjSq3IG2ZacNqX1iqesB2oIGN  
b1RkX0882zI8L6fRVrU2SMES0XDcV1wdIJbr8/bNXTk5qryJip6uipB1g6EnYMEN

F4fdb9XrWTOoyNrakaJvT/wwC33Npn/jlisu6g4VPbKu0+O/kYVQZ04n0Wuruerc  
CBFOXQJ8T/lrSWS38tFkasb/8zRjCtWv1WVxjTMzbW17bos07A1pNsyiwCg1yWk  
e1nWvu6MrWlIXKinvuxRbZC6honkGgWh/esSq4yY9BDVbF1GYR1j0GHsChqrNFyS  
SNHpbDCZqOrYZyl+soT2Ck04TbYM2ztAer5HsQP3/DnC9Gg4hUy3HUXb8TEXPLn  
SSa+vf2dlgXDCPi3BT3y/TfDUZ3MjsWXGr7yUYT5nKZYqoZYxvSGyo6R4SUXMLJ  
OltSKyAwyeLhutQkMGr8JzMSqpmWPmQRvt1bkPG2THa+8MBZzeokaPMzWnUYSXI6  
mru0MZMIYcXCMr2LkYLsIuU+ZfasF4k+HjgioRGqjeR2hPZ7F1PFAZj2Nntd9kqO  
QC30bde/BfFn8KV3ZtC7irN+40HKqj1lbArNAZlPX7q8YAr2kocePRd4fCcWyPi  
SVT7JXq0osnh5HA0mU8QHzkTmyznT0TbPiJgGDSYoWItq1gRgnPvNYrEX2k1kgdp  
o1e7iAUa+lwoelZNTZh1y4lj6aVt/9oiwl1rauapzRnbDIXPpjPg0Imc8jAfX9J  
H1tnYY+6WQQ+mZ8A/iLtfMCuUM/V6/oC0iJ91DsQshpoq5zTnPjcQDOOnqu5lmjFV  
JcJho+iiTNhu7HqRWe4XCvtAVKJJrxBvKEX2GZmVIAJSe5vps2Q017QIIXEAT38D  
hmpIUQW7zYTsu5DQ1+qoeT7OYRaHcMvWEneGaJ/PTweRIDLIxpgaNjkLs+6gmk91V  
q/gVNzGkBWMN51aX/BEhUbN5CsrEJ/KSvnixeybX7c0Duagmukk3ciT4iNa1/hDn  
qGjQf7w9/6+6rtx3D+jAll0UrkwTsTK7NtURdQb373f+Kv1xuDL1ncsOJ5W4pq4/  
kkraKpc6V/f6i/xySQMC9Skj8zI3r2X5r29+z4/vnAPZNVrTCShlZZnGTDr2n7ti  
BoveTo7Gcg8T04no4UvYq+qgOnreZ8sGxdjDI7AgXulUIxN1mt7760bYRxeD3Xlr  
UcMOehd5iQzfNgspDzdAYmBQ445+h/YQGfSGLHYavbvzNhtMHkq38aGQ+w5ZM3EZ  
fSeB+IDds7XrXlt7GOzHsu40gLirg1weqhRgs8hxqVFNSAgfMdGg2cDaOVx828J8  
iotRoQ53o0gWsTKv9iOx++EZr8CVBcoWZ2aNp5rJ3MX519ID2IHx9YMGpQz9MKy  
ptBsA8+vPfZlh19fUAdEASSDlglfDmj4Lk3fLcW9sm674haXrMjyrsIKkM8yPKHfr  
gPJ0xw7NJmu6gK4BA9SiosUEKbryXjE0nGR2TnuwLOv7MVYLQ2i0Eap0GJCE5Wrs  
O7AArKzOSAr76NEYakjXuzz+kgVuCb1LTTTGrNNbVGhrRWgcd0ZwEF6AnHeTe7vp  
mUP2rS29p3Rn7VjNnXlgHT46R9GTRYflUiGI4cvZlqiAoij7mgQZ2S3Z5dxZ37+d  
MGWuhrlwhqKcV+LNM4BYMwWJpy2yOMyEob0zW+oJdRa4K8S9w358vCJoctM2HPeQ  
tLB+ESEkKt3jQ/AOyOSRDxsBuFmmsQh4+Bnn95eW6CyWJlz1XfSG4Wakku07MCe  
0Df5beIpQB1K1bVi16en8mMRsexOSSOuroheicA4M1fFjNtL0aVxRIHhYikddMAa  
GZguTo+Fn6+z9C7ypl90UY2i27Ld7GlxumLWC6DEA3eFwDvgmPS8g0MxvRtsbnI8  
IbVCBPmfOUf711/+QY4flkX6KKZMWv36yz+Oot+n2ij4GTOmOFDyvi/GJu0uGjZ  
uS8Z8WQbpKwmSKg1JqTr0owbraDLGTVCP7g+hToENexKf0sxG5YWtkbpIyC2Eox  
IFtCx0ebkHPqLIm4szDycg55G6QhNfqEz9ZkZJ/xSefU9gnXk27NakRfyT42M5  
1RMvIMRwVu9zFL4BD3n2CXHOkNMCHS21lfjBOwtEqtboV/bLQc9WzYp1tsj4MbOA  
EuTDGGNDDJvfzCrE4WnPqmhdgC9y/KdiPqbm+T7y9EKVltjooace8fFbjOYDLwO  
C5oR5qJ/is5b1p1OjunXIEf3DoxSrHJctDhGwdMRIKqjvx6PTg6NoBxww3woytzs  
I9HkZNYz7HyUWQFOXMka+8rdM1GLaQ/tPSx02uXB8+hVgLO1LAFbwL+2SHbjwbWQ  
fSyWcO8XoYRYejG1Sql9rQBnUWhEzA66ib9sRSVxtPeW7CPXFC1clhr9phubsqG5  
7d5DC9Lp26+HHVXQK0uA4MzWodvr0DVoxsbsRh1Rpulr5VZNx84TNenBogM5zacS  
Y2GF112mTGlg29JmuRMZUViZu3ocuXciEF1g8zyAFDpq/iqukHUOfE6BBbK0GoZI  
eG8tKwDLx1uoHC1w9NhAPewg6IL+C0eppEKFgA6WOBG3marWajGY8rXmzSpmNBIN  
eUoRLFRYPEMfOlsYbX7MavpaeDkoeKInVGInJy4/xtbvVhncGz1qUCKdjqiMCoUw  
H7fMtqL5USFkYZswVNOFZqwgxoduOmSf5+y3LgEnRFBnC60+1qhb4FpZj48CAyWN  
IWAKSbGp6bmkGSusl0tPVyJSmAzaKJBCd9VMDmhXEDS9NIFqFRbKqqjtFypIBwC  
+XuidPkZ9b1fDRGfit47nYkG1SdkQWSqH/nqwAWZcSttxeCxLr4tz5tztXsxLkQ5  
fb55EYDxfKUU+7z8SR510iv7dacemA+LtHnEKXRt2TABXbt3v+OEfFEaFITvYwlb  
E7qWUZAc0fR8ELcSp7iEQWYJGe2yYQ+IUQY5rxI3DvxiFDHwb7JGradkG29ycU22  
oMQQlmy10igcbYi9N+z2rxAEMj0cdzGFJz1zFSqxq9Sh/iEGk229CcYidNd+ONRu  
Udf5aU1zDuygF7/5+Jd6RdWz9MQqOxHbpKzhqrSSGKYk+qvTGmX1uAXXkOpOsZGl  
vKB3CTyXKPO9wg1NjOj7eAtMRBZCpkFabDQ9nPCKzI6AwgoIuUDOQUPXpA+o0i2

63gvMhDCtaRlcSlk3YTtBd1yAwwQhtbVQIH0gSAkwloPogR1laYiffS9x66NT7Yy  
51aOncw0u9wZk0ZBIMO98wZL7vKUEtTWxEPy2cahZht91gtfSDflKi8XisPizfSS  
jWm9st642W0VG7V3fgROYzfPdDyOLvtLgADuGimfCNWncaVpeNLhZjIQ2nEl6uPp  
QTscMy0Ei9XUXQTUss1mOyAzJiZk7dNVVj52cXN2fk2RflG28uzhLepqYYvcXJ1F  
Z9ZxKP5OXLMT7DrPViValX7WrI76c8h+DK0nZKh2Abt6YHrVxJiiJkZNAPM5mqjW  
CMvLdx+5nouKMJ3vxUXWuOLF2c2Hs0F08fHmTGXW1buzdxfgUng6g+l4Kv+faRwJ  
XXZM8lj5lbHXt9yP6WrVFbER97sOApOgKD20GrvtRNs5V18III6yYkpczU1g/0/H  
3s8hVRq3oBATfQzCq5sMpQQOKtAV4tJFZ5NhWvwcy2OOnrpLlqaA34VKHL/2Dzc3  
tz/RhSorrjaAA4DHjqQWioNXoe5xynY6VkilsspW9ECzAoaWjhSNIOBwfifyXQgYZ  
W8gftSjNwJWFd0qtiEuq8nPdwJegQucrsqVLPUBaggEGLC1YSqdXWnRjrcKCCs  
xBScjk+eSfwzGGw4WqyNsRBPP0ZyB/eWZylqhpt+9ZG6PJr3pxWJRElqVE0zJ1Wp  
+OSKehhd3anZOoFdrGFyU197YJuukdooyXwv9TBqlxj8GIRm88Sn7aFjqk1lgXRL  
IdaKlwnNACRWdBXUXwXLZPHRnesfWgBFROieFY7tFtFFxGYq9nmonebyl3hz91Dz  
C+q9mgOoyox9n30oujiriDs4sfhhQ18ICajqwq1blqyTLUP0EDChvTiZEhRGyA  
O8sK5NAM7elAsYYBdn5xvhpsc84/sqyxgkx08MVNxajCvl7+mwKYdEGEDWJYab  
YyXKK2Yt0bggwipbOhjWDqO4035dHvgRaOMDc2G6W3cA27m29alkFyagmTOxkh0I  
1rvYIQj2kb6J3LC3SHUYy+DDL+d7w4uwzFJQMAORYGBEgfR1AHzasN2TPo2wDO5  
8NXO9S6oKFGB4x8hbD6aTiwFfzQEhnO0akWA5B6dNIDcNt/WfNasyDzo2Y3vuKaG  
qaoAjbuUJwC6goe9h3ZrYXAn9sfz36JSVaxosIn7grctUKoFK09kfYLGkgogy3GO  
3upECVN+E6IRWQBMVia7m/F+jgC4XLly/vreoHRzxD/03xZldstHsYmuxCCPRgGw  
gAVj1SzybH+X5WCHzpnXeG2IlctVvFWjVT+lbVQWvYSTwVqUXpeQcYqu9D5NtwE7  
cWVKSGBxWgYoe3HIM+tSE19AONPu/C6ObiulsuWBauOnICL6AGeusQOAyVsU8gN  
MLqOs6V+xQ74eDB1FSIGEznsBbr2T8F2Gc3wp4hS0NThpjMHlnI4Vz75MD48DA4E  
FviHsw83L8/ID/Vpo9nhZhNdnX28js5f3Vz1PpyhfzIHsIDmUSTs6QowtHtI7wkt  
s0vYZSMrEYGRA4TWypyEG5id0e9alcy6dLhAeqPAi5FDobQAnuF7CNs9iN5Q12i3  
ixI24g/pI2PabXOHVlrv7FVqgS6g9GM5kFSzMZ2EGE0V8286jy4UYbcxRBU8TBs4  
5PmTw8PpwFXLnW3KXfQdmn6JIJfQoRQXQ6yBKlWEHjeQUXA7Y8DFrse9uhhritGC  
TyVI2QJiwUQN7pJcMb wz9cOnrDWZTp8zHEKIIqJeaUNIt2cY0s4E1Dthm5FYTWB9  
YoZrXaoeogFLVXA++SbRvJD0C23upOgXLSyEvLJ6Mrffnoo0nOfoAjnEqnZQd0kX  
m+pBu hLUFGh3XD u4Aqw7V4HSSW8PbGRX2iVkxBonPDlscPcyM8GAsVYrQytstoc  
z0ImWxTzz2Emw4SIVeee69S2GxOw1AwREFOSxIQ/3ZLCAi+iL5dMirqCRXx+7+uA  
XKW95nRa0X1g4AsH7XnwvNgaJ/RCvpoJX13tA3rLk/zJq6DWIRbd8cLViSvrtCOX  
Co0VF+5AvS/Z9Xc8A7u418KQ1YocZYW4HXK4o8w98PAQODxiaXTxjM/Qrl3RGE1n  
4h7NZgcHZ90z99Gjw0wAMEFc4GV+xUmgSEpCEC2GnRld2HPDvz1foaXnfjWXrZz  
bS0sQtwAIsbALhWfU+1AwlgMgX5PPdv0auSbPsi5ImfVrmlDtjqXrR71sF8RoCmH  
5uMK9bsvgwEYOvw57ZnwRfqo9TNalOXz+lp3QoOttXC3X8ciRzfOCFavhjg7T7eO  
tPoTggH1DhXLa7ylApUnRpViOrCU2qr7rUyA2s9hgxON5Q7+9vBVVI59hLnuX6Oy  
IEy9wlqvGsPkkadlaonSABLpgNJ4bc9el40aulrsjGLoemvAYegIYGFBH3/7Tjdh  
ZT8oQRYZhkB3AEgAaZzhXTwZT6uZfGZTZlvdgwe+Ek6CrDDfjOPb57IOoREyQcq  
cuGOBhWpKCYDSAkrIjXlaepLIMUGUQwRMqvStMzHNfDziuMlpzSq7JFWZcb10bj  
v/AEbWSpLaZfx+6i2/5Qjqbz8WA6V5u+Dr/Z/zjXoqBnXXr8KdhZryNVKz+TdWkt  
H ZwNQg27B3K3LME11s60jLcM8faFkRoSBm5VFkMFFTP8cBMy3kjseazPnOlX29Ac  
NINOH3Aicp9u79Ay9Jy5Z+pnwDdXRrzN1zfFaIu1yBmSknaKPrs0B8Nnms76vizO  
MxeROp/xBL//d99rKTyGGvxBqDyJe0xZMyugre2EGIO7mRBZSFekRami4CElhg4U  
/xMYOvhNtDrcsARG4p8ypqzMVdr4NdDi8rgyRF3Os2VX1cjdZXykiFvXJaV+2tvX  
Pwwnp1OVPK9vRudHHv0oAKtK0gqyAyyXaT2IXBsHXiEcC2tTmxctEAXbC5xwJGd4  
/AzgXWikdQhznu4UhRC+vcszdli4zE64INTYOHG1J68phOyuZhtxTQAI2uFM2Jgb  
IMnIGmWdYlfqu1wEYdEnmJCptgBAEruoemLnpF5JZUUn1sjPxOQpp8TNs/JDr82G

njzLal2Fj4+u/sdnoAy14G2TOwgJ+SAqCGC43HdtpSKPK5cnkbcR GdiKdU0KOawu  
OeJRqkIzVziHo7be4xC18gm0kD7M3M2kZGjHYA/YuxpoA5vxpYmA+elgenTYNd/E  
LnFLbBzsmKWS+mSmRlwY1N/McwqNmWGoCH+Yqmn9NS6zpdng8e75K+S0GqFyoEMI  
SbsxEGREfRI+zBhsQy7H4PU7JDKNFPI4ikH62+yFpSLHEv2s3oNC3IMgfopFRytP  
HGFYgW5UG3XEaHo0NqHx3MmAf613V9YTuzl4amfYT Xmb3Mtxo7YZgs0bxoyuVtrj  
Wptt7qDmlnuwcLb6wnek1la6GcgiPNhfjvYR0fnifDuLILju3cQhYyepVYHFjWxz  
lqQzRV45MFi0iKHaKISmfK8Fe1cZm9zuLKS BchcPbQjq9GAfnW3Deu9U5JQv86M  
kBXMnpjeSnXhC8TL9sNN9C1E1MJm3hc91ogaY48ZEKFYY4XeYC3R05uvLVDLEZ  
N1AqV8cORRbLkfZOBW+BN77ZWue5eyMqvfgkZheYK7/jTjyavnmEQL/N/WNt7AN6  
n83a96/Rz9d7dS76Op yxt42cC5WhXvhRs ySRWIZqGvE0RQIkDFlg8mItLSGMITC  
CBflOdu2QGsHfojwrUOnfUQoJIKlreE2+PYovCq0MkcReB4D+7CzBi0rotZXBqoT  
n+ToCLcTdls hTdXdY1sVJYUZ11rglpwVpa1qceG7t7TKYukpzLOZCHli+0Jh+ny8  
mzGVtpX+AvMxjmifH50eHJyb3u6cyk4iPZ0YRYeQHy3zHXITlvQAYijmT+TH76DK  
RcpZ3I6IngYg1iVD63k3qqcWwSIOWSJCA1Ysu0zVuBCS q4j+ipotrSsWcZjVG4+n  
26XrXwSTMEQ4ys2ZV5MAZa+qv6EZqZHkZWh6fBj5ohuXRzUglWrgsYuOB TtV0YDd  
phbiB3i0wxgypQWU6hKBqt izc+BVIISBY8KEKLIEAgSDZc0BPIVbjarPTD7damd  
iLdyVprR02P0QE5RE/nEm lBWl a6ZjQ4jsOWKYHi3ZysPbcnQosJbehiqfnL7Wlyi  
Y+JmMfzQNSeY1nx19XF8NFIMvJTTrKEV71DV iOz6Ux1VaAhtINzD7WaiuUjXbLr  
4/ubGTiyhxS10mw9rh1ryOpOMWErG+q2A/OetrAulwuW HtZ8sASlbc rQKfATkLxM  
9oRoVgkRknt9tYwUdKlmvc3Ts luNpnNZ8HDST39oznctNpoVw1dxJXu4tTbmQfTK  
wUx/iPPa0jC+chPN7xUhleTyKpbw6qyHfiLN7sgjmj6DM9C5Rtq/t nOQOVOil09P  
Zs8QHPFvYDQxQecwIDkDAaY7aIKhhsS8PWuWWWkZBwt07TuQKauMdWRNu lKwWB Vr  
wrzFcGyBdTRM0dgVQ6bcCvfWsjUx DzMUsBrwhayYtSQnp88luc65GDyBw+daevlb  
qgijDwWrhsRaGfYKJU4P96QtrMbdLHrIR+uM1ZKXYNSP6zfpcvWnh88cscVtarXF  
2hpO6oebmzOz5PUUzQMXGidcayi3R9Eb/pDiMBigoB6QE7MDh+2pJaOFJkE6ZG3X  
AKVrspv0aJeAd9UGtCVaBrQkjXJMjwMReO4xy5dDFK58DZzU9+jK44NjgAhnITML  
UFLCV/jlomRbDxd0liWwLQcOIWCNNItOE OIGmzbxhpU8Kzl vEvbp9KuSdFuh2iVX  
St/ErsfU5ilqvHmXA UOEUx7KrOHpkcLU82GiOW5eXajecTCp6RZTSYY OFc8bPxa2  
oGSON7ucsB4AHl4ZlhlZK2ed6YDDUBnPHylUS5UlwwmD6L36eMueoWk1QW7mFA3  
ulW/yimNZ/nP6zTba l3yIArmNa lDRv6TG9XI XvbgsWmwzWMfz2HcInAGFs8U7Y0V  
xmrLdgDmDT/bcEdeVYEWP e85UkgOFYVjoV kD9Y+LjvX5Kv7aT7gjdHj4eKLKeJrb  
jlo1MyCcA7f3EgQXGm0zp5XBjaLKa3bYY02z4/Szi1QURx9k15fgXgDW NFUK+tcN  
2mSRsQ0ymh2O+e6T6A3ZL8iS4H5phoAXaGP6l3cm3jMrM5Q9YyNXGSZLGwVWEw6z  
i2rZZ65dBdGZtyxusylsxUcaZgEnw3pUnfZh0nRLFJLecIRAAbtBpowhKMzMMC1s  
Sq65IFlh9akaTaOLy1LC3idROyAHdzqYjdIDpMcevMolfOxFQdLHHBqEQ/1EU0UR  
p8QDQKyboNUFJ3tJG9de9eQRwf sZMTVlluLxs4gkduPo2JbyER/PiYhodmeQguNU  
DueD9jb7exB/bxIPy+Vw/8On9/J6z4xi7YpnKFqg3juDJ+7N+uoSI27cHz/kK6PV  
E7QiP/JC9AZRHYPHc2UCK9QqoOQg/OSAwVzE+oJQs44H0CE0Xbx FycO6K6HV5YEU  
SwMVTmJzWbjsdDERGii13caZBs11wH30pPjXhxLaxM6jk6LgPTN/cl3wXK5IKM r  
nxP3BQWmyUBXnsZ7IDC2I3VY1NsO+kSfJltkOFipTqBzw1PRZMpClwQzHMHA FQ7  
Nxo89JpAPktXW29t76SpQlsWxIAZRbdxUd5I WtEpN/YQAxHRmZr4ot24Fv2Fbr0B  
/LnovS3L16Z3rZ31XojfDHwTq0X8p//xQcQkoaxmg LJ6pwWYz1SAuuvR4p01ZFqx  
CiPkduCx Fgr5oub9q9V yGG/PP7eFgRzlxJoKPCy wVRYAc kZRFyUcspxaTzetrKuo  
27PxcVcQrMWhbDbaCy GTVrsEr8dEVRO6i1Z1AW+R2/Qp3F30MnvBExCwSJc6FoiP  
uLg66xl4d6lhPMHYNE3tf cqK3ngaUx3v3129Ho615cCgfG siaRnyBhOWy1SXqyu3  
oJnG2sK1u9kD+FcLkxECwiJSZVt1Uh6FWTh+SSx0Q28IW3wd/FtBeU0aC8/ftjC  
76wYQoyO4HZililYn8bg+qZGYqahZxwvBUfoeMdHiHKH3z+XGNm/O4QwfLzevl0G  
8+IYsc5yncy97NCrXfCg7mKVT+RDEXTZwq5AcYsuust87Poo3vbYp0t38jGreqHd

2nsOQZ0k6BwQmULnNK6ehQF7BX+pTFwTUZiO6qRMOCBLH+zTt36lvcRrgLSrkV33  
jk4uP81IjalzNhqaTaM1dxRlvfmhhhVXIXK2GwceFIIQrxlvru+1Uwd2cu2Dub4Y  
wkBhrXUgdEudbd8Z7I81zGWIXdFIUSqiqs9elix37upDn1w2E+30fznnYqOFmbXP  
fViG9I5lsmGhD1NB4lbFcLQ2KFIZIO5Sbk1CoqwRK+pVR527nuhzP069VyHIQ/5W  
Bax1bcvUFU4TcVepYkTBpzkcz1xJuLLQbHQMMNqVQFkocIM2GJZ3Qx8McsPJ9Wpz  
rYLViSDywOPRjJBjs8IUpZ//+KPBUlgmYXPjO83bdIzRMWL8ZVsR7dfrmLsUiBK5  
q5JXCsjHjzDfGrFXX13LQRyE+fbNRrMdXg57V7iSttkeu5H4XPQXPHj1XI0jhI0  
efQ24/RRcborxKRiZvn1Tn6D1/sD6rFihQm08neaZ5ouBNThcuCyE3JbnIlzMAI0  
R4L5+rE+xh4DokTRVJN2Z7T382eWPJvMBrOJG9v0aPEXkHlv+Tnhv/sLBNPeiZYu  
QHbhWfLs1In0B9niKs8Mn0bYII61FgtU3Lxy+FihXFwMEvSrQKrYiLvZ5Kh3PRu2  
VKT950IXoiNi/2hEl2Vb5HYAfnstaLVGubaxnXN2SQO/9dPTHJ+kEbIWxbFCBgS  
P43r92C9k4M9f2ovLjGnGppgkZWPabwlsNlt781epdOaWnOqFkOs7+P6tFbnMurl  
Da8i5LyQkphNrQPZ9ZA41fB16tmnEPMo1fYgy2VNqwB2PylzQDJvTBt9AHxBdBHX  
P8f3o96/oqrVgJpwmjNSxiflwWY+o7Nc0ZNGz/yMRjBnp2ye7woma2PSSrrrfIYr  
N9fRL5lf02e/fPpbTmOTVVUrbfx811VZX7hWrw5BsMcL36hovsDgFdFQH7V28iZ1  
EOTnojSSxfQiHJv646183pXasjFlv/1N10D6Y0EEI9uGyUh7CO7vHfzuwu3gokMk  
HUVX796+1EauDrp0yeDDozs9d3L6lvR/8S8/3uJbnAwSfhVdfJgCfOboXS9ME0pp  
kQF5NxrrSeYHlrBb6fL+SkJzuiZTwcHB89cf90unAuqeRk5Y5PmZmj/GdocMEu5  
AJlo14uzZnTmsrY3kh+tMBIOcOWajsoqtzIoOovx3R0iPz7Msut6njhO9qtMpZWI  
3uO4i3GVH2ZYmSb4KVxYiC/WHdZrNWgUVUmGsoXHuguWye06iwteDdsq9GDilojA  
AgC3ACQaDK0vvVJ51CIGzRWDSACKwaN2wQNpEWuIFU/V5NoieYJaAgTusDiXXClY  
ADOMLcL0AJSIdsh1sj+9pCq1OjQVM/IEMTVTJglo9rE+RCndlYFkOsWpRtobdgn  
0ac1labY76BjD53uV2rlqeYUhz7oJ2djmg+0I6hK32TWj8KOnNBJfRJEEd9idRhA  
AFq1qsNhEoIw5LuZQjqITowD8WW7XluqNatvCkv3aY0PdN6hR8BZpLiltMuiBDPX  
CDwKyTbkIq0NgumBduUlhsMEsyG5IOkbiSm3Z9v2JPcdAOEgQhMf0rhHrncBvG  
U+OKXiGxEAlbw0PWKuN96yEQU8FKPWFSvweCX80DoPPH/W8lua7qQGkRj+dYjen  
VFtHfd8+77tHI0vigwTUp6UUGPkI4pnNJoPZbHpwcCF6hQc1ngA7Us8qXB6yGBsf  
I67eiy14KJ48Q86FsruFk4eCuzj7xuoiobbEOvLh4F74YOhyL66aDAC8LB8LLUYL  
C5RFrMuyxS6bzS3Hp8FoNZpjK64QDYgqcDyNSbfv46JFg8F4rNsD9qOiO1ISQgev  
0iUNnwLFk2rjB5Voj91YUYuFaZQxrnuWxuxIFnbsFOxqR7GwDnNyfYKDQGwGLcpe  
rPgolp/j5JeC6nk6SrOTaA1AGXknvdg5vNjmT/+8XSOb/wrqwgDhrafQ+On99TYAo  
XZvtN0QZgYftA+INXb5p3+usrT9AuZ/l19Gzp5DZv2E6BJFtGpE2pBRDTWjGs3A  
xMTtWhUlhDL5baCJcb1RSKsz5js96rRbD4ezOaTvR9b/2UA0rbMHrJIS7zGNSfQ  
GCaXTZKyIluHfAxiF3+GxTXDTS0kC2FAbz4PsOlx9NqTGdt4Z4TpOGvQAnW9rCF4  
5+N34+nAxUhiJLpdea/LGuH0RTTvfLLaOZg+0xRrtMYvAWO1bA5PyRKpJl4wfcr+  
6FQLpxi15rDRLnFKOeHA7sJ1+vwJrQBLGMdP1XeyRqYuDipG/7LYxEqxrTQj9aMv  
yHqyTF9EVCOG7mjDvQgdlh7tG0a9blhhHcKP4596vNrogRCv78un0k7Z4OVszNhA  
vtwl3c6+N8dKJKrwslijhfk53d1wKX+RQu8i/SjbPiM46myvGjinjSlvcyzqzn/J+  
fwf5QB5xOpgBuVS8OSPQybELNIVTK0QB+NLz9+BrQG1zh7KvymOFw1TCEWusQui/  
0Hi/x4Zpup1j1+Lh3ne9un/BbnQ6HSW3Yh00muVEzqtuRrOjcXTtWJRZQtIvz+ER  
4tG57o5ldW4oe7IBCSBvXRHX0Jeq8rV0HBdZqsxMcggQj2FeBMn6als7xkTGsqua  
AG4iqwEqyezopL8E1tDn6X2dZiL0Ny1oWQ6WIRJhr/C23iVrjd1xh6zQoPs37OAv  
WisgmhwensirT/feoTC8a0PqHfRBxsNLTuJtoynphRup5oYVo7Q/hI3UVWJvRrNj  
jBaZYal7ABQuRKmKEwkAAGAIWEnywFIRMWaSL4VFIB3KdtH4DqsgqkSx4hr1tZm/  
7j4G44zDIC+H52eXpsO6wl9tW4xZbuPo3zDhdBKMPs/ZO+SAAnwnFEoHZ8c60iXA  
M+uaelxOvbW3tvkyrmSOAS7ZhfaGGcSRaGittHUQiN8eHNyktRmr3hlnxzymudbF  
ueLYXgeoi/vFrZC4jZZBmLcgVIuc6h/FvkCetRDr8+QQsY4rMeh+Lxp9oLnFp+jf  
2p5sZITIQu6FKHVWhrLwU37gOqg3fsJiCcxlArr2hr8DR6ImmJh8CLupDBHtoc0R

qmUfqsoXjtXqoe9YmlkUdolqeWpSS03LzbAla3YydXHjH38Y0NYSMZmnC8XdsRPi  
6CJ58qd4JzLhdsMOjhAXgfrlVwdx1bZaOpilZelyGTZnVfvQ5XSLRk+dHvgy/rnM  
400/1wkE0mZt57qQX6c92PXfRWsVTbmhP7T0hxA1BTAGWiPzXXgmsu0Zt310cPCJ  
hZVN2Nvou5Urljstnaz5rWzRX68DR0bdMdvrappyAd2C3rQ4yy30KXo7ud/iZVen  
86DjXyNnwJ3aetgxLZLwFEwHZmrDmo/NzYFp1Tk5w8dn18mj2cKFCIPr2OG5Z2  
qSBCTQfoiJ89FYsdTJ+l4WYcqgerAHxvij0tLw3aAL48b6JKFxh+4jFHOu4ezU4P  
B7PTcfQmj3eqVp24PBZe7El+q4LdvkB2Y9QEKBwKcORuEJkkd3ivvAwk86vQLY  
24EiTbrcHRhWrHdxKpB5c7QmJGL9669u1WmwLyx1a0FXf2y0WBia1epYCayy/58  
OL9hA6wJ3W7Cl4vbkl1CEpTHio+zZljZfcMIT30Czj25w6NgZhi9unH3LavW1GSk  
hnKjBgzHUKcYqkDEjr3o3atThqnUcX0tOxzLxiLYSfxysX3nFm3oWhWF5ZPU7wM  
7Gtvr/jW7BDmIsf40ZBiwaO1M3e7tSbCf91FbfLNmdU8KPmbmhjAS1OuiLlkhaw  
ayqlx3HWsX7ch8jZWxQ1vig/cascSfSr4FQ7qyiPPEHFFupZOvgkDWN3eGoVxqU  
sVxZipYR4UIhHDopj4pTAbAZkQBpQ1NZDXHKJPanT06so8ShqCNCknYwAUGxSQ/x  
TjMz+m4FvleCc9NzdKUFawAfdPR3W/dm4PqEaOmOhFG5Dm+TEbmsorCey0czkAwX  
JlqkhC/G9FPdaztUH6+i3AgFoDDWAaZ3qjXhX+RBpZ4VRzy44jvwlxzr6WB+aAmB  
N6/eIu8K7S/8AVF2aS6sXOztOs3IkR/FIKjX2Ra9PM1ao9RNvdpkgIWNNMgwSowC  
Aj/99Zd/6EgvmCOBwXkEPSZ1BajVqSIE600TKfEOwd4HLTb4KSNWZ3ROLNNgWARi  
gEQNIulZ6hAWYN9FiTlu9VwU1TbfaXPmV9Arn0xmUlcTpRHmyD5GYeD+8uzj2996  
JB+dM5/opcAm/RC3uZmk2T3nxMxZUTg/nEd28BcodqIRHgx7efEHjKtPvvHDT005  
R1cXI2fRi6shRwVi5riC7xGf9ButVN5YiGIOPzyS1x1j2oN7bhbuisuRvN3DQyS+  
Z6PTz6G7DENP2zieToDxkJR1ggtaKVzu3rrhY60VJ3IKrfw5TNTRZDaWJZ8EZ6Ne  
kvZHBWnzp6N24qD1MpDafsJ2tDdJaKCDEdhimObkacvOY0VnG7GuCvUXidMBKu8K  
LOQAM3Y2ClvLj4X+5pxEOEd525NCio+hayoPQFTC678QkMzNpmx1EWYqEvYKQgA  
BWlpXyq8TFA1N6nF25VaQQZ2gb70ZQSsmOuQb0v6vl0gjdmyd28NJuzdT5F5Vm  
PVCRoMiGvEMelaVmldWgFQuPxtV0sIURYbuChBAri5/mQxczoSajm3fn1z6ebjay  
yL96P/28H1gOoraDMCOsu3oalrRtwdtJdHYLqy72UcSo4T0GnfBfmrRnt37gE2HV  
YrOYlteYxGNQmxAiGSMs3cRffAKNcg8FxcvumWIOBfmZXaJixbLwPqCW+MINCFql  
LEpVi675ipEO/t5/g8BCvUbzLI7ifMe96YZKLLwhRK6H48nxVCcUO3f+ySP+UmxM  
T/3Ppj93GpVDxli7G3h0NZKIDvaYBRCqSRjNYoqO8Sr0ogw9o1qoxl6EH+acoGt  
qqIIIVqcShNj0kFSxYrEYgdadHx3U2llBpsVoKpugmuY7z90Elg8At8P5fQYaFW/N  
xShj5kRmgDyKXJkw+/s14enXIJfhMOJq9Z1BVvro3JWbhDhwBZBktjgBVO04Mdsg  
hiQ0uq0DmacQhjoy2InR+smcJo+q6mMQhnD/6P1FcZhY32J0ljt2g9oJKx97Mp1S  
18+mQGQeXZYpWZup4RK237JzvLGtJCZELBHx64WqYwocd6lO8B2jPHVMV1EDrF  
TCR84xkm6jlQZ0Bq1XGX8MP+vc7XUdLpHGKL5vyYL1Q1wHmare6iKCJG4eQC/My  
YTLSfRvAK1kNC6V+Hvwq4GI86X1mYATMXmIISb0x0Vkb7kLvkr04exs0w8yxwnpF  
GuTy8z98TMppCD+5CNSjuTeOvg55j5LEdb+Rxpve7GTKIGGttlqoG4WFu0Rfl53c  
BRE7SAiTMECbKpbntQsWPua3BttFzTIB7hEGnvR/irtQTw4uC6i71FufNrl0M7F  
7kBg8n2WlhQt4W1cPaDhee95XeTZkuY6d40RKhsRZeolaDrHNI0Z9xfX3+ulJdjS  
o/I4uvfW/29FMV+rOhn4OTH0VHidFIVAbFvDbmglaGGgwWdvrn9vVPZdX930bIBM  
Cv788t3Hm9ey7ln0FkSm2TIYgYZaYCiZ8hLhLZ7bY2ajtfMsBw3SQMlo2mYbcRRO  
xZEZBL0X+7bUBiWDkGcFtjDofoffIPDK1wGMuMs6oje18ffXzRwDh2MOzs5wnefj  
efRWI2k+rhc2pQbP298UgttwzXR3VI8AY7uwFJ/GmX01XMIyCdwEUggMMeNF1FUI  
eGldBJ+5C1G1rPhNfPv0dw7rrBfpDlh8gdxTSKtsk2J0LrdZN0ANt488wxjz8RGt  
X8sFKfmSqny9j9uWpuY5Z8IVZaqR8KMiWJuP+tGvZYSTRiHAUjGzlxlh4Oe6EX5  
bu12eHF9YRVBZtkRMIXCP9j/cnFP8fLSAcfQxzqnetjmTLZFrn+6mV7hCliA03xqa  
/QL+ZvQJ8GbVnmiC97bW0B5iYnLx5KObf3cRhYMM/azkhVWNhPO6Prw/U8RtWILp  
CmlWjmYj2ISONo4HSjT7MqFr5NcUn3OL/zzH0ZVHidMQ1kdLcA4kuYCLpR2KYmmi  
+hkdwPlzNNQ34V0xz9N/lelpLji26IUHEXM4EE+XUWru0umXzcBxuetYZGwyGHGh

zw+Bt+cT0uTkZP9grIrV8xjecVMuUMX7noVCAON2JWsxgUG0KQpB4Dy6HUU/IHAf  
rJK948LY7E/bOJdaUe/B+dJmbvjKd3eIXUYBTDY0/gaUZOw4ruNCC9oDGyDektsh  
zTRWdc8np4M5ajt722D5iUhe2UO7Kaz4ycqVs6jZ5h5Hv5q4MYNOTCEcwg1C5ru  
Mx9gNJ+OedUF7DyGgyw48tfz0dh5OaJgLqIO/Oh5/8EpbA5zkdOZCfTg4NXcD33  
7o31QuEOzVkJugwK8ugX4hqe6QdSrxAnmdfrxV2HXp+x7JG5IE9pEspqZrGYe/ZCL  
hRrdJutHVOjR19Mz8WUVcF1RrFqUMILelApab1PJRdpmjfbqrTP7YQ8w8TsreA3T  
hhAd0EukOzEVlbvsLfJUB67AbPqlCeQTnT/nOhHXhgneiR7AAhYpjNvUvZWPaRa  
/1z7oVus6DG3rZs3ySR31ycbzs99Jusp5oLrWIHMo2o8YZQyqFz63sISLJKVPDM  
Z3PFk9I1dq/qRIFoyqoFOHquhZg+6GX5zCerGc1nIAQzkQTf9RfhJpF9yRSGZNSb  
LYBAcBGM3eHJyGdTVVFBIrnrsV kW6aevu76vzOQpliFcOkdeVMOJWkyz38fj2lmJ  
DqlQqZDEorcyaf6WnO29UGIFBJhw7VrO7KAAttGHbbNnc6T3KqG0oeapMKvkH8R  
r632g132McqdOg0BWHx1Dn/BjvH5nFHP+TzyF+DanA08wlpmdaeEwQk6HnuNMHD7  
N/GKKGTyVN7r/NR1n0wNq5Jvvl7IJ0VRAla1bly0gDYrOz6StWUOXt2cvbsyqHws  
4Hf2ExdBEB2y06F5r3g8N86C+mjdImeM+uL83hVF+aAO0hUUUpjb/1//B3NonWvh  
/kf9XKzlayq4Vy3QzTc263yvgyGcrz4wyTiZmvI7LxDz5r4FW0aQJaIG1rWED8  
j6PDCJDsLmFsEb7QdXJazY/ZQZ5WbVYtgPPDQ9QKFL9GW9b0rQpOkBqAlY1p0l8I  
NrBYwfNq+T0LVbLNoh50lgErSU�9OCc3Gcm+y4Usq5LQjUS/M0A/OYTISBxnhWCA  
oyBEHY4RELb00+UhcdMHh9gRdv2XWwRDSaP1YH40lv8DSxxUG/4cWa350Txq0YRa  
41zh6Too5PAHOicHfm1SJDjQ9Us2m8pioqF2ysHzKdIt4z/E6dofsyKBVZwFZ6P  
NAmtkIUIGi1MVMeEr8R/2XqTKqSDwTY8OEQKaA2raANwvXunA5OoyoVLv9NiXMBU  
AV/6pHxqLqBWm1r6LwDqJUhQ9yjZygy+t7dKdFAyZSLr3513+ur8nWMvBr7I7bza  
q6n7hfdtrkS4Db+zDr4SldKF45Y97t113/XFgmEW6KkEaUJGt0JpjVxmX4RRsDzK  
zlfQtDmyo+dxVYhpj8RbnpehOzSlvi/XYjq/LbdAFgkdpTOWNCyD5xvUWOgj6mk  
QfTh7OZ8EN1AM4XPoq8jNLXcFei8HM8V/L9/nh59RzbhVshTpAC8/Xh9c8ndfWb2  
p4vjXr4uPqqTYNSutCt0SWMTFAtFCgf6+EiFlc5iEOVdSSzSzt/F4I88RLdEndSI  
iluLxxbKkCX+9eTQ947A0kTOjdJdQW1thHuvG2V+fCwMdKITXvnOrhTPXSh6YHSz  
1LMq81+Znv2gV/o7U97+s0sRjYW6Z0sLVMkqnmlfcUbhny2nB8Lm58c+h5DNQ/2  
DQNtQOIBuDiV79GVnzEVBh5PRd4xjgzBhmF7qxV4Auczmp+IVX5io0bkloOC4kfg  
PulkFvMpwYNhJMEJ39eg6su2vld+pAuJWJJoPk5sYpturUCehmVjoQNxmh8YbC3c  
PBH4eW0Da3vHeSJLP8bA+ZnKfugDplqxfFglbPsj2WBEh7/q7tKM5T+BFql4vFZI  
jlgc0SOiR/eY724v4dGLKGfRNZEIhdg5rKgtVkhjcxIq0t5wq6vaLmYx0zGYsq  
UEpX0ch6BXD6yFa70Brk0QqfwQUN5fi2a2bRu8cbg0IxCzBEIrov0jtTedY8ghtH  
2dccAzTP7IZCdB/oBivWUk/KqwWPmV+Ft6KqwMpmYFaV6l2bF1/phD8dc00mRlwu  
0VC7PxwSljXdb2vpVTqA73UG7F1Pqxu3oNU83GdHnSbNtAjrjWTrsN0i+ixqGIkp  
b8zzuQ8ZocASlqrjzmo3F1rMAINAd2vAjxR0DP1OX1xukYKHebvUVc4s0mc3twFq  
XcgAFOZl5Xu8eJR1u/jcrpTkDGFEI4rgIPIYg31N7Gbsilu9zFKbNmijG6ownOG  
XRw1OwhiPv5RLm0J21/8J5H8dOe9fYdyZ1dXo7MiMh0bZS1VG4OnKQISWWWeNWeo0  
GvMteUuo46728yngjdQsWWIemzNGXRVutCxX0X3K1iChYhGkwHQT0qm7UlsmrWph  
QLVbjnzKrWQG54n8mluhE2kzMhQ6Ryylu2ghLypL45zNw2hIWnVACTyYrlKNuh9V  
r7g2tDRIoOo7BljVCaCvhGpspBze3atZdAk/7BT3kLolaGFHeXbcNbAawn5aeLIIE  
iTHe3m+b+3PpNzmR0GTlzhzWxt1LW1pifLsVEoWiYnwrs1mID1II1XYitjWuDikf  
13n5ylW9FSKA6qXHfMUkVXTmPhpCYdDDwOAmmyiuk1n9eO2QmlWmubpqx/L+QNwE  
JSHpOu22z84SoFCmae7O27Vw1CzDQ52XsNmTB9FRE1oVIZkTNjBbIMWQdOUBjUFq  
LLII8XzAvkvtDeXsJu3Plava4dXpF0WUWmVK/k/eKkoHVYF+/d1AQNOBkOCxaGjI  
pFzHNpecasoy+hCC1CNIhTw9IKEPlmU98wqcV5reW/J3wSE3D6ID1zJC0eJFei7I  
TJT8Im4wu+N/bHYMxYRNsi0NB9oWqH4lgA7pzu2rdqtxwA6rbLnUsT8GU2owh/DR  
t9uYLt1oTjjBOeAE35iN/6hImopkaSHrOpBiaCUDQjMN0BJixwAVKRyZud2iRdWP  
rbGQod04jAN594pFNdpbQ8RM75jW0QvGFeVFv/7yD+mXUuX/r7/8o2vtLI3oNcoq

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 e6STwZz5yi7yYe/D4EqPFa5bPneJuuh9ZSOEp5wV2VScJrstpLxaoQloMtcPLtowWd1oB6FdSq4Cu9CWU/rRRKGr1KtvPW6hHFVBhOKiNdFecfb0i3ytfMESRy+EMi1WchN+KRi4MDTzuv0oxOIXBCfobp6qHoJIWev/xKwz8D3Uq+boS2fVgOwnKbz0AIGkedyWCi9v2eNtsLgov8myba+iCxIGiNq4OCbPyNfW9cuMbJkNF5JCTMWOIW2a7jWluxV6+N8QQe2dU75xi6c4MFZsQsqW7sw9qNDbXSGH/xpzbpbWsdrrvrJbRZ7oKjtC78qEGzUIvitQOOyCu991kvssS/Y11O5kYwMI6HywhGGSyaNALYRdzV7qjU0H5i7gOS/J+BQQgWLdL0156RR7Ckq7B5Ep5hZDwMoOoV4eDSlex2Sh0Rkljq1FgSwGsNY

KtmbCrlLiz1ecjKnHLGsr2iREPeseh8BUUuqdPVxiViVSQ5ahxECZ63LVGoBTpG  
tL3wbXGavBByhJarM8K31DTI1iTW5I1OfzU16FU867Ebhnpg56+JQJeVdGlw8F1q  
yc3WRQqj7gRE0pPvNkUs3WjFlolGQ/GgxenhelxmkOSME2BwZuDkEr2pxmZfbnXn  
lumDOXbIAIJdSTkCTV0JSxkmmZA5zdsVh7Xa1RD/DIBQZ8Qq5vIDL9Wc0btEty9  
2aMt0h9mCacF07/w+nTKi3XCmrQhwB2Bj8J2bw3BmcIZBN6cdQeGsShvHhn0m9AW  
Lh7zi4vO6vfVxKRmP9Qc9B3sfqFCA5Y9CkNrTq6BliLssnlcE0Pu0MxjeK4s142W  
7Z2/C1dQJqhb5R5cx49eAgpX6KQ9xAAMSAjqpuwSC0V85tQAYIOdAB8k/YsU5GcZ  
RauU7nqTepBHsxE6FsC2Xcfv0OlGkPt7ugWcR1xUS7Z7+Lj5KPodVwhDhSZAkp9  
YsNAVjzGQNBjzvikFRhQRKQFwhuF2trQFVpEaMmYwHLTZmbt27cdLctRdNsulIWt  
RffVBollWh9ijsaiPsbQ0hRCBzb10p5F8cN1D9xlu4eUWbx+H3xRBqluei0HF7C  
eB114kasBUUgeOqPV9RuAFhexuKRTA99hOJWfITYMithV+V3JZ+ioh7RxVF00+qs  
9GDesAOLRS+rj4Z69VV34yqDM7bljCeKZWN5XRvWjtxVoei2qZlZ2jzDTFn1oOE+  
EjcOkJC4tauSrXPnqtYXn4hIWijmuzhRvFVmqlYVDHSawS7ki9fY24ZSRptag4  
vnaVpwpljUziC9A0JjmZ4kahvQ95nuckaBTJWHxCxukfoklTxC2OwdaHegE1SSDeW  
uMsUX91nWOENpZtCP9K1zfpqRhYvyIxLs1KgLEIDvvMistzKRIRjvzt/ffVuEOim  
r/RGdOimAapB1zdm/jv+jSRHCns7dVNzY8WoW5QRQESGIWUT/53+dD3SYcqlKXPe  
yRJqvlx6Q8usPpymWGGAcBH1moInbGrpMvBwt/rQrLmBD72ArOUPZ0hoRjM1jy5  
K1u55qbcjqLfW0GAg8xBshvF/OAIFGJa7UDlgZbt6vgzC4gmHJ3E2+ltzAJBruJM  
4SZiHYWnsYgHRWclssl0H/8VO9MHMKWjp9wWCBUAkAqrDvPXLC9jeseKG9yZGOB6  
qRhljLBdxButdoGewsRMHpC/xqU6kc6J8BLoDVTbj0XvcKkt/yW+i+cF2D1tSbqu  
qOA+WZ6WuV5n75Q2tPsAgICc4yXC4eBgPlp+8z5biK39YRC9/9P/Urnj+eMoACNi  
tbsL3Awia+mTf+cZQW9tEsprWcpbdrB9P2Kz9O9m4xfTyTffTg+nJ8Pp4Ww2wiF/  
Oz4cjQ9Ppy/TtmLD2+eX6TqOjybTg4ms5SexlePoD4PoDSa9AGz5+4EQVZphFpAs  
EUE3Ob/XwQo4+bLdv6K8c7/GrNewTUjjTQoqaqucn5fjA8n09k3345n4+Oh/HES  
rHR89PL2cDw7HB4dT49eTA6/mcrij4fzg6ms9ibGePf+27RKrNahydZggZGpOkr1  
596cxgC1q2sDxEyqYVkmE6Avbcplic1evroGVdnXPP7dZPLi6Jtv0/nkODzV+WQ+  
eYnxxiN8iL88kf//5rzNor9F67o4MZ8G0R+E2aO3/ig/tPmmLJD6eC1iM+41VX0w  
5MZvo8sUFW9iUeoGP3o8pQ8ukTYSei3xA1Zaix9vax1P5FyDZU6nJ6cv77byKS5z  
dHQ0m850D+ay0D88ljwAPrwdRJ+yz/fRzXdyImI//ic20yZ6E6423V/tt9Fr3yYm  
9Lyo4uXuHlrp30ff+/EO5/L46B1nheVGAOPZEU5zPjvP5PLn8/7Ifx59jpMMSz0c  
HZ6MhJYPjmSp3CtLhv8OsSw09ylGyK1hSiD672fvwJShBP9W3r3NXZKeYvMyLjS8  
cMtZc923/s6tk622Z/RgZGvygkahyyfHRCUQFl43zbb+9uXLx8fH0Z1bWVaMymr1  
OrVvfRnj1FpdvaHk5PZyUty4NjcB+UtNzh98P3o+BcMy38hDuq4LAKnIFRt8zS  
X2YJWje6Kz96MZUDnY6H4+nUH+dkMj5+ebdZDHGWw8PpeHlgjPab7/70P2/Sn4eX  
aR1H378eRN8hKLoshUNGxwghXMIMrqPLc/Ir+6f/qfzYb6efT9iV9ZmUfojL+NV  
mzM7sevz/XlrsaB/kaP5YtktdqalPTw8nk32rz7ZlvZ3r9+6OAUPIXs0ZUs6VOa  
NT9H378LjGYSLEJT+LpCg1nK03RJ+5QtB44IRbilBJqejlftk+7MxuOTyUvW9XMF  
8v7pdH4gv4h+c1016Sr+9Zf/7kP8c/QeLSXbconCh+hCzwwtoloiu8AK7mSTSC1  
HV3IoYWo9DbghNH4X3/5+7OakSHYYn/maL8VWfsQpY/Ox/+AHC2D8z5Gde5FXs08  
Hx7xhPYx29TOBwkkskKq00yEZTemT7gmR1qHuK1UFns0PwyO6Wj88vuzt2ejMdiU  
vzwYQ7ddlvdrIHGJHwfRW5QXFVn0RohsHd+hDD66GkSvRVKss00WvRpEv5dFrzdi  
WURn7vM/x8t0HX0X3C9tXgT5iXIILFPhgm+jM7G+KxsQVtn5BB0vxdt2MhTbuywx  
OapuSspgyxyWGPXSYWP52imuCPfcicdBcR5ePyyHgstzldkpdPT8Xw4PRhDgf4B  
gdRbSHskSb8XOX8bF/eA6pX/7+TPIvoJW6vuxeDY29Rlt6kbS2p8lXFcv9fnJBx  
jvYV5nOMlx86GE+fSE7N7aMSkg3nLnVyzUW8Q8NLj4+5TK9yOBlx3qYtiOfW4BJS  
PtjR4v+/khMkrpjzfjqdTKYqOcdQsq/E3aIE20SXYEWR2nn0QRjhx9tze3o+it  
mJV+G2eGogTmeaWTlb8/uzyLPiC5KuwHjHzS+/EjdNPryWR4FIqFw8Pxy89iW2y7  
z3NZh8B4HEOXilKSozuT/+8Emddffh+z6vFypA1vjIMvdrWH4sJRPxUOWPELt/Zv

cKlxZnkEtDA5fnEKiT85hcg/3CeHOKliU6Hz0eFkdgbq/o222lsDSNoDoebZn/4Z  
psnHuEgf6vss+t6bKReIkNRwZXRO+p0CCLsgYHe02n9tIYJaS3TDwYEGxwOxJtG  
M3dVCls06OUhk+LfKzEshx+HZllqS5A6YFTJbJbg9cxnL45l3/NTMR2OZL8phE5/  
7zob1a7naHR4ODkYQ9feCOELE3z/ATfUwl89l92+EmkjsU62Lm7LPWStOTYX3ul  
G/otvG8GApmONxFeaZU28VA2me+M0WjNs21YOymoxt2R3VUWtDm/umXy8w5VaV0P  
xL24TGkHo2Qij0JN16r/waChpwR9OgGICPcMT2fBWYn+e/m5KLYwDkQFTo5mh6Ln  
YB+cLdCVAafijJsAleNdbZkWMcPr7vyhTHxKn/IDWstdPJ3O8/+TwZHjSuytjKLsn  
Ea4HY+p5L3hQ2frB9S+cx1aNd7krKemc5f+BLpz+YNSlh5LDlzhbalg/M8TTXGS  
UCQh5F83QxST+sd0cgrfe3k4eXk4fzk+fTk9folH/M00/pvJnfwwel7867knyY/d  
s+SveJr853CCP+byx/hU/pgeyx9J+ZAtAaAa18N46Lo6hqzpRL3bpjsVzgO3wakc  
TGC9vPo5zX7Ooh/ENIkSRYjGEACX5RpO3xJa+Sz/Y7xBoaowwvfxpl5nS2rrV1Wp  
1awX4hVRivagc0tNwWGKgVa1M6n15zIdbCjHG6PoNskCR2s8fjGGjpufnga0Mj15  
Wc+E6U+GINaT0/I4Ojw9mKi9gaFvlwPtIW3EeBHR/zpPH2hSvefSXhc/7zaKCOuc  
LMs5ekZ+X5b32kVxJrbcx7KEhxzb8SjbQShjl9YDQEVeblth+sRsOILJgP8fzU/m  
WDfMhnd/RPJb/O63JY2GM/FcYuAYPDPOynond5ln4vbG6Saj/7V9dg8aMtR+VUJU  
WF7gW2D5Gi4NsD9yQ4QGeBam3SIIL5Ldb1+f3XyMfvxB2ATRt7IWuqxKXpI67uPp  
t+PjkSicoyf6Zu8LqnpORfieHExghNw2ogmjhhtp2zRK7LdfVykmlETv/M5/cvDa  
3fRo4pMV2u2JWaF5qlgkzx8EEw6AlRc14F1iUNV0Pp09larZOTGJajl9OTkSm24C  
2+JtvENN9eUNGZDfOUBVhvF7DLT9mFYbltc787rHE5fxTvYvfUQ54kTIR3QuHSok  
vzu21gL28xQYanl0U2or0b/8p+E51F9gHQhVbIF24DwCuNtldyZeOF4Gdu45EcP0  
wk5fjGXbk9nxPAgGnB6+jKrY6XiM3xxMYLxctvdygZ/TIfciVMK/Xw8QRV6t6RTG  
n8Vg/8EM2lheF9ltTQU02cpyVAz2crMLwMmiLefv0Xi72yJgQ1IKjqOJF9HtrlhW  
PjDwYi6q6kiY+2i2T2LL+ouRlej0mXARLUpPbXQ+FE/jfbasxb7+lJb232ZxGf3e  
k9OT4I+1YoQU9S//ycYqM5SFnmD5IP0QYfk4q9RH4gVx3U67TWmSz4/mw/H8+GiU  
PgImJClwnKkoak4IDLble8zAViPsFZ4pB/ymrMRsfN+FiXouXs/uEC3gncYYILnR  
fbZEPooN6ztIAHEYxSzYirP3nL/zfSumyFw1H5ydp4wxF88YjHF4OJtPhocHE9gG  
Vy2L+0RFnN2Le9vCa/u9aPFN2YSHfoYCINqhrZxxiT/oEs3FcJwk/LAk6qf9+o0z  
jM9Y2/nWBpFABiOmt0l5DvwsL8c/ZVZp+cmC6p0YolF/ITaP0TXhk2v0ge7sZDw+  
PJ0/tUas2xtZErl00fOxgogEIIWfl6xbbf5+1wV0FRHauaKvP7RkICq7dzCaeyk5u  
Umz/Y7togdrkMT2VBHKDr7q4yaki39l8L6wHEvVhvZOjkwP4Ar/5jmt8K1T+iu7I  
CtZcp+y+Qxn9CTsbNrm8/fKpzdn5fG8Ajyh8f25mXzsV0RmXR/EDm0zsJSP53Si  
xvPxibDFONTk86nwxlpfM26eCGPMdqaMi6druYICXMHwYQ1z5W2aLxsoDTvrt+Re  
Lf4KttBFdhe7HtpXvWCwNTpt2qSs99WMJteRTiRnnV+c/Db6aBCM4inrN3wo8wIL  
nbXseZ2MO66aPOGq6cncccdX0ePjzwZQhBPQ2ww37Af8VGvuu1H87VywDXjehe7Xs  
IFPMehDGOyZ7jkmiMt37geSqrAXU1Y+20h47HIlLaEuqE3gZbow8sV6piFOmi+Tn  
CTGDv2tdGP/olHcsIvtQ/jjpexartvc5P8vd/S28i2pYmNU78iDJQNJSqdCc  
qBwcUKTeoqRLkjNvpmeKgmRIDllksCIYUIK4gzNpNAx40MCtQtDQhpRnPXAAb5QbK  
A7cndVzT+hHnl3h9a+8dsYOkzsks0yrfhi6o8khgk93M9v/UtExh0HbpD7h4Ck29u  
0ilbRfeojzKH5ExkaSpCP4dRPqX/QyjtmFZ/iphRZ5TO7umvZMUYPw2NfQUA1AmD  
i/RIhWzRIXUI2GEWwnjhEHQX9J6d8SpCxwNynOQfUUfC0/Ft64DUoemF20HJcVSF  
o+32HqwluWdfzEtYcIXxGT9cJkZPaCPj2Pyye8Q/7j7CRMYf5ZjpQ6UzJkceWtgi  
z7NNzwu0sYdW07Lclk/GsgwKBa3QD4M9Fxr/j0kMgf1JnrhLaM1TqPlsRufghF4p  
sBm3ePOTWdRkgNI+iBjGO2NMIxG4YFH4t3OeK528TnVN3KjROVi+FTjsd6XlhCZQ  
MRALVh05rnr0tkUWtxMGbWFx+25Apt0eDfaaMebyBzpgsZhD3M+3CXEz7hNRW5c  
rufLKZNpLtFJHLLjhizldCXYYLQYB8bcI8fJnlGrQ0CFJ0iaiE9IJiLAVsp3PSEi  
MjZO29kQ7VrWoEWCK2bBUYwpeW7mkln3F8aRiV4dQmSxVQhOuWIU5KVNqgmx3zKZ  
hWWTFod8Q99WKd+2XTTPcaV4C3zLJLEOo+GiyBcywjuI5r/8r1n8Yg6LX/6e9v2+  
SCDaj6MH8rZSBerVZnBuBIUYALDtdngUfyiw0MDIVU39LuYQi8gQaSQ/fxaE2OgU

WxPv8ELrm9La98kYjclY9QJdJpAH1MzHSSIflq/vubAReuRdfURqyuiRDrtI5uZw  
PC1mL2xWnxYs5c1Krne4c5I4RMxeQgftkek9kvuFCBFJVHeuc6gDJLjaS/KA7In2  
fiZMvn6sshtOa9+2SDq3XHLXwp67w5e2+YbQwaJ93MMdesNhHcn8KCKloLirekyt  
q+bEuWjYIFBLW33nfmLBytG9/46cbwFvw5W5ip/z3UGYcDMIMyYLDDUACMKMyiwH  
ejDOwTe4blZVZqZMiTcxAVNNwNwYvKkGb2LwiMNg8GZpU6vBN9th8zkelbZDArTb  
Q9DszQ30YrTYDM7VhPmvP/8d6r9p69lsKltZpaIXJ1C+3zVvBI3mE4AoGuN03hyj  
eFJUYZD4UpGnpuNYYbvdHFehY7NYTiB7mksxVLM+VLOMIJEGNssx7iEF9+YclcUp  
X9DODfY8R7OEw0MX03QSTXB1T7eCo4o/SPWr2liM57If9zOgZGBfE6AmAXUGlgoU  
eSlwgD/9pIKZeuhY2ZMBBL0TtrYEfTvwhKC3235A8gYn/c2XYkTywOjAax13ZuCC  
MS6HSHRmpJuQmDqOsilNizaU/nxRZMVTgohY74jE6plckvEUPMQ8nKWeMcEEeqgXY  
NJuvyqs2pWpq15GxyFcSgchliQxf6bYUWRnsDwKR+IE5bTnBLreFn2Yt71gtfw/p  
/zd/gADEtp6xxfUyr1bGpzMliD5VYoh9lbOc7xbndlHuJZQb8g/qiC8Ayeqbflm  
WzdxkRMc3g6uL47KxBrB2FrD17Lm0GyhmjBYdfcwrHd/oi1cl2MmIOyFgOFs/S  
B2Tr/bX4Xcf9T9Ob0kGqSF5mqAzi8pg8G6nGDSnrN8c2woCbbFtL2xmkcqx2eLi  
Pa/FxiD7pO+MP7Lj9Rnr2yuntctv990wdiOEkQl7C0elDZWpcxE3HRXdnMIhSG9  
MyAiyW5DSznO1ykDlwOrZrjtkrQdcYcsN3BNmhHMjCsgk+9ZCrCJ2Psk/EkyGS/j  
Z3A/HrKJeN7dSGmK4HaFxGh/EBcdEH3VA2c0YNqmmA9WIpubnkVwqinQG1Oe/me  
a/r+9kz8ljT7PI4Pe5zNINf13w2jUcRRLP7tNJqQUBNeJv36OS3lphpy1Bu+MP48  
j14AGoAU4NnRYzhlZwxJ5+KCUZwrJvzGvNDZQ15qpaWI93E9wpxezTqj0QWHj2Ny  
8fVYDP2PhPyowX/e82BjnJDRSm08ScD2ncN66uSrEeILV309AMMnjeWS6ukxSidr  
k3s9AVf5rQ6ZKc0KGm3rn/6Pdsn9WJaNQpMjc3gg6PvVXnFjL5GjM9EqfII/cFfQ  
XNw42VG6jPsBSjYmc6AKbMB/ccledP123fcaOg7tJJyWfcd+a1mk9GhfgUN4c57w  
YTxDIMg+S/+ZYzRDIK6khOuRqAOUQlevRWZ5zLu3kY0tRcqJ7a6gistHR4taVEi  
60sfuY72tmIW3UcApII9HwbISYYdHDKWRChyLrEQWNS8DhDUJsQJzIQ5QgUI9yRG  
RTTRYRRoSRRTn0rNSpqOzz8i8tmn7W3l0g+kn6vMstXa8x2O3DwBH8SYD0BKjE8k  
DK+fi7wwD9MoWZFLeUXbk46ntCTGBUelZuTuD+mxfryOs5Tk+Yt5Ea1esF0ifqiA  
0vg81TJF9q+ooj130YrZ+gyxEHq3wR2+5bu6Y6kqXbiu2D2UyY/YmSsyMAFmeV96v  
yoTQ7jm0SDa5O7bthtspH1/ajVarTUp7z4dd0u1BWEZMjNgrKSOHZMLHMD/oljQ4  
K4DAF+ahDISuVIN2I+kBYBtV4uQ4HmUF9KYtgk/WdxrZMDbHk3HjPn3SbckmTBjz  
Mea/4rSB4LJZNU1ig5IkHUOs181pqaD5JZObJJujtYkGGtPVfLbnMyoSH2WcHQ/I  
71F+/e+OkgYZLxPZn6GxiFdNcf7pY8zyY+g79gAjfDOMU248B56lfCyLfeW9IGw8  
7KGrY2VW8PLtXqC1o5VIUxU147LYDltCm3B5PTSur44qJJ4DuJTjtUJXS3e7AVlq  
ZhrTkBuowWrlJ/Z82A+nBelQjwWHYBgueiM76zEucAPZld7psYq6nabU5hZCsM2g  
O48kjr8j1q/iJSRy2hA5gYiXMMwNMpWMmmPwv8Qcn70t9QwnsmhaMjcP+hBOa6AX  
Bda5XNWzsPqrz//Ld71AT0GRNEQZ9QuZWEntZb85wWdHI7ay2YPW7Ef2AF1eHN6  
IoZonygiP2EPxsEb2CtdqQO6SikMd0RVh8qt3QXFRRkGnpq6kEOpKw9YubPxcipi  
V2XZ3XCV0n0VmoczBVce4ZSvvXnZxKIZoBsFoBZlItRj6rrDLMktmu2rBDNN13Ot  
djN6uCf5q/2vpefMXn1kz2///1UUYbilmyyi0K8tCyRChxeQptkK3DXdKBvMi6u  
/lztOQqkVLtOrk+QEKFgy15DinPl0oLZQJbImedbOWZLihc83wq2o2KcY7ZMO3QC  
h7zUFjT6GRMpX50jKHbH7aU6JESO5HhwUncMRpLnidb0XOV3I3CD8rHYS+49LDYT  
+UV6FBGieA3jM0vHGPVMoMkY0CAhF+G+a+u3KXCbs7ltG+TiuDRiemCvBS3fisso  
IUMaMFxayRGJpQf63hWJyOEhBBb/OOiTlyXKugYbWYku3cRPmu4Oglrgp2m8kHBW  
WcN4rTrecz3FSBw4Rpj/hKAAsPPZzbOsKfgF3UTzu4jgzlfKu7+74HKoHzTf2qPK  
wPE4LU7K2yflrbnTvmX5zYelKeV0bkKbAxnQ8tp7LWjwM9Sadwbku6YvLwUpIg5t  
xzh9LMJPJR2JqMPW0QGycokrcdChFQX66owNgRDIU6Vn/jxhK26FWx1y2WT4o2W1  
zdYeJMCby4jl9UnMrmihAdugijpbhSq0I5ajOwo3uiNRmjkjEcenL5wzu7koxxQg  
r073yCmfIOWdsTJrQ3s/CK3gLbnPvuk41rauCVs8ZscOLDpfa0Fvs/1+zn1mk9UD  
Am3Dc7rLF2k8JQvXqPyafjqLhWOpoQQIi8M0GSU7LrKayauD332Ndazc1jV2bV5t

qG7+PFATwynIRQcNFJ6J4kHgjgzH+O9P03lq5OhBSld4nwElb/8HwzTQH4H+c9U9  
PPsBObkYj5LGYjZvLJIpC0zEp5p+m+7qXguqe0ieLFwc6O8PpFCNw16DZw5EP5IC  
fRRL3QJRf840vXRRxYKwsBeLd02LV0tHSx1ctyxowawD1w42chfjZD6SXgJiQHut  
kBGyq5ihDoOouEPY5wljAPZpVJhnL4uYzMNb0A7p9pjakprRbJKCIQDVb/uDTmf4  
VkB0ihE4b1ZMbC4So9wLBTS8JOXLCAieKKISwO3as4dHUTNzEo6ZHbwvu1hHqbr  
bEE4aLLLKVANE2S7lbb3mu1GVA6pzEZXRjdZaQL97n6oSMcUNXKe41BgvirEXF  
CoO+cuJ3LcQTLTWgvipFzlluJtajIXxf2fZxD1AfBzT8TeyzQtwkSPLbvuN1I4A  
HYIFE8vb0Za3Uy2vOeR1JMMUjpO5H/8erHvreK7wvnlc4VY4ig1UWsQheHx6U1Jh  
grCPNsDMfmvD1Xv2AijNYwhNCCRA5i6Z55u0fkODn78TEzS0CRpqUmeLA9bfN0Di  
wk0vf1YGDN3a93JG3+Oa7LyM3BiseXV44QWWZ1s0cujo7VFpyy5HSJIAfBNPKC2O  
n40/QUkti5Ql8ZtuTz/wfkRC7eJiOeSNW/BFlqJSJFFP1zJE0MILAmrL/WfN7  
dmvcvNnennN5/tk74zaZQ9J9Ik1ZoB484ctxiYQe3ZYrsu1y5JifEJ1J6c6e0okT  
rZCAE8+SUaEkOctXCUuQzeFkclOLrfElqGZjnACBe0bOi9DxdYrUvl5PbwPPDWj  
rvhyWd57x3LhzbVc22y5tbC708QbG+Q4WXsBIK4cvYasUGM3FW8t/YT7J/ArN7JB  
WGc1i35kS+VKRPw25MaOroYnbNvbLmoqTXxnU7SV2gPuj++8akemAz8Y0R+Xwy7  
bYv35qxr+VxWlogF95ZUe9wG9L5eBjnPhcDHS3uBcGqh1T/L6FyXg+N/5H8/CfzU  
sLIJZABC21pxuzKtJHPjlqEiZ3SgBeNg1ovMimy5WFEl6FGhhkCBIFWTgDhW9bMo  
qmAv2fZ2ZLctW8aXQ5/M+IBV7VTaLp9kdJyc+AqsxlpTQGi0GGJtQq9a5rBFOO5J  
lwqcgIYU1PCrpZUOFeuG9PJeEFbljosoe0yM7iEcYC0ZwV3w1PGrDUW4gNVCfwAr  
5UtMvt8dly+v9JpUsqYOE4m6k0cax0gZDDg7dGzycirBgbFcCBZI40Ev22HgbsX  
QKsO14vxmjbuqlq31hBdpnCG4POI1D2X6qoSaLe97wDgB9R1K9g4o3SxHvgLxat7  
IXRiPxJBl0LAYBZ6pe46U/BbYKj0gQkg2V2Rbxuc4oBiMbEiprzC9XNV4L7OHym  
io6Egb8DnewoEKZr07nbC20ZmBHu1glX6jTeDXeNF3wBqtsVG8ELxKie1meZy41A  
AMZFSn+/M+gN35qCHIXZT+OygV1po0hOJ9nnke8fwuIc7ZYTThcS5AsvaSGOGXmCG  
rW2/wHMcoVWfrGtvD5iLN1dJvErNW9A05gZcgo9xNkl++Xvz8Je/vy/iRYS7dg5I  
E7+YJ+Aljn/5h9Q4728ASXZMuypyjpKM03KxuJ0WehOgG85snBRzozTOFEZQgCSu  
Lgc3bgnkAKigUTKbSiuN5MWB61qm67Y3jUvmsxVGGsPLal+hS/sk4x+RvCVn8yaa  
wFC+gGkDgCSDSbhU0uhPzpCzn5PYOBbRONZqeprZjco5jbi1QTkd0a2J0U2kTeB+  
C2+Ph0/vlDtne+/ttn0Ad82ulcSp8Rc5rSum4PEULHsv9NjcX4gwZsyIzs98wbaP  
6VU5vCVDq2hVt1dUT9qgkz3js0RtRB0v8Ar036sFxzah/z6tPvlzoS/k+RR1msJ+  
1xbSFKCwiRzdmT66CoGFTHQFne1BEcnjc3Txq0J+LSawCxYG8U+jdewNqalgYSi7  
pVf3Qsa2FSL9IdA9psUFPDtZrAGcPOvsWnSczyXaPaP5wf296Dccb0yNrwkMoudo  
3Xgvwo+yurThBA3XDwl9xE0Horn18I4IJXk9i+4XYEdieGcWQYsYR2QmTtcZN1g4  
3xqkY8qii0nVLkel2qvBsWMyQorj+6qIThgCmhSS3lZi1jBWZXtn+iTPTMer9cxM  
VmQILFSBxyQBT9R6RtIdXJWr+PUoQdvdTkJXUYKg5ZnuXhhysWqR/00RM3K+yxS+  
M+PcpNvRfQHg8hmlIxUg4yq7g5qTAQ7U/BVgNIK8bVU8bYV2G3fcUIKyVDMIO8t9  
l5pEsxGQLjubxwoNy5nJmSJpKD15TERPqwUjdtSdo/lthyT9CaHkItokkWTFAb9  
Dfb7cS7KGZCq0U0gmAYaQIFsIOpjlIVCvC5ZeNTUfsI9gbDSzLTSlhBmGqrBamao  
kEerZKnKjwIEh/ba1ub615b8S0HG9ghns8pqVBf4DJvAIEOVRMfe0MEd3HRs2e1x  
cPPRxu2+KjdJ0c92q2aq1U0H/LiDrVIMGRtY0JDzr65DZ0c/XbbfbIrQjZ5jeXtt  
Ln0bd6MMVAtdwHWT2fhIvcCswOXBkKxZVBjdY/w2GhkDIEW5cyudvkxxORloRfay  
mfo+Lkk8zERKvRLRMU5rCdKP/PdtEhI3oGG3QmerVOxpOVU16nh5ry3yxwmMmC/K  
mB6ihvUJJbqDXeKrZsQyKoP8vFqSv6wjeSJjqZc+L6qYg3R5DPrebKNNQPFdkJZ  
Ve2a9i8ON2vZze7ZoDs4Ggpsk91w7bBtOXtrrm5LZmQiAbM+pLNFX3ECIBMtCZki  
JI2Fj9Ev/xu5d0hM7hyLizWa6Miot2mVgVp2wn/9+c96oFHVAugbJ+ncn7k3pSBN  
/Y33/mScQoNyvkStAl0vrmkKfc8M/da2ePNkMaMXoFyuzZndRBSU9mubNNk9Uw7J  
zWlaSoZghBHLYnxz+Ine7AwOaSivjAylzCiiDH9rZGFovuyhvOfNJYe/hwVZlj36  
zASM9Xd3iWCpTkpmqtfcS9WPKhD0fZKP1GA1uukgnSYUqZIHIAL1kvKHDA/r4P

kECI7Cr9G+q6lvCaD6NxY9AR/Bm+C0kFTX6dw8L7BD05nSTGcYfL9KUiv5iSzpsl  
xmkHNSKP9Fss46hz8lGOYe0iW9qVFh6W+mPC7duNnsg05AewaTLZnI42NILQHz1L  
gXiADrwrMdhgV0jXdMUULu+dcc2tjURdxUamFgQiJAl8ulCtLdsxeUgmsjbOA5PC  
XpsR7IGcMypwGAGC1Ytfoke2FvppmkdLMHBVLhodkxQGraqNVegYtsNECYggOsnQ  
+ZPDRMIh6CkarbOMk0pV4KfM4tOJMm2/GrVrdrt5tn5jZRfruWRHHY8MNSwko8X  
i5R8EMEGQktKJ5r8tAuYLInEV57qiZ55xIYjDCrtqhXonNkgdz5o7mKnmWCrLq  
GOTPblSty3aF8wbHkaR5QXU86yuVYLJ4vhbNt6ZRUUJCRpwfOJ6cM4kEFDGiOvvN  
4SyCsU5HET4MTQEmTUPauyoB9uvPf3ceLcibAKs0UNCqqbNjVoRRWkLmSFQqXyOy  
e8vUaPxxwhNx39u6T28HTdsLnNBxHLgfbNOAqS4bctioZxFpF5PAey7u+P1p2Nw  
n84SGs1pQ1NyNJgqlDhPJ0z0C0YLGYjKVxEj34CBc7YwVZqs2siFwy+3W4HdVV  
2Y3Tz3SM2g23EfBDZhB5mt6GAanh2xStkshW5r8Ma0NVyge9J3+DdxYUVnLmm6e  
cA90s6piU5KM3g1iEZ1PURfN8ALzIGFQuP0FZIIJFzHudVU9UVQ7T1Ao5Zk4JPN  
5yl6OMwLVIFzogUhZgRmMP/3LunWm5WBcGrYNlvQG//v813L+bgiYbjpd0kfh+3A  
adjCwprojd9oVocoZaTfaSfB1xfuyoWsdAHyPswCwoQ34AXGccDsDZNuPOWMtiv  
rXnl79dX0+hi/mT+rJhdGs0HJSx+NpPVnSvUdcJqEqEfRnzIZIU5IHNS/oxFCtv  
HT9ABfQx2DKOQ/2s277TjB6WfCQbeLBzzb8Bh6IWbuC3QV0OB8PkZ6mLwVtKRfb  
xzjzOE4fowVKZMnPuem/dqhWllzMtKrqlaxLk7osOGIRTbvnM5O/QbntSVZMt8p  
KUpemhpMUa7luWbi092XEEk6MqRBfQdiCYXIPvnMNE0YGydTyJqMtIJ5LGikaA8P  
6clxWPk0mi40b7JLY09JZdOd0PU1M+tv27i0+0AAx99Amx/IMqTQEUBWvGeeSI57  
0f7o1XQinCnHpY1rB/rV30wnthviCZqZz8ktASIfrkhepcxthDKiwwy whole string

3bhzwjVh8v3Ku4TMWKGL0nQ9YVzpEoUuAtNL+p7vqj69xa69OxDpemFEsLGMrGAm  
2NGQL8603yUqtzI7ymAF25mVW2MjD0MayXTtGvqLDKBR0qY9bLlkqTG93fUL8OuZ  
YDR+oYvKsl4QpE1RdSd8NY3Xf/eE9q+u3+ruNxecX6P3GdmkySySz9GooJpTOvl  
rrQixyyjtxzgZY8WhQI/sbY4lSRsZTjd9jy4qO1gu8wvnq5Vkgav0yxZH6OSBiV7  
Q3QUHHShNmL0m10zMxwTgcZXpMPIkebm9rW5ya4qPPJ1WqAbBnYq32Bhr+WXfkLh  
vGDJypVYBvcQBk5Xe0tIR1mmxo2Xadw+o0g0afWXclyUwGZYJcwv4cWIJTF5SWh4  
LVU8GXOs+KZYJNMljlA9iAD+++2hXgL2UssLKfLALX13BsoQhs7uLPWMnc6HykKK  
brSwmc3WdsLRJRkAbm9HUOhCQs+Yc/kiZgP/5hym54j86QEdATWe2sbLQz9SAF2N  
1K7EZ9eJ7sjwL+8AM36BiZT+Ynzung6h/pwbJ/4pq6YkYh2LSYF8tJ02vYDVB0QyX3  
yc3oGAjVVqldMsgFtnBzrDqpgFaTzgmO+D5jbFtVTRLsu1rpjB+QOjrr94ERtTwL  
38918WRMFzWb0ASN48u+sGZTbA9yhl3urZ4x/c3pL/94D43Yr2spbgegWYRI1qxO  
CcC cubWiZKbr28yuc7oKOJSpllyzuSIznTdq1yoMm3bgO2Zgt9xmNBq7oFNmkrlf  
/s0jcpXZL//lxKUnBXkDguz8AgRL3Vtmjzl+mwjnkA/9lgdiUU0YJfj31r+tGLr  
0b2/A62WbkM6LpEcW6Xrer50WPo63DbqTiAG67gsqy1akWyW1tRgWeAwBY1pQJO2  
GeM8Eek3bJrRZUoBMnuel7DIntcLzTUmzwN560rLYZDkj8ZxxHmcdb9I7X9fqA4VN  
oexUfp5JYXno/nub6zID17Yz/FcNpbfbtCp+k+brMHBiEa9WiXFzDXmU4WheVj92  
Xp0wDSmDuBKcsLK1gZiRcr0s973D+GphHvlbNI3n9qOw6XwyRLyG5yIAfNzd4x4X  
b175YtzgkmrgT9WPKAL7XuohPKplHVQxGIOtZY04pus1ydRdzpg896vTHDohmZqu  
Vxa5gIn+l+ngl78p4hcGLnaylHzFwaC+Yhvka507Zq82FY11rrKqGgsGHVvaGl43  
P9hIViYPsFjxdkNAscTZhRq8QIAoZeALDaiXjsh8oJ/PbhGjoZfwAupv0AZW1duT  
iXunmhdtmmLV4WaWqrzkFUYqX8ykJORmxPAOUxkIDJmGkqb7kuEcKXB8G6Eaezt1  
1j0b8Lkg2WqFQSOk2TmNoLPHvMRvPizun9Bo4gvET4YI3olhMRdJnmsYn9d2QYT9  
7pos86if1WKLBImiZyNKH7bQVcCj4y5z33SrH7L34pHMV2JHQJWZZkve7bgd4uL  
fDxFVrVHRgDJAVLhKac4Urr8iKJd6lxMAFFMk9lGz6VXSOba/iYEW+OY8x0Phh4z  
tnXJ2pzRrq1ic5jMniLjUoo8+vM0NXpdFHMk88j45Xkraox+OgjqkPVEJXM0oib  
ct5FmTjYYoTLdexQG1XOgeNu4wVoM+dLzeDhCRov9OsFt38YMG6omK1eYr5y4pcY  
HGykS5aJoEHtpwsw+sm4aD8aY7yMaf6eJXR+aw0DeA7tPzv1PpxMkG+IXI8iJI7  
ZohWPgvmVO9H2Qv/fPqFQZH3AjSg4B0dTlnjEA82xzvfPd4DLs9fyAardymu1laY  
sX1ALr+1DZnTwoxtjnJyjP6EvnFfymTOSnbL4IaJFVpiDKkZTkcGp8oqKqw3lcF  
ynz+UsOM7rNEZDijGQ9U46eTb8qbOvPccmojYXOWtggR9Mh9L1ZwC/9SI+eskHy1  
WYX1wOUhRkKDhBLrr7lyIFOx4f/KPtO8PhwaJCO16S3MaQZpdA6SfBEpvokQ3V48  
psZ1v0ZUlagfJVMBKMnH01maoXo0GicyfFnSQ4qkcdn0U1idoupjYziyKy9z9Oey  
uogDCsmc3A2hs633XgBYZxi2zbDdbtAUuERKG8RXDOIHFnGEbssrUV8ZL5oADY0x  
LDJcmtuFyzwJtqD2KmW0yHQj0MpamX5esIRJJ+ThEML6oc/yUJvyVOX/26ztN32  
p9CXGHRpdS6yRBTX2mhBwqxdF9ESvkSf2RGQd07rumXnuPevjm7ztwekMwu0xgCD  
likb7ggp20cc4J2U7WTO1QSMQ7Kwaa/6E3lrQXkknOKQI4400CokOivt7Vleu/mg  
6D8RZQiQABPcXOj4tRKMp9lUDHcpF/MuDXwMexmhDdoHLcwwO4Xv/xH49zs4+fi  
2x2UJqKTR7clizGOJA+zLBGtCf2NJoFanyZVZZD/VpfAttZkY7NLYGCF7Oox2VYn  
I2PggaHel+I9gVwG5oWqG5jW3cPaPSt1WQqGvC7Jy7/oSodp9YcSW8gokDsdrlv  
7qAe4AYilm0ApDb0+QYRp1MJrN4RbbfUYerqf5ofob1hXYmMTZty7bZOQtO8qFw  
VUQc+XxUrejqPbV+vwwJru1kd87naZDLadqC5q1v96tByw2ZSLrJ7fvIHulwkFk8q  
IhHcqWE0B5wLleUe3WbA1WZrlanAAQQJfv2oXW8gSt793q6K+ygx8qKVglbIQSJj  
ItjtgU8qKqbLA+75txXYeyBxV4b28MAelzPfnKQFntbEFwyxAiUAkP87bQP5I7q  
b2aeJqsyAJpwN6N09iQCi1Lgy3TNUAp8Ng431OCR4sYtl2u9mJ3crKKT01akUTVr  
UnhxPF2NeIWTs6ioqEzKgC5cM3kY5Q3fDm3MEvr4aBILeoFhNIungiljnecpybTi  
G0hIQCZzQN8iW+SO1lzlTDInzYwnUqlQcmSyLEGHop9Evfz5p90IXut9O0BL2V3w  
HgXgZTI4ztsyDddpNEpGtAPvjDPR6o85+dAnr1P9CXIG4RQIIYGM3MrDqpGu1rhT  
ONwl256syllqoYARTSFFVWUPZAtpfOx4inh4mv0GYgsICy26YLbjbDXXKxFbaAjB

T+wxYObNIOJ6vA5czVGu58Ucgr2TRXeoZujQVaKpTvD6h9ksmpKKgYRJc1TEnYMM  
cMZdyAWgo37feAnKLE994vOybaOq7Fk3VMntTMjCV2ikHLck767Vs4O0jqSkJO9u  
uT5I62ymAbslE1xo4svfsoBy/MCyCtEfz6h+kRtjpwO41MYj32W07W8u5tJ+pUb  
RWosgJDChN9N0mMxx6zrt0xXLxa1W14zG4/nQtq1TlcG2b2hobLVEJOjlxnN+Jk  
0TGMM/NTDMdf2X6SX5Pnq1o8cdsEtzipyo+iAxJmzEwrrlJhZiTz26ZXuh+27es  
t5blgCOAhgEr4FOUTeai+LGLWwhqkEsa0zGtTiqadrBdy5ZzgANKUPdMHY4kpDL  
ZDmZusgg+g4NQSu2c1zaMtcP2g58dua/GtKJXtISgmU9HY0YC9UlcfxonB9upDxZ  
TvFgmrxFv/78Z7FK42po9ah41W+CMVesEPHzyqjDFEgJjrmvcw1SE7nsSyLsFxk  
1JFwRK8IPY1rebhoZKDaJvQ0F7U3sMV24xtN0GabkL7Z6EUcxfkEdpv+gLtFJPPI  
pNIPjluGpqaqGQqGecB6MrHa5+pg7T9oQUx6UToFKm2jcqaK8vTN7mcBjHOv0H/IK  
LcBFXFfSo5JYEStIKj6p0HaaqMpTbhdmFZDsYDKtQ3olyV9QiBYZHbOPrmXFmEcv  
illqDGdpHWw25kShYirtW7T80hjZcMqEPDiThYSqCltk/fzt5BICw45qeoPkGXNe  
Xa3W6el+Mm/SRWr0AfDfQZXI8nbDQuAmJEy5wZzsKVBEJRkj4ETVclWtq8T5T3Dh  
EEHktGVZ2e/vc8wVEPI667TINzFRXFT2N1y/4TRIQgcBjd9jVC0Zr5OUTgJKSAo0  
vltYJF/P6LltyUu8RkDmMzozoKgf5/EjSH0aoETY+jrfXRpsbdOGZ+dWtmsajhS  
bz9Qa796UMPKVaY7snmRoMToVFct/30qJjC5HXj+a1RMCPF5oe3Ssvhcvjf5uBl  
7RwrOdHpce9amZjiNoDjR8bgdtAOI56hBxM8MT1DJjAr8IL8+vPfchOBsk1LseyG  
KIDmFDI+5GjsUrCQI8sTgQDRvwlv/BRz87RLEMaL9DBnOZWNPowzdaS59po/DBe3  
dHoa5crJ4QI05E7Gb/rHaStPtcp6teniys6zJINwloS/PgGkYSacUtqhv1RgBG01  
p6Kz4wxNqphMSYWapnJUpjTgabBQ3Cez5J6cpidZEoodeRTR/wF3SxxBhNILhxMw  
EKG74wJZrwVWkbSd1c/85tzJwv/15//l+vStIDUyO8+cVP6+Aw5hF80l6N/2Bnx0  
nPIMaDGikUJvX64X93kSw0u5ylp5smDi0duC9ohv6k2cwdg1SPaAMK3qgKdmXoKs  
FPhDyXQFsotkVTc9zO/5myJZYNbMAcLUei5RbRllyouUfMs7fB9KDpThjuaCLJj  
aYem07YC3/RpWrADbqPHeBIBsXhcPCR59Mw/X6UPijxztycBEPwQiz0ZRo/FPZ46  
bVSrrZyy+2riok+VMQUKdZk+02kq0MPqiQQBuaq069MV+eDjhXJJEmBK/nw0bw8  
6r0V6Y0KDsbYeAlnBqv+2rJW1hOTujLvh5BJwPalK1Hpwz+N9CpIOyBtYx2E9fZy  
wp9bqvjdXjWgoMiUYZqyizSbACaWpjzBdwAkrZAP21y5pgRg2Z6HyErUpYBblxM  
7Zyo0gdIEmEECF4Tpfn5cDNL9MKUmOoVGYjpzDwu6Yi4BjLF7T0j1PjE9+k5Ve7h  
Ovs22tySO26Gds2yEXjpBuY653dYY7olwNQzpVkvFixJX6ZRing/+cUoOZ0oJZMu  
IDlhwbffub7J30Krflplej/j83S5J0BeKTniq/LkqlxxC9nCzabmnhu4LRP8Fx+b+  
ednjhCIHjr/RFk+TxV8u+ltB/afa190IGPVMb5003zH3tZsnM7akUdi37tOcly4a  
GYBB8PxS9allSRUZ5TykG1/7dPRejstzzrypr0SA1QWk3ZKV1+nudChzAdBCfYmj  
meh4AvhbFo1G5ObIQih0wxG1JyUsQI/QIQuPlvbW2wMy8c16EVE7aHJS3EV5Kj1o  
w1Ux8Sfs7UxGdpzc02dsCssq3g9zWC2AWVuNEgy+mDQaVQPoEwbdPcOKzYKNlItm  
zu675L7I4mY1HvQs1vIPo7W5czymHA9rvqtO79Qc9m8k5xwaiZMF9ZU+2/4KR6jt  
t/cYRvDmJBPFb72rCpG0a4oGmnAWM5nlQuBb9ECJzCymsUI2J9VUcxPKHIYo6Nh  
GaKs8dR2EJxzakAGAWWecldsvKNB72i0GvzsHt/GN33Rel1J0jpSDHwW+E/RUu4U  
tMXjccLx6wp2QO4C3Fbajl9//rubPC4mqQwkoMq2xluz4y2IdfDfWXIntwCgnHv1  
I+NOaFX1oAs6a6eTII2By+Q+4i+v7WWHOP/8M2yxyme3DmKSOK3Q0iOUDD53rKZ8  
hebNLVCLx7VA7I/2kJ3P8OPnM7QlgGKg8We0EbJ0YoZYfkn5Uvffuf+8QhfK+ydX  
QhnNG15a+8DViGmFmbxFrnE+lsuaylBHmtzOrPGBSmdszl4QM7ZMVbhmfq1Yswq  
NBHkRvnXGo+Z4pQhMQOnn9NHebm7k1i9nV9gZZ3DIMGL8uBucQ1YznsnCPY9/+2B  
5/gt16R/a8UMkmug71he2w/pDXscQX7zBzKckGxpXoLANDM6l2xqxU+kdsfT5BEb  
cvbxHfQL3fV74xwlsuPHDHL4ECUZooVtr75IM9EXOf5mnJ2x2S9vffx6qHUIKmoG  
kbyGhygkZnWdZs8o3xJc0kDwVm0731olmxYiDPZduoxOQBfNpH9rtE9qlVD44wZe  
y6GzyBxw3fQZJ4zsjGOEPsB3MTTxjg68A00unEm5AFbR6m0Ac9H8Ya4i+4iMYL92  
XD8qEEExPtcaBEyUxNjt19JGNsvlxXiU69znsrQ+LhHHMgqyhM4lnEY4Y2OdzMDTZ  
/yrEpaRanFbQpMXhqq5iYxxBSgQg9FPzRJDI9cw/cJlk3rhEAgt/ujG/qG5B5mGj

CpLj4gJLxE3RaNjy+ull9v8VdK+Uv+Md8IeAnDmSMwN2mBujldVAF0oQXRydHOsE  
I1VFkjClvC1Z6JUtIEWGpdIrAF6T7sAHbkAHblam92w7TTjITRTvdAh656p6U4S  
OMTG+TEQHGNAlY2bDooO0ScBeT3E39KcC3rHSJLcHH3U41Oq8jbNa4W6soP7smYF  
9Rs66aBykWfRSDFcX3PX8pLjqZqiz31CNZZB8LsHzUhNznlbALQz/9ynwrgCcw33  
BT1GU1PA+7nJzhDLPzSVzvqMx0SPYfOcMx3kisQLJmWuRGOJMBAYVSWtn2IJUUVb  
HREO0gFXdFh4szXTqszCs/sDHhY6RemsmMf6YRIdQ9FPTN9iJJd07SyhbhZBoB6Y  
lueFJiQCk6gjmy8qGJQV/l8FpMGoAnOpjYMGCBunsybrkjkti/+IX0x+miYm93/  
8l8Ay85BGGrE9hQNYADLW/K4Mb+Vz2f2h1K91gdWPZjAmohlrJ3FwPVN6XKZjXpEj  
zdGVV+vSUGdiewduy/Lc7ao0ryle0llxUVrCiasuklzMhqb/YQMnfijrOYr0Fyt  
XlbFnK38M5HS55roWsiU7MsSvxgvE3RvZUEwrWq+JiqKq4B7GtLLboEAJqS7AprX  
9kY/B4IWaDVaZG6Hopl7MioWk3vyuU70EZlqyJN58hjxdlz/xtg4DKHgFNljzpeo  
4UWYkO9xJHlxyxFmgLckttG7FbHeQAF4JC3svsxXEKMU6kXJ7nvbYG+reK/qShI  
ckVB0nYr+43XafpslyVcCPD5DDiTYRo+ESKHYbTTemiV/Mfqvkfqfl3QMjDNrvZ  
qar5q2qnG9GIgtH6cUrKRPbxln9Wf+VbOih5KOg8yBNyVol+dMlvG9xEIzbAccIW  
0MvlNum+ICsdNwwwZvhOX6bJE0iJYLhG96ig7JbHMRFwDQRVyyAC3+LqdCqcPvx2  
+hm9rjaSeVuncityqYmXquH4NmWxHwSSVbVlhybdsbbgvB1PcJqYePEEDXfWxqkg  
igOxt3E1aGwl/IXDhH4FmpJI6MZStGhGo6zOliK1PJW5njbTCjkouXb1EGDbbY4e  
omYU31uuR0NiFAb5ZyDmS7jp+22ezrDAH5E3flyz60a69Kjy53aG4Ot26AYqfMgD  
3QTKcAyeiRFFv8BxFdwEPvt0He2PRs7aMpXaCoOZ0yLu/gRFCxAAkGITWguOSzz  
m+O4pDoQGdYyWfgi6qqV94gzo0v+arUZhQzoA5iu0eQ24YAc/Nm5uYjvxcKMRMVQ  
dIAodox9kYJep5VtRnJ1Eot2PyoLWzltId4520i5Oh7bdtsID6ItgjJzfA5uuSch  
hf1DqmPC2NWq01KsqEpqVWybxR819ykvZndl6hE9oeZIUDSYFOuV3CAAsAOUKudlb  
kHhVyc25LTwyxyE60XcEWYOIs+oxl6nVfEDxw5cgeKCHsVINpSbAJYwBI0DYi6B  
J0aKvt/0acCbxCK7JifufxGY4G23rdELcoO4gLHKvk32+YzDR4WwDmJ8hFz7F9G  
c6bb56qsbpW4Te9yDZTNkBRjpnqZ03pzGWs0lmzOXNiwasWmNaDWI1YEQFiet8  
XVKuRrVIKztWk3097KJwJVvRdycltofpBAaBY7p1rgOLD0zpnDowHXJPaXItjp2T  
gE25W8gwTu7QkXhhPoVWdqRwXkmtglnqbQrBQm1qY+KueDZ1k5XxoPodpJXQRSd  
r6PaSYaJIAgMeCCq51SFaMNYNKN9+v+39fGPohFKZls0eiaFTxeLzzNuOeHaTyd  
Cz47dnu0FmRlbCSi7xIzJjlwk5doGL2TSS31C6hcpSc5HyC7XUtUE1vNWuMTiR9B  
0lXSw/3683+AcOHgBN3/jaaeBp0sMnSV0VFv6ClhG1XpmMNsU7Q2rKt265kjrV9  
r2Xi2sFi+Of/i+5y+pT83/8WJt11Fk/JrB6jeJzsCfICVeAZu0smXMDefKzmbMx  
V+yleq5eln7tsNyI1VtZrQthsoqV4zffK7TJkaVX7Fvf370Se9LJ8+oJWUlVKChD  
Ncia67atpoBJOOFo4zWaeJvDSdOMETSDaDoiu6ZDltLJFJQRR3RQhin5fliFo/xO  
UCT3BZBlzCqC6ZBqlIA5sxpWWa6SgqQkaxRV1LB613TqRw+likvkAjTdTgDxWk6K  
Bls5UVlgOxZMTkiMtrhs3WG2vS75iV9kjADze8hHEeo2xZ/+KF3EU9HW8Mb83DA+  
iO49Wt5JE7/Xg+MgqjhjBy645c4HlpbtyhwYkpZ0syeyBgrk04VfH9DpC7wdZM2O  
q/p0Wq7Z2uOS4jeChpa7AsTqB72PVjlys59OyJJF6AgOrTw6Wq+CM9Wr4DTNZfcU  
A1kRB05zpOpwtcn7Zcr1X3/+Mz94ttHcSscNcNjNfdvuDewzFbQvzUlknx6W8h3M  
2BPUeifL/NTWI7QYjCKdMhHBI4LD0lckl180CXa0weimCLpEO7RVMqIF2iytoZM3  
+JY84WIVwceZPakqR8ZG7m7L3VZdufnkkR4PSeA6vmXpWFFJQb75AM2E+6/ytg6A  
9kCDtQ5g18J+Aa45Nq7M25oJ0FcE5K8WdeJyVrakMk27UzqZshpbN1ErKLbMISjQ  
Bgpst4DYa1mu07L8toXN8ERRkfHlk2ic8yl5eDT+CAwUOXZz4/SG64oSAS1UY3li  
EBMZ+KNMoFNRCvptJprD1U2j+2LGLe8ZIM+a7zlalbg8m2wUXyT2Tdu1/bpN/xDN  
5s2Hu2hkeQ6N1xdW/RhgEu5AT5MH+o/zGp1sRWukGSIYyk6v078d2q65Meo7Mero  
24YeVGIOY5UVpqdRPMcNOr89rTqfgkSQPtXXxRk6az9wCx/yP2i0XlgfTRKy240j  
ZoV8ikh3RiSdZJcy0k10GC+qmpKPO0e5//TpmGwIIzs3yTmkwSWg/YwNF9nAvla2  
/klQ0uloSCx7bAehGduaeRuE5KjClpcymQSZ60GKwQhBCebCuDzkpmSLfAU+aPxG  
MhL8DNCij3o/6a1uCgp0ujrbqsZrQE5W3NmRDeyNMW5AVFNrlvOIG+NR6oCs28i

i42z87Oe3rFxxe0at6DHpD8PXCCwXXdHmWuJPW7TfcEsYVuc0G6QaZc/iLzzQ45k  
MSVkN13PavvXj6RM50kekbm4EHB2ja4ekQnthjAesAbBu70cmKWgEFXqZ9oaHtRx  
NByhWbAdYQ6T+1k8NkP+Db3ZXy06bNWMi826Tct1cYDb7B18cUyws0yYkMpAQPpS  
ogzJnLioXTfRyVhEHnYUI9xxRaEqKPzJOO+eKZ3VMPx9m0+kZwW2fqsCp/IAQjyR  
z4nX9xym57tKs6TsEXAvbv8gnhcvLwmafvOQIkFkog1NO0/63WcHSzpXZB0B3ng  
eB2rhGSbozuu7Zmus3V+HkntVo3MbZcGyQX+KQxxmiwwJ/l4+kjSm6tv6Y9HBoib  
FB09Lxmcqd1jzbdMdl3g4478lhRT6VPaybf9O+2hPATJC8Ye+VatdWHVHsq2fM9C  
eyjHftQ9aYHYCu0CSEzBp30linv5yJwDEfaEqWjhkzl8dxoa+jrY61aB75DDZ5/  
wNE3rIPAsOQSzw9uA9VKvX64fRv9xOyW75j0T3vDKXxgPKrlhUjtO0x+d/nLf17G  
L+ZNPMnAvdaVSDby9x4iTKPsBURi5wUGC6iuUcicm0e0X0/0RzBv3xegBGKwdNnH  
AmpzK+j1SkGCiLJq5T2be81+aMXrSR5JWcmEC5WrwzMrLuRxx9maPhDQ0bzID7hJ  
Q43FQ6JmYewNpnGBB8lZ+XZHsm9Cl7gs8THdhMh+k6dd2cqbbehlvYxfqYjQSvK  
YBGwj+QM/jwpaEacxjwnz+P6CRzJom76UMh2nZpsk7ch0+LZiOhlvZUNPERmVA8A  
Bgt3IWapEEfoOOYLjU2YD+OeiFPCZJgh97mQ5fy36aygNTeq0rPaSAYdI5+ynwzG  
ohtbFG0mEzUFWI8a5AQ0Rblx0zMv7b/WCppk8XrP9v7amKv660ZdAkpzyNbpX7bf  
X+CxZGmJcixUq57ATGN4yqHinu7h+i1T0h1c8a2xOD0loFSgDaj1sCm3AScxw56t  
Eq1JaHIEqqZ9SGa0fNMLdqx86Mm2Cb7NC881otFsFIk2yghcxNN70msXOCHLVaRZ  
bTewDkQ5WznqSutjQJXp6HAFLHrJtOwdZAht2enMdKXX8EtY+ncz/hsfowWR7OX  
6BFGVf+wwfFZ8Z2ocdLGMQTv6Syq82Ht33SG3bdccHGtMnhgr64qFyQXC7rirhiD  
3K3V88IIDsB6hZf9rrbRGE7dM41BKBsdpMFQy7HdotyLM204UU6M4L/2NO1kkf  
GYWUbMeUTCPgMYaLNbJhw1MV7kzmo4gbtBtk9j3mG/UA62jG7ED0+nJK9itOPQ5H  
cyx9kjuSbvdFrG3Sb/cF93b2Bbccz/VD9AXnDs80C/jeQoVfXTevr66vzY+y7AwU  
3LEGmYkEx3i35CyTlzuWIxvKkTX7cjJhm5Np7H5PuTHis7ITwtMudzJaiAb175hN  
pUFzULx7fVzEVDTQSBQQFjkUxUhCpeZpJir8Zjt12O538vAgkIrLSAeKXFa0MN8K  
yTCrVIIqYRINK/zTnYVKnCASHByQL2tt4t7gLEfLWL14Bn9hxm5LtFv/eFLICf  
kB10WUmSdwb3a00msjf8vBiT7I6PU65DEJD9hUGiD1GwOd8JtE0VzWQeF+lzo+q+  
fl0+pWRgm3W4TiPn0a1uJg9p4+z8+qtte+5Xh4xAZsrTix5g+l7Z59SAzafxkr1Y  
WEbVWp7RWtY7W6iVJTHDapCGVskaN2TmISAlzCDUV9FvNa+OzvtpBOyDB5ulme20  
NRRouSIZs+yJKvhnBNDEeiyKDKdrzNqFiw+gu38qqW6MKzygHzxRe2fzgfsuh17C  
CNB9lh/KX8ooAQBWFDl/N59ppCaNxMRIGSZJlXFSE0xUhMjNXmkeGrepDkzgmCa  
y/bbgnKkM9NpS3VcbF63WZAGqOro+fQCUKNpfAvJZUYdu+3Q9KztQi+3he7wXI  
noBWqnzbQwKMqw4RxsYFc+r+vloVhplh+wz9SVnBPk55Pndxt9WtZAYB49EhQe08H  
ctPbzpGT5txZ8G5ifgsujzZmQuNLnRF3evxl//W7fztbP4qtfxfv2IX8uHvu5/ocVi  
vqy3TSvE42WnsK/kHEKcLFZfo/yrHI1uhrQoeLZah6/p3Vesw1e1DI8T+qZp/BX  
QEsxXMGN4MhIE1tfx7CWGQOtFxUgL2JW4Mr0yhiyMd+oPdLIgaWKR9bhXjWFwqAhG  
95nu8UNJMyrrvV8IBQNW7jKaCjpt3FbhReVSE6+395r7qNbC7sMlghdxxng3D4T  
qgWk7di2jFDTbZGm6ZstzTBeksGb7qwdxSGCWTRZ02Y+GR+vhM7SvxJ/gJHFOQB  
Z50jWTeRJslnAOcpv4I5Yin/5vXko4UyyZPujhW2uYWFUZkWvjo6rYYbbADqTM  
sMs+WTJJwF8Uc90vXGcw1GvtTc+6H3iJFPaJG9hIBWVEc4x4QyNFE/KclQwtY7J  
EZPd0c2RLiYJbIQtgKX5CVz/93mySPwRx+ju5j7bnxRsdUL+qlkHuAT/Lm/npH  
bhxdcB/QKfmPU6Q/xj+REz9C4XJWlCxX2EAarpqU3n6qNm5krYRYijiOxswkZQ8h  
2MLicoDiYFw1eQsRS/P8gKzh2mZYTtVvwXM/zLJkpboPOkdwkJv47THOUBg  
v9ihZqMM6Yhv2qgril9FG9ZF1rnMVGBLlgYGIoQwBlg6doQvIUCbpJg7Fhfhzog  
FeNaGltKycNCJ3/wpadKeIovMp/YZvtVtAih3uPURlvrxFx0UHVEaaWJY9TwfMB  
P3tQJC+a uY/Tlqpjsk4oyJZ+YoL1jS3adA+lzJ4hRU62hYRisRKtgk+idpiM8VI  
KJz8iOX5j4uX66qjqy4XmzmR+ti0dSeYGdIMS9TWWKZIH8ok9JhF7g1nIU  
w6GMck1gMzkclGf /arqjH0UZbO1ZurJok4FXdB76vb0DHI5fmXP  
sSX36FjTvqRZ/OvPf+5HEKgQDCst wdoVKdWh2MOqBP6IS2WVGbPf0u3vdt  
Dsdo8EJ6L6n+c7NEvYMOfF4h4U3blxTP5R

v3N7+tecKEoZ8XV82e12jT9Jn+USCrPcG2VniRF0Zki2j7+bLRF2mN1WUobJE2Gn  
jKV9Zi7IGPIm3dKpuSS/vfwb2SJMTQgEQ4JoTicjE2LCPKHHaQoSKEkrFWd15nl  
YEDjySpDL6AgTOwZ267vBxtB/7vRuMF/p++GufHP/2ch6yl5gzJO4ofxy/qRxRdt  
3UvxqKX+jkreOiuM45X69kYp5cLSxa6oklvN7RJeKfFIES2cKzVXAzp4DzBGTh  
UqFjDa4UAQ+Pt8QzAWXLC1haAwn2wf68ilgKgVgKD+iWOWk1emeJWAqb8hVaAk4V  
0JivEoQmOrMV3E/m9OOMjdZQYmvGFeSiJAQQ0MpitpxynRHdnUdOBQLke6AYtnKE  
wp+n61pbIYXKC9/7DhyKAH1pWs6GhLYCCGVu9xY2bK8V+iyhQwHKWwE8MBb9mzcG  
e6BvDuYp0azDMdDKpLDEhtBljsuC1lwQsjuCi4PjCzbENkv3a3QavwykjDpt0Z7  
hI63E1JDBVxs7Fu8fKSQqQwJuoC5j+Ouh4yt8sLs4IAS7xEo1/+M5hd+sxcws2D  
ALjJ1XBxJmrtA3TCP+641rKYM+jmkkmDgo0SzNyy0GLWschRCt5CkgAe6HiSSoIM  
DijqC+S+hlfCOTirMifloG4EaDvf4so5BXd7T+N6V3RWOWx7sNdU2dbRGor1zIR1  
I4K5vORq6zBNmq4YUOHIFIYMOu9A52rfVgziCZoolPrRLI+Q1eljguBygeThX8yO  
+O2QWYynkXHeExYio4S7svcbxkmUI1yoldkXNTldza9mxVP6TcAl1hOiOBy2XeM  
G4qOjWI2jjPzzEnkNMmaj6Zc9MHXXGv14LIR4zim525hNB5Whey2FXK3LuuOVMM  
9siq+uU/4hj2yMZCdcSn/gdIOct60MD1ozByzVtyV7RO5azQj7UpKEBfblyli3kK  
q7MMvnBHjXSpHlzO4kqilUy3YDSaBG3WRBypaRIWJBzqPBuvSbmy4sxue/WYcllx  
Jl+h6cMMOMyiepxDF9OnESBkzxGfAoV0bFx79Hu3iLQeXfHfCNHdMQQi0IMw4JE  
47KtON+s+qrdrPpLikiH5mThYR3yMRf3yNoObh6n02cxPyS8VgXQVgw0/vvAx8G2  
uYOsdq8S5OxWGLYcl6bH2IDkMZ09RtBiF+kyWXCLHO4mOR+LYi56osiTiH++3FBp  
uahlyxDKook3R9WcZQbHkGXyEnuk6bLSI2fYGViCdbwpmfT0OcW8PO7yKVE9VZZU  
ap2okBc+Rxlz+dowHcs0R4thqWS9t/wGTvwaD/A2jRsGHjFZ7jDO0HH1fANIK4ZO  
951GPmYXbwxaAHKyFqSo7/A58ucsAp5c/CwiqzNuxgU7lw4xF0tT8R3N5dCAV00  
Tw3V9Ymb4fDV1ghPdHuZOVLuUxwNAcNEm/qMydpG6yUdU+B671bYHRL8ayV52CWQ  
Z4UEPqBoFjdj8W3fJNWzwVhE6qli+hYCY/bbtXyyAGiBYQFBDTJI/WM/cqLLInv  
ZRMb/B3R509kqxuH5wL/ZirxhsZP5GYlwt85dcyyhWqj1sKhLo/XYpM40xxDFKxh  
YGY1Fp4t/gGN/IDICAM8yYzcLrYUvkTVfnSzqNqTWIXtI7uZnNGiyml2mSATF1a  
I4cU/YzWiLv8TbE/t+YI6s9pOGQYDfqQGQARoNIHeZA08rFTra+stigwnJi44a6Y  
bU+2VPGKZ2CDxYfnEYoOxTZHG9NguYWtAMxCzu2/WSPyxve3IDpATDCHlqc4Y5k  
E951XJuTU3KLpNdx+vkJQjV6Wza54oqlTVzkCmHjaiIZoeE4/KgHIUepwdT0G7Q  
7615WNVENhfRWjC28yadNAOzHrWEIOxW7bptVxrP2jTVCzPM8miYqpNbqTFttJp  
9PxIzxDoxcbcF6eX3Cua1hINA18mKCHNjeEnOr83Nx1jPyJrYr1IVP+AOCWX463W  
97fEzTIIAHTsgjJ2U26ruJZggEUkmNQCo0YI+k0yGONjBOZdCJOyDeTt1fG//INe  
T8E+NYeORNMeCSwPKLKIZoDu4ziG7aBXveP69ehXTzYGMiMKpnMpr/nMJPNaVzM  
ZWs+ZDks+CAih57mkTIMgAzXeDU6aqnOoOo5SyDPRzrVillfL7lrcbFz0mgrhXOR  
4mJHV6cQ6X9cRhC9b/K8n36+ORrcHl0Nz66vuAbHChgVYJPQYtpO8I7P5iDZNjqk  
0shwxORFufExmcXcjv6dKINfpOZVvOLQzR8ZhKCPHlvAn4q/isLUTRsWaRm5ABXG  
pzZT7zbQZg0HV2rHVD2yBc7wFnnpFZm571kOnDD6h1+g+cA4q3fjk/NGMhyvkWP9  
a5EyQI+jHoBf5bd+Vd/6VXzr1/JbaYywoD5GGVIQX96RMYiSg4w17JD8q/taqdcm  
KHSDKKwExCGZV4eGYk8usR0KwsMdOizHhRHk2SQiPhtDRgzRssRsBS5JROuta7Xd  
gE87TCL+YhzuySwdweYT1TM/GOHA6t3zB5ii/MaM1AelphAcANlzbPclB7Yu42jC  
AlyElg82+7Ajn8VAurNcgaaGsozqu0ckImgz8UUGzo5E2EVW9nDwp8mG2MoUwTiz  
DMIIGJ9obSonReOHLDJSAS50Zk/0bo78Dcm6N/pHslijjLSweYlmDh8rLHQekxbj  
uSBIxgvT0EpPHoonGAuywwkD4lbC3RIO0/EjV78jcZln1FNZM36LCi5O7hgXUbEA  
g2JSpkf91r5NRuBRS/PBGXQv+cMjv2XbVov3JNgxJ5AcvJi3aYbmuShbjBDyWOCZ  
+CHVIh61sZU1U6tM8rTpzp4ykncEqnm2OWbb0Cr9RVNprntOl1zAotbq1Y9SMTZR  
VJSU9TujtXaFqtSMNwA9TvkDbtNOqdu18uBj221m082rZrg4CZPFyUJpKppSS7J  
KyPtckXFN5EnR0YCDDzH+LaM7EMmLRIPV/T34Sc0XH9m07IjrvWRYoVW0GRVydMV  
5ZCVuynPCF+HMIVWttWGxjhy2k595xeFjdfp7zR6Jt9CCvfXn/+OlgjoVPRGj3/9

+X8+2MU+IFP3TLbd/dAwhred21r+trhH4ZBjqeX7/iLvVbRaxM85X0283LRC+m8T  
6CMTQzPl0JCZpT9kj2YOQpz0zqzGaWrjJCeKH03GRXPPYeLPYzLNOH4PzOJpanyG  
jXoYg2T2sNO/0epoykiFTrvA1qqWuNhIF72eeKkXYFxADbqQpTMyDrCMiGhU8CJ  
2iC3ZUu6WfJiHfOZZsMhmTLAKmt1ROAHhG2ib6cOkvxuRAApktAVbWXQbMWxPGsn  
KMBy6AS1aCjQyDfpcsmky6v4PibTjxk9+vHqBQosI3PBrCJiZyRg51jdRY3acnFf  
UVsmCrDEQ+ySf5Jxs1hygkZQ+UiFlj3u7PfBQbdn2b5l14h6nabttXw7pBtavrws  
RnTqmayzM4ajjeA/sGUCzdZr1OpH9ORU6ZJ3Br3hwY5icjoefGeX6bLs0gMcpyWB  
O/89el3uhNqh27Rdc14ktatHXgo435ij5Y1mv306aZQUmNMkX8lsbA3ppNqnA5wy  
A9c/V4RVIZgayiRV7a5fo36GVEFvFHRGfZ36mXOi9ASNF3q+98s/zh5jkQZcyc4T  
w2WYQNF7twdBp5/QcpOG5ZUUyaVvCpWww0Enr8XkB18A2dAZLpD4vgGvOPQDF/XL  
D1CJp+tFHq9+/flvL+Ocg+IMmCkbnBV5letEAumg3XLrvwLJdq2WRX+muWi0lvpN  
m6CXI0omR3Rq7kBcJtLGNYzyRg75SiUmzb5KlkVKxkZEKm+/aszcEVW5+UqfRKi  
s61Oyvd3kZCMNRctphAi58z0XW25MTUpmRiSiZNyZRTMsWUTH1KpYIEKwPLQbvW  
nzguuRjbV9nn8HR6kA6iRXYP5aZDBGrQNofxcPGz8Rl0+rake/yIgbdYr/gduupw  
raaw+2R6LSnHz8KHJNktDzv3+3CYXZPBTMym1OsYz2yZTVKBVwNjTkwl+SjndA1m  
Un10o4i2MdgiMyq7vIHZkTwihnl+YLN5knMeF76OmGqlnEwxqacHuOa7iaRyQM2  
5YBNjNZUozXFaLVFoBkzgGI0+piNokX0QzNZfk8i/3bbG3wzsIB9oQSRINz8K6s  
OEhjfufMhG++JGVYzHmzcBKb0Wj0INCBeXQD4NO3WJn4dujw0hSnLzfH4svN6stJ  
tzMTZncK03RtnH8URtRwdxR29F8Ixes7Tcy8I2uVT6U4g2z/9MpZf6LvRUo1G/3Q  
GbwtB8Cs8oTuc/PhaSyGJI+k3XTtZIYOQs5LqybHTKDXP6xWIPLlyF3Jp8Y9eHQW  
ovQEQQaYpZtEhGqXjrzEJQ2TzuljHC8N0WHuiQMporWtMQM4kV15AVA8EsEUXdAA  
zWs7P2S7JfxhMjCjd6tpjhNEPJuzYgzV0ywwLbp7PC2zmhb2Ndevp5iJuUpNzMQU  
ozdp9MAE2QGZRLRQsDp4HmbkTua5vhQAy7BtBPuqo3f0DP3z8Y1qQuROommwkZ  
5d/d7jDFOWFumdwIMncPCp5vjeV0Kxe53SRlyGtijnlg+szIH47VwEzZalScA0yJ  
aSJlw7TYr6OjOFzxEyzUw4tz7g1I7wHESxnbjN4WM9oMGyqPT1EqfQPSxyxh6Mo  
i7S3Jgv5d5NeMLVXkIFkPpGgycycR5pXA8U0PLUzW6Ph3rwQ959OryFG4jvBDIV7  
zIK0jwh+v8gQStcNAL67WZTcD1latkAX/sCFXNLbx3h7Vr29cizcVyZHEobHaD5P  
U0ib+k6NSNsakbyQPDfnPEbM1mfVh/YT//SfjP1qr9/yUauO4SR+RpMckj0ruuql  
jt0JABqSRrURm+s44jbbqQofWeD9Iz+nYFQ3/gYr9hjj3aAzdnX4pr772+IRY6S  
+kCWWIJfsEkWLfmkTdk4Nm8mPDoPlpmDs梓40L+BBffP/1P/w6ADuqbq5r2jSf97  
0v7YP7BJgDmBedfOo2W0EKAGERqG/Kp1DGZs/flylaH1sMY5pVxrBGPbsikC+UNa  
7xEH9vLyIRo1wqCBiJmzewCEJyj08EQtUTLOAXJCEOVDjCcAg2wVhOWYIL2wW  
Clsg2WOZ013ANMMR5V8iY0RDJN8zAp0jnX08F81+pCPZHg+bineVelXBVKGO7r  
oNFgqLYg5BY3HFpU9GAw1ZkORRCLxhuD7CNhpsCCY+zVycQekQbOqzOjbYq0+giN  
3OMWzB7cieQHZrcq3yQcnWqKRTIUUw7V5KFCz9Pd46HWVAHGaapx0j2trIFykGqt  
vrp22w+9O8e0/cnYtO14bEb0Df9ketH7ck4sO/u1Dq2FaXN8ArtZ1Yim85QUmzf  
6NbKP0eiHScOK1kufGo4HqvqmC0ERUbU9RVLwoalOjxtMgRo4fTCE7jhEv/9D8  
I//djmmOtCTo1jORMBQfqjWa5iZPxTcypNp2tcgiq0RMe2nNCwQmerxeRcQwG9YgE  
CJPdzlpvwgW7yKlin0Y0sAuwUoqitYGYZ32AFftaUiYyNC0byWzl6dkx7dCSPH29  
Q49imygrsBobDKT+e7fdEqVuLrrzui3Ne/dtvznNX0yH6bbtwKap2QJuMx1FL4v4  
leJct170lBYTxuQf5TNcxZNdYXrdNlhUoZBP9TiN7IEIAKtVHc8EraLyTstuvIO  
1DsJpt3NKcxD/G+rTkkeu5VINJm2ZW8VqSBQyg64pAnxuAexw6yZX7hRdod3aYog  
ptlPoaKBvhPbVSf3rSja9U2S1k/F1cCVXYrLyhwXyLOM1wpYsCFvFBMboOI6le92  
/z9XKdVxyNBsf2SWs3WQwOKPKQtA1ieayHnwMyZG5Ggaifoas9MuHRo2wLOUuS+  
RTym5XMYLflu2zx5muNDWAbr97J1kmcRuVSVByMs61L+jbl4ZSTbZklVzdAD46/s  
5iRai+U/j0ISk88yZ7CO8SfjHP/FF/2ArHxYyvdIb1X1qmgmYpCa9cF2cin/eJDk  
oJtykGyciB4yNg3RbAV+y3Zoxj4HPguAExrGSYI0CKsxnceqCgdVDgq0IWJkxl+5  
72zHgro2PjRI30unUsQ0yAR5Yi6/RV5kllPUvTrs1utKqs4hPxK6GC9GY+XSW02r

1XTazXsef667TZUmMDXvirwHDN4E57tYGgSEaYy0UmXBuFAGzKUpQ10cB2Map/kS  
wC+kuNfwnEi+f5NIbvq6pcE9D5HmJ1sJQR82c4SP8RSBpJoPqAoGqJbDYHAhAQOM  
DbpOxLXap2o91GX6kYDBXT5mCxd6Nktp1Za1GZnljGj6a/ameEZcCIUzmWpGppiR  
PGIqMrRMMKquRwBoxYZI8qmpykJWIOUaBHMvyldVswLtGyUYqiZrBo2gMkx9Kzz7n  
z8KYjxdVZ1Rh2HtwSzEoM7Jstb3h9vZ2y+0d0NS5dGU+R1Ux7NA74A2Oq/38KJfa  
+Eya5SZA4/FLOhG30TdBxM2YKa5OpowC/0jQYMzvm4i3qd17Jt+y8ib91zcyE2M3  
EzF2uXH5xs6Z63iFPceTtO20IDB+jhYLwTBxm8yS+wjNV8jeBV6a0YhZyQ1aR5DL  
nP0rbEplnNIWs7U2iDYBt0A3esV0BIQmqXYm2jwFgwyI0AeHyM2IX8Rv3WhBlqRG  
BNkraLbTrcGCs3r8COYFkQOMV0mWvli+HBVirQQmVsTRuUjk7qbMYXLkCnN3W0XD  
W4JG0duizFgWy5UyzfA6TZKpOvwBxHCToaPaQkBrlqlp8xCjo2rC4HaApQDFjY2b  
I/3hAYLlNPVnvkRKiYsY5HyJoiCWoOl1qBapBqoSbPmJLB51nHd+y9o1c1GbJXh1  
mRfuVvA2ahaOpGLc1vlu21F8qmHbXO9xIpJ07zQFGzMat6e5QJB2RsATJcbwDMfx  
4QHER6c0b9JmplZOQZZLI6aVGzY0ptsRk/1h7glrvwyBL0EvXE1791ouw1XT1ZH  
IO2RMuIWc+2tF3KO1j46ypo1PEVIKilw2ZtObIIKgxcJkhivk8BurpgxkyarM70  
+iU7AJoHRGtYTj0dIK6mlvIxtbyHbqReRZkEVlr20vy6zPEcqSMhqFtIE8wjielU  
cjMxxxblJndOAMqDOLfMON/iMY6X9KRGYYfZecK3XhrXJ2Uv2ZN0UcxmhdHr4jiv  
o0eUetUazGrgfEIJF28kSpG6YfQFyJ+Y6pH2YHA9RKAcrB8FS8Z7H1Gmup+o4rF  
cVy0JPW91hbGO8HjZMOWXUI9ED+1BWsgXQEuTet3uHC7xOBJT9jPAKbmu8kMgUU  
YQE3g1PxpZXd3Gxoy45Bte7W+8BD2TXKbnREGspukofxssF/p1HCNvIciM4Bh9Fd  
NjkKh64n+z2ca5X30wguiQZHrlf2Mr2/iIGsBBkoF+QrCqFNgDJUk2htLv/w4cLY  
vxmcXXXPbi6PQHEK5C98ohw+UdV95J2Bui5zFo3i2Ttan2jh3VJmwgaHIEJ2clv  
2eQOhvskOyyXTqPnbp9GHb1kvyWn0PPMP9IKwSw5GjGl4Wm1ChoQfSDIPffHk1Nm  
iAUawcMFlpzCdHuiWSFRmpmWPi/htPXUJPe5OY7mVbfWkuJy7AeOX3MtPX9Rlx0  
t2QzgP6rQpWW1VyCpUwYM0wK2pkDhQ9wfgL4AMP1uglao+gFiPphnkYbbUIFpIFJ  
mLj8VXMTdcegDEuUEt9qAaYQwqcl2Y79atCoBMwUmW6U53RmYzCoMWMa2QsJe+FP  
CF1Hs3FSzMsCl9UuGUdS6inlZgzCwBjLtKhcXG4zyz3kddKeeL6cNuM0iyy62y7T  
blo620vzgvscN8wSVGpgO5yNHciSQgl64FGGc1n6SRZQnmM4nwN4VMBjXzvQlg  
ABNy3ame1tzGZWdxq9DLNYSnoDmuERzvcKG1WSBg92iSdoMUxbBKkUZegLuSfp4  
9+aYK3sBlvv9lpXO9QaG6jWiYwE8r01gKkj4SNDtA0/ytsyqe6D9ObBbVo3VPgh2  
++1adabtBW2aE9NoRo8ZtuuQPp10PKbFdUVcZwc/Ft2y83mUCJ6dLC2WhpBQ5jk4  
gSLQGpKMm29t3hbnyG7IjrFcxAwZhuiKVAfqaLwZHpM0B9Zmc2iaiuup5tBtn+xb  
lyk1PyxSNJHXR5fURqcLa/G92ULIKQ2bY/t898BVT/+Em1BmmiywScUoc1/NNrKjH  
V6HAKvYKUGAPU8nknRTGH2BzZhkjdtBvu8Ax+gOIA9DMahHDwR0JImE+H6UCLJcK  
Yf7c2C+nhbNxFd3JX9/CzhIR/xzOYSzameAk3fZvBsOhl+pNipUyujQ26fOSlvLA  
a6EGfUu1j/OR7GVrOw2L9CU3Xn9zUkCWnaNH6yqKs0dyTA5hck1pNv1TPUBYFrfg  
+MgRadHO8dZm6UDDHQAPFzxBr2KHipFydDIKnYoFeGRiiEqeg6ID7etMeavVOTs  
Vuhhf1t8tmq9jqJsCtEtUduRwliVO9RXc0k1Z+es4nDnTttPMRlg98DRmWco72Fx  
p8dAb2bkkY5Ss6vp/Rsmujg7i1Q0VMUVeaY5cCjvN+Ma1+Nvh6jtakQt9/cHK+c  
JvkPz82r7q3luQ5JEkh75hGn43qHzpjVWgCKobk1IYuArvGlbZGm4oe1uVac+6d  
kHGt9+bSiRopkW7HN09givEiC6LCoSSQFjHmfjKbgP9Y9Paq7vj/t8vjO16r5dLy  
hFzPOJqi5I0JDE9SOpCrGrFw9opRvDaGF9Da8belg5xcvzll1nRrBwlCN31i3smB  
5mTBtljPEAsazYpYGYI006P7eNttUaRWzNE60Rq3RWS8sj9NgKNxIHnkKVPP/4G  
Ag1mPp6g2beZTy65BwydAcval6Jz9cY0xiU2si8LaunLNaCY12IA3LazNI+n6wr+  
5pM0Elye0XoOr9NgrGn2nJBpNET7gTyXxWMwgyEiaXAnyeQZ7u8H9JJL1wjK4BrH  
0lyVtchATZQiBEfSYp5EZLEkk1wgl3jf/3537HFITpKy36M3Lgv1V06RDJ6mDYc  
P2yFNFBKQ6TnHbjFPQpacpc/CfcAr5zjUQjupOTpQikyNYgEdt5hfgBbms34o50  
SDDRgKKaL2QLXwiEdpo6dWY3+cdOp24m0BM0VO4Knz5Ekxc6Tz22OKMXOtzXNO5i  
PH0GD+KNvrmH2NwzVUyEhdLYq4fL5BH0E53ukSowv8nCIP/VCcBpkUijZ2NeRER3

6/x3+llqmdDRJnYNh8LHS1Fca62GmKp0i986yhS/teUGDk0f9kT/7BbcFPTGBYin  
U8GWesA54QOjN+h0r/UIXS8eS8+jvcWtVQoZe8spiUfgsZ8iRQ+/hH5HPQ5dLqdt  
tb2W02pqbfJms8Y8WTXIhbZXjElxlxcJtD8BH4PRKgEABAvg6aBmVQ4kB6a0aXL  
XIVdjdv0u4aaQXvGjZWAOjaf8VUmiLwQ/J/QDqYmDU5Lp0zkF6IAKacMCvB/zWay  
3ENavfkeE3gj+5ituPz5iMzPOJmRUEyLJ16gBboTzOlP21kpyvcgbAfoDD8DWeVF  
CiQ0uUcNIVhkgNoEavWqo3iUkVFEG0vgVtGTHPmDF5ruPq8V0d29GDVv8GhG4xnC  
KffvSt6nJ0mprAnSkppcM6sUAY71fv9ahG2PkxfVewpZDO27eZDNMqUNEMrb1oD  
mBqDBBriFjt36L/YFYS/K/C20J8vUSgH+XbL3HrjFCWf5+BvKHJIOCCsD5FM585W  
nEvvRq7x3eUbtAUIMwYkIRzHDzRHypuzwOlnaKzc1p2coa5ox2dwoSPTh+K3z8L8  
/WNDHsKyzJDE01jEiCUGRrEV6IzEJT+tkHT0bNkknM7BEzoVys4RH5NsZ0sq7p66  
6TcElS/tpR1ETj2aQyhIAI3BWe9oUEGFUQnVzdLnyV0hLPO/ct6RaMT/A7Yop6Sv  
q+TpPIx34OJoiKuCHaIOOUQIKjoOzJBmX/i7bBGBKSJzGG/QIYDmiEswMhwapN/E  
BOivSW6OtSmYjik7M2vXtYxTmFwDMo/WShduA+ie1AzUzcUMzOYe84686WWledHW  
PpFYBtlWqmgLOQsKFpOytnFVSwAMl1kcTX7ahEe6P5ybI0NmSVbRKkXquIRb0bwY  
Vod5M/42nhVwMvNm2wFNCzfdVOZT3ISCEt1koyEPeQigvLzhKthaZDxYIER/B0t  
E6h+SU+J2rk3J9ojsu2mVI//kdQdfS+uXobVEKxnCAH1hzRd+VNvGwuVTzMxB9F  
+jbiwqBmJEEdPW8wzlikMoi9THhiaOKwQugGyHFba0NdQ4cm9wHqKZhK6rUEXolyW  
f10oOYL8SctKrDUNrAlu0cBMEjrmKLkXWE8+63pmGvWPclxSDTL/6Ek6m0AaHqHo  
Mbq/I9wtKhy70ja2FkJCU2RyYjjKEKn220AHlvD+SRBws0SjaHtBa5JFnFbIH/6  
LdskUclco5fxM3IUQMy6HZI1vElyLkHQ3E/lbwXGMEwZVgcPJ5n1OghnjIB9Biw  
J2imn0RpivJn/ba1H4Se9/bAaenoPQ5wTcCu3JL5lse3lf+YbvRjwtVztXZjbL/R  
woqm9coNR4uF+WYgR/nqf6po+37k2mZ4h6hcRRxo1azz/YvoBAuujcBt+082Ddnn  
Yihw74IlmdkBuKjgU2xcLNjno6NYUKsDK8SMCkJ09eDrBVnj4EYZQZEC7bcLL+Ba  
PwSueJwuymRzEywjmnnv8WN5Vk39BNYotASnkBwmi2diRkKemuKQkMRIUtKOcV8k  
qFIYsD2MjlQr5jdABk7N+tVD/ifj5qoz/BGJBj7I2h7ZYdMOmmivHrbbPriXXUcQ  
U6DzE6KlaEXyGMO7kirBIMGF4gPRB74664LZYB7lj7lo+SNk8EC5phwJG0l02uG  
W+xRdrtltnzf3bf8t6Fley7ickyvCaOQ45rkDD1GOVdg9ZE3P0lwP445CYoV7M0T  
OOzGCRPPTzkPqsZ9nMzUsDmelXBSAwsqlAnHZMaRPYXiY+4+MtDsmO4M3cP7cnLd  
Id3XRVq5ZP7bg5ZLAq/lenqQUxB4LfCoNbboyEOGMHNXoXJO7F/Fs6qr5w1zaQh4  
haqsPPqbllmWVaxVQoatUR4nA4lzY5/ePS5UOPKm7F5vmmTaQkq9fWdcnZ0b4vtp  
gCRC3hkfRafjs7PxrnlrDOq8QDjie5XfInlopA9LDrsA8RaFHaIQR4QsmnzozVxN  
G52Iec5mxXtlxmrOpvLo1+Yd5mtm5XwRMWbm0A9D4+imY5Abh/8oLgOsyc2oGUtT  
TIWUk8SJxW4iM5RXTAJwg1OS4dsu6CaW/MdxR/Ey4iWRkmHOtWbjolmiC3c5YpN0  
1qoy3biiHmrE5JsFP6scrTkXo63XR6DOzGV20W6UFciBnpvcFOA+Kr5xU44swihX  
WgYM3ZBXgHfcRzlFVICjs0QDEGCXE+Q4iA3CWN6BXKWOtRoo2Zimd3jgBts8/x  
FWV2asvIL2uhHetgNH+Yy+FwKacJyjv9Wtluq/nKQ3vc0ueNbvBUI4A2fALIQL6u  
WvT1o2+kXYxu52bwT/8JkAkyN+tVpvBNnB8G5M35gwRjZaUTltWFnNNYTPKY18I4  
gjk0j75FKHaKlhnpB+YYvaAZPiRzJsPtTBHI+wRCsRGZN1XXnbrCfyY/MiaXPs4O  
hBWr1GVV1CqdND5xxiKOJ7nge71NYRscLZ7Ax6Ny7277wHbb1nZGgY7xCkmOJ+n6  
8kM0bk+6/8kdYndnj3TacNlupkWWT5OJdup6ejdmkW+axYSIi8ZxN9kW8tYDFFS  
gYEuNk5mon8BqSZUwzEhfpM CqVpzCggTM8OKopIFshd6EXVN3e7iim1Jrlj/9Xtc  
sT5ihcxEehOPycgHAuFLMRPE6Id0eR7RWah3pDEgRoBdqpiwtrElfNSXBZfvMa9h  
D5QQm6wX0ZwjA+iVUcUzyqj1pnC07ZZn0j/BVv7UVyQ/rdAzX2gKMFX64wvUldPB  
GzCl5d74jNAAG8O3Jw11bOSebNosnC2nwXTm6do4ibJJvGB8inyXlre2Wu9bIWKc  
ZPq61nvjb0AWTFau7zRoJLBNTsH0djmUtYv44Fj4cGNRyk+vkrVwf2Cg3NOYyWL  
afTE1vdMFDX/RF8+4PZgMmOlztLc0sQNPSS/RFHaDxKGovZvKwgXs7HFdzypt/1  
yeZtebjUoearkt3BnNzCqL2VIIQPDULnKvf9QqoDKE9OwmWyePwRtCTeg14eWu2o  
DDSUZfr89ab4eIN+vUlfb/LXm+LrTZ08bMuioNu+fXnf38ZR49rIMGUWM9upJqh

cilpyvVYH5FYkm1ny0iJ2GWuc9ki0+fWoAj1/ChXjaqakaBwnusMg6xgneMllcw8  
QjOXIzSf5AhBi6EiVbgBLa/5zJhab9nHJ420MWVwx/DVboEwJCECoeSKv+kLnsu  
I+RPDD7ExmVDoe13MX/8eHgEaH8ulZE2hB5ByvWKPYRxoJR8OuyHPFX7tbA5P7K  
UPIqluhr0LYt35KuN9OYdntd9qPgK9lh7NWb6jofw3e3QPh/qnsXIEfW6zyMlkjV  
cZ1YrgpNpaQkapsUtWvND6Ab71na15jXzuzOi8Dc3bvXFjcNoAH0TgMNdqNnFuur  
yrVLKou0TEIFRqlerMgv0XSkrGSpKJdsR5EYSGcUJErlkuu1y+kkiqKpFiW4rC  
yLFzvnP+v7sBzNw7uCKrHBZr78wAajz/df7z/D7emf0enxE GFyqmr fUse1yql0tq  
PL6MUIPGSMRpjCgh38vaZ2k2rV1awTnpWkOhwXZLMtX+U2y99upHYLiwZh6ILGgV  
wS+WMAg8j5tjCXTSAEmAd2sWmR0vmLn0lsiHKxFfkqcuL7zYAWxn7Avl0gSgKtE6  
vYT6o77+JJSh/Z5ikVQmEvawSh1D9H25kTb/9NhUHyLC8rEVGT0MRHroyuVoSDTo  
gksmBhY+8nooK5rnii/fDLqCWXZnfev3SnQFf5SavsrYw4GMQ5lxKB6H4nEoM46c  
qcswpff5+Q5g5pxFHjPpSW0rTGZco1OkzGLOXuVoMKcmAmDsS5OtFxoKFMzGsg  
o0sv2tiCDiEbcwul1MYVTusD4oLkqDW7bKPgVICNVHMq+Yh2xi678AYaF9Op0PQG  
Oui1rGaWOqpwn+5YnWQaues01fRj/gT2YuAN3UDuiuxrszYak/xJwcCa1Ua1TLca  
w30+8oTZjOkjG6xSLeOcOOmPaKjkKnosndc4sM6y4Ty1dAa0C5YZ3eBLjU+dwFR  
jKGwEEU8VkcF8cQK5Hpfvrb2sDYWqc0I4HTvMJfQ3zaKDxu++elyfa06Invau2  
yNQ8j3sjTnruFKwxrDPT36ERKObabhWaPoQApkZPs+ESQcv4Fxp/to4IQpnkY/M5  
5TuqVoszchPwFgT8ybpmwM1HGheSk+36G0AjE5A3C21Hdo5py5qEC9LFS6VTaDHk  
HfRuYBvRG6QtRcjNwPq9yYFgJQjqrTYfREXufCkzHwUtdSK5VUir4Jw6alUm82i  
TyazQHHiwnmR3fyZKzcujyTdXuayRU0gEs8yNpNL387h5J6mCLmrrl1lbUVmLrB8  
Dzly9wrYyMV0LH1/wKBss2x4Y3IP9H3GsJkpIdTiEnHNIJ2QfihMUfBnXkBdSB/X  
wWIACgco5pL7uyn1ED4KkgQWfag/Xkzy81vU5XUsZyo0yWqLS90F0eCDTgZ+uvOA  
wdlQDNu+yhtdOhdlx5LrhiA147gyXcNsPs2IMIFwxcVCEwbbbyMXES3erjdrteqNM  
jku1VlfVBZYV47bU2G0hBeqg6pMBME9HpBOPyPSkCV06CbgJTwe cNBaQfpqLicvT  
vaHb2I3R4ArpgFhxhruLlwONK4MOm3ntAZQXoC9KOjUywR3xE0RJmit6Jm9/lfy  
tAoVFRYIU18QXk1ZeG5LG4vwggQDs i6lhgS9ygueUnkxrxcERya/6ykIrmLOAZJH  
YFdLTpmO1YNz0imZfebHQX4K+hSath0UB5OSdtU2WGNAGso8yFHyXLW9+DOfoL3E  
eliaDIV13PHUJ73Ct7P5uQXuxZ4LOrnchknt5y3utQ0IfcE1J9a9YN4TXHzdcBA  
gQzqDO9So14+FMstvpb62KnXI5kUM+7jOgOg0fBhV5BfM556MyBdMJXNA28WkAe7  
vYFu ce Sek3mZi8Ts5PZ7D4cK+T7wJob9Jzsj5jHp4cSWB7B4ZiSSuvNRli12zAU9  
shnvVI0NW CxbRI7aN859CGMOz17LbNMolV6XwEDeQYQOu5h1UPZ0eU5Bn+vbGqtLv  
o/7bm80zSFNcwmnPsmJnHMaeDttk6j07sTmtfcEyqLxWgtGRkqBZbfTkeQE3KC6G  
lckB0J2V5DBFAANnx23VTKFZDBjqmZGpZwZmlm1woHBwUiBGMcPKZwtmdlGjdtl  
G1QKFUdVGEh/MXamP5e1CzmY+7ouYtiFxLGJ2111PtrC4YrlxfYoQlQsB6P1bjlt  
OAiT w5OJA bmyfbTTuvNlaaPtjsuryMk55gdqPxW0zOKewt5eSMLSMu1o1DIO7E  
ZdgbwZZ6MwxBKGrjzfCeFqs1mq1vgOus0av2NOPNqBRrpQp8aPp25nQnMz9+LnH  
DDzthLwOKTgMwnNuKcxo7TozRth+bgKQvSBksZbP8SwSYIpjxnDD6Ux1DVowFjeA  
7IGoSyzNKZXJh3t2q8yom1h9cn7mwCpyz3JHV613b6yhl6zCCLYIIMHtPIUmw2  
ij5uCcbXIBk5SS9946Hc3jo+s2sOOwJ7Cr49aLfVWE6hVqgsUOaayr5znw0Tydq8  
gkh3J5yE4/lagD3dWD6DkdFvM+9Z0Wk2nVLPK9cq5YHrDCqDftfr9XoDt1qvN0t9  
p19EQfTIHZPeZ5TOB8giPreOOL99BgV2z7tomls7TI6NeIO261CvojUaH7agNPR  
PHCf gQb1dPeejjC8gB3uRRpq3b5b51Cy3SxXaDrLS3xStGPB8+w4JA9fw+Fw5I99  
NmXkM UXulOc3aGVfc3Pk8PhUyTV6hcV8IO/Nte86TdwTjWZDNUsr+CnzMW19ran  
/2WyrBhbM79+HO7V0K+3tZ9DmoajfoBS5K21hOf0MVd/CotocB7cqe oKoyNbsCqD  
uNet+Ybz tZiTp+jmf1OhlpoGUeUDF45dWtNjutr9sfXgvRvWUW8fNt4u83ahxO2c  
3u73nqP99mVmmdxHUjk4R8cM41UJXjLKjbH3AykCCa3I74Z8XZCBz cj7JvHSSxhd  
mcVamDq6X7q0pHSW3QJXd0bW2S7vtkiiGMjUeGBk0kZxc9Or2c1cHr1erVaK8g5+  
gYZZY9TlyBOLOyXIDbjfXevIY9DzxFzPdZbJsm m1tfiqlXVx8QDFpRJD7L2J9HBp

dys1udhB0bRCzc08nZCYW1g/zSVUoldvMaTN246AgTuJudr+gubjQeINvQCOwTGq  
lZ8yPPUhFya01JD/KMCQ6X1whmT4kVAaPzwWYhsPTn06bQOyXqck9EB+WpjNL9  
HuuVidOVioUIZloro8eAA5qJluZEGveC6+pTZl70hpFut2W6FmOQAWCaDgC4iHtk  
AqUoRfbdSv02XWeQG0a5WYThbZaLEzczqDs/dbp1PGfOPJefctHiELcT0cdiyUyAw  
ZT4XDws7O0f6IPssRr7WnzJ+FkgmohC+1pyzUzZoaBeaWZJu1sX5KVhp9FrMmn5  
dq1abXLyyEbyKM8e5NTMSS243W6ZLDQaQzNtL+xkBaxXcgvfY8Hue6hfu4Q9hgtav  
A6G6R5CVDpLZliGSWqao6ZjOMYocOpqbZWnfXn4pl1rOFFvPKdUqDab1QrdYlyJ  
+SDAdqYjvtsj9YPmGDR8DMhIfrx6spiwCU+46Tqwo809HUYzHFhldR/QVrgtVc/  
kla9xxsp9Z5Uhr/26g+f0BBee/VjqDSOQpcpcRkSmYbjRurFrv/+xJ9x7QYdyZxq  
oNXL8/yIZHKGmY9p1bEs5TqWpbFSKJZ5C4KdVDIObS9GEDzM98XMYbCHu2HGRic  
DkDSGQ4N73oM3nvukp9pP6xjfzt9/jz2MCXj7mK7UJDxg/ARiUcKKg2G4U5tczt  
Ptp2chjjFoH33B9tXJVHu/LLlgdpCWxsaGetNa+wpoSDtKTqFbz04PsZ6OWhNx7L  
oj5wgy78BESY4cHuuwycuMMMdTfTHGTbhXkhmdF9q+6TFLo0OMZkVI1NPqHDFuiP  
SNv00mngyQnCcHqFCS8G4zDnzCINmnX0Bai05vFWWE2UGyv38dO4+8wAZuANNFom  
lvOCMHmOrcsnLbEebgvzzsxFq+69dsGUzuucrJFsoXt1wTG1LnxXbwHOo09zOz4d  
LXCAL8MMhyCWqktGKSSDONawhQJLWGrSOtzu25U7m9VG3Vb0T76woF4uco1aqVFq  
Vh1aTFIhJJ5MnRnrXaE1UxtLZVC2Bf8VMaL9P+ZCF+P+rxf0PKEX6MVg9ITPl  
ro4pS89XijjW7Wyh7qQ2LKrdCQVjtYJ4gUwMFrx2DXXPhiTyuIn2l7Pn2pgEIYz  
WCo+te/ephu1W6lV7yxehRFPUrNHIpHXC5RfzsFGn3oA8z1NrZ17ry/gL4nhy+  
xX2opb0u9oA27Qi1VpEG71rl3ANqA0QAM11LcCTUQ2kshVsNGs0m2Y3N1UNZ0829  
pWapocjiYITMLTLtA48PIX19n/RaGzb2uJtE+Y5z02HKENiiU2glu7jXYUTKfhRQ  
/GxPugv7e7EuRlprXT+6dOfs2McZt2XO95QKidvNbF2cWrXUKAax4LXTxd3ApjRF  
kkNuk01vuNMwiujEWes2syqUDUj9XNhHODeJGvZlwbbqY4hi1WMmEVd8Xga6sFKpX  
wkiTWMBn3iX9dLbdRjMFFTL0o8Ve26xp3hcEIn1jXH0g+Z6s367ATa061Yqifxf4  
Uc2RpGumRP4lvfkWV0e8bSsKL5m8YAv35aX71DrWg72tR3tHlZ0uAX7IVgKP9mJg  
zmHeprqj8n0rZi/V63ovVUUowtmAYbH3mU+PSPGitz3rke8IRAXc0CMvCXJZPxwN  
cUS7S0HpVcw/aWchu24cy25LUTmEY2vCrc2LAbrgru1ZyhCi5HF+Vy6Btp1qr4g5m  
EEoDSMBGENrM2d80/B06NI7dDXzBEHh+KVcaNsRjHGZOsCMzLowRRhvnsqlZju0  
HsULckoZYpKhANuMDzQCuH8v4XrNR1vYB2PgeW9ekbTUYThycMj9bIPkoHPpwxW9  
Mi7VWCsu1afT1xvF/LwM4b5ZtGkTiURxpDO1QEualRQPjrX6o6840RdlYeGmuG2m  
+I71lvd0bEoRS9bwsrfTWilxeRptMIO+u510ZwtfAecrQRUp/y1fZJgOUNpN1FP6  
bgUUYHo6DVGbCgEnYk/dij5bLS4RWEJw63CXwkNkMtvMu7JSv2LX/uDtPSaXnsS6  
gdAQX+nVKTYrpRrEhhGw714EXETX6Y2SYpacXQgTAZ7gCO2Ho2DgBX34RjvuxDvn  
ysPP/L3xIP5qnRV0xTS9nTR/PEuvijHQTIH3E9PIGTHGh9RNSBGChrVJq0Yla6TI  
XDsg6u9KgA4m3TGcrasa2gQD1F46aaazrQIUv4aLqVX40mRQyi20vkww9Id0O5O3  
CZrdXeSnj2DkQXO66wUgjjDOFFpfBv5idF20LYTRMuxSi943dXORYIOk0GWr9DI  
2e1ebcDkFmxlJsE68g0XIKkvT0jPw4RD0hnvN5vQKMHaeUes4dIkiAk31Rdecg1H  
Zsvkn6YlnWehtBsPON2N1/Jxcj6lu5MZeE1Rrc/eEj831tcex2aBD+KQ9WJzm/SS  
xwSHiT1m1O4z71eZcr13XDrL98HQ4o9JR8xmDOQj/mOWCsoGoWwh2c6txessRd7h  
JkOkXroNYh4yssjfbtSq17nb/XIJvZwM4Hjsat9mL/Ck2RRF30kUeHPrHui3yaLz  
ARol8sqcFLge6Gg8Jdm8HNeexDkY6fjis58qM9Ypoge02TVNY38eLzh5ivs6DTFx  
roT+mIraanmhbeKK7BS/g4bX5C1Gztl5rvfTZDbyuTYafws0M/FqHnrR4AVIC8fn  
TKgNKZ5pOCUbMqbjj8plzb/cDUN0BNIHU0sKzoOBgsIpRyCVIYm2/Kwt3WG5qZd  
U82Fg0P2/dNxr1scP3XdUo3Gw2iOneR5cu5bj0n0e/Pe6Ny1OvcWxBe/20TcdjlV  
GMu3CuigL/zl+2zh7mOb4cV4czFFij2X4txtw24R137RZni4nNEyDguDSZVruWgK  
OH/0ewC8XiqTXczQjYiYI9nrgRyP7MJTGPjoJ3p5wSQ7bbdbiPTA/NVkmMuJRA+QU  
4Q7NnJpqszOcqHi8Zntz7BtwBC/GOgbBVUhl1dBbBwTevC2YnO7ZPQAC3DfNxqCB  
tBINoV611QKtINMo3n94UDCv0MhgG9wPRwx+vsWsn571EocWEBMaQwnowe2xv2JC

QjKcg5jO3XzJvs8zaBVoY4bSdndte0RNQ4WaljqnRv9vNKqVFVNz8WWSnhkzPH91  
gj1GS2SXOxBesDgUAxFcxNXTfi7m3fbEnoSNjOyelaZNewcY9sNPxsu0KOW12iXm  
CQ4cJIN54Gu6m0BLCHPGUamAylQyINUIASHYsoBZTeGgWev36xVSKQj0MR7jmTfj  
WDr/9+HCQQM51kQd4rTthGN4Bhycyh8/3CrcZQI6LWB9DAa+qRnEJrx8XQLSQRq  
bEzrUrNSgTE3pc0yi9m3LBdKFccpoD2SMRF3ojnSDW0kJQ495FIEfT7yhDrX6rgD  
yCoMNyz+vXAADcABIGu1yuvp2BK/g74Y13gHZFbcv3EM9MN7DEYMJCokdLhEVqy1  
FzSwJgdbEE9JFcyLE9wbDNqwrGsY/CaXJbyq20qQIFNci5EHxcs4KLloOidXyw1V  
vymhh//0YjaNlshoDu4/PDtp+XxGE4RcDiMlnjQJ1uLi14ekHaNljbMUiQlgz/R  
Xrg7ngeh39f+m/HRNnNmTC9AjJ42D1saF5/jJM/YxreA1TPnNMJidrlarWw2K6q5  
EiLsdiMDRVqGZUmDgWHQHnmutQs8s3AY9+kgl562Lybkg6MF3dyx02EtatsewFo1  
QmQ3CMP+a69+ultOAbpOyayAyWyKUWBVLtlcTgVR6nKtIROWK1HcsiGXrpO1Q1Jn  
2YNDFhBCot4N8Z/Ve/6NZeOsDkNCaxgygPpzu82Y9gwzJ5IfEiT1N7nOkuuCnmq  
tQvZcsEsXaSbw/7aqzZ0hvtbjZ07eavCalxbyfNRfw4DDTG/He+Ejjt4ULfc0E8n  
TR16aKGPCrb02esF+FjaOJ2CVIsDzXiHM1scW+hb5R2LqcUHQeL3uZlGG3IoLgvS  
oyuBNJ5ftTC72uiFD5HrsmcQqFLVltvLu3TS7ZswNI6m0duMmtKD/j2hUV2G9Bxd  
RSnsCmF/rnZSAo3dycjVLrB1u7Wze4cxS1ccnVYaN7m2IKxGM5/DAFguCZOXSUCH  
vdAgnqFjpwOz350994IJgFwOdTGAlbOisFHjFLcS88agOGEpHwh64zmWbrutfk  
YqXNp77rVhcAI ZugZBrQTi3q10i0Mt0OjHw29kf0wwT1NftI7YAy1AdGYFqarje  
OsMorxbMqTTKhGL7IXm/Ou6KxQ8jXNS04R8l4LDaqdmVe0h/ujrps9A6gVKUXBce  
gzZw1x24q0y7A0NymBnJgUhfgU08KjhCeTI3aci4zm93z17ceXzHejSao/KStuZC  
c0eOymglV40GHPtMEK23k/V62+kVC42Mc3JbZ7NzH31kN7xoYv6Ym34qz7bl1Lzc  
hRmHCvLmOz9EXoWiJS2vgrxFGm2VM1qe9aiDtI7nzuDPgfPkAQTu3leqeBDG53NS  
FoXsuGR8M15ufPnQIC36Qu2xIAHzcVkJNDJTuVnX3YKOqbLt5RRkuBwZYizeaqkqs  
S3sAhy8kZM6YQuDSyTixX19cR17OoT2IebCC6EFX3WalUVaVxgp9jP/U19qm1KTt  
A7HqEnuFNB2+Y+4L/G1W/5UhqGdQZtjAb6CLGFigxbqOETqdUjlBoMGkPMLGKM8  
203qeehXSNCG9qlAvxQh08jVKvHIP3cv3aUUUG5R5SzqYlgYjKchAKjZVO1xxofD  
L6DLg20BGHhkeunlR0BhPENlithi/qSu43NDiFCrVum2v+h+LL9MYspu8xVijPdq8  
+2RWHSUBze85/QZ8LB04OuoUQD0omqaVpk46/mSTC7klirf7bBqiXRarN/VizuYE  
6P7EJ+jqBwEDWZ3PXROPOpCofduUzTI+enYT2M27JDhSEOVyVZVzXM6kaZqkafvb  
7QQZ1RVaF4YsICz17iGAzmj/KIHls+vFZ+OZPoIOMCYgkqeGgp5x5I05wrBc3rzY  
tTHuoKCDLKwapPVKpVK1phbyDbSHzJvMqyQvrtc30HsKKSITlwX9JxGmHdossG3I  
/75x0wEzlcvH+/xx1olzfkrTR4CJx4VZfYOaiedFdUQMqpwZoClIASTW/iXYNetgw  
8Yp8VaHZoTf2ir3euIh4dLXeqGrY8AoJbnZGyXngQj+1XbqtyI63HoqWGcdD8vXb  
AAEdJU/5Lahym7Jlfr2+XmBox5FLOxxkq9yslh1PfA1rX46lzkqjxV7hWI/Wdsqv  
2C5tVpv1JdOl54+7usil7tQaWPYKgHsaHlqB0lZ3Sedp8VvJYvAddko0dkLqn2mv  
r5DrC13mLlovx8Es9mSQSu8uanVz1JM6vsnyAveC5VXohZC1TDM4A8iLTgaNr5Di  
YZicwi3uuHvbkTviYBktYEfQnDHZw4dwglKbjHAA1GSbCfLQq1MEHemCOb04j1k  
I+/aTQ4tQ4/Y5VxpZ5leLXplb5B2tB27QQ53hbEC93VHHHP+vDuK35+Ed2Ot5xa+  
XGKsOxHDwrB7jR40PwYwQFQw4JBgojOMSksXdPoGV79eqqDvjExIBgi8i6W8AlTv  
cli46+Hg0p256nForpzjDDp/JT/CFSX56y/18g9NYeRpyiYj2o/bfzj8JMSn+oSk  
6RZ+5EO5+ReCG87dOsCEvHK1kld/VwQ3+B00xEbeoUTykRuZGJ6CtkY+P7EEvoAW  
MhAscnlEL/K7NPOSEU6rAP2JzoSKh0RKpxx77MYjrlcutGnEtFY6WLxi+KfAozpT  
qAN9pPTo/xXHqdq1KwJ9+ZdphE0NePpuFDIdcDkQlzR3kuHQw8lfKNA+Ytf2IDNo  
tC8Y2pBrpAC0yRmwVhAgTcvVeBjwXuR5/XAcX5UQXO/wR/zQgXneZRj1M2ZkYy3b  
5SKwSEcyFiXGc6zHstAUpcZ4HrCEzFgUu76qT++R7mHaWaQLHFNpfzB5qhEz9i3  
6TMN7YE0+x+HtAvSWcILnZDsFD+D5b3JCEfYADF/kAcFzDfFtaRqhkBRLwbVYy5D  
1TcSqQEKeUqCoArl8Okilb3Motwc/87DzinW8+4q1ffwKN+LTCd7zaEMH/mB2fdzW  
mij/s0Hmb/nWjECm2egOdtqt03XuVr9PnkjhGU9SJFuVo6pFW2S9aDvFAcmkIJOE

alfjtCyQYnmUkedWhREAt7whOTobnbPWGcC8mFaPLL0Z41EiQPOBiyhRvjcznM+  
b3CcVjGViRiB7TR2faWqXM+yWdCjC2ieiZIB0xZNpQRtqwHxXGCMVqCYUXCPBYgi  
nResNsyR44N9PWYzylPOwNGw7+IFNpWmuQGu2dufaZ+G2UtrN/dza5Wi34rghL5k  
R5a7/MUCDKNibIA1pftf5sjMimyDq/cITQVMmLYbTEfYCFt0qHpo9ihTXG8DbpG  
300xigPCMMBI7wnz3h1ys0c+OkIdglva7d/8YT54mhdI3w9rW0X366moz6WqJrK  
xUJtWicSJBFj7ZAvvvWfEEbF2YhUH6YdNO9kefMoOP5L91BAh8p/E/zkLn8wlZ27  
+UVoEZImFOpmANGUwEvQ7snXjwBVdgbRyMxi0TDEmlTno2KZru2H5Lg9DhMaHlyn  
Ha/b9SfnueR3S27PAL4j4Fp1tVsvV5rZBSB49q00AYDjzxNHYYrkJk0h3XVAQgB7  
7CoqxpgVt1pqKLiu6TKY6GRfKzQZ5+oxoKHAdQoDmI0pCEshxs7xcBxUjlQM4JzZa  
gR1iRLsKDL99JlhKsFYk97Eu2zN/VthjczcdU3baJafuNEvF1YQWJFapxConsWJh  
ldZCsIlvOTRHw25wdjmakxUXufh3whzkJKLufs4X/gpWq5Xbx6+9+IH6M/rsYq13  
2QzAfACg82rdUVkr95fE0excN2qFI+DS00XBSLj5PSsyYEQwbuB7XHreuXUyVbv9  
TVTVk84fcfgEcyQ0yQChG9rQm+L4hxOj/jk+XQ3SvHJyaWNjaqMNne2uEmwDqQm  
3h7jAV5aqQXpVDhVDJ4hkqkxSaamLBn5vCyZEEm0pldUM0KTCilZbXLR9bMi/ugq4  
SynFgi8xMHILfT4Y0VUgLetBG0xAvaBTY7khpzdaXkUgOevFPXfK6BphNNe+M6MO  
HnqRZmvccyDXjfxdg8Q8bPt+lyEEjugY04W2o+sFGaIPZHczwZ3S8vGGw3VHcl97  
ych50WdTDDrSNKgYuqaYsLTWjNDQ/PSB+WpC+r+slxdfH0CmvYsAxJunRxtdfZ3  
Dw830WnR860HQApIL3OPTW43fu6es/XJQ8LGxsAzr1l/GPuV0Z79cVbr+656ocqR  
M8yMIK2dRcl4CmAuwlj0BRM1ZxDs+YG34rqv6bnrZ+Fw5MnphuMug3qQO04jFEiB  
9GL32BDnEcaioFYnzcsGJqCldVUlo57HpQ14wOBPAefF41JDjAtzDCNpzHEdck8j  
T+AjXuy0DnZAxLe7c7B9doc8Imy7e8CBe5dIf5rpnGm3Twb99qODh3dw4jJENhZb  
7fZCbTqZavG7+iVQwNB9AWYvI/RHNKP9HwMi7RFgtUNeyQcc2cT6aTS0u+QF0k4H  
+x7yhW1kyOOZRIkX0Y9C4O1xNsuneXDRhkyWQ4QOycMQmaGa33LyoJmNYY3a6he  
mr+r/LFa0bZJabu096fMlsHGHi3lhads1Uxxi24hWBmy0Jf+BWsMU7oh20B5vVBD  
tpn2bPPKDNOpwBThqqmeTkG2oEef80Smig1dTKJy+yS9mgYuyngrZUGECglXNRrA  
QPdj1OBt+QAQxxU/4eJjPorMvMc6GqbGEUNNmI8uF7Y46ymQYfqcUUjC5mDPplY3  
BT9L3wiAdGDT9SM5RTQWLv+kG9FqFazVLujWV6t92rLowjnAQaEOdJKPNgfC+lwr  
ARO05RqEeC7JBnILXTF9qOGYW4qH6LwPhuSuoBV+eLUKdZz16bb5mbyJ5PFPDNQ9  
K1PHKV65E6lpjBkalegC34yKfg36vDloVDCJtLIQjRzwoFSfBoW0aBoChlpW6hZ  
rletDWsAxJZ7lpvMRiEzbZ96wnZrYSNbehNzqGp1xvk8Xnoucgj5j1p6BgoZmj4T  
3K+gHK55JaeM9zJbdXB2T7WwcuqMsDhyV8wjHk5hXQCCTTqjH+A4DuSuGB+YR6c  
3G3cAfaQ6EJowVaMXQLNecKg2doyPwCF2FgXUE8yEGWkfe9axxllxU3XEqhqvOLE  
78nmdlvxEjlBNPNdFOVcmcf1uglY50w/kMluBPRg8Qyms6Tvl75bWJvAjL7/yLrg  
SZCjkVg3fYIVktVQMBUs7x9ALtNHERfxqoL1q8i21P6UoH84y+FaLCHT6akuGkJ  
XtfwvzmW1p70Z14y4insiNgdeICKBcdFkjLQG6N2uLI2pWeWYEGFdN5G87oW2Rb  
L3DMpy+muzUukWJNC1Ep2hVx/JHX0clpEU6JcEokUyJZtmWVEYudhwWxiq8/y7cq  
DOJ56qJE20UJ24sdRLx4tjXinJCKeH3aUboLBOIRelB6ogCexE26AOq6arIWxViu  
hZkBIBc1H1l7ebIx7M2JEJfHc9IBWBAKFJ9+Nxsa1WJxUuiGzeZWhC3Z2heYK  
lvvt0529O2xIT00Zn7ZwsXcE4wytRlustzawZXkWE6J3ISxK/S/eIG/VVBORQ0M  
4VTR8uXB44uoO66D3OwJCfrECPpEC/okHDxJBX2SE5SGyM09AMuxtgtWOafiYKZp  
i41JWw+CgFepjSmNcx1Lj7zu0c4ai0bDHAsEYZBMNIkE3lWqOpVifi0y9HdfvpvE  
LTPSHxQ5uev3tbUCXuAgljwJrE3ATlgGs8Ya/gdVO0hq0JLJEHOPZzdp3w+CFWNx  
PWeRjDv0ofLQpiGtzbyYpfCK1WqtYVe1HmWBYbiJPTcLjcpVWmCIBYYvIHOSE5jm  
gUnUw8nA7+vAUHZVISknfGM3BZzIR+DBK7mn+ANaUAumrQcDWieLQCee2x1vQGM  
8AUmwe2U6vAnCiFyNazXGnWDTETit6NRA25FOg0rvCSXTkGLAYRokM5L32dN2NzMN  
WloknyFTcjToGQaUvoFTwKFMg10+TA+6b87C8NJGkbPQInITVGkaCN78v7kPPNx  
Gv+OzTQM2Pt0km17OeODSJtoAmPIWBrc0eqjY54UBWmdvMbesECu0/dcuvW+likf  
3Ph2UU67EUpoRSEYnjj/IRNOKUPgWisXJU1CgNPJ1CxxgK3sDCIVMlvpBgV/bR7

asf1g3UAh0yZCn8MZY4PS83DccBVbdt2pV5pINhFgnlPNJC1n1mdY6s16Ucwo5PJ  
BFVaAPDRu58jOsMIXW6MxbhkNqS9yGRHaZBMSeo/5ZYPWsZ5/GW3HMwGNt935f4I  
e8FR+HqxEmybBs3ZZX2qM2HZ5FkdESqMWX4G1x7l0X9VFox6RedpuBakR/Om0zZr  
YJkN8w+Qa7ZeaTqleio0d6VUDzMLxFXizzjIAJtf4FnhldNhflRmKrRVPvKsfZfr  
I1PdxXEj3q1gT3udoGwala+vFSC/LirL+9J2csNb6mqWxdFxWUZw5S74ULMv7+h8  
HJsJXT888iLfS55tAJ6AoSC6qARwmapevzKi/elOpyEEQVGBNx2hXn6Lg3H6gV4S  
pSmssPp0h1K3cJv3kDUgte72EG+nZj/SiO4tfjUr0iMMWC9jyqNLEmz7zCXkXXSDT  
kMmhyRgDwMVa0HDMEkqP4Rn1JsUu5iNNTiKaZN6h9ETAoPbBtCN/pUIQ6SSQcyKT  
QM4JJkE/iCZBSR8Hph5WZ2f2mU8szNYr1v7BUadzTYxlfUzikT+OBcpPjgLyDlw3  
3/PAolhcwrKwJBosTL3lZnpJfg/kiryxYYPMyKwGHpEJ17VxVY3J8iGN2SfHb8oh  
SFK96SP2oOKM5sRVUXhheiv0wYf6ieadeCh0voJWPnCCpkRcAAyN4IOZBTxCNQg  
HYFCzBOJXEZ83fL8p7wLXzp7dLh9IlmFzPPTjYo92CHMqScqL8vn3/Te0dbvs8zQ  
M+5BSZUqOU8NX6VMa3/2LfpxsHGbsDBBMSREbdMQkQmy8LZwadohjgiEKDi0Kpg  
KjoGOU2hKPqfjHOB+ouLlsPhTYZFo/ImQyx44XLkhxekjGlkWCWuBCF1NZP/2s4T  
u1GvORUzCqbL5e5MxGkHtF8RSSNVte+iBPyxhcenbo+ndEpf4SMq6650N3Z0C6D  
ZZifrr+2nn0trEemeEDZphAppqkoZoXNMgRLdJpHNHvgIqlKL63j3UWclZryWvh/y  
JYbdbTfJNyBpNPfSc7Uql3JgsWy0NKaf9RSpwdMojJE/ma1j+EA1TLMPYqbocCRj  
xWW6uWJBpb8WlqnMJc4Lp2NDKxS4Y9px0j1AvpE/BgkQ5o1DqroNI8cX/5XLpJfh  
KaGJ36mVixi1YiDYPESEGIbt4tWkyxmAFXWYj/ZPsAthC3BFQChcS1Yfld654cGO  
jy5CliddcwIhaKziCSMeoLNCdIvY0KmuLA4/RzxWm3QeevEeHOGAocNTW+JIRQWQM  
yRYIqCAgqz0RUKUCxoXNK0ERRm+973GifLsgySfnIxpx4jYGM8IVGTSjCE0IkylJ  
IUSuOoLks4Qn+xrNv15CCvPCJjnS/7TAcNHyTEaq2WyA9o3WW4nMKlcwTFOCr9cJ  
arWdT/oy4zVq5RPyBBELTAALIPyHKNPxeqoxvWY/z+ksr1HXpRWrafagraClhp  
80YwnecL6iLI6DL9+vGG+G8FUbRoEtCQfuUy9w3SXWDnsbsZJ8R2nCpdE3YDvHeO  
qpPQ3OAt6UiEjrKzsBjfHwbd4sL2wKE45ixdr299uoP098ZKK3HjfS88AXkLY86  
x+sgvcQTbWSpJDacwPrOK+o8H2r/cyvGcgruXAWymCKnyuRcuBSNkMoISdtCtVqH  
Z43LGk1HhW2brptl+/J9KQfWBn9h79zg4ma1Fa1YI5LoB2PMba8nfWzb/sx/jn54  
/aAvW3aspx9s6pVpsvSPmsqbZTXZLexXgDG7cX4GIpESOozNAZcFi5jQ3Y1oVwXM  
5h4Gl+gjaOfhrTXJNYDNBWXM6LJsXTYsCb9asoHldQ0EY9QF4Qj2lgk9LrzEwRm2  
TggfkB6eLYKBSF0LFtpgnQCNoeQ4wASpOMqrLHMyI+xKsdXq5ZpwMldo9zdpvDXm  
PsKD2LuUVTVx6ykZvAF6esnoRUwUHQ8zX1quV8ouVpN9BSu+9Ac0H27/erW2ZrBv  
8YmCdQDpDXKTKSph0ZURnYGLFUTnRoeFeorVvB+2AgdS6CoTiHXhCF8ds2R++3ql  
aPdPtILCum5vn+oihLOldHCOCx5b5CxKzqM85/ue143Ec1t0ftdIROPh1w6KIMh  
NWlLo5W0bl/Hk3upxKrXmyog8syh+/1Agf4P9wBJqarVKuIXDKnbTmbP4c4DvMK1  
MIJnugM3mBm2G4bnlvAxpJqR7wkvp1exg84nobEloDxxNC1dEEVu0LMVGuo3UWcj  
7s8ziW0gcsP1A1qbZrLHC/ZNqidpxM3sXmCg3TG5CKglaNFQSRvsoQ7wXgQ+3LPw  
tVd/IMtTAIxLmL+A8jDjexgY6P+9sNmumuXldlcpo3S/RdWTXyqp8q8KYulu4HkfW  
GSM2JyhChPlpkKYQSAUDcafpeZi5QVJIMSOPcvWVKTQy9FDSSeVqFk8OSTCSlipD  
wk5aHOoAsAbdcUBZLlevg74AX5R+BwlL8wV2YLcPrGbTRvNW5uWnFSiSztzA7sh  
jsMovmvRbqQdNNmQktUN6A3oi1SlapBTwQKoNpVdK10ziU1VcipV9YzkgSFyzyOz  
gxtrmrswP1YMkQM0GKRHN0WXNE057KR2jVEiJbk5i4Rt9MSgjjCOTqRBt/IEPHb5  
brUVl2v1Ot3NqvIqqqWI/AbJvxe26njnNWFkG4GxID01OwnDM0Y+Be0kA+yjVd  
kcmCA7xBIY7M6nmJP3S1XNifGMPp5g02DE5jL4DoVAtlu2DTatRW8RoXX6ZRVbgR  
19pXjF2dWPfUfYP9+Vi9nCt/fj/Dogs8POeKMYbnYTgJEZmXRniNyuaOObIaMQOd  
IXMViEcrDhPOYqcDRddztpsEaQqlmXXVqc6jA8y0yeWPXjf2Nwlf1cJnMNxHdGxc  
0hlUM71r4bloSHs4WJdUat1MJ9LTHneHWSv5lsYz7tJV44rNWXkA04IYXZCi6Cv  
2JDNjfxoe+HU28CTkTMxIkVG0KsPfCH/kNY4BsaInhD7rl0GaHK5tII1QdfCKJgJ  
foC8g2akxmBpF0wr3xnRiLvJeRKF1v1O7sTTyUueW53DLV1iOp4ChCbrLjkvd3G

ZhAy7IMU2jAlJdtNE1cCD0OXRC/hN2fAFVuR+9zHsT5stZH2RcTkbpXRvaEfKgsE  
DVjqwl3on2eIMjRY/f+Hrgujyb6MtsNDBZBjN6TTdAZMV9F8WmqW7o0AnQW9KS/3  
o4OHNi1SL+wzvAHtyhnWle9eARVimBTSTu29lZomBdhcCEZGA1BloPLZnC1pT7y  
hc5+u3a3WWJ461q1Xla1ag5/PmvtL5fqdANUaehyO8NAO+Lot2wySfWnaCI7KHLw  
It19f7NAXL7aQkIHMZP16KS8SRf05dG3KoxEa9fscqNarpWq1UoVy5KfyBRg+NHu  
4c7ujrQ7jgxrgtiPnMJy0bYjp4OXRzqJG4hTnTGFKjAWClzJc21ImUcBUJMI5lk  
0dNyvVGvVRc517XYipyfvocWO7KfWWwkuMSIdEGo6oKGncRWWmzY2Q2OczHYbb6A  
sCWVg7vYExvWGR1mWNV7FoD+DQy5AdTjb/MUHT+2JknErJAYbVvDVC2BoqHHrF+C  
Kcb1qYD4leNkEz5V13u9ukJDbpbeTdxKbSHdeHSJz5UWkadl7xMzgqjKxLCM51I  
H2NfuUPFIKeuMLGB+oduSHWTptVOOPOXHAcPiWaoB1xTNqf7ig6T4uTQrdhyA3x  
MAISzbWV31URF+V0ycuoPcjK/nNJt3W2j2TVeBo4vinbaJHaUUMIV3TRf36CYjM3  
fn6EtOcUzvJpsE0yKMIxedgemAUkflo3/NnprmR7i8NDX20Jp0qnnVtm7Wz3kDsD  
emc4DmkSBkAVILsz4uveSUG3YXzpDUNwiU9mc/Y4aGpvEkrvkxDy53v8cQwenT3p  
eUKmfo7Ca+1fsjqB2mUkUalwpjA3JOKV2vU64Oasvt1V9m211Pd+qCnnLLndhv1  
ftNtaCLMCgP7Mv+XLL/b6zEzCSlclVDIUP4glW3i9dmgYn2CKnBtEJKrQPcSeQLv  
T8gER96fcVAWIYwAMK8Xi9dbRBRMGnwEBnapapOSAUiPbAltEpFXPDG+r6ntGzY  
BVW+oucA3h6TFbDB4h7xzURHEkPmP/h99zkZ9mN6iRubmLCCJ2ofVREdVJeglYND  
sjVALICgJDChjca4TR9fy/MOq6bxUulp2Klx3FjuuyVp6WTPxjpQEUN5iZlp9IZ  
UbFlp6mbUduBkcPe2vElRfDaqx8VdINH7gXKAshx09CC+fHqa3eXNhDEc8jl6+nM  
vJCW/IDlgI7ktcp+LvGZSFf+XlrIF/qSNOTEbrk6urc6HQm3RNzPog8nQcMr66b  
0zY5iCB05DHdEzOAgE5BJAnY1p1t2r+FQsG6zZlvVtbeoUXcEtI3BhLQUSJ0hx4f  
om9qe+tgnbbcXtcvTIJx2p+ru5LSvmve0Y1GmUwRhg7evWA8OE2sxC1Y2xowD4Xh  
/gBW4VIIa0RW1nGzmrPByMrN4f0C3/mSt7ZmUAXDyXAYsMo6Pm0vyTmNFnA/nGqR  
DlmzUW00yMJFL7WB7SMPUaTA7TwMkdSkWYUGMll0QR3WNxcqizQTapwTYlla70bk  
h7cqAj+sjwwMtnO67E/6feYFx2wcYck7Zsl3IBXty9YFWV9MJIjc3EMPDtQai3gh  
H5AakJicEsT30uowPw6Vr9mSiiZ8QjMD2VTIsxEUYTcqsxtRHQLRIJsTjbYw4xEf  
yDGkDUInjqjt39Ck0T9+QRck2xxBRScsk/ePWiaOhgFDiLEFZozllsDXBVBt2IkB  
ulaaL+a0h2mkW23XrzRfuHdj+IXOKGSX0iV9atOZwS+kkzPBIQguyTN3okEleHel  
gmddFvQ4M5tsP+q2W10nVoWhMKjX3Izje6pZavDIR/Zls1dS9XK3Wa44Tr/WtJ+w  
scFX4BttOkZUjo8dUYJhQ295sQnU/zFltTNEuSmHyWIAZcBaFNyU9fFfyXq1XPz  
HnlPmu/n2kIPpviLXU+7yrKZf5mlLo10F2Mz7yRDunLIYDwCwRiwgc/nVvsUmP/B  
TOA6rV0ul0dDygZ+lppFiCnRhvxJNxuUdfmRa9zz1K7Pk4rfbx21pPI0YgKQiM40  
StKeXiM/F65V3h02i09dQAzPeDo0NF3FAZQjYzWnkXbXOt1uWzMqYvbmZFwBotmj  
gxz0UxpqH4wGcEEAcJkgqOv2FnwEu7ZZqW+W64Uqyi4a31IqbZZuagWR6RVgRVhB  
66ASC6JSQdSFCxhbKBCBaHg6dwP3PB6NGRq/QwMlj1pQl9pev09Od3sDEAdRgg5n  
8sCHEzrQpFMf4kGYeWTieLRn5kuQjoOficLcaOzlaC1PtYcHP4NJZe9b2xHNCrtL  
tBzWqUebC3wzJ4MBz4p5YyfsLb7VwNRWODziOKrsZJA7VbL7ik+nSgePgd1Sqtik  
1Nzr2INSdi2uvIswNq0XJ1kJxYZ1EEummN3i6nE36SPWPtsgF5+ziycDkHrGUJF0  
y3Zm4RQHfozL1HolJcsNmP6AYzA3L/fgGwPF+LnwZD6Z3bnNoIMvTgBjEka05w1c  
k44y8TiV5Mai/HQonMUDpEMhPfpcw3JHMhlcYIJ3U6jeMW5k7JOaLkjMFpE2ObO+  
ZkDpzLRhbIltB6HkFINcTcGu5efwWOnqcR7j2pVflxdJFvqrLpKgm1Dq/OqfXWMtT  
mJpvVtkUCdpdiuxjN9W0RyqOhojajXNkqclFq4knEZPDVJiY9gsoPiRrHoOHMB+M  
MVNFfI6QPHYbqj3mXXOGZRpydkPKYkS0pN0bqVp6xz7lofM1TR1RfYw1gUZijnnNk  
IDzsJ7m2VuCfnBsFcGh8Db34e+FwgXtx525AvDIMK49LmdHOzKPBepW/vaCBRx+  
6xCp8YVyw5t33dHnA3ycj4AQ5Uh4LBzmi++Ixh01NwzUyt8OTBvgEpl48gcsWZ09  
2ATwGKTh1D7WtL/J1r4JcfOSeqMD/hDP5oldCTnYHUyMwQsL5XEPLZ5/C3ODzx0  
nz2jWei/YfsJl5ytV0B6g+6TatGpkMOL8SkUxY54fKrX76FOFsOTnZ1eCXzqL8zw  
yGnSw9O1/8LMzZOJ4dEF8uwZbf0q41+fRW4XuWoQ2exsb9JmeOaPkzFJbm2fCecb

3Ram0llPlrkY+3+c0LRC5anZr3ka6yfch6PQ6Gw78O2ZnGU01C9GTfY5sXRgzNn  
PcagYMHtHW5vbytTV6COWmf704DOFMLPYS8M1O7xvcODzn5h2h+so9HtZo8uMITy  
GT0RS3Y55UJRkp12dhC6/TgN8a0jBQnOTNgwukn9+OSU39uwDmkX7ntkniXPg0mx  
zZWS260NsRk45gRA5Yee3xuB5K/zCKyal4B0ReqUu3OQAmHsXxTNc33pDGkiasR  
P9c6o1tDmlcZ98CbMtBjCtKL9B2fS3ztOs08u2uzVJwkNI6nv5P0MKNOuj4Ack9d  
GNzwYY8E0pP2Inf/PdTpkfuMATmFAXcMSSEFJ51YAEenXXBh4QD5+NETs3E070c0  
e9GMnLGJh8QXTXtkSOMZ10GoFUF84IK5m87DMz8q5C0Vg65c33TKMCpWElyf9hjU  
324C7q9k2zRCIcWksDbkUZPNdOYiC8WE9VK+FCCBU MOAWSwK6CQ/43v5Kb7OKY8I  
7WOKuOBEzrCjbOAVYVPVazWa8XKzXhz7zzwcPO38tFwRS+QStWzp3r891h/a3Y6  
T3qzklsEpbfnDS6RKsNhTxKGcx0CioJ3Rw+QpDQPu7RAPVaskkSM+OdkQmeUHoY9  
S9OzmRKow9pIV5eXSq/7DPRABevq77i5GOaKjxdbGlcn7TBqFFOp2abSUqu81Mpl  
LOpVZnQ7N60Kjabp4Ypqg04gY9rZxWwwN52mrYs1lzdcvFaeUA4pyeMdcm poQI7G  
nupZtyPYjH6fdv2dFX67INos0G0bb4rlrh8lw5j/NZ3LmleFGAW9VfPaxfziFWR4  
atlfu+o5S60yoWIOYFdh8Mjl+zDPj0O5SnzcYLwReNCMjZV9co2RRO5Uqre5jpel  
I2WO9V/Mb6yQazwclQ1ZxmpRGBklhFkcBsny1mjs9n0krne7kTvyx8/dvjeyjpCc  
wkuqFY8id+DD5WK2d59J2NwRjEqmXO3QX+nHDrpQ9r2pOws1ei5ZkxvMAjAJez42  
niG/xN/CZwBnnBkOLF+Q7XpkQIp4G7i5E+5WuuDNrzEXr7PitPazOhM8GIAWPt/e  
AEUiV5FZc09HbjR2ezq1yn6ZLQyhecB0m3zpgl2hPzcc2veosymUSg167RnNFteo  
4/rg9ZWtsNcRd79gHe52UAGKAGu1SY5chX4o1YtOuah7Kz146PKhMOwzSPN MtEpr  
Og3AI51+fBXtY/2MpjkK/kQ6KuE/lfafL2wPqBuyz3l30d0PuypQS3EwgCowNhyX  
0MZFAC3QGYqVDFKV6k4Zkt2qMoj5ix0rFgy0DboHWtz4E7OewJFobXNx aCDHS1cF  
AVcxCsF4El sHx52Dnd32VYiw6wN1TOTpU/3wfPxIV5kgTuc2i5ZYTaa uVgM4TaQs  
VU5aGqB9xUWhktgVJb7dPgaE3EcNRhAYyaV7Bm46bGE9BwUkKa5/zpu+DMwj8hcC  
W9y0rUk4BcHgMQIGVrITWG8lhqZ6EoyGyKjoY/c5SdqT+EhsMRiSxaivYzIUURLy  
ZhYSRvP6PJ83W0SXRVZGZMFvUkbeK5ayLPYOoxrnGsVPpeyYNUmfaWNMt5ppMkX/  
Gnh5uKxDcDc7QCKBwyWVC2nji7tEkruUX1/nMKODFOxIONDhFKhPRYNjnGsHnxrp  
+UTPLsO0U82UPqj3jaXXuJyxFl2iTdYQneankr/006hOQV5GgXOPUqYv3YvCZMoF  
2PICupOn3HkVs a1G4Vox8b20WETYQbJOnZ0R9TEnYQxCjqv+5abJaJ746Cgp4bb  
yuk4k8tBn8tSVbEeDg2zygj97iVKCxhNTXX850hMoWiQ+5RoBc0+OXKH7vOl2u0M  
rpK3tr3Oomoxx+ax4iTb7F5JmCSGMAIULsLcYuDut4Gipu/TPZpuz2wX0M0IOg56  
eMBMFjyTZJX2QVMJHT5PYTxeWLuvXVxX7RlaPEcQ0PT9DEkrtyMhC285vjZYftUP  
IRYkQ+StMmL8owiJV0u0vQ+EUM9ISMPAH0izdzfxA/5LF/GW3Lrcc5/jcrrqqHE6  
Dkrt5hwC+c0zICfrgg48CWsTiWRAHAZsnBZLiVjkpTM0/HYYCak3czdsH6mj/Uzi  
HG4D35B4C/b/JZau71344LcT4/T1h5kigb2Rm7PGGJtAbzPaJY8woSVVRIKIjdVm  
NEbefCO1inA5UjWMs036yMu1johiXS1zX9/2yatLuhSRDHpDlelrydQAYqkUXVpr  
TDp6jqCpRrSvdskWRq00o0Gx2uctekh2cDxiw5N+SdD9zsnNjC2jw10PFmoXDmbW  
PY8bZtoeMm8vvln4qoMcdxILRgYMM3w/Y2XSL/h+ZChzjVFoZO Cz6s/ACoW8Y8Rf  
vhKJT WvpajcKxVYZS76TdtLtwEdwJsjFmI4B6kElZpAZJclE4HTPpopFrU3oA4xEo  
0SLQkKkdX3ESUxItmtB8GXm/YlcbNU0g5TRt5ZCU sG9Ow2gGE dvc1DQFyGmBr3IA  
bulsgYAUm/tnF6b7FOVim7nVPkNqEFHaXpT4EmIC2QxJTDI0MSe wMh5E/tDD/QI0  
8cAFTkIEMiQEn/EtSoZ/5k1iXRLbAlY2MhXbYaC7q9knMOaFccXZobgy8LF+dRJv  
oJ48EThZvL34j096SRQxiBzIPYqxHoVCoAcjUFxUIYhMMgbOZusxkEmWGwOpCIZe  
39s6eMJ1yk/Owid6uO4a8co8tFd hGiesyADhgObWgZsEsyLQZOPitV9EguDuf/nS  
84fMyYnQHS1562i3fbDdsrb3W4eHu8f3yKnb3j84btGCd8jsPTs4OW4dWmcteu2M  
LqqTe+0WKKY2abLpkbU8NRX9EKI2/nGYkG+8Ya7ibRTfGF3P9Y4G5a3PVCyC4E9W  
S5Cwn8nEiKTA+HaVRpYBrVQsT7HOwr47N31vNm rWG3kCE82PSH5x2NchP34HCVvn  
JmWS9d6ibIyQ4wXkM4JGNLPU pG03Yn7RFBwMOPmCpY6saJ6jk0mwQMtdLpdUuVJd  
ZXdrIBWgd6QZjwTCtSnM00w6be2C9VPPFFKy u7u7dHAg1yJRcGaD8U0BC+mGyPz6

Wb7niWXD6UzVw7cr0gbpTQfl35RUE4qQaJWG2rnr0tsK1IYYo85kH0Ad/WvzWTe2  
Q7jqgR85kidqy9DRCTXUIV14aqj9OMigHDpbDPd9hnT0FpY0QSx6hyxJ6yzjoXN7  
UTgNI/QSpBYHftALDnYxssIHA04scfxyjg4QpNRngv6nofPdmdCS2s5d22by6yZp  
22azsgyd787KIVKFpLO5kWsZNmbTavUvNIMkA3tp5CVyAzQ80Dq9wvKJ2bM8NhHZ  
alvgLCQL7oEzUFJOfFzhABFIL2lazi4aSoHwu0W7HMWkLwtsLskcA5cLkxeecdzMI  
Rp0Z+vfaCLOiYS/qeuv07A/kA1w7zFps6Lv0SzgTCTVGj80wPX6uN50G1kWPM4B+  
uyKpclU3k5Trq885hZYijUFSxQFhbJlyBsPEI1puIFybF+dnw83Pwjg3i0dDIT21  
5OrIoNJVykngBXlxfnLw4LgFWnWhViH3G7+YV7FHGYpdw3jEuLempTm4IZyy/fs  
3VWgKecLhr60yn0+k1Bt+bkTExe+zB6r1FbiWAJHKPdFJAKXvqKOdAKz5UHgJkxU  
cul2N+lbPdbEMZ12AD4igQGuLozUvYTti5OBdZKQjzWax5gYUhD+OJ/hh3dzr5tu  
5jlgxLrZnPv1ueie76G8bsNFkYPhubG54WdPwzY4xwhoS2MEAogBsNMxAzpgB51  
LtAcsPTI/pA3r6ZaejrSLDxmSUuufC05lqsu7v3UJND2Eq5h01Wle/QoRrnuk45G  
sgN3WHrtzhfmFvTlbPnEFppSGs16w272ag0HKdm2ygnAbeaPwHzQzjeZ5RuGt4m  
HZ/wfB1dMJXnRPyckXIOEZ3EcBhabDjVEkhhp6aAesBjMtWJAx4TnBk9JgAN6jEB  
EGFhtrmm2pNokWdAtQSuCvfgJRjk0BI+CbmohOFcuFh5oudCIQcAl5eRjU/aj3YP  
D63tg7PHmxnEM1ss/IhXAjK7/MB/DgD7H1ig7kWfLvoE3WCOfjn3bAowJk/DTVjv  
pTmZoa0crDROJeS+bI3JDaNLbtLA/jAlwjkZFGQRQrgaVyiAdBIUGSX7sC/ts6MFw  
OnXJVeNEndn4JMm9yJ2OPDLUkN4A8F3Polzp5O4Q/Ne4VxkgTMAO3GIG0EknLAzm  
Y+nXQxbXAQFgwymrRrm+YkNVnIY4OOVqSTVvVRmo+AHN9uP9Des+XU9I2tCv9zNG  
HS4qJIM9GtPSoGmTJz9tLR0uDIBNgymCgtrenNGfxerFiRv0bAcFbo5TUc5CH2+D  
dHu9UqY5K8HubBTsStku2w2S0dbV7dbP/ZS1vbVdyEjsA1Rr0Rfoetl+vEa/mwgl  
nhUzHZNkGukyQZUCI/y+NyHd20NV29a2bpSXx+ZCz9DJa6Ir8MXV7aU4gD3aF32X  
rqvJjLRRUJT6UskQnhoeQsXyI7LwfpZKaagVEVjZhWqzVis36jQTTLLe2iMDMmP1  
2PHjaRhzMcQWShhzVaN7BjRnW3C4SK0/QzVgKybrYRbG0rJITrh3+VQA70UhXPE  
I9hWTxnluPGSREK5DquYm1LrrXxQTIIIR9zRTwehuQlwAt4uuBWGjlmodJgYjj  
yjVjQF+5is0YBLqkr8egAh4DTiMpHcY1/o2f/Mhv/I2Pf+Fv/s0N6zf/q49+/qN/  
ccP6/F/7C1/8bz+wYX3hlz/xmx/7Afr9Yx/6zR/621/40Kfox0995xe+50e165Rv  
Xoc3M+76cJRS0MmZIGwunQi6AXqGpX41bW0AB1f7AlxzvIry5844iTImw6FmQJE/  
FbePbdtxnFLTbraK3oRGDKPnpQSMky/5uthE0znr023oXVC6QV+6JDtAnJCqR3mM  
IKGasbKt4fafJheuLpghzxSuSzzx7nWVfhGTGPtp0WPxyZwr7tWG+z01RtVVa43  
F9y+ZnG7etwuNZ1SY48Gw2RnHvcrMukBMoWrGoiFzbi8jMB6DSSdbORWiyzDN5n9  
q7mF9V/SELfbjYtT3y92Skc59VLNdkrIEjm21Rfoxvim8o4/Sro0limVSKR++r47  
dQGGE4PAN7bsQu215iKWPHeKZzwCPeRAoyhxRtvVDlu4LqF1U6V285xZt5eifLDq  
4pu8+BQCKSQsLVtrFigzDcYgSFyoLGSMMk0xnusJrZTr9dquGnqgtksbxLgHzOo  
tAzTLNYFA+UL5hd3B2BmgFI79mYAmulZU1PPkLUM7PloZpXE/Tq+FH9sKh/jw8Q/  
FnuzRoparFMWVKsomS70cxkpVSqlnhCaBi6hAGcM7irm/mqZpe8kHGGIrfw0HWTT  
INLZAvpPf8UGMshcmiPupTuceLOYM8aMuppwNh5xxhmwJ6+KNdTXvuXlcOzKg6fm  
uXniVkee3zq9Wazyc4nglj5OPYucZE7nLOLBSEcGDwaaG4bUhvcf0f3ok+PhDmmb  
cRUKYj90Jti2mvmltGvVtmhalW9ywQVGsE4QkHLhc7RtuFZ/Hg9SNYj4hTtF+ILG  
hqyAr4sumIYXH0cljF9Cq/DkmC9sDd6ILgZaTNqttKoxQ4OM8UXYIKa2v25vkiKo  
V1YK7Lr5NwtSBL/vVpxhgDthOBsZnySej6ezcMxawXw9Fwku6sHc+PcCdwi00ZsC  
QerPqYH5njekfxT9EGuBBNpPCwSXQgskVn/6IBallpHBgHNQhZ0p7A8Ng8BYFVEy  
ITjZvhCGfbUFrw+UgFDdGwt2HxgSuJgTmCBomEEo0XijO+4YbXCoqVtt1TjzxkCE  
XluUU4Af8TkNS4ToHzNd6AnJ4A1jDEr4wIGI1ZdBSeCNByUB2q4MSk2zMTGRBmaV  
+VjR75UbExmEGJPK8fWIAAM0s7AMj3dfbj8cney8eNg6O2k/tnb39na3zrWyZ7G  
hzzBpj8cW2f7u9bW4cnJtpqtW6Ora1Wu32A4ovt9skB97klgO86hm8U+hnyr54e  
aLgeZoiGMRZECwAietz+xPsIn2+aHvSKOcLO4YraETI07KCcJ9ACoAen/fnUHzOO  
Sus5GZoiXXbcc/x0QC+T7Xu2AAKgd1E4nXFhNxLmDPMOt8Uoa1Mx60dAkkbqb54x

bLNkZGQgwS7OpqlcSNDrFfNVAHe6h1cxmNde/bB8SA+HvtyTBnoyPsDqbCqLSwdx  
0nCWE1OIfTfB6tXnWoZjhsDBj9MrKNjVBU/dWPvfASWNhwSIDfvnKZ6sE2+fx98  
riAa03Gu49x4BZfkwo1TFB3XOvJpQQdBA4pPDAz0IY5oQ3EJoGdzucP2ZmMRZVLd5  
1wEhut2oVJTdqObownEruL3YnYwLjs4Noloj8bmQwqVpuXBR1XwauZ/5OP+050UR  
zbzgdSENEWNJ07+SjbuFuwOZhNA6LCyMhHk92HWWCUC9Z7qEm9YJ/YfuKV0ScMXC  
MN4qImK8Y/ueQGlzFaKGIIq5CJqxkAPQG7YFr9bsk65ulmuqEp9tYA6nEQ0e5xs  
KFULpUqF5qDGPb3TKdk1SB6iEUyuPD8eZ8YPNh3bYxwAgV/DVZqWuTAKFsZn6i24  
IuyKDN965Kg40UtPza6FESlzkP6gOdWIqwMeDGssdsV84rvn6r7b/fm/GJ6HI1wf  
eubSVQuIsxcb6Mp+7gW95/NzrPSe13ej5FynWMc+rRnqyjsBfZIUKszbwH2WehVT  
ThoPhW1CspDs2S9fgSsbjjR+90uOpt0jOxSdXI5evI2TneValEcrA6DH8NnOmKI  
pgI8J4RGSPbHifXgfsHazVlgXP01Av8717QBO1AXqKa3MN6ivRdJYEgwln19i5vD  
smfGUuaZhnmw0RcsChpSk5sF65WIVgR6ZxP+Rh3jgOl0cCyKni/JXHiYNkEvQVTk  
XXY95aQkoToeg+62Up5QrkJI0ITWgWJUbK+fiq6v6QOTalyNpJTXYy/Md/Ei4ZQ5  
JoB4EB4jcqZKpWq50QAYux6fWh6f0uNDK68eHi5QGZ5qKT08rmLn4alseGpxeCod  
3q0q4zUL+6Gr8RLMFPgz35WuuDWAhqOpWxj7QVFT+RURsk6j+sJHyAV6uB5ZFj/9  
HhKGcZRDugixQ9sJkbMz9ixQ4h4VrBoyzTQFCvIKW27vXAhBNuBCjMJ+ajOlm5IL  
81P/Ob8JpQ0Zujek66LHfn2awcDHgGvZ44o3ISBH1oN2D/1H4X1VVffZPDUDNM2  
msUBehf6CJboVRoY09eGc2QudpFqzwOQhvwDwgrkQBo5YM+hPwjco+qa9T4vE7OB  
+4bENkATGkls04bill5k237btY4Xa7YpeJWGVwkVUY8PoQf8BipA8+6r5P3OwaS  
r6PuF7QvlPM5aUzz5rwJqQJxL2SajEua08VHF9A8EZ0tfvcwLbj+8MMKBE2xBY6  
rzV7gOYnr5U2nSsQ0OwK3U/0ui01S44q0VAq3PG5IKm54OLczsbqbhknhwR82eui  
yD/W647iKwt36t8jy8azXsGP5mlQ9d6Y3TTpWeqkCWlJH81XwEpFaVvRnU+vs9Ly  
Qfl4C31RFePF8ahhyHBJ3IQguNjzRIYlwxaTP730Eakw9S4X9tkL1u7R1kmKjFeu  
6R77Cu2KWiVn8ZCR5hTpYD/Ffq4363a9Tt+E/5xGMKCPQJsVxDDQ7B22gCpBP/5  
hnWlbLv/DBuK01ARWVj3CoLVh9qw1MIkmw0osbFo9ImAlh556lgMY1TVsNGy7QY9  
n6xcmr8kDcphCQ6Yxc2dAKG4hRL/gT7iAvSWIVRy/YdtN2tXI1SmL9PwcPXLWTjj  
IwAFA2C91A7V0k+4UIk3mPHboGbMPtdUvfkHBQS81eHpErzFPW0IWofebGYSdy3b  
9TubFbvSUGQ/V1fsURS5hOhSgFVaaparNIYgdx2OfQZg3G8BjEk5TDDWciRh2MU  
8k3CgTsME2t3t5Bfk+Ocn0Nyb2qJyTyK03siU6wI6iVA4goBptTjhU2htI6NAkiJ  
xzMD3mhX5GS1Qm1s2tXSkkKdjuaC7QCKehx1ZlBy5zCeaSdvAAetPwlfAW2GM/51  
TBNqtXW/5lszF8IO+HBoMOSseFrl04oi0zqVlbWA9M0EcwPaZQ1A5UrC60kCHQu  
VCTp58HGnI5c0gWRdN/w6DlpiyvDbjbr5B3pxFFjtUOxAxhdVak1K7ebtTvNql2v  
QbcxEvBuQHN3IMTnqDBsiZUylPyaa3OtHullqvD/TYjmApp0hpyoQ3gOz5dgNAL6D  
IG8wibaxyRz7tl26kwro0Ok02jW7SbYYo/x26F5+SSOhMtqn6yN41RI5cp/cp5N8  
X67vlwrmeOTwIlfAWTElhC\_rngAvPe+h8wrvMZLftbejs6POHQH43D6wdicjV/er  
saVH048YTbodaU0mCcO9lgwgNVs7MllxX7gbAVxx9V8XPqkPIf6hNas7iv6p5pVI  
s0jKdFtSfY2q7TRqWDGG8QtD2ltwiXZ371mXAreGXlvGLqXhQHLJY2NM2EjjbuAy  
rcdChHMa+YGE8FFjfYNrBA5kItFMD4+E2VL0vKEUF2gxJLo1GzMMj06nd3t+rCqN  
ij2ol6pVt0wKn5GI73Pa5fB0gwtleiFuYsHpsLm1Qyew1eXdM5pb91vsBNPkAamE  
bln2Ke1X3qHH3gwHjZWFOiVPB5sgkkzYsukt3Zacl1isBqXLe3bpefqT8ULsgR0J  
+85mzbavqlpD5MFukg5tNksKw4LF0KFL6pTRJXVY5DgEQJRYklnVxDUnbJ3cRGYd  
cxujxHC57FyVqgp9ZAwv/OUTKN0c9psUp8ZV37jgA080GW1Md5wZ2CAAGAGU9+CA  
K9vYkTguMxoNM3lfVapYXXHgX1/Q1/efSrZjA1SmXmb/yYgrDpSCuMqli13G4qqD  
A4TsWFx1XFZaXBoxl83M3MHA2jVmL0IYpEfnAqmCjnv2dmWsqc9AM7EjZvu1yhhn  
LUxmVocW0wO6vVFy8ZX9NdwAsJrRuH6ujAEeG7a7NKAbrpC54KVEkB+nXZyxtDNo  
BixKll8tIN2q9JJTWn4Vi/xkcjLocDrjh+gewvZ4xCFwnh/mNctPzsEEgFVIj2+Q  
vlVywCVdIQpg29yuOSfcfMXNt4z5gGkjZjagJbLyxV+V5gYyH1UB+o+wfs45+C2+  
K4aTnys/HY7q+rrMUhB9Fm2FbBpp1pq6jwmtEC1UT3HnLqoXXOF53+HqGA0TyKck

XL5nPTrisia17uCzfBRyqNM6BGjc/veUR7zgLM2rmF24ya8wRhL553WFoSoTI12KM  
0ligrhEDe2iD+ItFcyZ1QZCjkP9zvwEGexXEH9RXukGTeTW6WodrRXViE+DK4  
9Fy0r6UdEtBuaJnrcX3TLqEbnqEVRN862p6mWIQ1ZDxLg2NH+2B17ByBSbjMBOM  
PWeSNz4woONYovfiH1yTJPrjN93skpRALSbETIMqPmCbY402yt90XVbiFgNs+2e  
SwbaBdw1Tjv/wQ4dAj/CPBLnmcfj4jBBz7yK+Vvom2Fa7DJMjYieR72HzdOes3elw  
8RUzY64X+sSQA8gM9yPHZEyHOeGi+R2a8c7Nb0OatXiUdLkFRJMIVprVWIGqnGij  
m+rDSbo6/yVS0XtZKo3SsyAVjbfcJWAwhf3J+WLQjcd75OZveoA5+jNri64N0hir  
FqHDdh9aCG9mhtDDusnscjQ3hfV1VC9NjDw6+M3wuoKlTn55e4vMu8nQwxpymnrk  
niPLEsHay6rrpH+BB1LcDsKkn9fg4uYtNumAaMB2lny9Cw6HTyjV0kY5iZCs7GO  
Xj/esB5J8AF/ffCAJ3FfHRc0Ax6TtvQ63GsL+PVS8XqGCYE/Kk3OqEzjohBDmCQ  
rAGnWK1VjyUSop7rCkalvu+NaTfPuPIZSCK5OAwsIPh+bmUB59Cl3yc9dmnEuc6D  
hLEM7Mmsc3CdADM+mjjJs+JSpblq20X+uiG6nl0ENBSu2zjgWXvYFreLfUS4hwyL  
RSq4JZ46eynZXJL9Yp1Gs9RAotol+7AuXmBb/pRronXeJZFOkzDYq6gVvJaHBuv  
F12fl8YXktQDM+3oTEuqNI6LGRx8FxqgtGLGXuCiRP60ID2H1k7lGUvmMP24ZVd  
IXUQci7uPOwlC2+5cha8+E5HzFLDnO5OGW48RUylit2YyU8WXLQ4+OopkNuBzkb  
DAuLZ1i6iZa/SUdxV/ZDrktcYsLaR/TRMYW8H12oLt91kX8BlrnOSeeGCzGVT8Sh  
gKzkm5yehIMnOsZM39F/oiWIS4wBVAU52njm+XQIQQMZV16bo8Ok0U1wzIT2GPFD  
WFFMBPbmGOvdZDBwgzDb5zl+cWAo1Yvk9NkNrcIYzXTrmgYya+yi0MXiUCTtdikB  
znGwkD0CoJK0qM5kL9eoRqMzPCmMxosdx4PAjUfSaXyNIR3Tn+ZKgNAhITISKUhU  
fOHs6/4p+92X/cOT9p/qNet75a1ay1ZbdqOlKuXyjmrWtpG2re81GluVWqtRpqko  
Sy/AxEPY7+ioKB6AK2aGYXvQfiPwt/Sd0vS03N/mIDS0aVerFWVz6H3F2dYtbpVG  
Q81JCNx7J1N/ArVS1MR1pDWFBcu9dcfesxnEw1FTjOvFlyHDmSvyO7kSf02wEDf7  
VFFM1mKtVqs0y/Vlj6AO5rxIKFkytYTqKCIV2niaklyQkeRjDSuKqd2JqQ8kN3f  
9yLa6Yh6HbmzAlSn20zw8tyjH/fRCos0nqnd8J4x4pn3DFGR2SWdn7kAp3MmOEhb  
8FziKnASwTMUeHQR487axDpUJH6VlbkwzAo6qij0wSDnb3auY9NTt/VTbzv29qM7  
BYsvvMqmrRql8azjk/bWbvsM13CIUGs0y01cxlw3uk13XB+/2ix6lOtrY/rkA6T  
aw1xZkjB+9pgd83LYLieMshmOHmB1nEXzv/L3mjCcMhfgUfeeG949Lhn+IMaHBw5  
NFS8w+U7ZygwpjzFl6qup1wFmZTIpOHZMpmUkYmmi2MJfoA+7/saUBHs7Jy9Qx6D  
2UHBQEz+VRRpltzTMMCe9/IQMjmm3LdTRIS4JQkPatHeImXbW/F1hJhrrXZLEiY  
x2EKNGap5r7Rzzd1vp9jlz+TNTBtjkPUavmZVDGTH4ww00z4olMrVcnepjkrNuYR  
3Rs+d7Gdyfs0/TjtUMpGLZm2sOfLb9kcoUBBWk0foajEOuAezdde/eBrr36E/tXv  
oqtpV/fxaIBq8PNNeHZlaq7IkF2CvdiHpeTUzEkftQ7FBohNOVPTSp4jq6SiFx9WM  
MjeTbqCYvUN1a3Vv0CzVyxXk4AQsNRwzRZKgmznm7hK3TTdpOclxTi5ZSDlodkn  
/bHHIUbQEIC3gVuyA2+MWnkwbwl+zlliy/S2gX73QgChVxlym8HzCj6+dPTi6Pi  
rRoDmDp2SumDbMXuyRUjOZnAvU/f+MLayPdsR5Cqj8kkCVKJipdTbPsaM9bUiKia  
MhlArMiw1t/FALdeyEC2C8MKJ8BUT9/3Bq0INFhYVke97SQIOBqgVUW2/5Fk3D35  
crTWPqX7aEwHV75Jo086GOXiXgR2gRdiIRwNMnyd27LjmWBvrW4Qf7SmmVwEgOG  
oRNSNwONeOPknanLxVoeE3p7Ew1q4DTqjnOL/rcdTuf8tbduisWKFleqCBu5QeJl/  
7hp8PBQ1Zq/RFicfFnZ93+L2P2t729p6rDotq1KgPxGAEsaAch2p3PRRNInNuhF  
mse0d5XRTS/QPANPkG1p/U7yaOYqdoV00OLP/eyf+/fe8oduveVr3vpVbv+zX/2W  
W2/7o7/y8dvqgy8+/u3/7oWv/dlf+ue/9ph3NT7xw5+ffEN4WfpHjfbP/Oc/8k8e  
/b5798/9w+/7fPFL/YPwt77h7R/+L77qH/zt9//aj/0v3/Zj892//pF3/dK//cLv  
fdtv/cJbf/7b3/6BF/p7P/aN7/iNT//ln/qP9t7VGv3in/0jX/c13/8f3n3Pzl/6  
gZ//wb/z3d/xPb/4PT/+f337q+ob/vUv/sB7/IX3l98x/6WPDj7zgd/9/fnX/eTf  
nf3LFw+/7WO//PBDH40ev+8n/tVfUW/79LO7zisf+a4f+8H3feLXH/7Ct//qP/vf  
Zp/9/h9/8FO/88GP/4/veN9/8/SHnt6t/s8/84N/a6q+9Z//iXd+/k+/7bs+Nzj+  
3n/xvZ/84Zfe+va9//PBs0n/c78zrP0n//Sf/NAHpj/+6gce/mr9Yz/9zq/dbL/n  
H279qvPvl7b73zn/7H5rZ+stX/q3p//vT3/h9169M/+w/fsbf+R9f2z6oVtPPvmt

v/yf/uu3/9av/4r11ke18D/+uc//47f+vQ++49d/4h9801+3us33FGtf//JfiH/3  
R87f875PPjwovv3rv+ZH/+xf/l9/W33pE6OTDwX/x08d/Q9fvP93P/XT7/yvP/d/  
/3L3nX/8W+5/84vf8zvf+V3Nn/3q/+n3fr/2/L0/8eC3vviN/88nk+1n+2//6Hf8  
B+/4Y69+zZ/+ws/uHL5j8ic/l3z19//j4Evf/Qu/8X2dbxu9bP+V3+7+0ke/4798  
2Nz6lXd96deeFr73O37m4J/94c+WWntf/fUvft3f+Ufb3//WtzY/2f/t7z7/W7f+  
/FdFP3N0+998+pv++0d/futH3nn6Offx137xP/vdf/NHz/4Z+7+y3/6pctPf/FT  
X/zm4k/+7y9/75fe8s3f+o1/tfxw5E98/EP/4ndKF/8fcrhdyA==  
=nMEG  
-----END PGP MESSAGE-----